CED Clinic: Personalized Cannabis Medicine

 

Medicinal cannabis is changing the face of clinical medicine.  We are the leaders of that change.

Mother,And,Daughter,Having,Fun,In,The,Park.,Happiness,And
Portrait,Of,Four,Cheerful,Senior,Friends,Enjoying,Picnic,On,Green
Spending,Time,With,Parents,Outside,In,Spring,Season,Is,Funny.
Couple,Wife,Husband,Dating,Relaxation,Love,Concept
Happy,Young,Family,Take,A,Self,Portrait,With,Smart,Phone.
Women,And,Boys,Walk,Hand,In,Hand,,Traveling,Adventure
Portrait,Of,A,Satisfied,Executive,Celebrating,Success,With,The,Arms
Family,Eating,Sandwiches,Outdoors,In,A,Forest,,Portrait
Adult,Female,Doctor,Has,Video,Call,And,Chatting,With,Colleague
Parents,Play,In,The,Park,With,Their,Son
Shot,Of,A,Family,Having,A,Meal,Together,At,Home
Busy,Young,African,Man,In,Shirt,Talking,With,Smiling,Man
Happy,Family,In,The,Park,On,A,Sunny,Day
Mother,And,Daughter,Having,Fun,In,The,Park.,Happiness,And
Portrait,Of,Smiling,Millennial,African,American,Man,In,Glasses,Pose
Soldier,Reunited,With,His,Parents,On,A,Sunny,Day
Satisfied,Senior,Man,With,Friends,Having,A,Picnic,In,A
Time,For,Family.,Spring,Season.
Young,Attractive,Couple,In,Love,In,An,Autumn,Setting,Following
Happy,Grandfather,,Grandmother,And,Grandson
Portrait,Of,Smiling,Woman,Working,With,Laptop,And,Cellphone,At
Happy,Woman,Have,A,Break,In,Office,,Folded,Arms,By
Businessman,Relaxing,At,His,Desk,In,The,Office,With,His
Group,Of,Senior,Retirement,Exercising,Togetherness,Concept
Happy,Family,With,The,Child,In,The,Field
Family,Of,Three,On,A,Walk,,Mother,Holding,Child,,Front
Irate,Employee,Laboring,With,Loathing
Portrait,Of,Happy,Family,Standing,In,Back,Yard,During,Sunny
Young,Woman,Suffering,From,Headache,In,Office
Group,Of,Senior,Trekkers,Checking,A,Map,For,Direction
Asian,Preteen,Boy,And,Young,Father,Jogging,Together,In,Nature
Beautiful,Couple,Taking,A,Walk,In,City,Park
Happy,Leisure
Group,Of,Senior,Retirement,Friends,Happiness,Concept
Cute,Couple,Holding,Hands,Happiness,Lifestyle,Meeting
Portrait,Of,Senior,People,Celebrating,Birthday
Cheerful,Multi,Generation,Family,With,Parents,Giving,Piggy,Back,Standing
Office,Workers,Diverse,Colleagues,Sitting,At,Desk,Looking,At,Each
Grandfather,With,Son,And,Grandson,Sitting,On,Swing,In,Garden
African,Female,Doctor,Holding,Hand,Supporting,Caucasian,Woman,Patient.,Kind
Portrait,Of,Cheerful,Girls,With,Grandparents,While,Sitting,In,Back
Cute,Couple,Walking,In,A,Autumn,Park.,Boy,And,Girl
Group,Of,Senior,Retirement,Friends,Happiness,Concept
Group,Of,Senior,Retirement,Friends,Happiness,Concept
Portrait,Of,Senior,Couple,Walking,Pet,Bulldog,In,Countryside
Shot,Of,A,Family,Having,A,Meal,Together,At,Home
Group,Of,People,Holding,Hands,Support,Team,Unity
Group,Of,Senior,Friends,On,Hike,In,Countryside,Looking,At
Happy,Grandparents,Dance,Waltz,In,Front,Of,Family,At,A
The,Adventure,Is,More,Fun,When,They,Are,Together.,Family
Group,Of,Senior,Friends,Hiking,In,Countryside
A,Family,Having,A,Walk,With,A,Dog
Group,Of,Senior,Trekkers,Checking,A,Map,For,Direction
Group,Of,Adult,Multiethnic,Friends,Playing,American,Football,On,The
Granddad,With,Cheerful,Granddaughter,Having,Fun
Beautiful,Couple,Taking,A,Walk,In,City,Park
Portrait,Of,Senior,Couple,Standing,With,Family,And,Friend,In


At CED Clinic, we’re redefining care. Step into a welcoming, professional space where the leading experts in medical cannabis are here to guide and support you!

 

1

You’ve found the right place!

website quotes professional

 

 

 

top 25 for CED website

 

Promotional poster featuring Dr. Benjamin Caplan, MD, recognized as one of the Top 25 in the USA out of 43,000 applicants. The design highlights his role as the only cannabis physician testifying at the 2025 DEA hearings, titled ‘National Voice for Medical Cannabis Reform,’ with the quote ‘Shaping Cannabis Medicine One Voice at a Time’ displayed below
Dr. Benjamin Caplan, MD — Top 25 in the USA. The only cannabis physician testifying at the 2025 DEA hearings, advancing national medical cannabis reform

 

🔥 CED Clinic: voted Best Medical Cannabis Clinic since 2013! 

Screenshot 2024 06 18 at 9.32.33 PMDr Caplan Best Medical Cannabis Doctor in the US

Our Services

  • Expert Telemedicine Medical Cannabis Consultations!
    • Medical Card Certifications (Massachusetts, New Hampshire, Rhode Island, Vermont, Maine)
    • Adult Cannabis Care (Everyone in the US + Internationally)
    • Pediatric Cannabis Care (Everyone in the US + Internationally)
  • In-Depth Consultations & Care Plans
    • Personalized Services (Medication, Diagnostic, and Management Review)
  • Cannabis and Non-Cannabis Medical Second Opinions
    • Long-term Talk Therapy
    • Advice, Support, and Cost-Savings Advice!

Our Mission

  • To Heal
  • To Listen
  • To Educate
  • To Learn and Understand

Questions? 👉 Contact Us Here

Our Team

Benjamin Caplan MD
 Benjamin Caplan, MD
Erin Caplan, NP
Erin Caplan, NP

 

Benjamin Caplan, MD, stands at the forefront of medical cannabis care as the Founder and Chief Medical Officer of CED Clinic and CED Foundation. His entrepreneurial journey further extends as the Founder of multiple medical cannabis technology and educational platforms and as a medical advisor to the prestigious cannabis investment fund, GreenAXS Capital. Within digital healthcare, Dr. Caplan co-founded EO Care, Inc, a pioneering digital therapeutic and telemedicine platform, offering personalized cannabis care and product plans and continuous clinical guidance to a global clientele seeking a reliable, evidence-based cannabis care partner. Adding to his repertoire of contributions to the medical cannabis arena, Dr. Caplan has recently published “The Doctor-Approved Cannabis Handbook,” an industry-first resource empowering readers with the full scope of the therapeutic potential of cannabis. Through his multifaceted involvement, Dr. Caplan continuously strives to bridge the gap between traditional medicine and cannabis care, making a significant impact in evolving holistic healthcare.

 

Erin Caplan, NP is a board-certified Pediatric Nurse Practitioner with a master’s-level medical education from Simmons. Her extensive clinical journey has been enriched through roles at Massachusetts General Hospital, Hyde Park Pediatrics, Atrius Healthcare, and Dana-Farber Cancer Institute, where she has provided both inpatient and outpatient primary care to some of the most fragile and challenging pediatric patients. A registered cannabis care provider licensed by the Massachusetts Cannabis Control Commission, Erin seamlessly blends her pediatric expertise with the nuance and adaptability required for personalized cannabis care. A community leader, avid athlete, and dedicated mother of four, Erin’s compassionate bedside manner and steadfast commitment to evidence-based practice have earned her the trust and appreciation of patients and families, showcasing her as a harmonious blend of clinical excellence with a personal touch.

Patient Stories

Navigating the Stigma as a Senior

Testimonial:

“At 68 years old, I never thought I’d be considering cannabis as part of my treatment. My generation didn’t grow up viewing it as medicine—we saw it as something entirely different. But after dealing with arthritis pain for over a decade, my daughter encouraged me to give it a try. Meeting with a professional who truly understood both the science and the hesitations I had made all the difference. Dr. Caplan explained how cannabis could work alongside my existing treatments and offered me a gradual approach to build my confidence. Now, I’m using a tincture daily, and I feel a level of relief and mobility that I hadn’t felt in years. Even better, I’ve been able to have open conversations with my friends about the benefits, helping them see it in a new light too.”

Peter H

Peter Hargrove

Reclaiming Life with Holistic Care

“I had been living with chronic fatigue for years, feeling like I was just existing rather than living. Traditional medicine had brought little relief, so I started looking into alternative options. Working with a doctor who truly listened to my struggles and offered a holistic approach to care was a game-changer. The cannabis regimen we developed not only improved my energy levels but also allowed me to engage in activities I hadn’t been able to enjoy in years. This isn’t just about managing symptoms—it’s about reclaiming a life I thought was out of reach. I’m grateful for the guidance and the opportunity to feel like myself again.”

Sarah M

Sarah Mitchell

A Patient’s Guide to Finding the Right Dose

“My journey with cannabis therapy was not a straight line. When I first started, I thought one dose or product would fix everything, but I quickly learned it’s a process of trial and adjustment. Working with a knowledgeable doctor made all the difference. We started low and slow, as they say, and I kept track of how I felt each day. Over time, I found the right balance that worked for my condition without unwanted side effects. The best part of this process was how involved I felt—I wasn’t just following instructions; I was an active participant in my own care. Now, I’m managing my symptoms better than ever and feel in control of my health.”

Michael T

Michael Torres

Finding Balance After Postpartum Anxiety

“After having my second baby, I struggled with severe postpartum anxiety. It was difficult to admit I wasn’t feeling okay, and even harder to ask for help. Traditional treatments left me feeling disconnected and foggy, and I didn’t want to spend my days like that. When I started exploring medical cannabis, I was cautious but hopeful. Meeting with a knowledgeable doctor helped me approach it with confidence. I started with a low dose of CBD and gradually added a small amount of THC for nighttime use. Within weeks, I noticed a difference—not just in my anxiety, but in my ability to enjoy motherhood again. This journey wasn’t just about managing symptoms; it was about regaining balance and finding joy in my life.”

Emily R

Emily Richards

New Hope for Fibromyalgia

“I never thought I’d find a doctor who could make me feel optimistic about managing my fibromyalgia, but Dr. Caplan did exactly that. He didn’t just focus on symptoms—he helped me think about my health in a holistic way, integrating cannabis into a broader plan for wellness. His recommendations were precise, and he made sure I knew how to adjust them as needed. What really impressed me was his dedication to follow-up care; he personally checked in to see how I was doing and offered adjustments based on my progress. It’s that level of personalized attention that makes Dr. Caplan and his clinic stand out.”

Grace N

Grace Newman

Overcoming My Fear of Cannabis Therapy

“For years, I hesitated to explore medical cannabis. I had so many misconceptions—fear of side effects, worries about legality, and even embarrassment about what others might think. But after years of struggling with my chronic anxiety, I decided it was time to explore new options. Meeting with Dr. Caplan completely shifted my perspective. He helped me understand that cannabis wasn’t about masking symptoms; it was about restoring balance in a way that felt right for me. My first steps were small, and we adjusted the plan together over time. Today, I feel a sense of calm and clarity I hadn’t thought possible. More importantly, I’ve let go of the stigma and feel proud of my decision to prioritize my health.”

Julia M

Julia Matthews

Care That Transcends Expectations

“Dr. Caplan’s clinic is a masterclass in patient care. From the moment you step in, you feel like you’re in capable, compassionate hands. He took the time to understand my chronic fatigue and explained how cannabis could help in ways I hadn’t considered. What stood out most was his emphasis on making informed decisions—he’s not just a doctor, but a teacher who ensures you leave with a clear understanding of your treatment. His book is a fantastic resource, and it was clear from our discussion that he truly believes in empowering his patients through education. I couldn’t be happier with my experience.”

Daniel R 

Daniel Roberts

The Expert You Can Trust

“Dr. Caplan’s reputation as a cannabis expert is well-earned. I came to him with a list of concerns about using cannabis for my autoimmune condition, and he addressed each one with patience and expertise. He went beyond the surface to help me understand not just the benefits but also potential risks, which made me feel secure in my treatment. His recommendations were so thoughtful and practical, and he even tailored them to fit my busy schedule. What really set him apart, though, was his genuine care—I could tell he wanted me to succeed in managing my health. It’s rare to find a doctor who combines this level of expertise with such a warm, approachable demeanor.”

Sophia L

Sophia Lewis

Empowering Through Education

“As a mother of two, I was cautious about trying medical cannabis for postpartum anxiety, but Dr. Caplan quickly put my fears at ease. He offered a science-backed approach that felt safe and sensible, walking me through each step with empathy and care. His book was also an invaluable tool—it gave me the confidence to understand how to approach treatment without guesswork. Now, I feel like I’m thriving instead of just surviving. I’m so grateful for Dr. Caplan’s guidance and for the way he made this process feel not only accessible but also empowering.”

Olivia G

Olivia Green

Clearer Days Ahead

“After years of chronic migraines and no relief from traditional treatments, I turned to Dr. Caplan as a last resort. What I found was a doctor who genuinely listened to my struggles and worked with me to find solutions. His clinic is a beacon for anyone looking to explore medical cannabis with confidence. He didn’t just give me a prescription—he educated me about dosing, timing, and the different products available. His insights were life-changing, and his approachable manner made even the complicated aspects of treatment easy to understand. For anyone hesitant about this path, Dr. Caplan is the guide you’ve been waiting for.”

Ryan T

Ryan Thompson

Game-Changer for Mental Health

“Finding Dr. Caplan was a game-changer for my mental health. For years, I struggled with anxiety and sleep issues, trying countless medications with limited success. Dr. Caplan’s personalized approach was a breath of fresh air. He didn’t just focus on my symptoms; he wanted to understand how my lifestyle and goals factored into the equation. His guidance helped me find a regimen that not only improved my sleep but also reduced my daily stress. The best part? He checked in after a few weeks to make sure everything was working smoothly. I’ve never felt so cared for by a doctor.”

Emily P

Emily Parker

A Senior’s New Hope

“As a senior struggling with arthritis, I was skeptical about cannabis therapy. But Dr. Caplan changed my perspective completely. His extensive knowledge, combined with a genuine compassion for his patients, made my first visit feel like a turning point. He introduced me to options that were gentle and easy to integrate into my daily life. What surprised me most was how much he emphasized education—his book became a valuable resource for me and my family to better understand how cannabis could help. If you’re new to this world, Dr. Caplan is the expert you can trust to guide you with care and patience.”

Lucas H

Lucas Howard

Skeptic to Believer

“I had given up on finding relief for my chronic pain until I met Dr. Caplan. His calm, reassuring demeanor put me at ease from the moment we sat down. He not only prescribed a cannabis regimen tailored to my needs but also took the time to address my fears about stigma and side effects. What made the experience even better was how he explained things—breaking down complex science into simple, relatable examples. I now feel in control of my health for the first time in years. If you’re hesitant about exploring cannabis as an option, Dr. Caplan’s patient-centered care will make all the difference.”

Chloe M

Chloe Martinez

Revolutionizing My Care

“Dr. Caplan’s approach to cannabis therapy is revolutionary. I had been to other clinics where the process felt rushed and impersonal, but my experience with him was the exact opposite. He asked thoughtful questions, delved into my medical history, and crafted a tailored plan to address my specific symptoms. What stood out the most was his ability to connect my condition to real-world cannabis applications, referencing research and patient success stories that inspired confidence. His clinic also provides resources beyond the appointment—like follow-ups and his book—which made me feel supported every step of the way. For anyone seeking a truly personalized and informed approach to medical cannabis, I can’t recommend Dr. Caplan enough.”

Ethan K

Ethan Keller

Trust Built Through Understanding

“Trust is not something I give easily when it comes to my healthcare, but Dr. Caplan earned it during our first appointment. He listened carefully to my concerns and explained the science behind medical cannabis in a way that was clear and accessible. He didn’t just focus on the benefits; he also made sure I understood potential challenges and how to navigate them. That kind of transparency and care is rare, and it’s the reason I feel confident in the treatment plan we developed together.”

Emily C

Emily Carsonally

Personalized Care That Stands Out

“Every aspect of my experience with Dr. Caplan reflected his commitment to personalized care. He took the time to ask about my lifestyle, my goals, and even my hesitations about using medical cannabis. His thoughtful questions and detailed explanations made it clear that he was focused on creating a plan that would work for me specifically. I also appreciated how he checked in with me after the visit to see how I was doing—a small gesture that made a big difference in my confidence and comfort moving forward.”

Olivia H

Olivia Robers-Harrison

Educational and Empowering

“Dr. Caplan doesn’t just prescribe cannabis—he educates you about it, so you feel confident and in control of your treatment. From our first appointment, it was clear that he cared about making sure I understood all my options. He referenced research, shared stories from other patients, and even recommended chapters from his book that were particularly relevant to my situation. By the end of the visit, I felt not only more informed but also more empowered to make decisions about my health. That kind of care is rare, and I’m grateful for it.”

Benjamin R

Benjamin Rochel

Clear Guidance Every Step of the Way

“What struck me most about Dr. Caplan was his ability to provide clear and actionable guidance. I had no prior experience with medical cannabis and was overwhelmed by all the information out there, but he made it manageable. He walked me through the options, explained the potential benefits and risks, and helped me navigate decisions in a way that felt completely tailored to my situation. His calm and thoughtful manner put me at ease, and I left the appointment feeling like I finally had a plan I could trust.”

Chloe M

Chloe Masterson

A Tailored and Thoughtful Plan

“Dr. Caplan approached my case with a level of care and detail I hadn’t experienced before. Instead of a one-size-fits-all recommendation, he tailored a plan based on my specific symptoms and preferences. He took the time to explain why certain options might work better for me and made sure I felt comfortable moving forward. His advice was practical and grounded in science, yet delivered in a way that felt approachable. I left feeling empowered, knowing I had the tools and knowledge to take the next steps with confidence.”

Ethan K

Ethan Kostenson

More Than Just a Weed Visit

“My first visit with Dr. Caplan felt like more than just a routine medical appointment—it was an opportunity to truly take charge of my health. He asked questions that no other doctor had asked and encouraged me to think about my goals for treatment in a way I hadn’t before. His book was an incredible resource, but what truly set him apart was his ability to make the information feel relevant to my unique situation. I felt supported not only as a patient but as a partner in my healthcare journey.”

Maria L

Maria Lolana

A Practical and Supportive Approach

“Dr. Caplan’s approach is refreshingly practical and supportive. During our consultation, he focused not just on recommending cannabis, but on helping me understand how to use it in a way that fit my lifestyle and goals. He walked me through options, shared insights from his book, and even helped me think through how to manage dosing and timing. What really impressed me was his focus on the long term—this wasn’t about a one-time solution but about creating sustainable improvements in my health. It’s rare to find a doctor who invests this level of thought and care into patient guidance.”

John W

John Waterson

Dr. Caplan’s Expertise and Patience

“I was initially unsure about whether medical cannabis was the right path for me, but Dr. Caplan quickly put my concerns to rest. He spent time understanding my medical history and current challenges, carefully explaining the science behind cannabis and how it could fit into my treatment plan. His depth of knowledge and ability to communicate complex concepts in simple terms stood out to me. I appreciated his patience, especially when I had a list of questions, all of which he addressed thoroughly. The care I received was thoughtful and personalized, and I left feeling confident in the steps we outlined together.”

-Sophia R

Sophia Rhiderson

A Lighthouse in the Storm

“When I first started exploring medical cannabis, I felt overwhelmed by conflicting advice online. Meeting Dr. Caplan was like finding a lighthouse in a storm. He didn’t just recommend a treatment plan; he broke down every step, explaining the science in plain terms so I could make informed decisions. His book, ‘The Doctor-Approved Cannabis Handbook,’ became my go-to guide between visits. It’s rare to find a doctor who takes so much time to ensure you feel educated and empowered. Now, not only am I managing my symptoms, but I feel like I truly understand my body better. If you’re looking for compassionate care and clear guidance, Dr. Caplan is the doctor you need.”

Sophia J

Sophia Jenkins

I Finally Got My Stress Under Control

I used to pride myself on being able to handle anything work threw at me. Long hours, tight deadlines, a demanding boss—it was all part of the game, and I thought I had it down. But somewhere along the way, the stress started to build up. Slowly at first, then all at once. I was losing sleep, snapping at my family, and my chest constantly felt tight. The smallest things would set me off, and no amount of weekends or ‘self-care’ could fix it. I didn’t recognize myself anymore.

My doctor had suggested anti-anxiety meds, but I didn’t want to go that route. I kept thinking, there’s got to be another way. A friend mentioned cannabis, and I’ll admit, I laughed at first. Cannabis? For work stress? I thought it was a joke. But after another sleepless week and two missed deadlines, I was willing to try anything. That’s when I found CED Clinic and Dr Caplan.

I wasn’t sure what to expect going in, but Dr. Caplan made me feel comfortable right away. He listened—not just to what I was saying, but to what I wasn’t saying, if that makes sense. He didn’t treat me like a case file or just another patient. We talked about the stress, sure, but also about why I’d been so hesitant to ask for help. He suggested a low-dose CBD regimen to help me unwind without feeling ‘off,’ and explained that it wasn’t about numbing out—it was about finding balance again.

It took a few weeks before I really started noticing a difference. At first, I wasn’t sure if it was doing anything, but then I realized I wasn’t lying awake at night, going over work problems in my head. I wasn’t clenching my jaw every time I opened an email. The stress didn’t go away, but I wasn’t drowning in it anymore. I felt like I could handle things again, like the weight had been lifted just enough for me to breathe.

Now, I can get through my workday without feeling like I’m on the verge of a meltdown. I’m more present with my family, more patient. It’s not perfect, and work is still stressful, but it doesn’t own me anymore. I can’t say enough about what Dr. Caplan did for me. I was lost, and he helped me find my way back.”*

– Jason B

J Bennett

Our Son Found Calm, and So Did We

Our son has always been… difficult, to put it lightly. He’s smart, no doubt about that, but for as long as I can remember, we’ve struggled with his defiance. It was like every day was a battle—he’d talk back, refuse to listen, and disrupt everything at home and at school. We’d get calls from his teachers constantly about how he couldn’t sit still or follow directions. He was failing classes, not because he didn’t understand the material, but because he just refused to engage. I started to feel like we were losing control, not just of him, but of our family. It was exhausting. We tried everything—therapy, behavior charts, punishments, rewards—but nothing seemed to get through to him.

When someone suggested we look into cannabis, I’ll admit, I was pretty skeptical. The idea of giving our son cannabis? It felt like too much. But at the same time, I felt like we were running out of options. I mean, we couldn’t keep going the way we were. So, I did some research and found Dr. Caplan. I didn’t really know what to expect, but I figured it was worth at least hearing what he had to say. When we met with him, Dr. Caplan was so calm, so understanding. He didn’t make us feel like we were bad parents, which, honestly, was a huge relief. We’d been feeling like failures for a long time. He explained that cannabis, in the right doses, might help our son relax, become more receptive, and just… chill out.

At first, I wasn’t sure. But we decided to give it a shot because we needed something to change. I remember the first few weeks—we were waiting for a miracle that didn’t come right away. But slowly, things started to shift. He wasn’t perfect, and I didn’t expect him to be, but we started seeing moments of calm, of compliance. He’d sit down and actually listen when we talked to him. His teachers noticed, too. The calls home weren’t as frequent, and when they did call, it wasn’t about him disrupting the class, but little moments where he was making an effort. He wasn’t fighting us over every single thing anymore. He even started being more responsible around the house—little things like cleaning up after himself, finishing homework without a meltdown.

It wasn’t an overnight transformation, but it was enough to make us believe that maybe—just maybe—things could get better. And they have. Our son is still a work in progress, but aren’t we all? He’s more in control now, more aware of his actions. I can’t tell you what a relief it is to have peace in our home again, even if it’s not perfect all the time. We can breathe. We can plan things without the constant fear of a blow-up. Dr. Caplan gave us the space to feel like parents again, instead of just referees in constant battles.

– Heather R.

Heather R

Finally Found Relief from Menopause

Menopause hit me like a freight train. One minute I was fine, and the next, I was drowning in hot flashes, mood swings, sleepless nights, and constant irritability. It felt like I couldn’t get through the day without snapping at someone or dripping in sweat. The worst part was the lack of sleep—I’d toss and turn all night, then drag myself through the day feeling exhausted. It was like I had no control over my own body, and everything just felt harder. I tried the usual over-the-counter remedies and even considered hormone replacement therapy, but I didn’t like the risks. Honestly, I was starting to lose hope.

A friend of mine, who had been seeing Dr. Caplan for her own health issues, suggested I give him a try. I wasn’t sure at first. Cannabis for menopause? It seemed a little out there. But after trying everything else and getting nowhere, I figured I had nothing to lose. From the moment I met with Dr. Caplan, I knew I was in the right place. He listened to all my complaints without judgment—he understood how tough it was. He didn’t just hand me a one-size-fits-all solution either. Instead, he explained how cannabis could help balance out my mood swings, improve my sleep, and even ease the intensity of the hot flashes. He was thorough, but he kept it simple, so I didn’t feel overwhelmed.

Within a few weeks of starting on a low-dose regimen, I noticed a real change. The hot flashes were still there, but they weren’t as intense, and I wasn’t waking up drenched in sweat every night. My mood swings started to even out too. I wasn’t losing my temper over every little thing, and I was able to get through the day without feeling like I was on edge all the time. Most importantly, I started sleeping again. I’m not talking about perfect, uninterrupted sleep, but I was actually getting solid rest and waking up feeling more human. My irritability softened as my body felt more balanced.

I can’t say enough good things about Dr. Caplan and the care he’s given me. Menopause doesn’t feel like it’s running my life anymore. I have a handle on it now, and I feel like myself again. Cannabis wasn’t something I ever thought I’d turn to, but I’m so glad I did. Dr. Caplan gave me back my peace of mind, and for that, I’ll be forever grateful.

– Lisa M.

Lisa Montingerie

Cannabis Gave Us Our Family Back

“We live in California. Our son has severe autism, OCD, and behavioral issues that have ruled our lives for as long as I can remember. He struggles with communication, and when things don’t go as expected, the meltdowns are explosive. There are days when he self-injures so severely that I can’t leave him alone for a second. The screams, the head-banging, the constant pacing—it’s heartbreaking and terrifying. My husband and I have felt like prisoners in our own home. We can’t go shopping, we can’t take vacations, we can’t even break from the daily routine without risking an episode that could throw him into a spiral for weeks. We’ve tried every therapy, every medication. Nothing seemed to give him—or us—a moment of peace. It was draining every ounce of energy and hope we had left.

When someone first suggested cannabis to us, I was hesitant, scared even. I didn’t know how it would affect him. I see potheads and druggies everywhere these days in my area, and it does not look appealing. Would it help, or make things worse? But we were desperate, and a friend had read The Cannabis Handbook and suggested that we reach out, so we decided to see Dr. Caplan. I’ll never forget that first meeting. He listened—really listened—to the hell we’ve been living through, and for the first time in a long time, I felt like someone understood. His questions made it clear that he’s been through this with many others. He seemed to get our struggle like no doctor I’ve ever encountered. He wasn’t dismissive, and he cetainly didn’t make us feel crazy for trying something new – the way all of my other doctors do. He explained how cannabis could help with the anxiety, the OCD, and even the self-injury, in a way that was calm and controlled, without overwhelming us. Our son came on camera with a tantrum, and Dr Caplan was as patient and attentive, supportive, as I wish docs all were. Dr. Caplan carefully walked us through everything, never pushing, always respecting our concerns. His focus is so clearly empowering us, not tripping on himself or being on high.

We started our son on small doses of a few products, and I won’t lie, it wasn’t a quick, overnight change. But over time, with adjustments that he oversaw with us, we saw it—he started to calm down. The meltdowns weren’t as frequent, and when they did happen, they didn’t last as long or get as intense. The self-injury started to lessen. It felt like we could breathe again, like we had a little more room to live. We’re still careful—routine is still important—but the constant terror of something going wrong isn’t hanging over our heads as much. For the first time in years, my husband and I were able to go out for dinner. It sounds like such a small thing, but it was a moment where we could remember what life used to be like, before we became prisoners to our son’s condition.

I can’t say that cannabis has fixed everything, but it’s given us something we didn’t have before: hope. We’re seeing glimpses of who our son is underneath the anxiety and the behavioral issues. Dr. Caplan’s patience and understanding have been a lifeline for us. He gave us a way to manage our lives again. We’re still on this journey, but for the first time, it feels like there’s light at the end of the tunnel.”

– Sarah W.

Sarah W

Finding Comfort and Connection Again

“Loneliness had been creeping up on me for years, but it really hit hard when I retired. My social circle started shrinking, and the days just felt longer and emptier. I had been keeping busy with hobbies, but the silence in my house became unbearable. I’d wake up in the morning with no motivation to get out of bed because I didn’t have anyone to talk to, nowhere I really needed to be. I tried to reach out to old friends, but it always felt awkward, like I didn’t fit into their lives anymore. My primary doctor referred me to Dr. Caplan, not because of anything physical, but because they thought cannabis might help me with the emotional side of things. I was pretty skeptical. Cannabis? For loneliness? I didn’t see how it could possibly make me feel less isolated.

When I met with Dr. Caplan, he listened without judgment. I explained how I felt like I was drifting through my days, disconnected from everyone around me. He was calm and compassionate, and he didn’t rush me at all. Instead of dismissing my feelings, he talked me through how cannabis might help me not feel so ‘stuck’ in my emotions. We started with a low-dose regimen that focused on CBD to help with the feelings of overwhelm and helplessness. It wasn’t a quick fix, but after a few weeks, I noticed I felt lighter, more at ease. I found it easier to pick up the phone and call an old friend, easier to motivate myself to go out for a walk or run errands.

It’s hard to explain, but it felt like a weight had lifted off my chest. The loneliness was still there, but it didn’t feel so suffocating. I could breathe again, could start imagining a life where I wasn’t so isolated. Over time, I’ve been able to reconnect with people, even make new friends. Cannabis didn’t solve everything, but it gave me the space I needed to start living again. Dr. Caplan was there every step of the way, adjusting the treatment as we went and always making sure I was comfortable. I never thought something like this could help with how I was feeling, but I’m so glad I gave it a chance.”*

– Tom B.

Tom B

Does Cannabis Work for Pediatric Autism? Yes!

“I wanted to take a moment to share a heartfelt message we recently received from one of Dr. Caplan’s patients. It’s moments like these that remind us why we’re so passionate about the work we do. The incredible progress described below is a testament to the power of personalized care and cannabis therapy. We’re grateful to witness such transformations and hope this story provides inspiration for others seeking hope and relief.”

Jack Thompson, CED Clinic Operations Manager

 

For anyone interested in seeing Dr. Caplan as a consulting physician, please visit this link:Book an Appointment to complete our intake form, make a payment, and schedule your visit—all in one easy step.

Screenshot 2025 12 07 at 3.22.20 PM

 

 

 

 

A heartfelt email from a patient expressing gratitude to Dr. Caplan for recommending a CBD/THC tincture that significantly improved their son’s behavior and well-being, detailing the progress in areas such as sleep, car rides, and eating habits.
Jack Thompson

Managing Anxiety with Cannabis: A Personal Story of Relief

“I heard about Dr. Caplan through a friend who had been his patient for a couple of years. I had been struggling with anxiety for a while but didn’t think cannabis was something I could handle. The stigma around it made me nervous, and I wasn’t sure it was for me. But my friend couldn’t stop raving about the difference Dr. Caplan had made in her life, so I finally decided to check him out. From the moment I sat down with him, I knew I was in good hands. He took the time to understand my situation, explaining how cannabis could be used to manage anxiety in a safe, controlled way. It wasn’t about pushing a product—it was about finding the right balance for my body and my needs. Now, I feel more in control of my anxiety than I have in years, and I’m grateful for Dr. Caplan’s thoughtful and thorough care.”

– Maria S.

Maria Sintira

Finally Found Relief for My Back Pain

“I was at my wit’s end with my lower back pain, and nothing seemed to work—painkillers, physical therapy, injections—you name it. My orthopedist mentioned Dr. Caplan, and honestly, I wasn’t sure about the whole cannabis thing. I mean, I wasn’t against it, but I didn’t think it was for me. Still, I was desperate, so I made the call. Dr. Caplan wasn’t like any other doctor I’d met. He really took the time to get to know me, my history, and my concerns about cannabis. He didn’t push anything but explained how it could help manage pain and inflammation in a way I could understand. He helped me feel like this was something worth trying, not some weird ‘last resort.’ Fast forward six months, and I’m moving around a lot better than I have in years. I never thought I’d say it, but cannabis has made a huge difference in my life. Dr. Caplan’s been there for every step, making sure I get the right balance for what I need.”

– Mike T.

Michael Tertansky

From Total Skeptic to Success: How Cannabis Helped My Skin Condition

“I came to CED Clinic on the recommendation of my dermatologist after battling severe eczema for most of my life. I’d tried everything from steroid creams to light therapy, but nothing seemed to keep the flare-ups at bay for long. The idea of using cannabis for my skin condition seemed strange at first, and I was pretty skeptical. It wasn’t something my friends or family had ever talked about, and I wasn’t sure how it could really help. But my dermatologist convinced me to at least have a conversation, and I’m so glad I did. Dr. Caplan didn’t make me feel awkward or silly for being uncertain. Instead, he walked me through how cannabis could potentially reduce inflammation and improve my skin health. A few months into the treatment plan, and my skin has never looked better. I wish I had come to him sooner.”

– Lindsey P.

Lindsey Peterson

Cannabis Helped Me Feel Less Alone

“I’ve been dealing with loneliness for years. After my kids moved out and my spouse passed away, the days just felt so empty. I tried therapy and even medication, but nothing really touched the feeling of being alone. A friend mentioned Dr. Caplan and how cannabis had helped her with anxiety, but I wasn’t sure if it could help with loneliness. It felt strange to think about cannabis as an option for something like that. Still, I figured it was worth a shot. Dr. Caplan was kind and understanding right from the start. He didn’t make me feel silly for bringing up something as hard to explain as loneliness. He explained how cannabis might help ease the constant heaviness I was feeling, not by curing loneliness but by helping me feel more connected to myself and the world around me. We started slow, and over time, I noticed a shift. The emptiness didn’t go away, but it didn’t feel so overwhelming anymore. I started going out more, seeing friends again, and just feeling a little lighter. I’m still working through it, but cannabis—along with Dr. Caplan’s care—has made it easier to handle.”

– Susan R.

Susan Ringly

Overcoming Arthritis Pain: My Journey to Relief at CED Clinic

“I was referred to Dr. Caplan by my podiatrist, who suggested I look into cannabis after dealing with arthritis in my feet for years. Honestly, I was hesitant. I’d never been a fan of the idea of using cannabis—it seemed like a last resort. But after cycling through endless medications with little success, I was willing to try something new. From the first consultation, Dr. Caplan made me feel completely at ease. He spent time learning about my history and concerns, and he carefully explained the options in a way that was easy to understand. He wasn’t just throwing solutions at me—he was building a plan around my life. I’ve been on the regimen we discussed for about four months now, and the improvement is undeniable. It’s not just the relief, but the care and commitment Dr. Caplan shows that keeps me confident in the process.”

– Robert H.

Robert Hickenlooper

I Overcame Insomnia with Dr. Caplan’s Help.

“I was referred to Dr. Caplan by my PCP after months of struggling with severe insomnia. For years, I had relied on prescription sleep aids, but over time, they stopped working, and the side effects were unbearable. I had heard about cannabis being used for sleep, but I wasn’t convinced it would work for me. The idea of using cannabis made me nervous—I had no experience with it and didn’t want to feel ‘high.’ But my doctor insisted that I give Dr. Caplan a try, so I booked an appointment. From the very first meeting, Dr. Caplan took the time to understand my fears and hesitations. He didn’t push anything on me but explained how cannabis, especially CBD, could help regulate my sleep cycle without the psychoactive effects I was worried about. His calm, knowledgeable approach reassured me, and we crafted a plan that I felt comfortable with. After just a few weeks on the treatment, I started sleeping better than I had in years. It wasn’t an overnight solution, but Dr. Caplan was with me every step of the way, adjusting the plan as needed. I’ve regained the energy I thought I had lost forever, and for that, I’m incredibly grateful.”

– Rachel S.

Rachel Samuelson

Finding Hope After Chronic Migraines: Dr. Caplan Helped Me See Cannabis

“I found Dr. Caplan after reading The Doctor-Approved Cannabis Handbook. I had been suffering from chronic migraines for years, but the idea of using cannabis never crossed my mind. To be honest, I had a lot of doubts—would it work? Would it make me feel ‘off’? But the book opened my eyes to the science behind it, and I decided it was time to explore other options. When I reached out to Dr. Caplan, I was still on the fence, but he took the time to listen, explain, and answer every question I had. He didn’t push anything on me, but instead guided me through the possibilities. Fast forward six months, and I’ve seen such a huge improvement in my quality of life. Dr. Caplan’s approach is professional, but also deeply personal. It’s clear he cares about getting things right for each patient.”

– Jessica M.

Jessica Montrouse

No More Painful Periods

“I’ve had awful period cramps for as long as I can remember, and nothing ever worked to ease the pain. My gynecologist suggested Dr. Caplan, but I wasn’t sure about using cannabis for menstrual pain—it seemed kind of odd to me. Still, I was tired of being in pain every month, so I decided to at least talk to him. Dr. Caplan was great—he explained how cannabis could help with cramps and inflammation and answered all my questions without making me feel rushed. He worked with me to figure out a plan that I was comfortable with, and within a few cycles, I started noticing a big difference. The pain isn’t completely gone, but it’s so much more manageable now. I don’t dread that time of the month anymore. I’m so glad I gave it a try—Dr. Caplan’s made this whole process easier than I expected.”

– Emily K.

Emily Kingston

Trustworthy & Easy

From the moment I first connected with Dr. Caplan on a telemedicine visit, I felt an immediate sense of relief. I had been struggling with anxiety for years, and previous doctors had only offered quick fixes that never addressed the root of the problem. Dr. Caplan took the time to understand my history, my triggers, and my lifestyle. The discussion was open and flowed easily and  to me, clearly shows that he actually cares. During our consultation, he explained the complex medical stuff in a way that made sense to me, and made sure I felt informed and empowered every step of the way. When I had a panic attack late one night, I emailed him in desperation, and to my surprise, he responded almost immediately with calming words and practical advice. His personalized follow-up call the next day was the reassurance I needed to stay on track. Dr. Caplan’s unwavering commitment and compassionate care have truly transformed my life.

— Michael Anderson

Michael Anderson

My anxiety is manageable!

Dr. Caplan’s thoughtful approach turned my anxiety into a manageable journey, offering not just treatment but a renewed sense of hope and understanding.

– S Christianson

Sandra Christianson

I’m a whole person. And I’m complicated.

“I found Dr Caplan after reading his book, The Doctor-Approved Cannabis Handbook. Dr. Caplan doesn’t just treat symptoms—he treats the whole person. From my very first appointment, he made sure I understood every part of my treatment plan, and I left feeling hopeful for the first time in years. His book has been a helpful resource, but it’s his personal touch and thoughtful care that really sets him apart. I’ve never felt rushed or like just another patient in a long line. Instead, I feel truly heard.”

– Sarah W.

Sarah W

My Son Was Right About Cannabis

“Funny enough, my teenage son was the one who pushed me to see Dr. Caplan. I’ve had a stressful job for years, and it’s been taking a toll on my health. My son did a project on cannabis for school and said I should check it out for stress. I was pretty hesitant—I mean, cannabis? It wasn’t something I ever thought I’d try. But after hearing my son talk about it for weeks, I figured, why not? I went to Dr. Caplan with a lot of questions, and he took the time to answer every one of them. He explained how I didn’t have to get ‘high’ to use cannabis for stress and that it could help me feel calmer without messing with my head. He started me on a low-dose CBD plan, and within a couple of weeks, I started noticing a difference. I was less anxious at work, more patient with my family, and just felt more balanced. Honestly, I owe my son for nudging me, but I’m grateful to Dr. Caplan for helping me find a solution that really works.”

– Janet W.

Janet Wishingsly

From Sleepless Nights to Peaceful Mornings

“I was dealing with sleepless nights for months—maybe even years—when my primary care doctor suggested I check out Dr. Caplan. I’d been on sleeping pills for ages, but they stopped working, and I was left exhausted all the time. The idea of using cannabis for sleep honestly sounded weird to me. I didn’t know much about it, and I figured it would just make me feel groggy or out of it. But I was tired of being tired, so I made the appointment. Dr. Caplan really gets it—he wasn’t pushy at all. He explained how CBD could help me without the ‘high’ I was worried about, and he was super patient with all my questions. Within a couple of weeks, I was actually sleeping through the night. It’s not an overnight fix, but it’s the best sleep I’ve had in years. I wake up feeling refreshed instead of like a zombie. Dr. Caplan’s follow-ups have been a game-changer too—he checks in to make sure everything’s working. It feels good to have a doctor who cares.”

– Laura B.

Laura Bonintue

Genuine care and great medical advice

Dr. Caplan’s genuine care and commitment are evident in every interaction. At CED Clinic, I received more than just medical advice; I gained a trusted advisor in my health journey. His use of personalized treatment plans and educational resources helped me understand and manage my condition better than ever before.
– Michael T.

Michael T

Awesome experience!

I never felt like just another patient at CED Clinic; Dr. Caplan made sure of that. His thorough understanding of my health needs, paired with his deep knowledge of cannabis therapy, provided a tailored experience that truly catered to my well-being. Every visit felt like a step forward in my journey dealing with sleeplessness, stress, and PTSD.
– Denise H.

 

Denise H

Happy customer!

My visit to CED Clinic was absolutely amazing, and it all started with Kim. She was so friendly and helpful right from the get-go, making the whole scheduling thing a breeze – a real breath of fresh air! Then there was Dr. Caplan. Honestly, chatting with him felt more like catching up with an old friend than a typical doctor’s visit. He didn’t seem to be watching the clock at all; he was all in, really getting to grips with what I’ve been going through, and dishing out advice that hit the nail on the head. And get this – he’s even written a book about it all! I can’t wait to get my hands on a copy. The whole experience at CED Clinic was just so warm and genuine. They’ve got something special going on over there, for sure.

Amanda Kimmel

I’m Free: My Journey Beyond Chronic Pain!

I felt trapped in a cycle of chronic pain, where prescription and over-the-counter meds were just dead ends. Then I found Dr. Caplan. His blend of medical expertise and cannabis knowledge opened a door I didn’t know existed. I read ‘The Doctor-Approved Cannabis Handbook’ and it was/is a turning point—packed with research and actionable advice, it guided me to a pain management plan that actually worked. Thanks to Dr. Caplan, I’m living with less pain and more hope. Highly recommend for anyone stuck in the pain cycle.

Emily Brasston

From Frayed Edges to Balance: Found My Center with Cannabis

Let me paint you a picture of my life not too long ago: a job that never hit ‘pause,’ kids that always needed me in a hundred different ways, and a level of work stress that had me teetering on the edge. I was juggling more plates than I had hands for, and it felt like I was one strong breeze away from watching them all come crashing down. Sleep was a luxury I couldn’t afford, and ‘me time’ was a concept so foreign it might as well have been from another planet.

Enter Dr. Benjamin Caplan and his life-altering approach to managing stress through cannabis medicine. At first, I was skeptical—could this really be the answer I’d been searching for? But from the moment we began, it was clear Dr. Caplan wasn’t just any doctor. His blend of traditional medical insight and innovative cannabis expertise was like a breath of fresh air.

What truly transformed my journey, though, was diving into ‘The Doctor-Approved Cannabis Handbook.’ This wasn’t just another self-help book; it was a treasure trove of evidence-based research, clinical wisdom, and, most importantly, actionable advice that felt like it was written just for me. It became my North Star, guiding me through the haze of stress and sleepless nights to a place of understanding and balance.

Thanks to the personalized strategy Dr. Caplan crafted with me, I’ve been able to reclaim control over my stress and find a sense of equilibrium I didn’t think was possible. My work no longer feels like a constant battle, and I’ve found more joy and presence in the time I spend with my kids. The difference is night and day.

I’m beyond grateful to Dr. Caplan and the invaluable lessons from his handbook. For anyone feeling overwhelmed by the demands of work, family, and everything in between, Dr. Caplan’s compassionate, evidence-based approach might just be the lifeline you need. I can’t recommend him enough.

Sam Dexter

My Journey to Conquering Chronic Insomnia with Dr. Caplan and Cannabis Medicine

I’ve been in this battle with chronic insomnia for what feels like forever. I hit a point where I felt completely out of options. I mean, you name it, I tried it—all those over-the-counter fixes, prescriptions from my doctors, and I even got creative mixing up my own cannabinoid solutions. But nothing worked. Those endless nights of tossing and turning weren’t just annoying; they were wrecking my health and my spirits.

Then, almost out of nowhere, I stumbled upon Dr. Benjamin Caplan and his work in the world of cannabis medicine. From the moment we started talking, I knew this was different. He’s got this unique blend of traditional medical wisdom and cutting-edge cannabis knowledge. It’s like he sees the whole picture in a way no one else had shown me before.

But here’s the real game-changer: “The Doctor-Approved Cannabis Handbook.” That book blew my mind. It’s packed with solid science and real-deal clinical insights on how cannabis can tackle not just insomnia but a whole list of issues. More than that, it gave me straightforward, practical steps tailored just for me. It turned into my guide on this journey to use cannabis safely and super effectively.

I owe so much to Dr. Caplan and the wisdom packed into that book. I’ve finally found some peace from my insomnia—a relief I thought was off the table for me. My sleep’s way better, and my days? They’ve transformed. I can’t thank Dr. Caplan enough. And seriously, if you’re hitting a wall with insomnia or any health problem that just won’t budge with the usual treatments, Dr. Caplan’s approach could be the breakthrough you’re looking for. Certainly was for me.

 

My Journey to Conquering Chronic Insomnia with Dr. Caplan and Cannabis Medicine

Hashimoto’s Disease and Cannabis: How I Found the Right Balance with Dr. Caplan’s Help

“My endocrinologist recommended Dr. Caplan after I’d been diagnosed with Hashimoto’s disease. I was dealing with a range of symptoms—fatigue, joint pain, brain fog—but I was really hesitant to try cannabis. I didn’t have any experience with it and was worried about how it might affect me. Still, after years of feeling like nothing was really working, I was ready to explore new options. Dr. Caplan’s approach made all the difference. He took the time to understand not only my medical history but also my reservations. He patiently explained how cannabis could help with my symptoms without overwhelming me. It wasn’t an instant fix, but over the months, I started noticing real improvements. What sets Dr. Caplan apart is how much he truly listens and adapts the treatment plan to my needs. I’ve never felt more supported by a doctor.”

– Megan L.

Megan Lincoln

A Lifeline in Chronic Pain: Cannabis Changed My Life

“I was referred to Dr. Caplan by my orthopedist after years of dealing with debilitating lower back pain. I had been through physical therapy, painkillers, and injections, but nothing offered lasting relief. Honestly, I was skeptical about trying cannabis. I had always associated it with recreational use and didn’t see how it could be a solution for chronic pain. But after my orthopedist explained the potential benefits and encouraged me to meet with Dr. Caplan, I decided to give it a chance. From the moment I walked into Dr. Caplan’s office, I felt like he was different from any doctor I’d seen before. He listened carefully to my history and my concerns, and instead of pushing cannabis on me, he educated me on the science behind it. He explained how it could help reduce inflammation and manage pain without the foggy side effects I was used to with traditional medications. Now, after six months of working with Dr. Caplan, my pain is more manageable than I ever thought possible. I’m not saying it’s a magic cure, but for the first time in years, I feel like I have control over my life again. His compassion and expertise have been a lifeline for me.”

– David P.

David Pelonsky

Used as a Human Target as a Kid, Medical Cannabis is the answer.

I’m totally blind. I live in a rural area. So when I was 12, same-age peers thought zapping the blind girl’s eyes with laser pointers would be a great idea. It got bad enough that my paraprofessional had to have the devices banned from the school for my safety. Shortly after, I began having intense eye aches. I differentiate them from headaches because even a 12 year old can tell the difference. Doctors told my parents and I they were migraines. It wasn’t until later in life that I began realizing there was something else going on here. Really studying migraines, studying the eye, studying neurology and understanding not all was as it seemed. I began developing my own theories as to what these “migraines” were. I take migraine meds, but they don’t treat the eye aches. They treat the other migraine symptoms just fine. My younger brother suggested I try edibles last year. Because by this point, I was in enough pain where I believed I’d have to have my eyes removed. None of us wanted to see that happen. So he took me to a dispensary, (he had spoken with someone he knew there about me prior, and they’d come up with a regimen they thought would work.) The first clue I had that we were on the right track, was that I slept for 14 hours. So I kept a calendar and a spreadsheet full of virtual sticky notes, and 2 weeks later came to Dr. Caplan for my medical card, crazy theories about optic neuropathy in underdeveloped optic nerves and all. A year later, I’m studying cybersecurity, because that’s something I found I’m passionate about, and I can do it now!

Krista Pennell

To sleep well again is life-changing

Dr. Caplan was coincidentally recommended by both my dentist and a close friend. I was concerned about finding a high level, knowledgeable, physician in a professional setting who understood using cannabis in a safe and effective manner. I can’t recommend Dr. Caplan more highly. His knowledge is vast and I am grateful for his expertise, care and compassion. To sleep well again is life-changing. Very few things literally change someone’s life. Dr. Caplan’s knowledge and guidance on cannabis did that for me.

Barbara M.

Not once did I feel rushed or embarrassed, in fact I felt like he really does care about my circumstances, and wanted for me to feel confident and prepared

Honestly, I was hesitant to try cannabis. I have debilitating menstrual cramps and my OB/GYN recommended Dr. Caplan. I was more than a little hesitant to try cannibas because all I really knew about it was that people used it to get “high” – and that was not something I was interested in. This perspective totally changed when I actually came in and met with Dr. Caplan. He was incredibly understanding and really took the time to ease my mind about the whole process, what kind of options there were to choose from, what they might do, and what would probably appeal to me. He spent a lot of time answering all my questions (and I had a lot!). Not once did I feel rushed or embarrassed, in fact I felt like he really does care about my circumstances, and wanted for me to feel confident and prepared.

Mark L.

Dr. Caplan was thorough in his evaluation and friendly and accessible in his approach

Dr. Caplan was thorough in his evaluation and friendly and accessible in his approach. He provided in depth information and step by step guidance for beginning the process of utilizing cannabis therapies. He is available to his patients by email and phone. I highly recommend an appointment with him if you are even remotely considering medicinal use. I was hesitant about this approach before my appointment but now, after talking with Dr. Caplan and learning a little bit more about the science, I am eager to explore and I feel better already!

Rachel M.

I saw Dr Caplan a few months ago, and from even before I met him, he has made himself available to me over email, for questions, more than even my regular doctor

I came into marijuana medicine with zero experience. I must say, I’ve been learning a ton, and I would recommend it to anyone with terrible anxiety and depression. I saw Dr Caplan a few months ago, and from even before I met him, he has made himself available to me over email, for questions, more than even my regular doctor. A friend told me that I should see Dr Caplan, but I was still unsure about becoming a medical marijuana patient. I called and was able to speak with Dr Caplan directly. He took time, on the phone, even before he had met me, to explain the whole process, which helped me feel more comfortable putting a voice and personality to the process. Later, when I finally came in, during the visit, he spent almost 40 minutes with me, walking me through how cannabis might fit in with some of the other treatments I currently use. We have kept in touch over email since, like 3 or 4 random questions, and has always responded promptly. I think he is a truly special doctor, and from what I’ve read on Twitter, has a passion for educating and helping improve the perception of cannabis.

Alan T.

I had an enjoyable visit with clear information and education about medical marijuana and the dispensaries

Full stars. I appreciate the great parking and simple scheduling system. I had an enjoyable visit with clear information and education about medical marijuana and the dispensaries. No fancy language, no time wasted. Works for me.

Michael J.

I am a survivor of breast, uterine, and ovarian cancers, and Dr Caplan of CED Clinic is, hands down, the favorite voice of support and cannabis education for our hospital list-serv care group

I am a survivor of breast, uterine, and ovarian cancers, and Dr Caplan of CED Clinic is, hands down, the favorite voice of support and cannabis education for our hospital list-serv care group. I have seen him speak publicly, and on TV, and of course he is also my doctor. In spite of having what seems to be a crowd of patients who are mostly in terrible pain or have a generous helping of emotional/mental issues, I see him work tirelessly for his patients and for the cause, in general. I appreciate his leadership in the cannabis field. He is one in a million.

Stephanie W.

Dr. Caplan is an extremely knowledgeable doctor in his field and very easy to speak with about any questions and concerns you may have

Dr. Caplan is an extremely knowledgeable doctor in his field and very easy to speak with about any questions and concerns you may have. As a person that suffers from anxiety, upon arriving at the office I felt welcomed and relaxed because the doctor is compassionate and kind. The office atmosphere is not what I expected at all and was very peaceful and relaxing, also there were snacks and beverages which I have never seen before in a doctor’s office. I would highly recommend Dr. Caplan because he will take the time to answer every question that you may have about treatment. I made an appointment on a Saturday and was seen right away on the same day! Very easy process and very responsive. I am happy I chose Dr. Caplan!

Joshua C.

This is our second visit to Dr. Caplan in a year, and on both occasions, we were just blown away by his caring and compassion

This is our second visit to Dr. Caplan in a year, and on both occasions, we were just blown away by his caring and compassion. He is a true healer, with a great heart, enormous patience, and extraordinary expertise. My wife and I were amazed to find a physician who truly puts his patients first, and who is passionate about figuring out the best way to help us with our chronic pain. In our 60+ years of experience with health care providers, Dr. Caplan is among the most committed, generous, and caring healers we have ever met.

Heather F.

I can’t recommend Dr. Caplan highly enough

I can’t recommend Dr. Caplan highly enough. This was my third medical marijuana certification review (original plus two renewals), and the previous two doctors were just perfunctory form-fillers in shabby offices in remote office parks. Dr. Caplan is a REAL cannabis doctor who’s deeply knowledgeable about medical marijuana and clearly explains EXACTLY how to use it for YOUR specific conditions. He also has a real doctor’s office in a real medical building right on Boylston Street (Route 9) in Chestnut Hill ( not far from NETA Brookline, my dispensary of choice.) AND THE VISIT IS COVERED BY MEDICAL INSURANCE! I’ve become somewhat knowledgeable about what works for my primary complaint (chronic pain from spinal stenosis w/ radiculopathy) and what to avoid, but he gave me brand new ways to deal with my insomnia (including how and when to use edibles, which hadn’t worked for me before b/c I didn’t really know what I was doing) and arthritis in my hands (including a simple recipe to make topical lotion that’s stronger and cheaper than the commercial products). I interrupted him with frequent questions, which he answered at whatever level of detail and technical information I wanted. I had been deeply dissatisfied with the cannabis doctors I went to before, but Dr. Caplan is an outstanding DOCTOR who happens to specialize in medical marijuana because he cares about helping patients for whom traditional medicine hasn’t fully met their needs. You can book appointments on his web site, although my wait time was more than 10 minutes (during which I filled out his online patient questionnaire on my phone and ate all the Kit Kats in his candy basket), it was well worth it. This is a relatively new practice, I believe, and it’s going to get a lot busier as word spreads. But just do yourself a favor and go: this is what state-of-the-art medical marijuana care is supposed to be like.

Steve G.

Dr. Caplan patiently explained how there are so many options to chose from and exactly what each was helpful for

I recently had my first appointment with Dr. Caplan after reading negative reviews of so many other medical marijuana certification “places”. I can’t say enough good things about my visit with him. To start with he’s a very compassionate, caring doctor. I’m a 63 yr old woman and had never used marijuana or “street drugs”, so I was feeling nervous about trying it. I recently started chemo therapy at Dana-Farber and the side effects have been difficult to deal with. In particular, insomnia and a bit of evening anxiety. He is extremely knowledgeable about all aspects of medical marijuana. Dr. Caplan patiently explained how there are so many options to chose from and exactly what each was helpful for. With that said, he suggested several products for me to try. I now know what helps me, but each person has to use the information he gives and then try different products from a reputable medical dispensary. I plan to have a 2nd appt. with him in a few months just to get his feedback on my experiences and possibly more recommendations. It’s not necessary to go back to him after getting your certification, but he truly knows so much about the medicinal benefits that I’d like to learn even more. I highly recommend him.

Nancy O.

I would highly recommend Dr. Caplan because he will take the time to answer every question that you may have about treatment

Dr. Caplan is an extremely knowledgeable doctor in his field and very easy to speak with about any questions and concerns you may have. As a person that suffers from anxiety, upon arriving at the office I felt welcomed and relaxed because the doctor is compassionate and kind. The office atmosphere is not what I expected at all and was very peaceful and relaxing, also there were snacks and beverages which I have never seen before in a doctor’s office. I would highly recommend Dr. Caplan because he will take the time to answer every question that you may have about treatment. I made an appointment on a Saturday and was seen right away on the same day! Very easy process and very responsive. I am happy I chose Dr. Caplan!

Robert M.

Dr. Caplan is extremely patient and compassionate

Dr. Caplan is extremely patient and compassionate. He answered all of my questions and gave me a great deal of useful information (while emphasizing that I didn’t have to absorb all of it right away). He encouraged me to contact him with any more questions I might have after the appointment, and began the process of registering me immediately after I left. I had an email from the Commonwealth of MA before I got home, and completed the application online within a few minutes. It couldn’t have been an easier or more stress-free experience. Dr. Caplan truly believes in the effectiveness of cannabis as a medicinal tool, and is committed to making it more widely available for that purpose and in dispelling the ocean of ignorance that has unfortunately been created around it in our society. I can’t recommend him highly enough.

Justice S.

Excellent Experience, top to bottom

Excellent Experience, top to bottom. I scheduled my appointment on CED clinic website, got in the next day – and visit was informative, and doc was kind, compassionate, and amazingly knowledgeable. I intend to follow him as a permanent addition to my healthcare and would recommend widely.

Ellison M.

I’m shy but felt comfortable and supported

Awesome doctor. Super easy to talk to. I’m shy but felt comfortable and supported. Great teacher too. I had no idea there was so much to know!

Sara E.

I learned about different options and lots of choices, and received handouts to learn even more

First heard of Dr Caplan on /r/BostonTrees subreddit. Made my appointment online, for the next day, and did all paperwork online before I came in. Building is very professional and comfortable, with great parking, and close to where I live. As I expected, doc was kind, thorough, and efficient. We reviewed my medical history, talked about what I had been doing in the past, and discussed a host of treatment ideas, and not just marijuana. I learned about different options and lots of choices, and received handouts to learn even more. I plan to follow up in a few months, and I look forward to it.

Ryan H.

Every time I come in, I learn something new and amazing.

I followed Dr Caplan from his position as the Medical Director of Canna Care Docs to CED Clinic – and would follow him again. I have had years of back pain and arthritis – my wrists and knees and hips. Dr Caplan has helped me understand much more about marijuana, and I have to say, it has been a wonderful improvement for me. Every time I come in, I learn something new and amazing. It’s a new industry for me, and I feel very well supported.

Elizabeth P.

My visit with Dr. Caplan made it comforting to know that someone was on my side

My visit with Dr. Caplan made it comforting to know that someone was on my side. I was surprised to find that Dr. Caplan does more than just write scripts for people to take to dispensaries. He sees some of his patients on a regular basis to personalize treatment plans and it’s clear he cares about education and the destigmatization of medical cannabinoids. He goes to assisted living centers, medical expos, wellness centers, and more to speak with people on the matter. This is his passion!

Benjamin T.

Dr. Caplan is extremely patient and compassionate

Dr. Caplan is extremely patient and compassionate. He answered all of my questions and gave me a great deal of useful information (while emphasizing that I didnâ€t have to absorb all of it right away). He encouraged me to contact him with any more questions I might have after the appointment, and began the process of registering me immediately after I left. I had an email from the Commonwealth of MA before I got home, and completed the application online within a few minutes. It couldn’t have been an easier or more stress-free experience.†“— Dr. Caplan truly believes in the effectiveness of cannabis as a medicinal tool, and is committed to making it more widely available for that purpose and in dispelling the ocean of ignorance that has unfortunately been created around it in our society. I can€t recommend him highly enough.

Jeff E.

Very knowledgeable and compassionate

Very knowledgeable and compassionate.

Irene C.

I would highly recommend Dr. Caplan

I wasn’t sure what to expect from the initial appointment.  It was informative, educational and an overall great experience!  Dr. Caplan is easy-going, kind, and gave clear, detailed information about medical cannabis and MA medical dispensaries.  I would highly recommend Dr. Caplan.  His clinic and his knowledge are certainly worth 5-star reviews!

Ashley S.

I had such a good experience with Dr. Caplan of CED Clinic.  

I had such a good experience with Dr. Caplan of CED Clinic.

Medical: I had a lot of worries going in, and Dr. Caplan put me at ease with his knowledge and calm manner.  As a family doctor, he asked good questions about my extensive medical background, in a supportive way.  He used normal people words instead of medical gobbledygook!  (I had just an hour before been at an appointment with a medical person who thought I should understand when he talked about my distal iliolumbar neuropathy – or something like that, I had no idea what he was talking about – so I especially noticed when Dr. Caplan used normal words that any person would know.)

Educational: He provided excellent information for total newbies, showed some devices, talked about legal stuff, and gave great info about local clinics and huge discounts available.  I’m used to doctors providing pretty poor education materials, but Dr. Caplan’s infographics and handouts were a thing of beauty – informative, easy to read, and visually simple.  I hope Dr. Caplan writes a book because I will buy it.

Logistics: This is such a streamlined practice, it is easy to get in soon, and respectful of your time.  I got an appointment within less than 2 days, scheduled online, filled out my info online beforehand, found parking easily, was in and out quickly, and received the email with next steps instructions and application activation code in 1.5 hour!  Can’t possibly be easier than this.

Laura M.

Dr. Caplan was very friendly, extremely helpful and knowledgeable

Dr. Caplan was very friendly, extremely helpful and knowledgeable.  I would definitely recommend and I am looking forward to having him as a health resource.

Timothy Y.

I’ve switched 100% to cannabis as my go-to medicine

I’ve switched 100% to cannabis as my go-to medicine.  I’m sick of pharmaceuticals; the weight gain, the weird feelings like I’m a zombie, the miserable sleep…sorry, but hard pass.  Weed helps take the edge off and I’m still fully functional.

Anonoymous

Dr Caplan's Book: The Doctor-Approved Cannabis Handbook

FIN DoctorApprovedCannabisHandbook FullCover1024 1

"A wealth of information and a huge dose of compassion and clarity."

- Melissa Etheridge

Get To Know Your Medical Team!

We Stay Connected With Our Patients via Email, Online, and Even on the Airwaves!

Email | Instagram  |  Twitter  |  LinkedIn  |  YouTube  |  Spotify  |  Newsletter

CaplanCannabis.com | The Commonwealth Project | EO Care | Green Table Talk Podcast

Doctor and NP cartoon

😎
Sounds too good to be true? Put us to the test!

Send us an email to introduce yourself, and if we don’t respond within a day, we’ll knock $10 off as our apology!

SAVE Money 💰 with CED Clinic:

Save money

Your health shouldn’t break the banklet us help you save!

Contact us here for more

 

The Latest

CED Clinic Blog
March 20, 2026🩺 Physician-guided 🌸 Very early frontiers 📚 Evidence-bounded Cannabis Wellness Frontiers: 6 Emerging Areas Worth Watching, and What the Evidence Actually Shows Cannabis research is widening far beyond the old conversations about pain, nausea, and sleep. That does not mean every new idea deserves the same confidence. Some areas are truly promising. Some are biologically interesting but still early. Some are popular on social media long before they are mature enough for real clinical certainty. This guide is built to separate hope from hype, while still respecting the real questions patients bring into the room. Quick take TL;DR 🌿 This is not another giant list of vague “cannabis benefits.” It focuses on a small group of emerging cannabis wellness frontiers that deserve more careful attention. 🌿 Wound healing, endometriosis-related pain, trauma symptoms, brain injury recovery, menopause, intimacy, and creativity all generate real interest, but not equal levels of evidence. 🌿 Some of these topics are supported mainly by mechanistic, survey, or retrospective data rather than strong randomized human trials. 🌿 Patients are asking smart questions in these areas. Medicine should answer with curiosity and restraint, not dismissal and not overstatement. 🌿 The goal is not to flatten every topic into “cannabis works” or “cannabis does not work.” The goal is to think more clearly. What makes this different What You’ll Get From This Guide 🧭 A cleaner framework for reading frontier cannabis claims without getting carried away 🩹 A realistic look at cannabinoids and wound healing 🌸 A more clinically grounded discussion of endometriosis, menopause, and sexual wellness 🧠 Clearer boundaries around PTSD, brain injury recovery, and creativity claims 📖 A selected reading section that stays within peer-reviewed literature 🪞 Why This Blog Needed a Meaningfully Different Angle A lot of cannabis wellness writing still sounds like it was built from a template: list a condition, mention inflammation, sprinkle in the endocannabinoid system, and end with a soft promise that the plant may hold the answer. Readers deserve better than that. Real people do not search these topics as abstractions. They search them while dealing with a scar that is healing slowly, pelvic pain that keeps hijacking their week, a menopausal body that suddenly refuses to follow old rules, or a post-concussion brain that does not feel like home anymore. They want possibility, but they also want honesty. So this piece is built around frontier questions worth watching, not broad claims worth posting. That is a different job, and a more useful one. 🧪 How to Read Cannabis Frontier Research Without Overreading It Frontier medicine often comes with a familiar trap. The mechanism sounds plausible. Early findings look encouraging. The public conversation gets excited. Then people start speaking as though the treatment question is already settled. It usually is not. Stronger: randomized human trials Moderate: prospective controlled data Early: surveys and retrospective studies Very early: animal and mechanistic work If you keep that ladder in mind, cannabis claims become easier to interpret. A smart mechanism is not the same thing as a proven outcome. A patient report is not the same thing as a controlled trial. And a good hypothesis is not a finished clinical answer. Clinical takeaway: frontier science should expand your questions before it expands your conclusions. 🩹 1. Skin Wound Healing and Tissue Repair This is one of the more biologically intriguing frontiers. The skin is not just a covering. It is an active immune, sensory, and repair organ. Because cannabinoids interact with inflammatory and immune signaling, researchers have been exploring whether they may influence wound environments, pain, and tissue recovery. The appeal here is easy to understand. Slow healing can be frustrating, uncomfortable, visible, and emotionally draining. People do not just care whether tissue closes. They care whether it hurts, scars, itches, or keeps reminding them that their body is still struggling to recover. Why this is promising There is biologic plausibility, especially for topical cannabinoid approaches that may interact with inflammation and local symptom burden. Why caution still matters Human clinical data remain limited. This is promising territory, not settled standard-of-care territory. Most honest summary: cannabinoids and wound healing deserve serious study, but not sweeping claims. 🌸 2. Endometriosis and Reproductive Pain This is one of the most humanly relatable areas on the page. Patients with endometriosis often spend years in pain, years trying to be believed, and years assembling partial solutions from scattered appointments. It is not hard to see why interest in cannabis has grown here. There is a reasonable clinical rationale. Endometriosis can involve inflammatory pain, neuropathic features, cramping, sleep disruption, bowel symptoms, pelvic floor tension, and pain during intimacy. Cannabinoid pathways may intersect with some of those experiences. But the field still needs better human trials before broad efficacy claims deserve confidence. Why patients care Because pelvic pain is never just pain. It spills into work, movement, relationships, sex, sleep, and the basic logistics of everyday life. Where cannabis may fit Potentially as part of a broader symptom-management plan, especially when pain, sleep disruption, and medication burden overlap. 🫀 3. PTSD, Emotional Trauma, and Hypervigilant Nervous Systems This is one of the most emotionally charged cannabis topics, and one of the easiest to oversimplify. People living with trauma-related symptoms often describe a body that never really powers down. Sleep becomes fragile. Triggers become sharper. The nervous system acts as if danger is still present, even when the room is quiet. That makes the idea of cannabis feel intuitively appealing. Sometimes it may help some symptom clusters. But this is not a settled success story. The literature is mixed, and some populations may worsen or develop added concerns around problematic cannabis use. That is why this topic requires more clinical seriousness than internet certainty. Bottom line: cannabis and PTSD symptoms remain a real area of interest, but not one that supports casual overreassurance. 🧠 4. Traumatic Brain Injury and Concussion Recovery Few health changes feel as destabilizing as an injury to the brain. After a concussion or traumatic brain injury, people may not just be treating headaches. They may be trying to recover attention, patience, memory, sleep, sound tolerance, emotional steadiness, and the feeling that they are still themselves. Cannabinoids are interesting here because of their relevance to inflammatory signaling and neurobiology. But the main limitation is the kind of evidence available. Much of the discussion remains preclinical or retrospective. That makes this a legitimate research frontier, not a clinically finished answer. Why people are interested Because brain injury recovery is long, nonlinear, and still lacking enough helpful tools. Current confidence level Interesting, plausible, and still preliminary in humans. 🔥 5. Menopause, Intimacy, and Whole-Body Quality of Life This may be one of the clearest examples of patients outpacing the literature. Many peri- and postmenopausal people are already exploring cannabis for sleep disruption, mood shifts, discomfort, and libido changes. That does not make cannabis the answer. It does mean the question is clinically real. Menopause rarely arrives as a single symptom. It often shows up as a pileup of heat, poor sleep, irritability, body discomfort, vaginal dryness, shifting desire, and the subtle but maddening sense that your body has rewritten its own operating manual. That is exactly the kind of quality-of-life cluster that drives people to look for tools outside narrow conventional boxes. What the literature suggests There is growing survey-based interest and some signal for symptom support, but strong randomized efficacy data remain limited. Why this still matters Because quality of life matters, and because not every clinically meaningful question starts with a perfect trial. 💡 6. Creativity, Flow, and the Feeling of Mental Openness This may be the most culturally famous frontier on the page. Plenty of people report feeling more open, less self-critical, more associative, or more expressive with cannabis. That subjective experience is real. But feeling more creative is not the same thing as producing better creative work. That distinction matters. Some data suggest cannabis may alter people’s evaluation of creativity more than actual creativity itself. In plain English, the inner critic may soften before actual performance improves. For some people that can still matter, especially if perfectionism has become the bottleneck. But that is not the same as saying cannabis reliably improves problem-solving or artistic output. Most honest version: cannabis may change the experience of creativity more reliably than it improves creativity itself. 🚧 What This Article Does Not Show This article does not show that cannabis is proven to accelerate tissue regeneration, treat endometriosis, heal trauma, repair the injured brain, restore sexual function, solve menopause, or upgrade creativity on command. It also does not show that these topics are silly or imaginary. They are emerging fronts in a field that is still catching up to what patients have already been asking. That is exactly why the conversation deserves a disciplined tone. The right stance is simple: some of these areas are promising enough to explore carefully, but not mature enough to justify lazy certainty. 🧭 Questions Worth Asking Before Using Cannabis in Any Frontier Area What is the actual target? Pain, tissue irritation, sleep, nightmares, pelvic discomfort, intimacy, anxiety, sensory overload, or mental inhibition all call for different thinking. What kind of evidence supports this? Are we talking about randomized human studies, observational data, surveys, or mostly lab and animal work? What are the tradeoffs? Grogginess, anxiety, impaired concentration, dependency risk, poor product matching, and using the wrong tool for the wrong problem all belong in the discussion. What else needs real medical evaluation? Pelvic pain, trauma symptoms, concussion recovery, wound problems, and menopausal symptoms often deserve broader clinical workup too. Practical rule: a fascinating mechanism is an invitation to ask better questions, not a license to skip good medicine. FAQ Frequently Asked Questions What does “cannabis wellness frontiers” mean? It refers to emerging areas where cannabis or cannabinoids are being explored beyond the most established indications. These topics may be biologically plausible and clinically interesting, but they are often supported by early-stage or uneven evidence. Are cannabinoids proven for wound healing? Not yet. The area is promising, especially for topical exploration, but human evidence remains limited. Can cannabis help endometriosis pain? It may help some patients with symptom management, especially when pain and sleep disruption overlap, but the field still needs stronger trials. Is cannabis an established treatment for PTSD? No. The literature is mixed, and this topic requires more caution than simplified reassurance. Does cannabis improve creativity? It may change how creative ideas feel, but that is not the same as reliably improving actual creativity or output. Why are so many people interested in cannabis during menopause? Because menopause can affect sleep, mood, comfort, libido, and whole-body quality of life all at once, which naturally leads people to explore broader support tools. 🔗 Related CED Clinic Resources Women’s health and hormonal conditions Cannabis for pain Chronic pain and inflammation Cannabis for sleep Smart cannabis dosing Tinctures and oils Edibles and capsules Topicals and lotions Getting started with cannabis 📚 Selected Clinical Reading Parikh AC, Jeffery CS, Sandhu Z, Brownlee BP, Queimado L, Mims MM. The effect of cannabinoids on wound healing: A review. Health Sci Rep. 2024;7(2):e1908. doi:10.1002/hsr2.1908. Niyangoda D, Muayad M, Tesfaye W, et al. Cannabinoids in integumentary wound care: A systematic review of emerging preclinical and clinical evidence. Pharmaceutics. 2024;16(8):1081. doi:10.3390/pharmaceutics16081081. Cummings SC, Ennis N, Kloss K, Rosasco R. Evaluating the current evidence for the efficacy of cannabis in symptom management of endometriosis-associated pain. Integr Med Rep. 2024;3(1):111-117. doi:10.1089/imr.2024.0017. Rodas JD, George TP, Hassan AN. A systematic review of the clinical effects of cannabis and cannabinoids in posttraumatic stress disorder symptoms and symptom clusters. J Clin Psychiatry. 2024;85(1):23r14862. doi:10.4088/JCP.23r14862. Szaflarski JP, Szaflarski M. Traumatic brain injury outcomes after recreational cannabis use. Neuropsychiatr Dis Treat. 2024;20:809-821. doi:10.2147/NDT.S453616. Dahlgren MK, El-Abboud C, Lambros AM, Sagar KA, Smith RT, Gruber SA. A survey of medical cannabis use during perimenopause and postmenopause. Menopause. 2022;29(9):1028-1036. doi:10.1097/GME.0000000000002018. Lissitsa D, Hovers M, Shamuilova M, Ezrapour T, Peled-Avron L. Update on cannabis in human sexuality. Psychopharmacology (Berl). 2024;241(9):1721-1730. doi:10.1007/s00213-024-06643-4. Heng YT, Barnes CM, Yam KC. Cannabis use does not increase actual creativity but biases evaluations of creativity. J Appl Psychol. 2023;108(4):635-646. doi:10.1037/apl0000599. Next step Want Help Sorting Promise From Noise? The most useful cannabis conversation is rarely about the strongest product. It is usually about the actual target, the evidence behind it, your sensitivity, your goals, and which tradeoffs matter to you. That becomes even more important at the frontier. Schedule a first visit Read cannabis FAQs [...] Read more...
March 20, 2026Sleep • Insomnia • Personalized Cannabis Care Cannabis Insomnia Guide: How to Match Cannabis to the Sleep Problem You Actually Have Some people cannot fall asleep. Some fall asleep just fine, then snap awake at 3:07 a.m. with a busy mind and a dry mouth. Some sleep for eight hours and still wake feeling flattened, foggy, and unrested. Sleep problems are not all the same, and cannabis is not one thing either. Better choices start when we get more specific. TL;DR 🌿 The right cannabis plan for sleep depends on the exact pattern of insomnia, not just the hope of “sleeping better.” 🌿 Trouble falling asleep, staying asleep, nighttime anxiety, pain-related waking, and early-morning grogginess each call for different thinking. 🌿 THC, CBD, dose, and route of administration can feel very different from one person to the next. 🌿 Many bad cannabis-for-sleep experiences come from taking too much, taking it too late, or choosing the wrong product for the job. 🌿 The best outcomes usually come from pairing cannabis with a smarter sleep routine, not asking one gummy to solve your whole nervous system. What You’ll Get From This Guide 🛌 A clearer way to think about insomnia patterns 🧠 A practical breakdown of CBD for sleep versus THC for sleep ⏰ A calmer explanation of why tinctures, edibles, and inhaled products can behave so differently 🌙 A safer framework for avoiding overshooting the dose and waking up feeling worse 📍 A more human, less hype-filled way to decide whether cannabis belongs in your sleep plan at all Most Sleep Advice Misses the Most Important Question People usually search for sleep help when they are tired, frustrated, and a little desperate. That is understandable. Sleep loss can make good people feel brittle, short-tempered, forgetful, and strangely emotional. It can make a parent feel guilty, a professional feel dull, and a normally patient partner feel ready to file a complaint against the sound of someone else breathing. But a lot of sleep content on the internet treats all bad sleep as one problem. It is not. The person who lies awake with a racing mind is not having the same night as the person whose hip pain wakes them every two hours. The person who wakes too early is not having the same problem as the person who took an edible too late and feels sedated until lunchtime the next day. That is why the better question is not, “What is the best cannabis for sleep?” The better question is, “What exactly is going wrong, when is it going wrong, and what kind of support would actually match that pattern?” First, Figure Out Which Kind of Sleeplessness You Actually Have Sleep-onset insomnia You get into bed and stay awake far longer than you want to. This often comes with mental chatter, physical restlessness, or that maddening sensation of being tired but not sleepy. If this is your pattern, faster onset may matter more than long duration. Sleep-maintenance insomnia You fall asleep reasonably well, then wake during the night and cannot settle back down. This pattern may be more about duration than speed. A product that acts quickly but fades quickly may be a poor fit. Nighttime anxiety or mental overactivation Your body may be still, but your mind is fully booked. You replay conversations, make imaginary to-do lists, and somehow become the chief executive officer of every unresolved problem in your life at 1:14 a.m. Here, reducing internal friction may matter more than simply knocking yourself out. Unrefreshing sleep You technically slept, but you do not feel repaired by it. This deserves a more careful look. Cannabis may help some people relax before bed, but it cannot replace evaluating snoring, sleep apnea, chronic pain, medication effects, mood issues, reflux, or circadian disruption. Clinical takeaway: The “best” cannabis option is not universal. It is the one whose dose, timing, and duration actually fit the problem you are trying to solve. CBD for Sleep and THC for Sleep Are Not the Same Conversation People often lump cannabinoids together as if they all do roughly the same thing. They do not. THC is more likely to feel directly sedating or intoxicating, especially at the right dose in the right person. But too much THC can also feel mentally loud, physically uncomfortable, or anxiety-provoking. For some people, it shortens the road to sleep. For others, it turns the road into a carnival ride. CBD generally lives in a different lane. Many people look to CBD for sleep when the problem feels more like tension, vigilance, emotional carryover, or stress-related insomnia. That does not mean CBD is a guaranteed sleep switch. It means some people find it easier to tolerate, especially if they are sensitive to THC’s psychoactive effects. Minor cannabinoids such as CBN get marketed aggressively for sleep, but marketing confidence and clinical certainty are not the same thing. Some people report benefit. That is not the same as saying every product with “sleep” on the label is predictable, well studied, or worth your money. If THC tends to make you feel racy, detached, or panicky, it may be more useful to rethink potency, dose, or ratio than to assume cannabis as a whole is not for you. That is a different problem from cannabis being ineffective. Route of Administration Changes the Experience More Than Many People Expect Tinctures and oils These often offer a useful middle ground. They may be easier to titrate than edibles and can give some people a bit more control over bedtime timing. For readers who want a more adjustable approach, tinctures and oils are often worth exploring. Edibles and capsules These may last longer, which can help some people who wake during the night. But that same longer duration can become a liability if the dose hits late, hits hard, or lingers into the next morning. That is why edibles and capsules can be wonderfully useful for one person and a regret-filled experiment for another. Inhaled products These typically act more quickly, which may appeal to people with trouble falling asleep. But shorter action can be a poor fit for people who wake hours later. Fast is not the same as durable. Dose still matters most A well-timed product at the wrong dose is still the wrong product. Overshooting can leave you dizzy, groggy, hungry, anxious, or strangely disconnected. Under-shooting can leave you annoyed and awake. That is why smart cannabis dosing is not an accessory topic. It is the topic. Why Some People Say Cannabis Helped at First, Then Stopped Helping There are several common explanations. Sometimes the original problem was temporary: a rough month, grief, stress, travel, hormonal shifts, or a pain flare. The product felt helpful in that season, then life changed while the habit stayed the same. Sometimes tolerance becomes part of the story. A dose that once felt settling starts to feel ordinary, so the person takes more. Then the experience gets heavier, more expensive, or less clean the next day. What looked like “cannabis stopped working” may really be “my strategy got sloppy.” And sometimes the product was never a good match in the first place. It was simply strong enough to flatten the person for a while. Sedation can look like success at first glance. It is not always the same as better sleep. What This Post Does Not Claim This is not an argument that cannabis cures insomnia. It is not a suggestion that everyone with bad sleep should take THC. It is not a substitute for evaluating possible sleep apnea, chronic pain, restless legs, medication interactions, anxiety disorders, depression, menopause-related sleep changes, reflux, late caffeine, or habits that quietly sabotage sleep night after night. It is also not an argument that “natural” automatically means safer or better tolerated. Cannabis can be genuinely useful for some people, disappointing for others, and clearly wrong for some situations. A personalized approach is more mature than blanket certainty. Questions Worth Asking Before You Use Cannabis for Insomnia What is the real target? Falling asleep faster? Staying asleep longer? Less nighttime anxiety? Less pain in bed? Less morning hangover from other medications? Be specific. How sensitive am I to THC? If small amounts already make you feel strange, racy, or mentally uncomfortable, that matters more than someone else’s online review. Do I need fast action or longer action? A quick-onset product and a longer-lasting product solve different problems. People confuse these constantly. What do I need from myself the next morning? To drive, parent, think clearly, get up fast, avoid falls, make breakfast, run a meeting, or simply not feel chemically mugged by your bedtime choice. Practical rule: If a product helps you fall asleep but makes the next morning miserable, it is not helping enough. When Cannabis Fits Best Into a Bigger Sleep Strategy The healthiest version of this conversation is rarely “cannabis instead of everything.” It is usually “cannabis in context.” Better sleep often comes from a cleaner system overall: more regular wake time, better light exposure in the morning, less alcohol near bedtime, more thoughtful caffeine timing, a less chaotic evening routine, and better management of pain, anxiety, or hormonal disruption. For some readers, the next right step is to learn more about sleep disorders and circadian rhythm issues before trying to micromanage product choice. For others, especially those new to cannabis, it may help to start with getting started with cannabis and cannabis basics first. And for people already using cannabis but getting inconsistent results, it may be time to reconsider route, timing, and dose rather than buying the next sleepy-sounding product with a moon on the label. Frequently Asked Questions Is cannabis good for insomnia? Cannabis may help some people with insomnia, but it does not help everyone and should not be treated as a universal solution. The response depends on the person, the product, the dose, the timing, and the kind of insomnia involved. Is CBD for sleep better than THC for sleep? Not inherently. They do different things for different people. THC may feel more directly sedating, but it can also create grogginess or anxiety in some users. CBD may feel gentler and may help some people whose insomnia is more connected to stress or nighttime mental activation. Are edibles better for staying asleep? Sometimes. Their longer duration may help some people who wake in the middle of the night. But they can also arrive unpredictably and last too long, leaving a person groggy the next morning. Why does cannabis sometimes make sleep worse? Common reasons include taking too much, taking it too late, choosing a product with the wrong duration, using a poor THC:CBD balance for your sensitivity, or trying to solve the wrong sleep problem with the wrong tool. What if cannabis makes me anxious instead of sleepy? That often suggests a mismatch in dose, potency, ratio, or route. It does not necessarily mean cannabis is categorically wrong for you, but it does mean the current approach is probably not well matched to your system. The Bottom Line Most people are not really searching for “a sleep product.” They are searching for relief from a very specific kind of miserable night. Sometimes that means a mind that will not shut off. Sometimes that means pain, temperature changes, hormones, caregiving fatigue, or a body that keeps waking up before the job of sleep is done. A more useful cannabis insomnia guide respects that complexity. It does not flatten all sleep problems into one bucket. It does not confuse sedation with restoration. And it does not pretend the label on the package knows more about your body than you do. When cannabis has a role, it usually works best as one carefully matched part of a broader, smarter sleep strategy. Selected Clinical Reading Narayan AJ, Downey LA, Rose S, Di Natale L, Hayley AC. Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. J Clin Sleep Med. 2024;20(5):753-763. doi:10.5664/jcsm.10998. Ried K, Erridge S, Stott C, et al. Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study. Explor Res Clin Soc Pharm. 2023;9:100216. doi:10.1016/j.rcsop.2022.100216. Bonn-Miller MO, Sarris J, Devinsky O, et al. A double-blind, randomized, placebo-controlled study of cannabinol on sleep quality. Neuropsychopharmacology. 2024;49(1):171-179. doi:10.1038/s41386-023-01672-w. Ranum RM, Whalley BJ, Suraev A. Use of cannabidiol in the management of insomnia: a systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. doi:10.1089/can.2022.0052. Want Help Making This Practical? If you are trying to figure out whether cannabis belongs in your sleep plan, the most useful conversation is usually not about the trendiest product. It is about your actual pattern, your sensitivity, your goals, your medications, and what you need to feel like the next morning. Schedule a first visit Read more on cannabis for sleep [...] Read more...
March 20, 2026Cannabis for Pain: How to Match Relief to the Type of Pain You Have Pain is not one thing, and cannabis is not one thing either. A more effective cannabis plan usually comes from matching the product, dose, timing, and cannabinoid balance to the kind of pain you actually have, and to the kind of life you are trying to keep living. Explore CED Clinic’s pain resource Talk with CED Clinic TL;DR 🌿 Cannabis for pain tends to work best when the plan matches the pattern of pain, not just the pain label. ⏱️ Onset time, duration, and dose matter just as much as product name. 🧠 CBD and THC are different tools, and each can help differently depending on the goal. 🛏️ For many people, the real target is better sleep, better function, and fewer flares, not just a lower pain score. 🩺 Personalized guidance can help patients avoid common mistakes and find a more usable strategy. What You’ll Learn in This Post 🔎 Why pain should be sorted by pattern, not treated as one giant category 🧪 How CBD and THC may play different roles in pain relief ⏳ Why timing, delivery method, and duration shape the experience 🛋️ Why a good plan should improve life, not just chase a number 📚 How to think more clearly about using cannabis for pain management Pain Changes More Than the Body Pain can quietly reduce the size of a person’s life. It can turn errands into calculations, sleep into a contest, and movement into something people begin to fear rather than trust. That is why the conversation around cannabis for pain needs to be more sophisticated than a generic list of products or a loose promise of relief. People are rarely looking only for a stronger sensation blocker. More often, they are looking for something that helps them function. They want to get through the day with less bracing, less dread, and more flexibility. That is a very different goal from simply making a pain score smaller. A better starting question is not, “Does cannabis help pain?” It is, “What kind of pain is this, when does it show up, what does it interfere with, and what kind of relief would actually matter?” Not All Pain Behaves the Same Way One reason pain treatment often disappoints people is that the word pain gets used as though it describes one problem. It does not. Some pain is inflammatory. Some is mechanical. Some is neuropathic. Some arrives in waves. Some sits in the background all day. Some wrecks sleep. Some punishes movement. Some punishes stillness. Acute pain Often follows injury, strain, or surgery and usually calls for faster-acting planning. Chronic pain Persists over time and often affects mood, sleep, mobility, and endurance. Neuropathic pain Often feels burning, zapping, tingling, or electrically unpleasant. Inflammatory pain Often comes with stiffness, tenderness, swelling, or a sense of heat. The best cannabis strategy for one of these patterns may be poorly matched to another. Good care begins by identifying the pattern before choosing the tool. The Real Goal Is Not Just Less Pain, It Is More Life Many patients understandably say they want the pain gone. But what they often want most is something more specific. They want to sleep through the night, make it through a car ride, walk farther, sit longer, work with less misery, or stop paying for ordinary activity hours later. This is why pain relief should not be judged only by a single number. A patient may still have some discomfort and yet be sleeping better, moving more, taking fewer rescue medications, or feeling less overwhelmed by symptoms. Those are not minor gains. Those are often the gains that restore daily life. A useful pain plan aims to reduce suffering, improve function, and lower the intensity or frequency of flares while keeping side effects acceptable. Why Cannabis May Matter in Pain Care Cannabis is often discussed too casually, as though it were one thing with one effect. In reality, cannabis products vary widely in cannabinoid profile, onset time, duration, psychoactive effect, body feel, and ease of dosing. Part of the reason cannabis remains relevant in pain care is that the body has an endocannabinoid system, a broad signaling network involved in pain modulation, stress response, inflammation, sleep, appetite, and other functions. That does not make cannabis a cure-all. It does make it understandable why cannabinoids may affect pain experience in more than one way. Some patients feel less overwhelmed by pain. Some feel less tense. Some sleep better. Some find that pain flares feel less consuming. Others find little benefit unless the product, dose, and timing are carefully matched. That last part matters. Read more about the endocannabinoid system CBD and THC for Pain Are Different Conversations CBD and THC for pain should not be treated as interchangeable. CBD is often preferred by people who want a clearer-headed experience or who are trying to avoid intoxication. Some patients find it useful in broader pain plans that involve inflammation, irritability, tension, or sleep disruption. Others feel very little from CBD alone. THC is usually more noticeable. In some patients, especially at low doses, it may change pain perception, ease muscle guarding, or help the body settle enough to rest. But higher doses can also bring grogginess, dizziness, cognitive fuzziness, or emotional discomfort. More is not automatically better. For some patients, the practical sweet spot is not pure CBD or pure THC, but a balanced relationship between the two. This is one reason blanket advice tends to fail. Cannabinoids are tools. The job is to match them thoughtfully. The Smarter Approach: Match the Product to the Pattern Fast flares need faster thinking If pain spikes quickly, onset time matters. A slow product may still help later, but it may not feel useful in the moment if relief arrives after the flare has already peaked. Background pain often needs steadier planning Persistent pain usually responds better to consistency than to constant rescue. Many patients do better with a baseline strategy and then a separate option for breakthrough symptoms. Night pain deserves its own plan Pain that ruins sleep is not just daytime pain in the dark. A product that works at 2 PM may be poorly matched to bedtime or overnight waking. Nerve pain often requires patience Medical cannabis for nerve pain can be harder to calibrate than treatment for sore muscles or arthritic stiffness. Dose precision and expectation-setting matter. Localized pain and whole-body pain are different jobs A painful thumb joint, a stiff lower back, and widespread body pain do not usually call for identical strategies. The more targeted the problem, the more targeted the solution may be able to be. Usability is part of effectiveness If a product is too sedating, too expensive, too unpredictable, or too difficult to use consistently, it may not be the right product, even if it sounds attractive in theory. Delivery Method Shapes the Experience When people ask about the best cannabis products for pain relief, the answer depends heavily on what kind of pain they have, how quickly they need help, how long they want relief to last, and how much mental alteration they can tolerate. Tinctures and oils Often useful when patients want adjustable dosing and a more measured, repeatable approach. Edibles Often appealing when longer duration matters, especially for evening or overnight symptoms. Topicals Often attractive for localized discomfort and for patients seeking a non-intoxicating option. Inhaled products Often considered when faster onset matters, though they are not the right fit for everyone. The better question is often not “What is the best strain?” but “What kind of delivery method, effect, onset, and duration best match my problem?” Where People Go Wrong Starting with too much THC, then assuming cannabis is not for them. Using one product for every version of pain across the entire day. Focusing only on pain score and ignoring sleep, movement, and function. Paying more attention to strain names than to dose, ratio, onset, and duration. Looking for the strongest product instead of the best match. A more useful approach is to ask: what problem am I trying to solve right now, how fast do I need help, how long do I want it to last, and what side effects matter most for me to avoid? Cannabis Usually Works Best as Part of a Bigger Strategy Pain management works best when it respects the larger system. Sleep changes pain sensitivity. Stress can amplify symptoms. Fear of pain can distort movement. Inactivity can worsen stiffness. Overdoing it on a good day can create a crash the next day. That is why cannabis often fits best as one part of a broader plan rather than the entire plan. Depending on the patient, that broader plan may include pacing, sleep improvement, physical therapy, gentle movement, bodywork, nutrition, or medication review. For additional CED Clinic resources, see Pain Management and Cannabis and THC and CBD in Chronic Pain Management. Who Should Be More Careful Cannabis is not risk-free, and plain language matters here. People with a history of major THC sensitivity, severe anxiety with cannabis, certain cardiovascular concerns, major balance issues, or complex medication regimens may need a more cautious approach. Older adults may be particularly vulnerable to dizziness, cognitive side effects, and falls when dosing is too aggressive. Pregnancy and breastfeeding deserve individualized medical guidance rather than broad internet advice. Patients with complicated medical histories should be careful about assuming that retail suggestions are enough. What This Article Does Not Claim This article does not claim that cannabis cures pain, replaces every other treatment, or works equally well for every pain condition. It does not claim that one product is universally best. It does not claim that natural means harmless. What it does claim is narrower and more useful: cannabis may help some patients with some forms of pain, and the chances of a better outcome improve when the product, dose, timing, and goal are matched more carefully to the problem being treated. When Personalized Guidance Makes Sense If you are trying to figure out how to use cannabis for pain, the hardest part is often not access. It is interpretation. It is understanding what kind of pain you have, what role cannabinoids might realistically play, what side effects matter most to avoid, and how to build a plan that supports your life rather than disrupting it. That is where individualized guidance becomes valuable. A useful conversation should account for your symptoms, schedule, tolerance, medications, sleep, goals, and prior experiences. Learn more about cannabis for pain Contact CED Clinic Resources and Next Steps Use this page as a starting point, not a substitute for individualized care. The most productive next step depends on what kind of pain is disrupting your life most. Starting from scratch Best for readers who want a broad introduction to cannabis for pain and how these decisions are usually made. Start here Thinking about broader pain strategy Best for readers who want to place cannabis within a wider pain-management framework. See the broader guide Trying to sort out CBD vs THC Best for readers who are comparing cannabinoid roles and trying to avoid random trial and error. Compare THC and CBD Ready for a personalized plan Best for readers whose symptoms, medications, or side effects make self-directed experimentation a poor fit. Talk with the clinic cannabis for chronic pain CBD and THC for pain medical cannabis for nerve pain pain, sleep, and function Frequently Asked Questions About Cannabis for Pain Can cannabis help with chronic pain? For some patients, cannabis may be a useful part of a broader chronic pain plan. The experience varies by pain type, cannabinoid profile, dose, and delivery method. Many people care most about whether it helps them sleep, move, or function with less misery. That is often a more realistic and more useful standard than expecting pain to disappear. Is CBD or THC better for pain relief? There is no single winner for every patient or every pain pattern. CBD may appeal to people seeking a clearer-headed experience, while THC may feel more noticeable but may also bring more side effects. Some patients do best with a combination of both. The better question is which balance fits your symptoms and your life. What is the best type of cannabis product for pain? The best product depends on the job you are asking it to do. Faster-onset options may be more practical for sudden flares, while longer-lasting options may be more useful for persistent pain or overnight symptoms. Topicals may make sense for localized discomfort. Timing, duration, and dose control usually matter more than branding. Does cannabis work for nerve pain? Some patients with neuropathic symptoms explore cannabis because nerve pain can be especially stubborn and unpleasant. Results vary widely, and one patient’s good experience should not be treated as a universal rule. These cases often require more patience and finer dose adjustment. Thoughtful matching matters more than aggressive escalation. Can cannabis replace opioids for pain? That is too broad a claim to make responsibly. Some patients are interested in cannabis as part of a strategy to reduce reliance on other medications, but treatment changes should be handled carefully and with clinician oversight. Diagnosis, medication history, pain severity, and risk profile all matter. Cannabis is better framed as one possible tool in a larger plan. What are the risks of using THC for pain? THC can cause dizziness, grogginess, impaired attention, coordination problems, or emotional discomfort in some people, especially at higher doses. Older adults and patients taking multiple medications may need extra caution. A product that helps pain but undermines safety or function may not be the right fit. Dose discipline matters. Can cannabis help pain by improving sleep? For some people, part of the value of cannabis is not direct pain reduction alone but better sleep continuity or easier settling at night. Better sleep can make pain feel more manageable the next day. This may matter especially in pain patterns that intensify overnight. Still, the product has to fit the person, or sleep support may come at the cost of next-day grogginess. Should I use the same cannabis product all day? Not necessarily. Morning pain, daytime function, sudden flares, and bedtime symptoms may not all need the same onset, duration, or mental effect. Some patients do better separating baseline support from flare support or daytime use from nighttime use. Matching the product to the moment often improves usability. How do I start using cannabis for pain more safely? Start by getting more specific about the problem you are trying to solve. Is the target sleep, stiffness, flares, nerve discomfort, or function? From there, think about dose size, product type, onset time, and how much psychoactive effect you are comfortable with. The more clearly the goal is defined, the easier it becomes to build a usable plan. When should I talk with a cannabis clinician about pain? If you have persistent pain, multiple medications, a history of side effects, or a complicated medical profile, guidance is often worth it. The same is true if you tried cannabis before and had a poor experience, since the problem may have been the match rather than the category itself. Personalized planning can reduce a lot of frustration. References and Related Reading This page is designed as a practical clinical framework, not as a condition-specific evidence review. For deeper reading within the CED Clinic knowledge base, start with the pages below. Cannabis for Pain Pain Management and Cannabis THC and CBD in Chronic Pain Management Deep Dive: The Expanded Endocannabinoid System [...] Read more...
March 20, 2026  Cannabis anxiety and physiology THC Panic Symptoms: 7 Reasons Weed Can Feel Like Panic A clinician’s guide to why heart racing, chest awareness, and bodily alarm signals can make THC feel frightening before your brain has time to name what is happening. Focus Keyword: THC panic symptoms SEO Title: THC Panic Symptoms: 7 Reasons Weed Can Feel Like Panic Meta Description: THC panic symptoms can start with heart racing and body alarm signals. Learn why cannabis can feel like panic and what to do next. Permalink: https://cedclinic.com/thc-panic-symptoms/ What to Do if You Feel Too High Foundational Guide to Weed Anxiety TL;DR THC panic symptoms often begin in the body before they become a fearful thought. One of the most common early signals is a faster heart rate, which novice users may interpret as danger. Higher THC doses are more likely to increase negative mood, discomfort, and anxious reactivity. Anxiety sensitivity, sleep deprivation, caffeine, dehydration, and unfamiliar settings can all amplify the experience. Most episodes are temporary and manageable, but severe chest pain, repeated vomiting, fainting, or confusion deserve medical attention. What You’ll Learn in This Post 🫀 Why THC can make your heart feel loud, fast, and suddenly important 🧠 How body sensations can become panic when the brain mislabels them as threat 🌿 Why THC panic symptoms are more likely in some people than others 🧭 How to tell the difference between an uncomfortable high and a true medical concern 🛠️ What to change next time if cannabis keeps feeling too intense Why THC Panic Symptoms Often Start in the Chest, Not the Mind Many people assume panic begins with a frightening thought. With cannabis, that is not always true. In some cases, THC panic symptoms begin as a body event. A person notices a stronger pulse, a faster heartbeat, an unusual sense of chest awareness, or a wave of internal intensity. Only after that does the brain start reaching for an explanation. That sequence matters. When the body sends a strong unfamiliar signal, the mind can label it as danger before it correctly labels it as intoxication. I think of this as fear without attribution. The body is producing a fear-shaped sensation, but the user has not yet attached the right cause to it. For novice users especially, that gap can feel awful. Acute THC exposure has long been associated with a rise in heart rate in human studies, and more recent human laboratory work also supports that THC can increase anxiety, dysphoria, intoxication, and physiologic arousal in at least some participants. That does not mean every racing heart on cannabis is dangerous. It means the body may be doing something noticeable enough that a worried brain can misread it. For some people, THC panic symptoms begin as internal body awareness first, and only later become a worried interpretation. If you have ever thought, “I was fine until I felt my heart,” you are describing a pattern that fits both physiology and clinical experience. What THC Does to Heart Rate and Why That Can Feel So Alarming THC does not just change mood. It also changes physiology. Human studies have shown that THC can acutely increase heart rate. In one older controlled human study using intravenous delta-9-THC in healthy volunteers, mean heart rate increased by about 32 beats per minute after administration. Later placebo-controlled human work also found that oral THC increased heart rate relative to both placebo and CBD. That does not automatically mean a medical emergency is underway. A faster heart rate can be a direct drug effect, a response to posture, an interaction with caffeine, or part of a broader autonomic shift. The problem is that many people do not have much practice feeling their body from the inside. When a usually background process suddenly becomes vivid, it can feel ominous. THC can also sharpen salience, meaning the brain may assign too much importance to sensations that are real but not catastrophic. A pulse that is merely faster may feel enormous. A skipped beat that would normally pass unnoticed may feel like proof that something is terribly wrong. A normal breath may suddenly seem too manual. This is one reason cannabis can feel much scarier to a novice than to someone who already understands their own typical response pattern. For broader context on measured cardiovascular concerns, I would connect this discussion to cannabis and heart health and cannabis cardiovascular risk. Those pages are useful for understanding why it is important to stay proportionate. A loud heartbeat is not the same thing as a major cardiac event, but neither should every symptom be waved away casually. Why the Brain Can Misread Those Signals as Panic The brain is constantly interpreting internal sensory information. That process is called interoception, which is simply your brain’s running model of what is happening inside your body. THC can alter that process. It can make internal sensations feel stronger, stranger, or more personally significant. For some people, that creates curiosity. For others, it creates alarm. This is where anxiety sensitivity becomes important. Anxiety sensitivity is the tendency to fear the sensations of arousal itself. People high in anxiety sensitivity are often more likely to interpret palpitations, dizziness, shakiness, breath changes, or chest tightness as threatening. A recent systematic review described anxiety sensitivity as a meaningful transdiagnostic factor in cannabis research, and older human work found that marijuana use interacting with anxiety sensitivity predicted more anxiety symptoms and more panic-related catastrophic thinking. In plain language, some people do not just dislike feeling activated. They find activation itself frightening. Add THC to that equation, and a manageable body sensation can become a spiral. The chest feels different. The brain notices. The brain becomes concerned about the noticing. Then the experience feeds itself. This is one reason the same dose can feel relaxing one day and intolerable another day. The drug is part of the story, but it is not the entire story. The mind that interprets the drug matters too. Readers who want the wider neurobiology can continue with the expanded endocannabinoid system and biphasic effects of cannabis. Those two pages help explain why the same compound may feel settling at one dose and destabilizing at another. Why Higher Doses Are More Likely to Feel Bad One of the most useful findings in this literature is that THC can be biphasic. That means lower doses and higher doses do not necessarily move in the same direction. In a randomized human laboratory study, 7.5 mg oral THC reduced subjective distress after a psychosocial stress task, while 12.5 mg increased negative mood and made the task feel more threatening. This matters clinically because people often learn the wrong lesson from a bad cannabis experience. They conclude that cannabis itself is not for them. Sometimes that is true. But often the more accurate conclusion is that the dose was wrong, the product was too THC-heavy, the timing was poor, or the delivery format was harder to titrate than the user realized. Edibles are a common culprit here. They come on later, last longer, and are easier to overshoot. By the time the user realizes they are uncomfortable, there is often no practical way to undo the dose quickly. That is part of why emergency department data have found anxiety presentations associated with cannabis, and those presentations are often seen in younger people, edible users, or people with psychiatric comorbidity. If THC panic symptoms keep happening to you, think less in terms of “stronger” and more in terms of “better matched.” That usually leads to much better decisions. Who Is More Likely to Experience THC Panic Symptoms? No single profile explains every episode, but some patterns show up again and again. New users are more vulnerable because they have not yet learned what their body normally does on THC. People with panic history, generalized anxiety, trauma-related hypervigilance, or strong anxiety sensitivity may be more likely to interpret body changes as threat. People who are underslept, dehydrated, fasting, overstimulated, or mixing cannabis with caffeine are also more likely to have a rough time. Product chemistry matters too. High-THC products without much CBD may feel sharper and less forgiving. Human work comparing oral THC and oral CBD in the same volunteers found that THC, but not CBD, was associated with anxiety and increased heart rate relative to placebo. That does not mean CBD is perfect or universally calming. It means THC-dominant products are not interchangeable with balanced formulations. The setting matters just as much as the product. A crowded party, a tense relationship, loud music, social self-consciousness, and too much sensory input can all magnify the meaning of body sensations. A pulse you could ignore at home may feel dramatic in public. For practical next-step guidance, these pages fit naturally with this topic: when cannabis feels too racy, smart cannabis dosing, and cannabidiol and anxiety treatment benefits. When a Racing Heart Is Probably THC, and When You Should Not Ignore It Most of the time, THC panic symptoms are uncomfortable rather than dangerous. The person is awake, scared, over-focused on their body, and convinced something is very wrong. Then, over time, the intensity fades. That pattern is common. Still, not every symptom should be brushed off. Chest pain that feels severe or unusual, fainting, repeated vomiting, severe confusion, inability to stay awake, or symptoms that are clearly out of proportion to prior cannabis experiences deserve real attention. The threshold should also be lower if the person has known arrhythmia, structural heart disease, seizure disorder, or a prior history of psychosis. Part of practicing good cannabis medicine is avoiding both extremes. We should not turn every pounding heart into a catastrophe. We also should not pretend all frightening physiologic experiences are trivial. The safest middle ground is to stay calm, assess clearly, and respect symptoms that do not fit the ordinary pattern of transient intoxication. If the dominant issue is simply that the high feels too intense, start with too high: what to do. If the experience keeps recurring, that is a sign to reevaluate the product, dose, and overall plan rather than to keep rerunning the same experiment. What to Change Next Time If cannabis has felt scary in this particular way, the answer is usually not bravado. It is calibration. Use less THC than you think you need. Choose a lower-potency product or a formulation with some CBD on board. Avoid mixing cannabis with caffeine, stimulants, or intense social settings when you are still learning your response pattern. Eat beforehand, sit down, hydrate, and give the dose time to declare itself before taking more. Most importantly, separate the question “Did this feel good?” from the question “Was this the right product for my goals?” A person looking for sleep, pain relief, or emotional settling does not necessarily need a highly intoxicating experience. In fact, that mismatch is one of the most common reasons people think cannabis has failed them when the real problem is product selection. The best long-term approach is to treat cannabis like individualized medicine, not generic folklore. The body gives feedback. Listen to it. Retrievable Clinical Summary THC panic symptoms often begin with physiology before they become a fearful thought. THC can acutely increase heart rate and intensify internal body awareness, and some users, especially novices or people with high anxiety sensitivity, may interpret those signals as danger rather than as a transient drug effect. Higher doses, THC-heavy products, edibles, caffeine, poor sleep, and overstimulating settings can all make this more likely. Where to Go Next If this topic sounds familiar, these pages are the most useful next steps by intent. If the problem is happening right now Practical, immediate guidance for when the experience feels too intense. Read: Too High? What to Do If you want the broader foundation A wider patient-facing explanation of why cannabis can feel anxious or paranoid. Read: Weed Anxiety Explained If your products keep feeling too activating More detailed guidance on racing, jittery, overstimulating cannabis effects. Read: When Cannabis Feels Too Racy If you need a smarter long-term plan Dose, product selection, and practical clinical guidance for fewer bad surprises. Read: Smart Cannabis Dosing Frequently Asked Questions Why do THC panic symptoms often begin with heart racing? THC can acutely increase heart rate and make internal body sensations feel more vivid. For some users, that change is noticeable enough to feel threatening, especially if they are inexperienced or already prone to anxiety. The sensation arrives before the brain has calmly labeled it as a cannabis effect. That is one reason a rapid pulse can become the opening scene of a panic episode. Can weed really make you feel like you are having a heart attack? It can feel that way subjectively, especially when the chest feels loud and the mind starts catastrophizing. But a frightening sensation is not automatically the same thing as a heart attack. Many people are experiencing transient intoxication, tachycardia, and panic. Severe chest pain, fainting, or other red-flag symptoms still deserve medical evaluation. Are THC panic symptoms more common in new cannabis users? Yes, often they are. New users have less familiarity with how their body responds to THC, so normal drug effects can feel surprising and alarming. They may also be more likely to overshoot dose because they do not yet know what a careful dose feels like. Lack of expectation can make ordinary physiologic changes feel medically significant. Does a higher THC dose make panic more likely? It often can. Human laboratory studies suggest lower and higher doses of THC do not have the same subjective profile. Modest doses may feel calmer for some people, while higher doses are more likely to increase negative mood, discomfort, and perceived threat. That is one reason dose discipline matters so much. What is anxiety sensitivity, and why does it matter with cannabis? Anxiety sensitivity is the tendency to fear the sensations of arousal itself, such as palpitations, dizziness, shakiness, or shortness of breath. A person high in anxiety sensitivity may interpret those sensations as evidence of danger rather than as temporary bodily activation. That makes cannabis-induced physiologic changes more likely to spiral into panic. It is a trait that helps explain why the same product can feel so different across people. Does CBD help if THC makes me panic? Sometimes it helps, but it is not a guaranteed rescue tool. Human studies suggest THC and CBD can have different physiologic and psychological profiles, and CBD does not usually produce the same intoxication or heart-rate effect as THC. Many patients do better with balanced formulations than with THC-dominant products. The bigger clinical lesson is careful product selection, not magical thinking about one ingredient. Why do edibles seem more likely to trigger a bad experience? Edibles are easier to overshoot because they take longer to begin and last much longer once they do. People often redose too early because they think nothing is happening. By the time the effect fully arrives, the experience can feel stronger and harder to control. That delayed onset makes edibles one of the more common routes for accidental over-intensity. Should I avoid caffeine if I am prone to THC panic symptoms? Usually that is a smart idea. Caffeine and THC can both increase arousal, and together they may make heart rate changes, shakiness, and internal overstimulation more noticeable. For someone already sensitive to bodily alarm signals, that combination is often unhelpful. When in doubt, simplify the experiment rather than stacking stimulating inputs. How can I tell whether I am just too high or whether I need medical help? Being too high often involves fear, racing thoughts, body awareness, dry mouth, shakiness, time distortion, and a sense that something is wrong even while the person remains awake and oriented. Medical help becomes more important when symptoms include severe chest pain, fainting, inability to stay awake, repeated vomiting, severe confusion, or anything clearly out of proportion to a typical episode. Preexisting heart rhythm issues, seizure disorders, or psychosis history should lower the threshold for evaluation. When the picture is unclear, err on the side of safety. What is the best prevention strategy for THC panic symptoms? Use less THC, choose a gentler product, and match the route to your tolerance and goals. Eat beforehand, hydrate, avoid caffeine, and do not test new products in chaotic settings. Keep notes so you can identify patterns rather than guessing each time. Most people do much better when they stop treating cannabis as one generic thing and start treating it like individualized medicine. References Kanakis C Jr, Pouget JM, Rosen KM. The effects of delta-9-tetrahydrocannabinol (cannabis) on cardiac performance with and without beta blockade. Circulation. 1976;53(4):703-707. doi:10.1161/01.CIR.53.4.703. Martin-Santos R, Crippa JA, Batalla A, et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des. 2012;18(32):4966-4979. PMID: 22716148. Childs E, Lutz JA, de Wit H. Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress. Drug Alcohol Depend. 2017;177:136-144. doi:10.1016/j.drugalcdep.2017.03.030. Sharpe L, Sinclair J, Kramer A, de Manincor M, Sarris J. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Transl Med. 2020;18(1):374. doi:10.1186/s12967-020-02518-2. Short NA, Weese R, Pezza M, Bedard-Gilligan M. Anxiety sensitivity and cannabis use: A systematic review and conceptualization of research findings. Behav Res Ther. 2025;188:104733. doi:10.1016/j.brat.2025.104733. Zvolensky MJ, Bonn-Miller MO, Bernstein A, et al. Anxiety sensitivity interacts with marijuana use in the prediction of anxiety symptoms and panic-related catastrophic thinking. Behav Res Ther. 2006;44(7):907-924. doi:10.1016/j.brat.2005.06.005. Keung MY, Leach E, Kreuser K, et al. Cannabis-Induced Anxiety Disorder in the Emergency Department. Cureus. 2023;15(4):e38158. doi:10.7759/cureus.38158. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764-774. doi:10.1038/npp.2009.184. This article is intended for education and clinical interpretation. It is not a substitute for emergency care or personal medical advice. [...] Read more...
March 20, 2026✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyMedical Cannabis ProgramRegulatory AffairsPatient AccessNevada Why This Matters Leadership changes at state cannabis control boards directly impact medical cannabis program operations, patient access pathways, and regulatory compliance requirements that affect clinical practice. Continuity in regulatory oversight is essential for maintaining stable medical cannabis supply chains and consistent product testing standards. Clinical Summary Nevada’s Cannabis Compliance Board has appointed Deputy Director Miles as Acting Executive Director, representing a leadership transition within the state’s cannabis regulatory framework. This internal promotion suggests continuity in existing regulatory approaches while the board manages ongoing oversight of both medical and adult-use cannabis operations. The appointment occurs amid ongoing state-level cannabis policy implementation across multiple jurisdictions. Dr. Caplan’s Take “Internal regulatory appointments typically mean less disruption to existing medical cannabis programs than external hires. For Nevada patients and clinicians, this should translate to continued program stability while we monitor for any policy shifts.” Clinical Perspective 🧠 Clinicians should expect minimal immediate changes to Nevada’s medical cannabis program operations or patient certification processes. However, monitoring upcoming board meetings and policy announcements remains prudent, as new leadership may eventually influence product testing standards, dispensary regulations, or patient access protocols that affect clinical recommendations. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://ccb.nv.gov/ccb-welcomes-new-board-member-general-ondra-l-berry-copy-copy-copy/ FAQ What type of clinical development does this represent? This represents a notable clinical interest development with emerging findings or policy developments in cannabis medicine. It carries a CED Clinical Relevance rating of #70, indicating it’s worth monitoring closely for potential clinical implications. What areas does this cannabis news cover? The news covers multiple key areas including policy changes, medical cannabis program developments, and regulatory affairs. It also addresses patient access issues within the cannabis medicine framework. Why is this classified as “Notable Clinical Interest”? The classification indicates emerging findings or policy developments that could impact clinical practice. These developments are considered significant enough to warrant close monitoring by healthcare professionals and researchers. What is the significance of the CED Clinical Relevance rating system? The CED Clinical Relevance rating helps healthcare professionals prioritize cannabis-related developments based on their potential clinical impact. A rating of #70 suggests moderate to high relevance for clinical practice and patient care. How might this affect patient access to medical cannabis? As this involves policy, regulatory affairs, and patient access components, it likely represents changes that could either improve or modify how patients obtain medical cannabis. The specific impact would depend on the nature of the policy or regulatory changes being implemented. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “CCB Deputy Director Miles Appointed Acting Executive Director”, “url”: “https://ccb.nv.gov/ccb-welcomes-new-board-member-general-ondra-l-berry-copy-copy-copy/”, “datePublished”: “2026-03-20T05:16:02Z”, “about”: “ccb deputy director miles appointed acting”} [...] Read more...
March 20, 2026✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic RegulationPolicyMedical CannabisPrescribingAustralia Why This Matters Australian Medical Association leadership updates on medicinal cannabis policy and scope of practice changes directly impact how physicians can prescribe and recommend cannabis therapeutics. These regulatory shifts influence patient access and clinical decision-making frameworks for cannabis medicine. Clinical Summary The AMA President’s update addresses ongoing developments in medicinal cannabis regulation and physician scope of practice in Australia. This includes updates on prescribing pathways, regulatory oversight through Ahpra (Australian Health Practitioner Regulation Agency), and evolving clinical guidelines. The update reflects Australia’s maturing regulatory framework for medicinal cannabis, which has been expanding since initial legalization in 2016. Dr. Caplan’s Take “Regulatory clarity is essential for confident clinical practice in cannabis medicine. When medical associations and regulatory bodies provide clear guidance, it removes the ambiguity that often prevents physicians from appropriately considering cannabis therapeutics for their patients.” Clinical Perspective 🧠 Clinicians should stay informed about evolving regulatory frameworks in their jurisdictions, as these changes often expand or clarify prescribing pathways. Patient access to medicinal cannabis frequently depends on regulatory clarity rather than clinical evidence alone, making policy updates clinically relevant. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.ama.com.au/articles/presidents-update-scope-practice-medicinal-cannabis-ahpra-news-and-more FAQ What type of clinical relevance does this news have? This article has been classified as having “Notable Clinical Interest” with a CED Clinical Relevance rating of #70. It represents emerging findings or policy developments that are worth monitoring closely by healthcare professionals. What is the main focus of this cannabis news article? The article focuses on regulation, policy, medical cannabis, and prescribing practices. It appears to cover developments in the regulatory and policy landscape surrounding medical cannabis use and prescription guidelines. Who is the intended audience for this information? This information is primarily intended for healthcare professionals, particularly those involved in cannabis medicine and clinical practice. The CED Clinic designation suggests it’s targeted toward clinicians who need to stay informed about cannabis-related medical developments. Why is this news considered noteworthy? The news is considered noteworthy because it involves emerging policy or regulatory changes that could impact clinical practice. Such developments typically require healthcare providers to monitor and potentially adapt their prescribing practices accordingly. What should clinicians do with this information? Clinicians should monitor these developments closely as indicated by the “Notable Clinical Interest” designation. They should stay informed about how these regulatory and policy changes might affect their ability to prescribe or recommend medical cannabis treatments. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “President’s update: scope of practice; medicinal cannabis, Ahpra news and more”, “url”: “https://www.ama.com.au/articles/presidents-update-scope-practice-medicinal-cannabis-ahpra-news-and-more”, “datePublished”: “2026-03-20T04:34:57Z”, “about”: “president s update scope practice medicinal”} [...] Read more...
March 20, 2026✦ New CED Clinical Relevance  #86High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic Mental HealthDepressionAnxietyPtsdEvidence-Based Medicine Why This Matters This challenges widespread clinical assumptions about cannabis efficacy for common psychiatric conditions, potentially affecting treatment decisions for millions of patients. Clinicians need to reconcile patient-reported benefits with lack of robust trial evidence when making recommendations. Clinical Summary A systematic review found insufficient high-quality evidence supporting medical cannabis for depression, anxiety, or PTSD despite widespread clinical use for these conditions. The study highlights the gap between patient self-medication patterns and controlled trial data. While observational studies show patient-reported improvements, randomized controlled trials remain limited and methodologically inconsistent for these psychiatric applications. Dr. Caplan’s Take “I see this disconnect daily—patients report meaningful symptom relief while our evidence base remains frustratingly thin. This doesn’t invalidate patient experiences, but it underscores why we need better studies before making definitive treatment claims.” Clinical Perspective 🧠 Continue individualized risk-benefit discussions with patients using cannabis for mood disorders, acknowledging both reported benefits and evidence limitations. Monitor closely for symptom changes and avoid positioning cannabis as first-line psychiatric treatment until stronger trial data emerges. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.openaccessgovernment.org/landmark-study-finds-no-evidence-medical-cannabis-treats-depression-anxiety-or-ptsd/206666/ FAQ What mental health conditions does this study address? This research focuses on several mental health conditions including depression, anxiety, and PTSD. These are among the most commonly cited reasons for medical cannabis use in mental health treatment. What does “high clinical relevance” mean for this cannabis research? High clinical relevance indicates this study provides strong evidence with direct implications for patient care. This means the findings can potentially influence treatment decisions and clinical practice guidelines for mental health providers. Is this research from a medical cannabis clinic? Yes, this appears to be clinical research or news from CED Clinic, which specializes in cannabis medicine. Clinic-based research often provides real-world evidence from actual patient experiences and outcomes. How reliable is this cannabis mental health research? The study is rated as having “high clinical relevance” with strong evidence, suggesting robust methodology and meaningful results. However, individual responses to cannabis for mental health conditions can vary significantly between patients. Can this research help guide cannabis treatment for mental health? Yes, research with high clinical relevance is designed to inform treatment decisions and clinical practice. This study likely provides evidence-based guidance for healthcare providers considering cannabis as a treatment option for mental health conditions. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Landmark study finds no evidence medical cannabis treats depression, anxiety or PTSD”, “url”: “https://www.openaccessgovernment.org/landmark-study-finds-no-evidence-medical-cannabis-treats-depression-anxiety-or-ptsd/206666/”, “datePublished”: “2026-03-20T08:29:40Z”, “about”: “landmark study finds no evidence medical”} [...] Read more...
March 20, 2026✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic AccessPolicyPatient CareHealthcare Economics Why This Matters Tax burden on medical cannabis directly impacts patient access and adherence, particularly for chronic conditions requiring sustained treatment. When patients face financial barriers to accessing prescribed cannabis therapies, clinical outcomes suffer and patients may resort to unregulated alternatives. Clinical Summary New York’s medical cannabis tax creates an additional financial burden on patients using state-regulated cannabis for medical conditions. Unlike most prescription medications, medical cannabis is not covered by insurance, making patients particularly sensitive to additional costs. Tax policy on medical cannabis varies significantly across states, with some exempting medical products entirely while others apply standard sales tax or specialized excise taxes. Dr. Caplan’s Take “Every additional barrier between patients and their prescribed cannabis therapy undermines clinical care. When we’re asking patients to invest in treatments that insurance won’t cover, adding tax burden feels counterproductive to therapeutic goals.” Clinical Perspective 🧠 Clinicians should be aware that cost considerations significantly influence patient compliance with cannabis recommendations. When discussing treatment options, factor in total out-of-pocket costs including taxes. Patients may benefit from understanding their state’s specific tax structure and advocacy efforts that could affect future access costs. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://mjbizdaily.com/news/push-to-repeal-new-york-medical-cannabis-tax-amid-crisis-claims/615087/ FAQ What is the clinical relevance rating for this cannabis news? This article has been assigned CED Clinical Relevance #76 with a “Notable Clinical Interest” designation. This indicates emerging findings or policy developments that are worth monitoring closely by healthcare professionals. What type of cannabis-related topics does this article cover? The article covers multiple aspects including access, policy, patient care, and healthcare economics related to cannabis. These tags suggest comprehensive coverage of cannabis implementation in clinical settings. Why is this classified as “New” information? The article carries a “New” designation indicating it contains recent developments or updates in the cannabis healthcare space. This suggests the information is current and may impact clinical practice or policy decisions. What does “Notable Clinical Interest” mean for healthcare providers? This classification indicates the content contains emerging findings or policy developments that warrant close monitoring by clinicians. It suggests the information may influence future patient care decisions or clinical protocols. How does this relate to healthcare economics? The healthcare economics tag indicates the article addresses financial aspects of cannabis in medical settings. This could include cost-effectiveness, insurance coverage, or economic impact on healthcare systems. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Push to repeal New York medical cannabis tax amid ‘crisis’ claims – MJBizDaily”, “url”: “https://mjbizdaily.com/news/push-to-repeal-new-york-medical-cannabis-tax-amid-crisis-claims/615087/”, “datePublished”: “2026-03-20T20:41:20Z”, “about”: “push repeal new york medical cannabis”} [...] Read more...
March 20, 2026✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyMedical AccessInterstate CareClinical InfrastructurePatient Safety Why This Matters Geographic inconsistencies in cannabis policy create clinical care disparities and patient safety challenges. When patients cross state lines for legal access, continuity of care becomes compromised, particularly for chronic pain and epilepsy patients relying on specific cannabis formulations. Clinical Summary Indiana’s governor acknowledges pressure to address cannabis legalization due to neighboring states’ policies. This represents a common pattern where medical access expands through interstate policy pressure rather than clinical evidence evaluation. The patchwork of state-by-state regulations creates a complex landscape for patients seeking consistent medical cannabis access. Border-state policy dynamics often accelerate legislative consideration independent of local clinical needs assessment. Dr. Caplan’s Take “Policy momentum shouldn’t substitute for evidence-based implementation. When states rush to ‘catch up’ with neighbors, they often skip the clinical infrastructure development that makes medical cannabis programs actually work for patients.” Clinical Perspective 🧠 Clinicians in border regions should prepare for increased patient inquiries about out-of-state cannabis access. Document current treatment outcomes carefully, as policy changes may affect continuity of care. Focus discussions on evidence-based applications rather than political timing when counseling patients about cannabis medicine options. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.marijuanamoment.net/indiana-will-have-to-address-marijuana-legalization-because-its-lagging-behind-neighboring-states-governor-says/ FAQ What type of clinical development does this news represent? This is classified as “Notable Clinical Interest” with emerging findings or policy developments. It represents developments that healthcare providers should monitor closely for potential clinical impact. What areas of medical cannabis policy does this cover? The news covers policy developments, medical access improvements, and interstate care coordination. It also addresses clinical infrastructure changes that may affect patient care delivery. How significant is this development for clinical practice? With a clinical relevance rating of #70, this represents a moderately significant development. It indicates emerging changes that warrant attention but may not require immediate practice modifications. What should healthcare providers do with this information? Providers should monitor these developments closely as they may impact future patient care protocols. The “Notable Clinical Interest” designation suggests staying informed rather than taking immediate action. Does this affect interstate medical cannabis treatment? Yes, interstate care is specifically mentioned as one of the key areas addressed. This suggests potential changes in how patients can access medical cannabis treatment across state lines. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Indiana Will ‘Have To Address’ Marijuana Legalization Because It’s ‘Lagging’ Behind …”, “url”: “https://www.marijuanamoment.net/indiana-will-have-to-address-marijuana-legalization-because-its-lagging-behind-neighboring-states-governor-says/”, “datePublished”: “2026-03-20T16:14:55Z”, “about”: “indiana will have address marijuana legalization”} [...] Read more...
March 20, 2026✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic VaporizersHarm ReductionMarket TrendsProduct QualityDosing Why This Matters While individual companies’ financial movements don’t directly impact clinical practice, the vaporizer market’s evolution affects product availability and quality standards that clinicians must understand. Market consolidation and capitalization patterns in cannabis delivery devices influence what products patients are actually using. Clinical Summary Papa Medical, a cannabis vaporizer company, has increased its IPO share offering, reflecting broader market dynamics in cannabis delivery technology. Vaporization remains a harm-reduction strategy compared to combustion, with better temperature control and reduced combustion byproducts. However, the clinical evidence for vaporizers primarily comes from flower vaporization studies, not concentrate-focused devices that dominate commercial markets. Dr. Caplan’s Take “I care less about any single company’s stock performance and more about whether the products patients are using have consistent dosing, quality testing, and appropriate temperature ranges. The disconnect between research on flower vaporization and the concentrate products driving these markets remains problematic.” Clinical Perspective 🧠 Clinicians should focus on the fundamentals: recommend vaporizers with temperature control, emphasize products with third-party testing, and counsel patients that ‘vaping’ encompasses vastly different delivery methods with different risk profiles. Market movements don’t change the core clinical guidance around harm reduction and product selection. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.renaissancecapital.com/IPO-Center/News/117782/Cannabis-vape-products-provider-Papa-Medical-more-than-doubles-shares-offer FAQ What are cannabis vaporizers and how do they work? Cannabis vaporizers are devices that heat cannabis flower or concentrates to temperatures that release active compounds without combustion. They offer a potentially less harmful alternative to smoking by avoiding the toxic byproducts created when cannabis is burned. How do vaporizers contribute to harm reduction in cannabis use? Vaporizers reduce harm by eliminating combustion, which produces tar and other harmful chemicals associated with smoking. This method of consumption may reduce respiratory irritation and exposure to carcinogenic compounds while still delivering therapeutic cannabinoids. What should patients consider when choosing a cannabis vaporizer? Patients should consider factors such as device quality, temperature control options, ease of use, and whether they prefer flower or concentrate consumption. Product quality and safety certifications are also important considerations for medical cannabis patients. Are there different types of cannabis vaporizers available? Yes, there are portable handheld vaporizers, desktop units, and pen-style devices designed for different cannabis products. Some are designed specifically for dry herb, others for concentrates, and some accommodate both forms of cannabis. What current market trends are affecting cannabis vaporizer availability? The cannabis vaporizer market is experiencing growth driven by increased consumer awareness of harm reduction and evolving cannabis legalization. Technological improvements and expanding product options are making vaporizers more accessible to medical and recreational users. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Cannabis vape products provider Papa Medical more than doubles shares offered ahead of …”, “url”: “https://www.renaissancecapital.com/IPO-Center/News/117782/Cannabis-vape-products-provider-Papa-Medical-more-than-doubles-shares-offer”, “datePublished”: “2026-03-20T18:38:04Z”, “about”: “cannabis vape products provider papa medical”} [...] Read more...
March 20, 2026✦ New CED Clinical Relevance  #84High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic RegulatoryAlabamaProgram AdministrationPatient AccessQuality Control Why This Matters Administrative oversight failures in state cannabis programs directly impact patient access to regulated, quality-controlled medical cannabis products. When regulatory bodies lack proper financial controls, it raises concerns about their capacity to effectively oversee product safety, testing standards, and dispensary operations that patients depend on. Clinical Summary An audit of Alabama’s Medical Cannabis Commission revealed financial violations and a $200,000 overpayment, though specific details of the administrative failures were not provided in available reporting. Alabama’s medical cannabis program is relatively new, having been authorized in 2021 with patient access beginning in 2023. Regulatory oversight is critical for ensuring product quality, safety testing, and proper dispensary operations in state medical cannabis programs. Dr. Caplan’s Take “Administrative chaos in cannabis regulatory bodies is unfortunately common during program launches, but it’s a red flag for clinical quality oversight. When I see financial mismanagement, I worry about corners being cut in laboratory testing and product safety monitoring.” Clinical Perspective 🧠 Clinicians in Alabama should stay informed about regulatory developments that may affect product availability or quality standards. Patients should continue following proper medical cannabis protocols through licensed dispensaries, but may want to discuss backup treatment options if regulatory disruptions affect access. This highlights the importance of working with established, compliant dispensaries. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn 🦥 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.wbrc.com/2026/03/20/alabama-medical-cannabis-commission-audit-finds-violations-200k-overpayment/ {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Alabama Medical Cannabis Commission audit finds violations, $200K overpayment – WBRC”, “url”: “https://www.wbrc.com/2026/03/20/alabama-medical-cannabis-commission-audit-finds-violations-200k-overpayment/”, “datePublished”: “2026-03-20T17:52:03Z”, “about”: “alabama medical cannabis commission audit finds”} [...] Read more...
March 20, 2026✦ New CED Clinical Relevance  #80High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic RegulationPatient AccessMedical CannabisPolicySafety Why This Matters Virginia’s potential cannabis marketplace timing directly impacts patient access to regulated products with known potency and purity. Regulatory frameworks determine whether patients can access consistent, lab-tested cannabis medicines versus relying on unregulated sources with variable quality and safety profiles. Clinical Summary Virginia is considering cannabis legislation that would establish a regulated marketplace, though specific timeline details are not provided. The state already permits medical cannabis use but lacks a fully developed commercial infrastructure. Regulatory timelines typically span 12-24 months from legislation passage to market opening, involving licensing, testing requirements, and facility establishment. Patient access during interim periods often remains limited to existing medical programs or unregulated sources. Dr. Caplan’s Take “Regulatory uncertainty creates a treatment gap where patients need guidance on accessing safe, consistent products while markets develop. I counsel patients to work within existing medical frameworks when possible and prioritize product testing and sourcing transparency regardless of legal status.” Clinical Perspective 🧠 Clinicians should prepare for increased patient inquiries about cannabis access as regulatory changes approach. Focus discussions on product safety, consistent dosing, and avoiding unregulated sources. Monitor existing medical programs for expanded access opportunities while commercial markets develop. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://wtop.com/virginia/2026/03/as-virginia-governor-considers-marijuana-legislation-when-would-the-marketplace-open/   {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “As Virginia governor considers marijuana legislation, when would the marketplace open?”, “url”: “https://wtop.com/virginia/2026/03/as-virginia-governor-considers-marijuana-legislation-when-would-the-marketplace-open/”, “datePublished”: “2026-03-20T17:27:31Z”, “about”: “virginia governor considers marijuana legislation when”} [...] Read more...
March 20, 2026CED Clinical Relevance  #84High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🧪 Clinical Trial Watch  |  CED Clinic Observational StudyDriving ImpairmentCannabis SafetyAlcohol InteractionCognitive Function Trial ID NCT02710097 Phase N/A Status Active Not Recruiting Condition Cannabis Intervention Active inhaled cannabis Why This Matters This study addresses a critical public safety question about the combined effects of alcohol and cannabis on driving performance. With increasing cannabis legalization and concurrent use patterns, understanding how these substances interact to impair driving-related cognitive functions is essential for evidence-based policy and clinical guidance. Clinical Summary This active observational study examines the effects of ethanol and inhaled cannabis on simulated driving performance and cognitive function. The trial uses a controlled laboratory setting to measure impairment parameters when subjects use cannabis alone, alcohol alone, and in combination. Primary endpoints focus on driving simulator performance metrics and standardized cognitive assessments. The study is currently active but not recruiting new participants. Dr. Caplan’s Take “This research could provide the objective data we desperately need to counsel patients about cannabis use and driving safety. If the results demonstrate measurable impairment thresholds, it would give clinicians evidence-based parameters for patient education about responsible use timing.” Clinical Perspective 🧠 Patients using cannabis should understand that this research aims to establish scientific baselines for impairment that could inform future legal standards. Clinicians should recognize that robust driving impairment data remains limited, making this type of controlled research valuable for developing clinical recommendations about cannabis use and driving safety intervals. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://clinicaltrials.gov/study/NCT02710097 {“@context”: “https://schema.org”, “@type”: “MedicalStudy”, “headline”: “Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II”, “url”: “https://clinicaltrials.gov/study/NCT02710097”, “about”: “n cannabis ethanol cannabinoid effects simulated”} [...] Read more...
March 19, 2026Cannabis-Based Medicines Show Promise for Insomnia Treatment A recent clinical outcomes analysis published in PLOS Mental Health has provided new evidence supporting the potential therapeutic role of cannabis-based medicinal products in treating insomnia. The UK-based study, which tracked 124 adult patients over an 18-month period, represents one of the more comprehensive real-world examinations of prescribed cannabis medicines for sleep disorders to date. Study Design and Patient Population Researchers analyzed data from the UK Medical Cannabis Registry (UKMCR), focusing on patients who had been prescribed cannabis-based medicinal products specifically for insomnia treatment. All participants had confirmed insomnia diagnoses and had previously failed to achieve improvement with at least two licensed conventional medications before being considered for cannabis-based therapy. The study employed patient-reported outcome measures (PROMs) to assess treatment efficacy, with follow-up evaluations conducted at 1, 3, 6, 12, and 18 months. This longitudinal approach allowed researchers to track both immediate and sustained treatment effects, addressing a critical gap in the literature regarding long-term outcomes of cannabis-based insomnia treatments. Dosing Patterns and Treatment Protocols The study revealed distinct dosing patterns for the two primary cannabinoids used in treatment: CBD dosing: Patients began with a median daily dose of 1 mg, which increased to 10 mg/day by month 3 and remained stable through month 18 THC dosing: Starting with a median of 20 mg/day at baseline, THC doses showed more substantial increases, reaching 120 mg/day by month 18 These dosing patterns suggest that while CBD requirements stabilized relatively quickly, THC dosing continued to be titrated upward throughout the treatment period, potentially indicating tolerance development or the need for individualized dose optimization. Clinical Context and Current Treatment Landscape The research addresses a significant clinical need, as insomnia affects approximately 10% of the global adult population. Current standard treatments include cognitive behavioral therapy for insomnia (CBT-I) and prescription medications, each presenting distinct challenges. CBT-I faces provider shortages that limit accessibility, while conventional sleep medications often lack robust evidence for long-term safety and efficacy. Clinical Takeaways This registry-based study provides preliminary evidence that cannabis-based medicinal products may offer a viable treatment option for patients with treatment-resistant insomnia. The structured approach requiring failure of at least two conventional treatments before cannabis prescription represents a responsible clinical framework that positions cannabis-based medicines as a secondary intervention rather than first-line therapy. Healthcare providers should note that this research represents real-world clinical outcomes rather than controlled trial data, which offers valuable insights into practical implementation while acknowledging the inherent limitations of registry-based studies. The findings support the need for larger, controlled clinical trials to further establish the efficacy and safety profile of cannabis-based treatments for insomnia. As the field continues to evolve, these preliminary results suggest that cannabis-based medicinal products warrant serious consideration within comprehensive insomnia treatment strategies, particularly for patients who have not responded adequately to conventional therapies. [...] Read more...
March 19, 2026Cannabis and Sleep: What the Clinical Evidence Actually Tells Us What You’ll Learn in This Post ❇️ How THC and CBD affect different stages of sleep architecture ♦︎ Why timing your cannabis dose matters more than you think ❇️ The tolerance trap that catches most sleep-seeking patients ♦︎ When cannabis helps sleep disorders and when it doesn’t ❇️ Evidence-based dosing strategies for sustainable sleep improvement TL;DR THC helps you fall asleep faster but suppresses REM sleep. CBD improves sleep quality without the high. Timing matters – dose 1-3 hours before bed. Tolerance develops with nightly use. Individual responses vary dramatically based on genetics and sleep disorders. Cannabis compounds interact differently with sleep stages, affecting both sleep onset and sleep architecture throughout the night. I’ve spent the better part of a decade watching patients navigate the complex relationship between cannabis and sleep. What I’ve learned might surprise you: it’s not as simple as “cannabis makes you sleepy.” The clinical evidence reveals a nuanced picture that every patient considering cannabis for sleep should understand. Sleep complaints drive nearly 40% of my cannabis consultations. Patients arrive frustrated by prescription sleep aids, desperate for natural alternatives, or simply seeking better sleep quality. What they discover is that cannabis and sleep involves a delicate dance between different compounds, timing, and individual biology. The Science Behind Cannabis Sleep Effects Let’s start with what we know from controlled studies. THC, the psychoactive compound in cannabis, consistently reduces sleep latency—the time it takes to fall asleep. In clinical trials, patients using THC-dominant preparations fall asleep an average of 30 minutes faster than placebo groups. But here’s where it gets interesting: THC also suppresses REM sleep, the stage associated with dreaming and memory consolidation. This creates what I call the “sleep paradox”—you fall asleep faster but potentially compromise sleep quality over time. THC and CBD have distinctly different effects on sleep architecture, with implications for long-term sleep health. CBD tells a different story entirely. Research from the University of Colorado showed that CBD for sleep disorders improved sleep scores in 79% of patients without causing daytime sedation. Unlike THC, CBD doesn’t suppress REM sleep and may actually normalize sleep architecture in people with anxiety-related sleep disturbances. The mechanism matters here. THC binds directly to CB1 receptors in areas of the brain that regulate sleep-wake cycles. CBD works more indirectly, modulating neurotransmitter systems involved in stress response and circadian rhythm regulation.</p Frequently Asked Questions Why should clinicians care about this topic? How cannabis affects sleep quality and architecture Where can patients learn more? Visit cedclinic.com for evidence-based cannabis medicine resources, clinical consultations, and educational content from Dr. Caplan and the CED team. How does this relate to the endocannabinoid system? The endocannabinoid system is a fundamental regulatory network throughout the body. Understanding how it functions is essential for evidence-based cannabis medicine practice. {“@context”: “https://schema.org”, “@type”: “Article”, “headline”: “Cannabis and Sleep: Clinical Evidence”, “url”: “https://example.com/cannabis-sleep”, “about”: “cannabis sleep clinical evidence”} [...] Read more...
March 19, 2026CED Clinical Relevance  #98High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🧪 Clinical Trial Watch  |  CED Clinic Clinical TrialVeteransCbdChronic PainPlacebo-Controlled Trial ID NCT06213233 Phase N/A Status Recruiting Condition Pain, Chronic Intervention Placebo Why This Matters Veterans experience disproportionately high rates of chronic pain, often inadequately managed with conventional therapies. This placebo-controlled trial addresses a critical evidence gap by rigorously testing CBD’s analgesic potential in this underserved population. Clinical Summary MIVetsCan is a randomized, placebo-controlled trial evaluating CBD versus placebo for chronic pain management in Veterans. The study is currently recruiting participants and will assess whether CBD can meaningfully improve overall pain symptoms compared to inactive treatment. This represents one of the first dedicated studies examining CBD’s therapeutic potential specifically within the veteran population. Dr. Caplan’s Take “If positive, this trial could provide the evidence base needed to confidently recommend CBD for veteran chronic pain management. The veteran-specific population makes these results particularly relevant for understanding CBD’s role in complex, treatment-resistant pain syndromes.” Clinical Perspective 🧠 Veterans with chronic pain should consider this an opportunity to contribute to meaningful research while potentially accessing CBD therapy. Clinicians should note that rigorous placebo-controlled data in this population remains limited, making participation valuable for advancing evidence-based cannabis medicine. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://clinicaltrials.gov/study/NCT06213233 {“@context”: “https://schema.org”, “@type”: “MedicalStudy”, “headline”: “MIVetsCan: Cannabidiol (CBD)-Care Trial”, “url”: “https://clinicaltrials.gov/study/NCT06213233”, “about”: “n pain chronic mivetscan cannabidiol cbd”} [...] Read more...
March 19, 2026CED Clinical Relevance  #90High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🧪 Clinical Trial Watch  |  CED Clinic Observational StudyThcDriving ImpairmentAlcohol InteractionPsychomotor Function Trial ID NCT02709954 Phase N/A Status Active Not Recruiting Condition Cannabis Intervention Active inhaled delta-9-THC Why This Matters With increasing cannabis legalization and concurrent alcohol use, understanding the combined cognitive and psychomotor effects of these substances on driving performance addresses a critical public safety gap. This research provides essential data for evidence-based impairment detection and policy development. Clinical Summary This active observational study examines the effects of inhaled delta-9-THC, ethanol, and their combination on simulated driving performance and cognitive function. The trial uses controlled administration of both substances to measure impairment patterns, reaction times, and driving simulator metrics. Currently active but not recruiting, this study aims to establish pharmacokinetic-pharmacodynamic relationships between substance levels and measurable impairment. Dr. Caplan’s Take “This trial could provide the objective impairment data we desperately need to counsel patients about cannabis use and driving safety. If successful, it may establish evidence-based guidelines for when patients can safely operate vehicles after cannabis use.” Clinical Perspective 🧠 Patients using cannabis should know that objective impairment data from controlled studies like this will inform future safety recommendations. Clinicians should monitor this research as it may provide the first robust framework for advising patients about cannabis, alcohol, and driving interactions. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://clinicaltrials.gov/study/NCT02709954 {“@context”: “https://schema.org”, “@type”: “MedicalStudy”, “headline”: “Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I”, “url”: “https://clinicaltrials.gov/study/NCT02709954”, “about”: “n cannabis ethanol cannabinoid effects simulated”} [...] Read more...
March 19, 2026CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🧪 Clinical Trial Watch  |  CED Clinic Observational StudyCannabis Use PatternsYoung AdultsLongitudinalMobile Health Technology Trial ID NCT07063589 Phase N/A Status Recruiting Condition Cannabis Use Intervention Mobile application Why This Matters Young adults represent the fastest-growing demographic of cannabis users, yet we lack comprehensive data on how consumption patterns evolve over time and correlate with health outcomes. This longitudinal study addresses a critical gap in understanding real-world cannabis use patterns during a formative developmental period. Clinical Summary This is an observational longitudinal study tracking cannabis consumption patterns in regular users aged 18-24 over two years using mobile application technology. The study employs a multi-factor approach examining frequency of use, product types, and cannabinoid dosages to characterize consumption patterns and their associations with social and health outcomes. Participants are currently being recruited for this naturalistic study of non-therapeutic cannabis use. Dr. Caplan’s Take “If this study successfully captures granular, real-time data on young adult cannabis use patterns, it could provide the evidence base we desperately need for age-appropriate clinical guidance and harm reduction strategies. The longitudinal design may finally give us insights into how early use patterns predict later health trajectories.” Clinical Perspective 🧠 This observational study offers young adults an opportunity to contribute to cannabis research while receiving no direct medical intervention. Clinicians should note this represents surveillance research rather than a treatment trial, but the findings may inform future clinical recommendations for this age group. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://clinicaltrials.gov/study/NCT07063589 {“@context”: “https://schema.org”, “@type”: “MedicalStudy”, “headline”: “Cannabis Use Patterns Among Young Adults and Associations With Social and Health Outcomes.”, “url”: “https://clinicaltrials.gov/study/NCT07063589”, “about”: “n cannabis use cannabis use patterns”} [...] Read more...
March 19, 2026Clinical Takeaway Low-dose balanced THC-CBD extract demonstrated statistically significant cognitive improvement in Alzheimer’s patients over 26 weeks with favorable safety profile. TL;DR ❇️ First long-term cannabis Alzheimer’s treatment trial shows cognitive improvement ❇️ Ultra-low doses (0.35mg THC, 0.245mg CBD daily) proved effective and safe ❇️ Mini-Mental State Exam scores significantly higher than placebo at 26 weeks ❇️ No significant adverse events compared to control group ❇️ Phase 2 trial sets foundation for larger Alzheimer’s cannabinoid studies What You’ll Learn in This Post —  How low-dose cannabis extract affects Alzheimer’s disease progression —  Specific THC and CBD dosing protocols used in clinical research —  Why balanced cannabinoid formulations target multiple AD pathways —  Clinical significance of improved Mini-Mental State Examination scores —  Safety considerations for cannabis use in elderly dementia patients Breakthrough Results in Cannabis Alzheimer’s Treatment Research A groundbreaking phase 2 clinical trial has provided the most compelling evidence to date that cannabis Alzheimer’s treatment may offer genuine therapeutic benefit for patients with dementia. Published in the Journal of Alzheimer’s Disease, this 26-week randomized, double-blind, placebo-controlled study represents the longest evaluation of cannabinoids in Alzheimer’s disease patients, delivering results that could reshape our approach to neurodegenerative disease management. The study, conducted by researchers at the Universidade Federal da Integração Latino-Americana in Brazil, demonstrated that patients receiving low-dose THC-CBD extract showed statistically significant improvement in Mini-Mental State Exam scores compared to placebo-treated patients. What makes this cannabis Alzheimer’s treatment particularly noteworthy is the remarkably low dosing—just 0.350 mg of THC and 0.245 mg of CBD administered daily. Understanding the Endocannabinoid System’s Role in Alzheimer’s Disease The rationale for investigating cannabis Alzheimer’s treatment stems from our growing understanding of how the endocannabinoid system intersects with Alzheimer’s pathophysiology. The disease’s hallmark features—amyloid-beta oligomers and hyperphosphorylated tau protein accumulation—trigger cascading inflammatory responses that the endocannabinoid system may help modulate. Neuroinflammation, gliosis, oxidative stress, insulin resistance, and neurotransmitter dysfunction all contribute to Alzheimer’s progression. The endocannabinoid system, through CB1 and CB2 receptors distributed throughout the central nervous system, offers multiple therapeutic targets for addressing these pathological processes simultaneously. Balanced THC-CBD Formulation Strategy The researchers chose a balanced THC-CBD formulation for several mechanistic reasons. THC’s interaction with CB1 receptors may help preserve cholinergic function and reduce amyloid-beta toxicity, while CBD’s anti-inflammatory properties and ability to modulate microglial activation could address the neuroinflammatory component of Alzheimer’s disease. This cannabis Alzheimer’s treatment approach recognizes that single-compound interventions may be insufficient for such a complex, multi-factorial disease. Clinical Trial Design and Patient Population The study enrolled patients aged 60-80 years with diagnosed Alzheimer’s-associated dementia, representing the demographic most affected by this devastating condition. The 26-week duration allowed researchers to observe sustained effects while minimizing the ethical concerns of prolonged placebo administration in this vulnerable population. Participants received either placebo or the THC-CBD extract orally once daily. The dosing protocol—0.350 mg THC and 0.245 mg CBD—represents a microdose approach that aims to achieve therapeutic benefit while minimizing psychoactive effects, a crucial consideration for elderly patients with cognitive impairment. Primary Outcome Measures The Mini-Mental State Examination (MMSE) served as the primary outcome measure, providing a standardized assessment of cognitive function across domains including orientation, attention, memory, language, and visuospatial skills. The statistically significant improvement in MMSE scores among cannabis Alzheimer’s treatment recipients suggests broad-spectrum cognitive benefit rather than improvement in isolated cognitive domains. Safety Profile and Tolerability Considerations Perhaps equally important as the efficacy findings is the trial’s safety data. No significant difference in adverse events was detected between the placebo and cannabis Alzheimer’s treatment groups, suggesting excellent tolerability of the low-dose cannabinoid formulation. This safety profile is particularly relevant for elderly patients who often have multiple comorbidities and complex medication regimens. The absence of significant adverse events supports the hypothesis that ultra-low-dose cannabinoid therapy can achieve therapeutic benefit without the side effects commonly associated with higher-dose cannabis use, such as cognitive impairment, sedation, or cardiovascular effects. Clinical Implications and Future Research Directions These findings position cannabis Alzheimer’s treatment as a potential addition to our limited therapeutic armamentarium for dementia care. Current FDA-approved treatments for Alzheimer’s disease provide modest symptomatic benefit but do not address disease progression comprehensively. The multi-target approach offered by balanced cannabinoid therapy could represent a paradigm shift toward treating the underlying pathophysiology rather than merely managing symptoms. Integration with Standard Care The study’s results suggest that low-dose cannabinoid therapy could potentially complement existing treatments such as cholinesterase inhibitors and NMDA receptor antagonists. However, larger trials will be necessary to establish optimal combination strategies and identify patient populations most likely to benefit from cannabis Alzheimer’s treatment. As we await larger, longer-duration trials, this breakthrough research provides compelling preliminary evidence that cannabinoid medicine may offer hope for the millions of patients and families affected by Alzheimer’s disease. The ultra-low dosing approach demonstrated in this study could make this therapy accessible and tolerable for elderly patients while potentially slowing cognitive decline in this devastating neurodegenerative condition. [...] Read more...
March 19, 2026Clinical Takeaway In this small three-month study of adults receiving buprenorphine for opioid use disorder, adjunctive medical cannabis was associated with modest improvements in pain, sleep, and several quality of life measures. Those findings are clinically interesting, especially in a population where chronic pain can destabilize recovery, but they do not show that cannabis treated opioid use disorder itself or clearly reduced illicit opioid use. TL;DR ❇️ Adults on buprenorphine with chronic pain reported lower pain scores after three months of adjunctive medical cannabis ❇️ Pain interference improved, and patients felt more capable of managing their pain ❇️ Seven of eight quality of life domains moved in a favorable direction ❇️ Sleep quality improved during follow-up ❇️ The study did not show a statistically significant reduction in craving or illicit opioid use What You’ll Learn in This Post 🧠 What this study actually tested in patients with opioid use disorder and chronic pain 💊 How a low-dose 1:1 THC:CBD formulation performed alongside buprenorphine treatment 🌙 What changed in pain, sleep, and quality of life over three months ⚖️ Why symptom improvement should not be confused with proof of addiction treatment efficacy 🔎 What clinicians should and should not take away from these findings Medical Cannabis in Opioid Use Disorder Care Deserves Careful Reading A recent study in the Journal of Cannabis Research looked at a question many clinicians quietly wrestle with: what do you do when a patient in treatment for opioid use disorder is still living with significant chronic pain? For many people, pain is not a side issue. It is part of the reason recovery feels fragile, exhausting, and hard to sustain. This study followed 47 adults receiving buprenorphine for opioid use disorder, all of whom were also dealing with chronic pain. Over three months, participants used a standardized 1:1 THC:CBD formulation at 5 mg of each cannabinoid daily. Researchers tracked pain, sleep, quality of life, craving, and illicit opioid use. The result is not a dramatic victory lap for cannabis, nor is it a dismissal. It is more useful than either of those. It is a measured, imperfect, clinically relevant signal. Pain Improved, and That Matters The clearest finding in the paper was the change in pain. Average pain severity fell from 5.18 at baseline to 4.39 at three months. Pain interference improved too, meaning patients were not only reporting less pain, but also less disruption from pain in daily life. For people trying to stabilize their lives while in treatment for opioid use disorder, that distinction matters. It is one thing to hurt less. It is another to function better. The study also found an increase in pain-related self-efficacy. That is an important detail. When patients feel more able to manage their symptoms, they often gain something larger than symptom relief alone. They gain a bit of traction. A little more confidence. A little more room to participate in their own care, rather than feeling pinned under it. Quality of Life Did Not Just Inch Up in One Corner One of the more encouraging parts of the paper is that the changes were not limited to a single pain score. Seven of the eight quality of life domains assessed improved over the study period. That does not prove a broad pharmacologic effect across every domain of functioning, but it does suggest that the participants’ experience of daily life may have shifted in a meaningful way. That kind of pattern is often more interesting than one isolated endpoint. Patients do not live inside a pain scale. They live inside routines, relationships, stress, fatigue, mood, sleep, and the thousand little negotiations required to get through a day. When several of those areas move in the right direction at once, clinicians should pay attention, even while staying cautious about overinterpreting why the changes occurred. Sleep Got Better Too, Though the Study Cannot Tell Us Exactly Why Sleep quality improved over the three months of follow-up. That is worth noting, especially in a population where poor sleep can worsen pain, increase irritability, erode coping, and complicate recovery. Better sleep is not a small luxury in addiction care. Sometimes it is one of the things holding the rest of the treatment plan together. Still, the mechanism here remains uncertain. The study shows that sleep scores improved. It does not tell us whether that happened because of a direct cannabinoid effect, because pain eased, because routines became more stable, or because participants benefited from being observed and treated in a structured context. The outcome is meaningful. The explanation is still open. The Most Important Caution Is Also the Easiest One to Miss People seemed to hurt less. They appeared to sleep somewhat better. Several quality of life measures improved. But the study did not show a statistically significant reduction in illicit opioid use. Craving did not change significantly either. That matters, and it should not be tucked into the fine print. If a reader walks away thinking this paper showed that medical cannabis meaningfully reduced opioid misuse, that would be more than an overstatement. It would be inaccurate. The paper supports the possibility that cannabis may help some patients feel and function better while receiving buprenorphine. It does not establish cannabis as a treatment for opioid use disorder itself. That Distinction Is Clinically Useful, Not Deflating There is a temptation in this area to force everything into a yes-or-no argument. Either cannabis is a breakthrough for addiction care, or it is irrelevant. Real medicine is rarely that tidy. A therapy can have value without solving the whole problem. In this case, the paper suggests that adjunctive cannabis may have a role in symptom management for some patients with co-occurring opioid use disorder and chronic pain, particularly when the goal is reducing suffering and improving day-to-day function. That is not a small contribution. It is just a bounded one. And bounded conclusions are often the ones most worth keeping. What Clinicians Can Reasonably Take From This If you are caring for a patient on buprenorphine who continues to struggle with chronic pain, this study offers some cautious reassurance that a low-dose 1:1 THC:CBD approach may be tolerated in that setting and may be associated with modest improvements in pain, sleep, and quality of life. It also suggests that the conversation should stay honest. Symptom relief is not the same as addiction remission. Better sleep is not the same as lower relapse risk. Improved pain scores are not a proxy for reduced opioid misuse. That kind of clarity is important because patients with opioid use disorder are often poorly served by simplistic thinking from both directions. Some are told cannabis is inherently risky and therefore off limits. Others are told it is an obvious substitute for more complex treatment. Neither posture reflects the nuance the evidence demands. What This Study Does Not Show This study does not show that medical cannabis treats opioid use disorder. It does not prove that cannabis caused the improvements observed. It does not identify the best dose, the best cannabinoid ratio, the best route of administration, or the kinds of patients most likely to benefit. It also does not show a clear reduction in illicit opioid use or craving. Just as importantly, it does not tell us what would happen over a longer window. Three months is useful, but it is short. Many of the questions clinicians care about most, including durability, tolerance, functional stability, and longer-term risk-benefit balance, remain unanswered here. The Study Is Interesting, but It Is Also Small This was a preliminary study with 47 participants and no control group. That alone should shape the tone of any public interpretation. Small studies can be important. They can surface real signals. They can also exaggerate them, flatten their context, or leave too much room for background factors to explain what changed. That does not make the paper weak. It makes it early. And early papers are often most useful when they sharpen the next question rather than pretending to settle the first one. Bottom Line This study adds to a clinically relevant conversation. In adults receiving buprenorphine for opioid use disorder who also had chronic pain, adjunctive medical cannabis was associated with improvements in pain, sleep, pain-related self-efficacy, and several quality of life measures over three months. That is meaningful, particularly in a population where persistent pain can wear down recovery. But the findings stop short of something larger that some headlines or advocates may want to imply. The study did not show a statistically significant reduction in craving or illicit opioid use, and it did not prove causality. The fairest reading is also the most useful one: adjunctive cannabis may help some patients feel better while in treatment, but this paper does not show that it treats opioid use disorder itself. [...] Read more...
March 19, 2026Clinical Takeaway In this registry-based study of adults with treatment-resistant insomnia, cannabis-based medicinal products were associated with improvements in patient-reported sleep quality and anxiety over follow-up. The findings are clinically interesting, but they come from an observational dataset, rely heavily on subjective outcomes, and sit alongside substantial THC dose escalation over time. TL;DR ❇️ Patient-reported sleep quality improved over 18 months in adults prescribed cannabis-based medicines for insomnia ❇️ Participants had already failed at least two conventional medications before entering treatment ❇️ Anxiety scores improved early in follow-up ❇️ THC doses rose substantially over time, while CBD dosing remained comparatively low and stable ❇️ Adverse events were reported, most commonly fatigue and dry mouth, and the study cannot prove causation or long-term durability What You’ll Learn in This Post 👉 What this UK registry study actually measured in patients with chronic insomnia 👉 How sleep and anxiety outcomes changed over time 👉 What the THC and CBD dosing pattern may suggest about tolerance and treatment drift 👉 How to think about adverse events in a long-term observational cannabis study 👉 What this paper does and does not allow clinicians to conclude This Insomnia Study Is Interesting, but It Needs a Careful Read Insomnia is common, disruptive, and stubborn. Many patients cycle through the standard options, from behavioral strategies to prescription sedatives, and still do not sleep well. That is part of what makes this UK Medical Cannabis Registry paper worth attention. It focuses on adults with insomnia severe enough that at least two licensed medications had already failed. In other words, this was not a casual first try. It was a more refractory group. The study looked at 124 adults prescribed cannabis-based medicinal products for insomnia and followed patient-reported outcomes at 1, 3, 6, 12, and 18 months. That gives the paper some practical value. It reflects real-world prescribing rather than an idealized experimental setting. But it also means the evidence has limits from the start. This was retrospective, observational, and heavily dependent on subjective reporting. Useful, yes. Definitive, no. What Changed Over Time The main signal was improvement in subjective sleep quality. The Single-Item Sleep Quality Score rose from 2.66 at baseline to 3.81 at 18 months. For patients who have already burned through standard treatment options, that kind of movement is not trivial. Better sleep can mean better coping, less irritability, less pain amplification, and a little more stability in the rest of life. Anxiety scores improved too, and they improved early. GAD-7 scores fell from 9.59 at baseline to 4.99 at one month. That is a notable shift. It also fits a pattern many clinicians will recognize: sometimes what improves first is not sleep itself, but the mental friction around sleep. Patients may feel less keyed up, less anticipatory, less trapped in the nightly ritual of worrying that they will not sleep. That can matter a great deal. It just should not be confused with proof that the medication directly corrected the underlying insomnia syndrome. The Broader Quality-of-Life Changes Are Encouraging, but Still Soft-Edged The paper also reports improvement in some EuroQol-5 Dimension measures, including pain/discomfort and anxiety/depression, along with overall index values. That broadens the conversation a bit. Patients with chronic insomnia rarely suffer in only one domain. Sleep problems bleed into mood, physical discomfort, concentration, patience, and daily function. Still, these are patient-reported measures in an uncontrolled registry. They are meaningful, but they are not immune to expectancy effects, treatment context, concurrent care, or selection bias. The right reading here is not skepticism for its own sake. It is proportion. The study shows a favorable pattern in self-reported outcomes. It does not settle mechanism, comparative effectiveness, or durability of benefit. The Dosing Story May Be the Most Important Part of the Paper One of the most revealing findings is not the improvement in scores. It is the way the dosing changed over time. CBD remained comparatively modest. Patients began at a median dose of 1 mg daily, rose to 10 mg by month 3, and then largely stayed there. THC moved very differently. Median THC dosing started around 20 mg daily and climbed to 120 mg daily by month 18. That is a large increase, and it deserves more attention than it usually gets in upbeat summaries of cannabis sleep research. Why? Because when benefit appears alongside major THC escalation, clinicians have to ask harder questions. Are patients maintaining effect, chasing diminishing returns, or adapting to tolerance over time? The paper cannot fully answer that. But it does make clear that any discussion of long-term cannabis therapy for insomnia has to include dose creep, tolerance, and the practical challenge of sustaining benefit without simply pushing THC upward. Adverse Events Were Not the Whole Story, but They Were Not Minimal Either The safety data are easy to oversimplify. Eleven patients reported 112 adverse events. Most were classified as mild or moderate. Eleven were severe, though none were described as life-threatening or disabling. The most common complaints included fatigue and dry mouth, which will not surprise anyone familiar with cannabinoid therapy. Even here, interpretation takes some care. In a sleep population, symptom boundaries can blur. If a patient reports ongoing insomnia during treatment, that may reflect insufficient response, tolerance, inconsistent use, or a true adverse effect. Registry data are not always good at sorting those categories cleanly. So the safety picture is neither alarming nor trivial. It is mixed, and it is exactly the kind of profile that requires follow-up, dose reassessment, and honest counseling rather than casual reassurance. What This Study Adds, and What It Does Not This paper adds something useful to the insomnia conversation. It suggests that cannabis-based medicines may be associated with better patient-reported sleep and lower anxiety in a treatment-resistant population over extended follow-up. That matters, particularly because these were not uncomplicated patients trying a first-line therapy. But the study does not show that cannabis is broadly effective for insomnia across populations. It does not prove causation. It does not tell us whether cannabis outperforms CBT-I, hypnotics, or other approaches. It does not resolve whether the apparent benefit remains worth it when THC doses climb sixfold. And it certainly does not identify an ideal formulation or dosing strategy for long-term care. The Most Honest Clinical Takeaway Is a Narrow One For clinicians, this study supports cautious interest, not sweeping endorsement. If a patient with chronic, treatment-resistant insomnia is considering cannabis-based therapy, this paper offers some real-world evidence that symptom improvement is possible. It also offers a warning embedded in the same dataset: longer-term use may involve substantial THC escalation, and that changes the clinical conversation. That means cannabis should not be framed as a simple substitute for conventional insomnia care. It is better understood as a possible option for carefully selected patients, ideally with clear goals, close monitoring, and a plan for reassessing whether benefit is being maintained at a sensible cost. Bottom Line The UK Medical Cannabis Registry study is worth reading because it reflects a difficult group of patients and follows them longer than many cannabis papers do. The outcomes are encouraging on the surface. Sleep improved. Anxiety improved. Some broader quality-of-life measures improved too. But the paper becomes more interesting, not less, when you resist the urge to oversell it. This was observational evidence built on subjective reporting, not a controlled efficacy trial. And the sharp rise in THC exposure over time is not a side note. It may be one of the central clinical lessons. Cannabis-based medicines may help some patients with treatment-resistant insomnia, but any serious interpretation has to hold both parts of the picture at once: the potential benefit, and the escalating cost of maintaining it. [...] Read more...
March 18, 2026CED Clinical Relevance  #91High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🔬 Evidence Watch  |  CED Clinic CbdAppetiteMetabolismRctWeight Management Journal Appetite Study Type Randomized Trial Population Human participants Why This Matters This is the first controlled human study documenting CBD’s effects on actual food intake, not just subjective appetite ratings. The finding that a single 298mg CBD dose increased caloric intake by nearly 200 calories challenges assumptions about CBD’s appetite-suppressing properties and has direct implications for patients using CBD products. Clinical Summary This double-blind crossover RCT in 15 healthy adults found that 298mg CBD significantly increased ad libitum lunch intake by 193 kcal compared to placebo, despite no changes in subjective appetite ratings or postprandial glucose/lipid metabolism. The study used a robust design with metabolic measurements via indirect calorimetry and blood sampling following a standardized breakfast. The small sample size and single-dose design limit broader generalizability, and the mechanism driving increased intake without corresponding appetite changes remains unclear. Dr. Caplan’s Take “This surprises me clinically, I’ve had patients report both appetite stimulation and suppression with CBD, but the disconnect between actual intake and perceived hunger is notable. It suggests CBD may influence eating behavior through pathways beyond conscious appetite awareness.” Clinical Perspective 🧠 Clinicians should counsel patients that CBD may increase caloric intake independent of hunger sensations, particularly relevant for those managing weight or metabolic conditions. The 298mg dose tested is higher than typical commercial products, so effects at lower doses remain unknown and warrant individualized monitoring of eating patterns. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://pubmed.ncbi.nlm.nih.gov/41825697/ FAQ This study item was assembled from normalized source metadata and pipeline scoring. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “A single dose of cannabidiol increases ad libitum energy intake in healthy adults but does not affect postprandial glucose or lipid metabolism.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41825697/”, “about”: “appetite randomized trial single dose cannabidiol”, “isPartOf”: “Appetite”} [...] Read more...
March 18, 2026CED Clinical Relevance  #97High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🧪 Clinical Trial Watch  |  CED Clinic Clinical TrialChronic PainLow Back PainDronabinolPlacebo-Controlled Trial ID NCT06454669 Phase N/A Status Recruiting Condition Low Back Pain Intervention Dronabinol Why This Matters Chronic low back pain affects millions globally with limited effective treatment options, and this represents one of the first rigorous placebo-controlled trials specifically examining synthetic THC for this indication. The study addresses a critical evidence gap in cannabinoid medicine where most chronic pain data comes from observational studies rather than controlled trials. Clinical Summary This is an exploratory proof-of-concept, double-blind, placebo-controlled trial randomizing up to 75 participants with chronic low back pain 2:1 to receive oral dronabinol (synthetic THC) up to 30mg daily versus placebo over 8 weeks. The primary focus is establishing safety profiles and feasibility rather than efficacy endpoints, with results intended to inform the design of future larger-scale trials. The study is currently recruiting participants at a single site. Dr. Caplan’s Take “If this trial demonstrates acceptable safety and tolerability profiles, it could provide the foundational data needed to advance synthetic THC into larger efficacy trials for chronic low back pain. This represents an important step toward evidence-based cannabinoid prescribing for one of the most common pain conditions I encounter in practice.” Clinical Perspective 🧠 Patients should understand this is an early-stage safety study, not designed to definitively prove effectiveness for pain relief. Clinicians interested in cannabinoid pain management should monitor these results closely, as they may inform future prescribing guidelines and help establish dosing frameworks for dronabinol in chronic pain conditions. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://clinicaltrials.gov/study/NCT06454669 FAQ This trial item was assembled from normalized source metadata and pipeline scoring. {“@context”: “https://schema.org”, “@type”: “MedicalStudy”, “headline”: “Dronabinol as an Adjunct for Reducing Pain”, “url”: “https://clinicaltrials.gov/study/NCT06454669”, “about”: “n low back pain dronabinol adjunct”} [...] Read more...
b marijuana b status based prohibition tag arch 3
March 18, 2026Study Review • Psychiatry • Evidence Interpretation Cannabis Use Disorder Psychiatric Risk: What This 2026 Study Actually Shows A careful review of a large new study comparing cannabis use disorder with other substance use disorders, with closer attention to youth risk, comparator choice, and the limits of ICD-coded psychiatric outcomes. Read related psychiatric context Browse the research library Cannabis use disorder psychiatric risk deserves a narrower reading than most headlines allow Every few months, a cannabis paper gets pulled into one of two familiar storylines. One version says cannabis is uniquely dangerous. The other says cannabis has been unfairly maligned and now looks comparatively benign. This 2026 paper does not cleanly support either of those instincts. The study compared patients diagnosed with cannabis use disorder, or CUD, against patients diagnosed with other substance use disorders, or SUDs. That is the first point that has to stay in view. This was not a comparison against nonuse. It was not a safety study in the broad public-health sense. It was a relative comparison inside already high-risk substance-using populations. Once that is clear, the paper becomes more useful and less likely to be misused. In adults, CUD often looked less psychiatrically adverse than some other SUD groupings. In youth, the pattern went in the opposite direction, with higher recorded rates of schizophrenia, depression, and anxiety after CUD than after other pediatric SUDs. That age split is where the study becomes genuinely interesting, and where caution matters most. What this page is doing: This is not a generic summary of cannabis and mental health. It is a study-interpretation page focused on exposure definition, comparator choice, outcome measurement, and what clinicians can responsibly say after reading the paper. What the study actually measured This was a retrospective cohort analysis using the TriNetX Research Network, which aggregates electronic health record and claims data from health systems across the United States. The authors identified patients with substance use disorders and no preceding mental disorder diagnosis, then compared three matched groups: adults with CUD only versus adults with another single SUD, pediatric patients with CUD only versus pediatric patients with another SUD, and adults with CUD plus another SUD versus adults with multiple non-cannabis SUDs. The exposure here was not dose, potency, route, or product chemistry. It was ICD-10 coding for cannabis-related disorder. The outcomes were also ICD-10-coded diagnoses, including schizophrenia, depressive disorders, anxiety disorders, bipolar disorder, suicide attempts, ADHD, borderline personality disorder, and psychotic disorders. That gives the study real scale, but it also places hard limits on what it can mean. In other words, this paper measured recorded clinical coding patterns after recorded SUD diagnoses. It did not measure THC percentage, CBD content, concentrates versus flower, inhalation versus ingestion, or age at first use. It did not tell us how much cannabis was used, how often it was used, or in what clinical or nonclinical context. That matters because ICD-coded cannabis use disorder is not a pharmacologically precise exposure, and it is not always a clinically uniform one. Key Study Parameters Study: Nicholson et al., American Journal of Psychiatry, published online March 4, 2026. Read the study Population: U.S. TriNetX patients with SUD diagnoses and no prior recorded mental disorder diagnosis Exposure: ICD-10-coded cannabis use disorder Comparator: Other ICD-10-coded substance use disorders, including alcohol, cocaine, opioid, and mixed SUD comparators Primary outcomes: Later ICD-10-coded psychiatric diagnoses Follow-up window: From qualifying SUD diagnosis until loss of tracked health information or study end date Main finding: Adult and pediatric patterns diverged sharply Primary limitation: No direct measurement of dose, potency, route, age at first use, or true psychiatric onset The adult findings look calmer, but only inside a very specific frame After matching, the main adult comparison included 345,903 patients in each cohort. Adults with CUD only had lower recorded risk of schizophrenia, recurrent major depressive disorder, suicide attempt, bipolar disorder, and psychotic disorders than adults with other single SUDs. The differences were statistically persuasive, but often modest in absolute terms. Schizophrenia, for example, was recorded in 0.34% of adults with CUD and 0.42% of adults with other SUDs. The adult polysubstance comparison showed a similar directional pattern. Adults with CUD plus another SUD had lower recorded risk of nearly every measured psychiatric diagnosis than adults with multiple non-cannabis SUDs. Again, this sounds more reassuring than it should if read too quickly. The study is not telling us that cannabis use disorder is good for mental health. It is telling us that among adults already in SUD-coded populations, CUD often looked less psychiatrically burdensome than some comparator groups. That is narrower, but it is the defensible reading. Relative burden inside an SUD population is not the same thing as absolute safety, and it is not the same thing as psychiatric protection. The pediatric findings are the part of the paper that should slow readers down In youth, the signal moved in the other direction. After matching 24,793 pediatric patients per cohort, the CUD group had higher recorded risk of schizophrenia, nonrecurrent depressive episodes, recurrent major depressive disorder, and anxiety disorders than the pediatric other-SUD group. Schizophrenia appeared in 0.29% of pediatric CUD patients versus 0.19% of pediatric other-SUD patients. Anxiety disorders were recorded in 8.13% versus 6.71%. That does not mean every adolescent using cannabis is headed toward psychiatric illness. It does mean that within this dataset, and within these coded definitions, youth CUD carried a more concerning psychiatric profile than other pediatric substance-use diagnoses. For clinicians, families, and policymakers, that portion of the paper deserves more attention than the tempting adult headline. It also fits more comfortably with what many readers already understand intuitively: adolescence is not just adulthood with a smaller shoe size. It is a neurodevelopmentally distinct window, and the endocannabinoid system is part of that developmental architecture. Comparator choice changes the story more than most readers will realize One of the most useful parts of the paper is the substance-specific adult comparison. When the authors compared CUD with alcohol use disorder, adult schizophrenia rates were not significantly different. When they compared CUD with cocaine use disorder, CUD looked less adverse on schizophrenia and psychotic disorders. When they compared CUD with opioid use disorder, CUD showed a slightly higher recorded schizophrenia rate, 0.25% versus 0.22%. That matters because it prevents the adult findings from being flattened into a slogan. If the result shifts when the comparator shifts, then the conclusion is not really “cannabis lowers psychiatric risk.” The conclusion is that psychiatric risk profiles differ across SUD categories, and cannabis occupies a different position depending on which substance it is compared against. From a study-interpretation standpoint, this is probably the single most important point in the entire paper. Comparator choice is not a detail. Comparator choice is the architecture of the conclusion. What this study does not show This study does not show that cannabis protects adults against schizophrenia, depression, bipolar disorder, or suicide. It does not show that cannabis is psychiatrically benign. It does not show that all forms of cannabis exposure behave alike. And it does not show that the youth findings are explained solely by cannabis itself rather than by shared vulnerability, prodromal symptoms, or uneven detection patterns. It also does not capture the variables that many clinicians would most want to see before advising real people. There was no reliable quantification of severity, no age-at-first-use measurement, no product chemistry, no route-of-administration stratification, no meaningful potency breakdown, and no ability to distinguish high-frequency exposure from lighter patterns of use. That means the paper should not be used to reassure adults too broadly, and it should not be used to panic families either. It should be used to sharpen the conversation. The key boundary: This is an observational EHR study using ICD-coded exposure and ICD-coded outcomes. It can identify associations inside a clinical database. It cannot establish causation, safety, or protection. Clinical Framing How I think about cannabis use disorder in real clinical life It is worth pausing here to acknowledge a complication that sits quietly underneath this entire paper. The study treats cannabis use disorder, or CUD, as a defined exposure category. In database research, that is unavoidable. In real clinical life, it is often much less tidy. I do believe cannabis use can become unhealthy, compulsive, destabilizing, or functionally impairing. I have seen patients use cannabis in ways that worsen anxiety, cloud judgment, intensify thought loops, reduce motivation, strain relationships, or interfere with work, parenting, or treatment goals. That is real, and it deserves to be taken seriously. At the same time, I also think the medical system has often been too quick to label recurring cannabis use as pathological without asking better questions about context, purpose, dose, product type, symptom burden, or alternative explanations. A person who uses cannabis regularly for sleep, pain, trauma-related distress, or chemotherapy-related suffering is not automatically showing the same pattern as someone whose use is repetitive, escalating, destabilizing, and increasingly disconnected from benefit. This distinction matters. Tolerance can happen with many biologically active substances. Withdrawal can happen when the body has adapted to repeated exposure. Craving can reflect compulsive reward-seeking, but it can also reflect remembered relief. None of those facts should be ignored, but none of them should be treated as self-interpreting either. For me, the more meaningful clinical question is not whether a person meets a checkbox definition in the abstract. It is whether cannabis use is improving life, narrowing life, or quietly beginning to run the show. I worry more when use is causing repeated functional fallout, unsafe behavior, worsening psychiatric symptoms, failed attempts to regain control, or continued use in the face of obvious and accumulating harm. That is part of why this study needs careful interpretation. Its exposure category is ICD-coded CUD, not a richly described clinical picture. Some people inside that category may indeed have serious, impairing cannabis-related illness. Others may have been coded in ways that flatten medical use, coping behavior, habituation, or symptom-directed reliance into a more stigmatized label than their lived reality deserves. Both possibilities can exist at the same time. So yes, cannabis use disorder can be real and important. But it should be diagnosed with nuance, not reflex. And when we read studies built on coded definitions, we should remember that the label is doing a lot of work that the underlying data cannot fully explain. Why the limitations are not technical footnotes The authors acknowledge several important limitations, and they deserve to stay in the foreground. The TriNetX system could not quantify SUD severity or age at first use. It did not record specific cannabis product types. It included variable lengths of patient history, which means psychiatric outcomes could be missed if patients left tracked systems. And because the study relied on people who sought treatment and entered health systems, it excludes many individuals with SUDs or psychiatric symptoms who never appear in those records. There is another problem here that matters clinically. Many psychiatric conditions begin before they are formally diagnosed. Anxiety, emerging psychosis, ADHD, trauma-related symptoms, and mood instability can precede clean coding by months or years. So even though the paper required that the SUD diagnosis appear first in the chart, that sequence may not reflect the real sequence of illness. That is why chart order and real-life order should never be treated as identical. In psychiatric research, they often are not. What clinicians and careful readers can responsibly take from this paper The study is useful. It adds texture. It tells us that psychiatric outcome patterns are not interchangeable across substance-use categories, and that age matters profoundly. It also gives a more structured way to talk about why adult cannabis findings can look different depending on the comparator used. At the same time, the most durable takeaway is not that adult cannabis use disorder is somehow protective. It is that adult CUD may rank differently than some other SUDs inside treatment-documented datasets, while youth CUD still appears meaningfully concerning. That is a much more restrained conclusion, but it is the one that survives scrutiny. Clinically, the youth signal supports careful psychiatric screening, cautious messaging, and continued respect for adolescent vulnerability. In adults, the paper supports nuance rather than reflexive alarm, but it does not support easy reassurance. If a reader wants one sentence to carry forward, it should be this: this study makes the adult story more conditional and the youth story harder to dismiss. Related pathways for readers who want deeper context This topic sits at the intersection of psychiatric nuance, adolescent vulnerability, and responsible interpretation of cannabis research. These pathways can help readers place the study in a broader clinical frame. Broader psychiatric context Cannabis and Psychiatric Disorders offers a wider clinical lens on psychiatric conditions, cannabis, and the importance of careful framing. Youth-specific evidence More Research on Adolescent Cannabis Use and Mental Disorders extends the adolescent conversation in a way that complements the youth signal in this paper. Adult mental health context Cannabis and Mental Health helps place psychiatric risk in a broader clinical landscape beyond a single study. Research interpretation and evidence depth CED Clinic’s Cannabis Literature Library is the best next stop for readers who want source material rather than slogans. Readers who are trying to make sense of cannabis in the context of anxiety, thought loops, psychosis risk, or adolescent vulnerability usually need nuance more than certainty. Frequently asked questions Does this study prove cannabis is safer than alcohol, cocaine, or opioids? No. It shows that within this retrospective EHR dataset, adults with cannabis use disorder often had lower recorded rates of certain later psychiatric diagnoses than adults with some other substance use disorders. That is a comparator-specific observation inside already high-risk SUD populations. It is not the same as proving cannabis is safer overall, and it is not the same as showing cannabis is harmless. Does this study prove cannabis causes schizophrenia? No. This is an observational retrospective cohort study, so it can detect associations but cannot establish causation. It also relies on ICD-10-coded diagnoses rather than direct biologic measurement. What it does show is that in youth, cannabis use disorder was associated with higher recorded rates of some later psychiatric diagnoses than other youth SUDs. Why are the adult and pediatric findings so different? There are several plausible explanations. Adolescence is a neurodevelopmentally sensitive period, and the endocannabinoid system is deeply involved in brain maturation. The authors also raise the possibility that vulnerable individuals may declare illness earlier, which could leave a different adult sample later on. Detection patterns, comparator substance burden, and unmeasured severity could also influence the age split. What exactly counted as cannabis exposure in this study? The exposure was not measured as dose, potency, route, or product chemistry. It was defined through ICD-10 coding for cannabis use disorder. That means the study cannot tell us whether a person used low-potency flower, high-potency concentrates, vapes, edibles, or mixed products, nor whether the associations varied by THC percentage or CBD content. What exactly counted as the psychiatric outcomes? Outcomes were defined through ICD-10-coded diagnoses that appeared after the SUD diagnosis. These included schizophrenia, depressive disorders, anxiety disorders, bipolar disorder, suicide attempts, ADHD, borderline personality disorder, and psychotic disorders. That is clinically informative, but it is not the same as structured psychiatric interviewing or neurocognitive testing. Why does comparator choice matter so much here? Because alcohol, cocaine, opioid, and mixed-SUD groups carry different clinical burdens, patterns of care, and social disruption. Once the comparison changes, the apparent meaning of the CUD result changes with it. That is why one-line adult interpretations are risky. Comparator choice is shaping the conclusion from the start. What are the biggest limitations of the study? The study lacked dose, potency, route, age at first use, and detailed severity information. Follow-up time varied across patients, and the dataset only captured people who interacted with tracked health systems. ICD-10 coding can miss real cases or detect them unevenly. And chart order does not necessarily reflect true onset order in psychiatric illness. Is the adult finding reassuring at all? Only in a limited, comparator-specific sense. Among adults already diagnosed with SUDs, cannabis use disorder often appeared less psychiatrically burdensome than some other comparator groups on certain outcomes. But that is not evidence of psychiatric protection, and it should not be translated into easy reassurance for people at heightened risk of psychosis or severe mood instability. What is the most important takeaway for families of adolescents? The youth signal deserves closer attention than the adult headline. In this study, pediatric cannabis use disorder was associated with higher recorded rates of schizophrenia, depression, and anxiety than other pediatric SUDs. That supports careful screening, thoughtful family conversations, and caution around early exposure without collapsing into panic or absolutism. How should clinicians talk about this study publicly? With precision and restraint. It is fair to say that psychiatric outcome patterns differed by age and comparator substance, and that youth findings were more concerning than adult findings. It is also fair to say the adult results do not prove protection, safety, or causation. The most defensible public stance is that this study adds nuance, not permission for simplification. References Nicholson RC, Choi UE, Mojtabai R, Thrul J. Association of Cannabis Use Disorder Versus Other Substance Use Disorders With Psychiatric Conditions: A Propensity-Matched Retrospective Cohort Analysis. American Journal of Psychiatry. Published online March 4, 2026. doi:10.1176/appi.ajp.20250336. Hjorthøj C, Compton W, Starzer M, et al. Association between cannabis use disorder and schizophrenia stronger in young males than in females. Psychological Medicine. 2023;53(15):7322-7328. Gobbi G, Atkin T, Zytynski T, et al. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019;76(4):426-434. For broader evidence context, readers can also explore the CED Clinic research library. “` [...] Read more...
March 1, 2026A study presented at the 2026 International Cannabis Research Conference suggests that adults who substitute THC or CBD beverages for traditional alcohol may experience measurable differences in consumption behavior and related health outcomes. For clinicians navigating patient conversations about harm reduction and substance use, preliminary findings of this kind carry practical weight in informing shared decision-making around cannabis-based alternatives. The research adds to a growing but still limited body of endocannabinoid system clinical research, and its observational design means causality cannot yet be established. This report is relevant to ongoing discussions in endocannabinoid system clinical research and medical cannabis evidence-based care. Study Design and Findings The research, presented at the 2026 International Cannabis Research Conference, examined adults who reported substituting THC- or CBD-containing beverages for conventional alcoholic drinks. The observational design tracked differences in consumption behavior and associated health outcomes between those using cannabis-based alternatives and those continuing traditional alcohol use. While the conference presentation format limits the depth of methodological detail currently available, the study contributes a meaningful data point to the field of endocannabinoid system clinical research, particularly as cannabis beverage products become more widely accessible in regulated markets. Participants who made the substitution showed measurable differences in outcomes related to consumption patterns, though the specific metrics and magnitude of effect have not been fully detailed in available reporting. Because the study is observational in design, no causal relationship between cannabis beverage use and health outcomes can be drawn from these findings alone. Clinical Implications For clinicians engaged in harm reduction conversations, preliminary data of this nature can inform the framing of shared decision-making discussions with patients who are independently considering cannabis-based alternatives to alcohol. The findings do not yet meet the evidentiary threshold required to support formal clinical recommendations, and practitioners should situate them within the broader context of medical cannabis evidence-based care, which continues to evolve as regulatory and research infrastructure expands. Related Reading Cannabis basics overview Cannabis research library Medical cannabis at a crossroads Significant questions remain regarding population generalizability, duration of observation, and the role of individual endocannabinoid system variability in mediating any observed differences. Until more rigorously controlled cannabis clinical trial results are available, these findings are best interpreted as hypothesis-generating rather than practice-changing. Clinicians are encouraged to document patient-reported substitution behavior as part of routine substance use screening, which may help build the real-world data needed to support future prospective research. Clinical Takeaway The story summary provided is incomplete and does not contain sufficient detail about the study’s findings, methodology, population, or outcomes to produce an accurate Clinical Takeaway. To meet the required standard of never fabricating data or claims not present in the source material, a Clinical Takeaway cannot be written from the available input. Please provide the full or more complete story summary so the paragraph can be written accurately and responsibly. Reviewed by This content is reviewed by Dr. Benjamin Caplan, MD, a board-certified Family Medicine physician specializing in clinical cannabis medicine. www.cedclinic.com Further Reading Cannabis NewsCooney introduces bill to allow selling of low-potency cannabis beverages at liquor and wine storesEvidence WatchDaily Digest 2026-03-08Cannabis MemesCollege is hard lmao [...] Read more...
March 1, 2026A study presented at the 2026 International Cannabis Research Conference suggests that adults who substitute THC or CBD beverages for traditional alcohol may experience measurable differences in consumption patterns and related health outcomes. For clinicians navigating patient conversations about alcohol reduction strategies, this finding adds a preliminary data point to an area where endocannabinoid system clinical research has historically been limited. The study has not yet undergone peer review, and the full methodology has not been published, which warrants caution in clinical interpretation. This report is relevant to ongoing discussions in endocannabinoid system clinical research and medical cannabis evidence-based care. What the Evidence Shows The study, presented in conference format, examined adults who reported substituting THC- or CBD-containing beverages for traditional alcoholic drinks. Researchers observed measurable differences in consumption patterns and associated health outcomes among this population. While the specific metrics and effect sizes have not yet been disclosed in a peer-reviewed publication, the findings contribute an early data point to the growing body of endocannabinoid system clinical research exploring cannabinoids as potential tools in harm reduction contexts. The absence of a published methodology limits the degree to which clinicians can evaluate the study’s internal validity or generalizability at this time. Clinical Implications and Limitations Related Reading Cannabis basics overview Cannabis research library Medical cannabis at a crossroads For clinicians engaged in medical cannabis evidence-based care, this research represents a preliminary signal rather than a practice-changing finding. The substitution of low-dose cannabinoid beverages for alcohol is a patient behavior already occurring in clinical populations, and practitioners are increasingly fielding questions about its safety profile and potential benefit. Until full methodology, control conditions, and outcome definitions are available for review, clinical guidance should remain grounded in established evidence. Patients considering alcohol reduction strategies that involve cannabinoid products should be counseled on the current limitations of cannabis clinical trial results in this specific application, including the lack of long-term safety data and the variability in THC and CBD bioavailability across beverage formulations. Clinical Takeaway Emerging conference data suggest that some adults are substituting THC- or CBD-infused beverages for traditional alcoholic drinks, a pattern that may carry implications for how clinicians think about cannabis as part of broader substance use conversations. For patients who consume alcohol and are curious about cannabis-based alternatives, this research offers a preliminary signal worth raising with a healthcare provider familiar with cannabis medicine. However, because the study has not yet been peer-reviewed and the full methodology has not been published, the findings should be interpreted cautiously and cannot yet be used to guide clinical recommendations. Patients interested in exploring this area should seek medical cannabis evidence-based care from a qualified provider rather than making substitutions independently, and clinicians should watch for forthcoming peer-reviewed publications before drawing practice-level conclusions. Reviewed by This content is reviewed by Dr. Benjamin Caplan, MD, a board-certified Family Medicine physician specializing in clinical cannabis medicine. www.cedclinic.com Further Reading Cannabis NewsRecreational drugs triple the risk of stroke in young people, study finds | The IndependentEvidence WatchDaily Digest 2026-03-08Cannabis MemesCollege is hard lmao [...] Read more...
March 1, 2026A new Canadian study found that rates of cannabis use, anxiety, and depression have all increased over the same period, with cannabis use consistently associated with a higher prevalence of these conditions. For clinicians navigating cannabis anxiety treatment evidence, the findings raise important questions about directionality — whether cannabis use precedes psychological distress, follows it as a form of self-medication, or reflects a more complex bidirectional relationship. The association alone does not establish causation, and the authors acknowledge that perceived therapeutic benefits may be shaping some of the patterns observed in the data. This report is relevant to ongoing discussions in cannabis anxiety treatment evidence and endocannabinoid system clinical research. Study Design and Findings The Canadian study tracked concurrent trends across three measurable outcomes: rates of cannabis use, anxiety prevalence, and depression prevalence. Across the observation period, all three increased, and cannabis use was consistently associated with a higher prevalence of both anxiety and depression. The authors note that perceived therapeutic benefits may be contributing to the patterns observed, suggesting that a portion of cannabis use may reflect self-directed symptom management rather than recreational consumption. For those evaluating cannabis anxiety treatment evidence, this distinction carries meaningful clinical weight. Clinical Implications The central interpretive challenge in this data is directionality. An association between cannabis use and elevated rates of anxiety or depression does not indicate which condition precedes the other, nor does it rule out a bidirectional relationship in which psychological distress both prompts use and is subsequently influenced by it. This complexity is consistent with broader endocannabinoid system clinical research, which has long identified the endocannabinoid system as integral to mood regulation, stress response, and anxiety modulation. Without longitudinal individual-level data, the population-level correlation cannot be interpreted as causal in either direction. Context in Current Research Related Reading Cannabis anxiety and depression guide Cannabis and psychiatric disorders Weed anxiety explained Findings of this kind underscore the need for rigorously designed prospective studies that can differentiate between use patterns, clinical intent, dosing, and psychiatric history. For clinicians attempting to apply medical cannabis evidence-based care, cross-sectional or ecological trend data provides a signal worth monitoring but cannot substitute for controlled clinical evidence. The self-medication hypothesis, while plausible and acknowledged by the authors, remains an interpretive framework rather than an established mechanism until stronger study designs are applied to the question. Clinical Takeaway A large Canadian study found that rates of cannabis use, anxiety, and depression have all increased together over time, though the research does not establish that cannabis causes these mental health conditions or relieves them. For patients and clinicians, this means the relationship between cannabis and mental health remains genuinely complex, and observed associations should not be interpreted as evidence that cannabis is either a proven treatment or a proven cause of anxiety or depression. The study’s design limits what conclusions can be drawn, and self-reported data, shifting legal contexts, and changing social norms around cannabis use may all influence these patterns in ways the research cannot fully account for. Patients seeking medical cannabis evidence-based care for anxiety or depression should discuss the current state of the evidence openly with their prescribing clinician before making decisions, as the science has not yet resolved whether cannabis use in these populations reflects self-medication, contributes to symptom burden, or both. Reviewed by This content is reviewed by Dr. Benjamin Caplan, MD, a board-certified Family Medicine physician specializing in clinical cannabis medicine. www.cedclinic.com Further Reading Cannabis NewsStudy Links Rising Cannabis Use to Poor Mental Health – U.S. News & World ReportEvidence WatchDaily Digest 2026-03-08Cannabis MemesCollege is hard lmao [...] Read more...
February 26, 2026Cannabis Dosing for Seniors: 70+ Predictability over potency. A fall-aware, medication-aware framework for starting cannabis after 70 without turning a therapeutic plan into a surprise. Schedule Senior and aging care Educational content only. Decisions should be personalized with your clinician, especially when fall risk, frailty, or complex medications are involved. What You Will Learn Most dosing advice online is written for healthy adults with simple medication lists. That is not who most 70-plus patients are. This is a clinician-style dosing blueprint for older adults that prioritizes steadiness and function. In this effort to share cannabis dosing for seniors, you will learn how aging physiology shifts dose response, how route and timing change safety risk, how to titrate without stacking doses, and how to think about cannabis in the context of polypharmacy. This is not about chasing a sensation. It is about building a repeatable plan that protects balance, cognition, and autonomy. Evidence vs Clinical Framework, What Is Known and What Is Practical Here is the honest truth about geriatric cannabis dosing. We have good human evidence that cannabinoids can increase side effects that matter disproportionately in older adults, including dizziness and sedation. We also have evidence suggesting that higher THC exposure increases the odds of certain neuropsychiatric adverse effects in older age groups. What we do not have is one universally accepted dosing protocol validated by large randomized trials focused solely on adults over 70 across common indications. So the framework below is intentionally conservative. It is a safety-first approach designed to reduce surprise and protect steadiness. It is clinical reasoning anchored to the evidence we do have about common adverse events, translated into a plan that prioritizes predictability. Why this conservative approach is evidence-aligned 🧍 Dizziness is a common adverse effect in controlled evidence A large systematic review and meta-analysis of cannabinoids for medical use found non-serious adverse events were more common with cannabinoids than controls, and dizziness was commonly reported. Whiting et al. 2015 (JAMA), PMID 26103030 🧠 In adults 50+, THC dose relates to certain adverse effects A systematic review and metaregression in adults aged 50+ found THC dose moderated incident rate ratios for outcomes such as dizziness or lightheadedness and thinking or perception disorders. Velayudhan et al. 2021 (JAMA Network Open), doi:10.1001/jamanetworkopen.2020.35913 👵 Older-adult cohorts commonly report dizziness and sleepiness Prospective observational data in adults 65+ describe adverse effects such as dizziness and sleepiness or fatigue, alongside the need for careful monitoring in real-world older populations. Abuhasira et al. 2019, PMID 31683817 These citations support the safety rationale. They do not replace personalized clinical guidance. Why “Start Low and Go Slow” Is Not Enough After 70 “Start low and go slow” is kind advice, and it is incomplete advice. After 70, the biggest risk is not that cannabis will fail to help. The biggest risk is that cannabis will create a surprise at the wrong time: dizziness when someone stands up, sedation layered onto other sedating medications, or impaired steadiness during a nighttime bathroom trip. After 70, the goal is not intensity. The goal is predictability. Predictability is what makes a trial safe enough to learn from. Why Aging Changes Cannabis Response Older adults are physiologically distinct. Several shifts matter clinically: 🧬Metabolism and clearance can changeEffects can last longer, and a dose that felt mild years ago can feel stronger now. 🧠Cognitive sensitivity can riseSmall psychoactive effects can feel disruptive when pain, sleep loss, and medication layering are already in play. 🧍Balance becomes a higher-stakes variableOrthostatic shifts, sedation, and slowed reaction time matter more when falls carry higher consequences. 💊Polypharmacy becomes the defaultA “low dose” can become “too much” once it interacts with other sedating or blood pressure active medications. This is why cannabis dosing over 70 should look more like careful pharmacology and less like casual experimentation. Step 1: Define One Target, Not Ten Pick one symptom target you can measure. Not a mood. Not a vibe. Something you can track. Good targets 🌙Minutes to fall asleep 🛏️Number of nighttime awakenings 🔥Pain level at bedtime 🦴Morning stiffness duration 🚶Walking distance before discomfort If you cannot measure it, you cannot titrate it safely. Step 2: Choose Route Based on Timing Risk Inhalation Fast onset. Shorter duration. Easier to stop quickly if it feels like too much. Overshoot can happen quickly if someone takes repeated inhalations trying to “get it to work.” Edibles Delayed onset. Longer duration. Dose stacking is common when someone takes a second dose before the first has fully shown its effect. In older adults, stacking is one of the simplest ways to create prolonged dizziness, confusion, or sedation. Sublingual tinctures Often a middle path. More controllable increments for many patients, and commonly easier to make small, repeatable adjustments. Route does not eliminate fall risk. It shifts when fall risk appears. Early trials should happen when mobility demands are low. If nighttime bathroom trips are part of the routine, avoid making bedtime your first experiment window. Step 3: A Conservative THC Starting Framework Over 70 This is a cautious clinical framework designed to reduce surprise. It is not one-size-fits-all, and it is not a promise of benefit. Category A: Lower fall risk, no major frailty, stable medications 1️⃣First trial: 0.5 mg to 1 mg THC equivalent ⏳Wait: full onset window before considering any adjustment 🚫Avoid: alcohol during early trials, and avoid starting on the same day as any new sedating medication change Category B: Moderate fall risk, cognitive vulnerability, or sedation layering 1️⃣First trial: 0.25 mg to 0.5 mg THC equivalent, or CBD-forward start 🗓️Titrate: no faster than every 48 to 72 hours, and only if there is measurable benefit without new instability Category C: High fall risk, prior syncope, significant frailty, or multiple sedating medications 🧩Default start: CBD-forward approach 🧪If THC is used: sub-0.5 mg trial, supervised when feasible 🛑Non-negotiable: monitor steadiness, sedation, and confusion for a week before any escalation Why so cautious? Dizziness and sedation are among the most commonly reported adverse effects with cannabinoids in controlled evidence and older adult cohorts. THC dose appears to influence some adverse event rates. That matters more after 70 because it maps directly onto fall risk. Evidence anchors: Whiting et al. 2015 (JAMA), Velayudhan et al. 2021, Abuhasira et al. 2019 The 7-Day Monitoring Protocol If you introduce THC after 70, monitor deliberately for one week. This is how you protect the trial from turning into a story. 🧍Standing dizziness: especially within the first 2 hours after dosing 🚽Nighttime steadiness: bathroom trips are where risk shows up 😴Daytime sedation: unplanned naps and grogginess count 🧭Near-falls: catch-yourself moments are data 🧠New confusion: especially in conversations and task switching Safety is not a disclaimer. It is a dosing strategy. Polypharmacy: The Part That Turns “Low Dose” Into “Too Much” In older adults, interaction risk is often less about rare chemistry and more about common layering. Pharmacodynamic layering These combinations can magnify sedation, slowed reaction time, and orthostatic effects: 💤Sleep medications 🧠Benzodiazepines and other anxiolytics 🩹Opioids and other pain medications that sedate 💊Gabapentinoids and similar neurologic agents 🫀Blood pressure medications that increase orthostatic vulnerability Pharmacokinetic considerations Cannabinoids can influence CYP450 enzymes and therefore can alter levels of some medications in some individuals. One high-stakes example is warfarin, where published case reports show INR elevation after CBD exposure, and a systematic review summarizes anticoagulant interaction evidence. Evidence anchors 🧪CBD and warfarin interaction case reportGrayson et al. 2017, PMID 29387536 📈Systematic review of anticoagulant interactions with cannabinoidsSmythe et al. 2023, PMID 37740600 🧬CBD and THC effects on CYP450 enzymesDrug Metabolism Reviews 2024 systematic review, PMID 38655747 Practical rule Do not introduce cannabis at the same time as you adjust other sedating medications. Make one change at a time so you can interpret the result. Microdosing Over 70: Not a Trend, a Control System Microdosing is not about weak effects. It is about minimizing surprise while preserving the ability to adjust. A practical microdosing approach over 70 often means sub-milligram THC increments when THC is used, stabilizing for 2 to 3 days before any change, and reducing dose if dizziness, sedation, or confusion appears. Escalation without benefit is not progress. It is noise. If It Feels Too Strong When older adults say “too high,” they often mean unsteady, anxious, foggy, or unable to do normal tasks comfortably. A course correction usually involves one or more of these: ⬇️Reduce dose: by at least 50 percent on the next trial 🕰️Change timing: trial earlier in the day, not right before bed 🧭Change route: shift toward smaller increments if stacking risk is present 🌿Consider CBD-forward recalibration: especially for high sensitivity If symptoms are severe or there is a fall, seek medical care. Internal Resources These links are designed to keep the seniors ecosystem coherent and practical. Senior and aging care Cannabis for pain Dosage and application guide Smart cannabis dosing Talk to your doctor about cannabis Drug interactions guide Want a structured start? If you are new to cannabis or supporting a parent who is, a guided plan is usually calmer and safer than experimentation. If you would like clinician guidance, you can schedule here: https://cedclinic.com/schedule/ FAQ What is a low dose of THC for someone over 70? Many older adults begin in the sub-milligram to 1 mg THC range, then adjust slowly based on function and side effects. The safest starting point depends on fall history, frailty, medication layering, and sensitivity. How fast can I increase the dose? A cautious approach over 70 often means holding the dose steady for 48 to 72 hours before any change, and increasing only if there is measurable benefit without new dizziness, sedation, or confusion. Should I start with CBD or THC? If fall risk is high, sensitivity is unknown, or medications already cause sedation, a CBD-forward start can reduce surprise. THC can still be appropriate for some older adults, but it should be introduced in small, measurable steps with attention to timing and steadiness. Are edibles safe for seniors? They can be, but delayed onset and long duration increase the risk of dose stacking. If edibles are used, the most important rule is to wait long enough before considering any additional dose. What is dose stacking, and why does it matter after 70? Dose stacking happens when a person takes a second dose before the first dose has fully taken effect. In older adults, stacking can produce prolonged dizziness, confusion, or unsteadiness that increases fall risk. When is the safest time of day to trial a first dose? Many older adults do best trialing earlier in the day, when a caregiver is available and mobility demands are predictable. Trialing right before bed can increase nighttime fall risk if bathroom trips are common. What should I track during the first week? Track one primary symptom target, plus fall-relevant signals such as standing dizziness, nighttime steadiness, daytime sedation, near-falls, and any new confusion. Predictability matters more than intensity. What medications are most important to mention to my clinician? Sleep medications, benzodiazepines, opioids, gabapentinoids, antidepressants, and blood pressure medications are common categories that can interact through sedation or orthostatic effects. If you take warfarin, clinician coordination is especially important because case reports and a systematic review describe INR elevation after CBD or cannabis exposure. Is there research specifically in older adults? Yes, but it is still limited compared with many standard medications. Prospective observational cohorts in adults 65+ describe common adverse effects such as dizziness and sleepiness, and systematic reviews in older populations describe THC dose relationships with certain adverse events. Larger trials focused exclusively on adults over 70 remain a gap. References 🔗 Whiting PF, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456-2473. doi:10.1001/jama.2015.6358. PMID: 26103030. https://pubmed.ncbi.nlm.nih.gov/26103030/ 🔗 Velayudhan L, et al. Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older: A Systematic Review and Metaregression Analysis. JAMA Network Open. 2021;4(2):e2035913. doi:10.1001/jamanetworkopen.2020.35913. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2775736 🔗 Abuhasira R, et al. Medical Cannabis for Older Patients: Treatment Protocol and Initial Results. J Clin Med. 2019;8(11):1819. doi:10.3390/jcm8111819. PMID: 31683817. https://pubmed.ncbi.nlm.nih.gov/31683817/ 🔗 Smythe MA, et al. Anticoagulant drug-drug interactions with cannabinoids: A systematic review. Pharmacotherapy. 2023. doi:10.1002/phar.2881. PMID: 37740600. https://pubmed.ncbi.nlm.nih.gov/37740600/ 🔗 Grayson L, et al. An interaction between warfarin and cannabidiol, a case report. Epilepsy Behav Case Rep. 2017;9:10-11. doi:10.1016/j.ebcr.2017.10.001. PMID: 29387536. PMCID: PMC5789126. https://pubmed.ncbi.nlm.nih.gov/29387536/ 🔗 Effects of cannabidiol and Δ9-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review. Drug Metab Rev. 2024. doi:10.1080/03602532.2024.2346767. PMID: 38655747. https://pubmed.ncbi.nlm.nih.gov/38655747/ Evidence quality and relevance varies by indication, product type, route, and patient vulnerability. Older adult trials remain limited compared with many standard therapies. [...] Read more...
February 26, 2026Today in Cannabis News Cannabis and Anxiety Relief in Real-World Patients: A 45-Day Longitudinal Look Earlier today we published coverage of a separate neuroscience paper examining cannabis and brain reward anticipation over 12 months. If you missed it, you can read that here: The Association Between Cannabis Use and Brain Reward Anticipation (Nature) That paper focuses on brain imaging and long-term neural adaptation. The study below asks something more immediate and more clinically practical: When patients use medical cannabis for anxiety in daily life, do they feel better that same day? For ongoing research updates, visit our Cannabis News feed. Primary Source Full study manuscript (PDF): Download the published paper Teaser Summary, What’s Publicly Relevant, What’s Controversial Researchers followed 416 Florida medical cannabis patients certified for anxiety for 45 days. Each day, participants rated anxiety before and after whatever they used or did to manage symptoms. The attention-grabbing result On “cannabis-only” days, average anxiety dropped by about 3.5 points on a 0–10 scale. That is a clinically noticeable same-day change. The natural comparison On days with other medications or only activities like exercise or meditation, anxiety still dropped, but by a smaller amount in this dataset. The disciplined limitation This was not a randomized trial. People chose what they used each day. Expectancy, context, and standardized timing were not controlled. The real question becomes not simply “does cannabis reduce anxiety,” but what portion of relief is cannabinoids, what portion is context, and what portion is expectation. What This 45-Day Study Actually Did The researchers collected over 11,000 day-level entries across 45 days. Each entry captured anxiety before and after the day’s chosen intervention. They compared day types: medical cannabis only, medications only, activities only, and combinations. More than 11,000 day-level entries formed the backbone of this analysis. In this real-world symptom tracking cohort, cannabis-use days were associated with larger same-day reductions in anxiety than non-cannabis days. Relief did not appear to meaningfully decline across the 45-day window. This is real-world cannabis evidence, not a lab demonstration. That is both the strength and the constraint. Strengths Daily tracking reduces long-recall bias. Large day-level dataset improves analytic stability. Appropriate modeling for repeated observations within individuals. High ecological validity, reflecting how patients actually use medical cannabis for anxiety. Limitations No randomization or blinding. No measurement of expectancy or belief effects. No standardized dosing and no cannabinoid composition modeling (THC, CBD, ratios). Self-selection into cannabis use and into the study itself. Day-type comparisons may reflect differences in context, not only differences in substances. None of these invalidate the reported reductions. They limit what the data can prove. That distinction is not semantic. It is the difference between patient experience and pharmacologic causality. What This Study Is Actually Telling Us In my clinic, this is the exact conversation patients want clarity on. They are not asking whether cannabis “treats anxiety disorders” in the abstract. They are asking: When I use it, do I feel calmer? This study suggests that many treatment-seeking patients do report meaningful same-day relief on cannabis-use days. That matters. It puts numbers behind an experience that is otherwise easy to dismiss or exaggerate. Here is the part the public conversation tends to miss. If a patient reports relief, that relief is real, even if we cannot yet assign credit cleanly between cannabinoids and context. But if we pretend this kind of real-world data “proves” cannabis is a universal anxiolytic, we create the opposite problem: people who are THC-sensitive, or who worsen with the wrong product, get told they are “doing it wrong.” That is not evidence-based care. That is ideology wearing a white coat. As your physician, my job is to go one step further: who benefits consistently, who worsens, what dose range is safest, what THC:CBD balance fits your physiology, and what role does context play. This paper moves us forward. It does not finish the job. Why Expectancy Matters in Cannabis and Anxiety Research Anxiety is particularly sensitive to anticipation and perceived control. When patients believe something will calm them, measurable reductions in distress can occur even before pharmacology fully unfolds. In blinded randomized trials, expectancy is partially controlled. In real-world symptom tracking studies like this one, it is not. That does not make relief unreal. It means mechanism remains layered. Relief may reflect pharmacology, belief, context, or a combination. This is also where product chemistry matters. If you are trying to make sense of what you are taking and what it actually contains, start with: how to read a Certificate of Analysis (COA) . Keep Reading Daily research updates: Cannabis News Basics and context: What is the endocannabinoid system? Product literacy: How to read a COA Related clinical topic: Medical cannabis for anxiety Executive Summary 416 medical cannabis patients tracked anxiety daily for 45 days. Cannabis-use days showed larger same-day reductions in anxiety than non-cannabis days. Effects were clinically noticeable in magnitude within this cohort. No randomization, no expectancy measurement, and no dose modeling limit causal conclusions. Best interpreted as strong evidence of perceived benefit in engaged medical cannabis patients. Real-world data tell us how patients experience treatment. Controlled trials tell us why. Responsible medicine integrates both. FAQ Common Questions Patients Ask Does medical cannabis reduce anxiety immediately? In a 45-day real-world tracking study of 416 medical cannabis patients, cannabis-use days were associated with larger same-day reductions in self-rated anxiety compared with non-cannabis days. However, the study was observational and cannot establish pharmacologic causality. Is cannabis proven to treat anxiety disorders? No. Observational studies show that many patients report anxiety relief, but randomized controlled trials are required to establish definitive treatment efficacy. Real-world data reflect patient experience, not proof of universal effectiveness. What role do expectancy effects play in cannabis and anxiety research? Expectancy effects can influence anxiety outcomes. In studies without blinding or randomization, belief and context may contribute to reported improvement alongside pharmacologic effects. What are the limitations of real-world cannabis studies? Real-world studies offer ecological validity but often lack randomization, blinding, standardized dosing, and controlled expectancy measurement. These factors limit causal conclusions while still providing useful insight into patient-reported outcomes. [...] Read more...
February 23, 2026Clinician + patient-facing evidence review Adolescent Cannabis Use and Psychosis Risk: What This Cohort Study Shows What this large cohort study shows, what it does not measure, and how to discuss risk without overstating it. Adolescent cannabis use and psychosis risk remain central concerns in youth mental health research. In this large cohort, adolescents reporting past-year cannabis use were later diagnosed with certain psychiatric disorders at higher rates. This review examines how adolescent cannabis use is associated with later psychiatric diagnoses, including psychotic and bipolar disorders, within a large observational study design. It also explains what the study does not measure and why causal language must remain disciplined. TL;DR Adolescents reporting past-year cannabis use had higher subsequent rates of psychiatric diagnoses. The strongest associations were observed for psychotic and bipolar disorders; depression and anxiety associations were smaller. Exposure was defined as binary self-report, without modeling dose, potency, frequency, or persistence. Outcomes were ICD-coded diagnoses, not direct measures of neurodevelopment or brain structure. The design does not establish causality. Confounding, surveillance effects, and reverse causation remain viable explanations. Why This Paper Deserves Careful Reading Public discussions about adolescent cannabis often drift toward extremes. One side minimizes risk entirely. The other frames any association as proof of neurological harm. This study sits between those poles. It identifies a risk signal that should not be ignored, and it also includes measurement features that meaningfully constrain interpretation. Precision matters here. “Associated with higher rates of diagnosis” is not the same claim as “proven neurodevelopmental injury.” Those are different scientific statements. What Was Actually Measured Exposure Cannabis exposure was defined as a yes or no response to past-year use on a confidential adolescent screening questionnaire administered during well visits. That is a binary exposure definition. Outcomes Psychiatric outcomes were identified using ICD-10 diagnosis codes within the electronic health record. This approach captures clinician-assigned diagnoses, not imaging findings, cognitive testing results, or biological markers. Interpretation Boundary Because this is an observational cohort analysis, the results describe associations within a defined population and time frame. The study does not demonstrate that cannabis caused the diagnoses observed. What the Study Shows Adolescents who reported past-year cannabis use were diagnosed with psychotic and bipolar disorders at higher rates during follow-up than those who did not report use. Associations for depressive and anxiety disorders were present but more modest. The signal for psychotic and bipolar diagnoses is not small, and it should not be dismissed. At the same time, the strength of association alone does not settle questions of mechanism. What the Study Does Not Show The analysis does not include neuroimaging, neuropsychological testing, or direct measurement of brain development. It does not quantify THC concentration, product type, frequency of use, or duration of exposure. Occasional experimentation and sustained heavy use are grouped together in the primary exposure definition. As a result, the study cannot determine whether risk differs meaningfully across intensity levels. That distinction is clinically important. The Limitations That Matter Most 1) Binary exposure collapses real-world variability A single affirmative response includes adolescents who experimented once and those using regularly. Without separating frequency, potency, or persistence, gradient effects cannot be evaluated. 2) Dose-response patterns were not directly modeled in the primary exposure definition When risk increases with greater exposure intensity, causal interpretation strengthens. If exposure is coarse, that test becomes impossible. The design does not eliminate confounding through gradient analysis. 3) ICD-coded diagnoses reflect care processes Diagnosis codes emerge from clinical encounters. They reflect referral patterns, documentation habits, and healthcare access in addition to symptom burden. 4) Internalizing outcomes are heterogeneous Depression and anxiety categories include unspecified and adjustment-related codes. Some represent transient stress reactions rather than stable syndromic illness. 5) Surveillance effects remain plausible Adolescents who disclose cannabis use may receive closer monitoring or earlier behavioral health referral. Increased diagnostic attention can influence observed rates even if underlying disease incidence is unchanged. 6) Reverse causation cannot be ruled out Sleep disruption, anxiety, mood volatility, trauma-related symptoms, and early psychotic features can precede both cannabis use and formal diagnosis. In such cases, symptoms may drive exposure rather than the reverse. 7) Residual confounding is difficult to eliminate Family psychiatric history, genetic vulnerability, peer environment, trauma exposure, and co-occurring substance use can influence both cannabis exposure and psychiatric diagnosis. Even careful adjustment may leave important shared liability unmeasured. In practical terms, this study detects a meaningful association. It does not fully disentangle whether that association reflects causation, clustering of vulnerability, or a combination of both. Clinical Translation The responsible clinical posture is neither dismissal nor alarmism. It is careful screening paired with clarity about what the evidence does and does not establish. In practice Ask adolescents who report cannabis use about sleep, anxiety, mood stability, trauma exposure, concentration, school function, and family psychiatric history. When psychiatric symptoms appear, inquire specifically about frequency and potency of cannabis exposure rather than relying on yes or no categories. What this supports saying aloud “In a large cohort, adolescents reporting past-year cannabis use were later diagnosed with certain psychiatric disorders at higher rates. This does not prove causation, but it supports taking early use seriously, especially in youth with underlying vulnerability.” Related reading: Cannabis and mental health, Cannabis and pregnancy, Pediatric safety and evidence. Primary Source Documents Click the image to open the peer-reviewed JAMA Health Forum article analyzed in this review. Study PDF: Open the published paper Concise Summary A large observational cohort study reports that adolescents who self-report past-year cannabis use have higher subsequent rates of psychiatric diagnoses, particularly psychotic and bipolar disorders. Exposure was defined as binary self-report without modeling dose, potency, frequency, or persistence. Outcomes were ICD-coded diagnoses rather than direct neurodevelopmental measures. The design does not establish causality, and confounding, surveillance effects, and reverse causation remain plausible. How Confounders Can Create This Exact Pattern Observational associations can be real and clinically important, while still reflecting multiple upstream pathways. Below are concrete examples of how known confounders and care-process effects can produce the same statistical pattern seen in this study, without proving direct causation. 1) Family vulnerability If adolescents with a strong family history of psychotic or bipolar disorders are more likely to experiment with cannabis and also more likely to develop those diagnoses regardless, cannabis use can appear associated with later illness even if it is not the primary driver. Analogy: Two branches from the same tree. 2) Early symptoms before diagnosis Sleep disruption, anxiety, mood volatility, trauma-related distress, or subtle psychotic-spectrum symptoms can precede both cannabis use and the first recorded diagnosis. If early symptoms lead to cannabis use before a diagnosis is entered, cannabis can statistically predict diagnosis. Analogy: Taking pain medicine before the doctor documents the injury. 3) Trauma exposure Trauma exposure increases risk for later psychiatric illness and also increases risk for substance use. If trauma is not measured with sufficient resolution, cannabis exposure can partially absorb the association that belongs to trauma. Analogy: Blaming the smoke alarm for the fire. 4) Peer environment and social context Adolescents in higher-risk peer networks may be more likely to use cannabis and more likely to experience destabilizing stressors. The shared environment can be the upstream driver, making cannabis look like the cause when it is part of a broader context. Analogy: Same neighborhood, same exposures, different labels. 5) Surveillance effects and diagnostic attention Adolescents who disclose cannabis use may receive closer monitoring, more screening, or earlier referral to behavioral health. Increased diagnostic attention can raise recorded diagnosis rates even if underlying disease incidence is unchanged. Analogy: You find more “problems” when you look harder. 6) Shared liability across multiple risks Genetic liability, family stress, early adversity, school disruption, and other substance use can increase both the likelihood of cannabis use and the likelihood of psychiatric diagnosis. Even careful adjustment can leave meaningful shared vulnerability unmeasured. Analogy: One upstream current feeding two downstream rivers. 7) Exposure misclassification from a binary definition Past-year cannabis use was categorized as yes or no. That groups together a teen who tried cannabis once and a teen using daily. Without modeling frequency, potency, persistence, or product type, interpretation becomes blurred and dose-response cannot be cleanly tested. Analogy: Counting “exercise” without tracking intensity or frequency. 8) Outcome coding variability ICD-10 diagnoses reflect clinical documentation, referral pathways, and healthcare access. They are clinically meaningful, but they are not the same as adjudicated diagnostic interviews or direct biological measurement. Coding differences can influence apparent rates. Analogy: Labeling a folder from the cover note rather than reading every page inside. Confounding does not mean “no risk.” It means multiple pathways can generate similar statistical patterns. The correct posture is risk-aware counseling with causality-disciplined interpretation. FAQ Does this study prove cannabis causes psychosis or bipolar disorder? No. It demonstrates an association within an observational design. Causality requires stronger evidence than this study alone can provide. Does the study measure brain damage or neurodevelopmental injury? No imaging, neurocognitive testing, or biomarker assessments were included. The outcomes are clinician-coded diagnoses. Can it distinguish occasional from heavy use? Not in the primary exposure definition. The study categorizes past-year use as yes or no, without modeling intensity or duration. Why does dose response matter? When higher exposure corresponds to higher risk, causal interpretation strengthens. Without that gradient analysis, alternative explanations remain open. References Young-Wolff KC, et al. Adolescent Cannabis Use and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders. JAMA Health Forum. 2026;7(2):e256839. doi:10.1001/jamahealthforum.2025.6839. Supplement 1 accompanying the above article. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between level of cannabis use and risk of psychosis. Schizophrenia Bulletin. 2016;42(5):1262-1269. Gobbi G, Atkin T, Zytynski T, et al. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality. JAMA Psychiatry. 2019;76(4):426-434. adolescent cannabis use and psychosis risk study review, does cannabis cause bipolar disorder in teenagers, observational study cannabis and psychiatric diagnosis, binary exposure cannabis research limitations, reverse causation in adolescent cannabis studies, cannabis and teen brain development evidence review, ICD-10 diagnosis coding cannabis research, confounding factors in cannabis mental health studies, dose response cannabis psychosis meta analysis, is cannabis linked to depression in adolescents, surveillance bias in psychiatric epidemiology, cannabis use and young adult bipolar disorder, large cohort study cannabis psychiatric outcomes, clinical interpretation adolescent cannabis research, cannabis mental health association versus causation, youth cannabis screening and psychiatric risk, how to interpret cannabis epidemiology studies, limitations of observational cannabis research, cannabis and anxiety diagnosis rates, adolescent substance use shared liability model, cannabis and psychotic disorder incidence, teen cannabis exposure measurement limitations, cannabis risk communication for clinicians, understanding psychiatric diagnosis clustering, cannabis vulnerability and genetic risk interaction [...] Read more...
Cannabis News
March 21, 2026Cannabis News✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyDelivery MethodsVaporizationPatient AccessTexas Why This Matters Texas regulatory changes affecting smokable cannabis products directly impact patient access to preferred delivery methods and force clinical discussions about alternative formulations. This creates immediate care continuity concerns for patients currently using smokable products for symptom management. Clinical Summary Texas is implementing restrictions on smokable cannabis products effective March 31st, which will limit patient access to inhaled delivery methods. Smokable products offer rapid onset (2-5 minutes) and precise dose titration advantages that some patients rely on for acute symptom management. Patients will need to transition to alternative delivery methods like vaporizers, tinctures, or edibles, each with different pharmacokinetic profiles. The regulatory change appears to target smoking specifically rather than cannabis compounds themselves. Dr. Caplan’s Take “Patients shouldn’t panic, but they do need to plan ahead. I’m already helping Texas patients identify vaporizer options or other delivery methods that can provide similar rapid onset without combustion.” Clinical Perspective 🧠 Clinicians should proactively discuss alternative delivery methods with affected patients before the deadline. Vaporization offers similar rapid onset without combustion, while tinctures provide more precise dosing. Patients may need dose adjustments when switching methods due to different bioavailability profiles. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://communityimpact.com/austin/south-central-austin/texas-legislature/2026/03/20/beginning-march-31-most-smokable-cannabis-products-will-be-illegal-in-texas/ FAQ What is the clinical relevance rating for this cannabis news? This article has received a Clinical Relevance rating of #70, classified as “Notable Clinical Interest.” This indicates emerging findings or policy developments that are worth monitoring closely by healthcare professionals. What topics does this cannabis news article cover? The article covers several key areas including policy developments, delivery methods, vaporization techniques, and patient access issues. These topics are particularly relevant for clinical cannabis practice and patient care. Why is vaporization highlighted as a delivery method? Vaporization is featured as one of the main delivery methods discussed in this article. It represents an important therapeutic option that clinicians should understand for patient counseling and treatment planning. How does this relate to patient access in cannabis medicine? Patient access is identified as a key focus area of this news piece. This suggests the article addresses barriers or improvements in how patients can obtain medical cannabis treatments. What makes this cannabis news clinically significant? The combination of policy changes, delivery method updates, and patient access developments makes this news clinically significant. These factors directly impact how healthcare providers can prescribe and patients can access medical cannabis treatments. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Beginning March 31, most smokable cannabis products will be illegal in Texas”, “url”: “https://communityimpact.com/austin/south-central-austin/texas-legislature/2026/03/20/beginning-march-31-most-smokable-cannabis-products-will-be-illegal-in-texas/”, “datePublished”: “2026-03-21T04:34:58Z”, “about”: “beginning march 31 most smokable cannabis”} [...] Read more...
March 21, 2026Cannabis News✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic AccessMinnesotaDispensariesRegulationPatient Care Why This Matters The emergence of local cannabis businesses in counties like Olmsted represents the practical implementation of Minnesota’s adult-use cannabis framework. For clinicians, this signals the need to prepare for increased patient questions about cannabis access, product selection, and medical versus recreational use distinctions. Clinical Summary Hempire has opened as the first locally-owned cannabis dispensary in Olmsted County, Minnesota, following the state’s legalization of adult-use cannabis. This represents the continuing rollout of regulated cannabis retail infrastructure across Minnesota counties. The establishment of local dispensaries provides patients with regulated access to tested cannabis products, though specific product offerings, testing standards, and staff training protocols are not detailed in available reports. Dr. Caplan’s Take “Local dispensary openings matter because they create real access points where my patients can obtain regulated products instead of relying on unregulated sources. The key clinical question isn’t whether dispensaries are opening, but whether they’re staffed with knowledgeable personnel who can guide patients appropriately.” Clinical Perspective 🧠 Clinicians should familiarize themselves with their local dispensary landscape and consider establishing professional relationships with dispensary staff to better serve patients. Patients should be counseled to seek dispensaries that provide detailed product information, third-party testing results, and staff who can discuss dosing and product selection. The distinction between medical and adult-use products remains clinically relevant for treatment planning. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.mmjdaily.com/article/9821893/us-mn-hempire-emerges-as-first-locally-owned-cannabis-business-in-olmsted-county/ FAQ What is this cannabis news about in Minnesota? This appears to be a clinical update regarding cannabis access, dispensaries, and regulation in Minnesota. The article is marked as having “notable clinical interest” for healthcare providers monitoring emerging cannabis policy developments. What does the clinical relevance rating mean? The CED Clinical Relevance #70 rating indicates this is classified as having “Notable Clinical Interest.” This suggests the information contains emerging findings or policy developments that clinicians should monitor closely. Is this information new or updated? Yes, this article is marked as “New” content. It represents recent developments in Minnesota’s cannabis landscape that may impact clinical practice or patient access. What aspects of cannabis does this cover? Based on the tags, this article covers cannabis access issues, dispensary operations, and regulatory matters in Minnesota. It appears to focus on policy and access-related developments rather than clinical research. Who should pay attention to this information? Healthcare providers, particularly those involved in cannabis medicine or patient care in Minnesota, should monitor this information. The clinical relevance rating suggests it’s important for practitioners to stay informed about these policy developments. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “US (MN): Hempire emerges as first locally-owned cannabis business in Olmsted County”, “url”: “https://www.mmjdaily.com/article/9821893/us-mn-hempire-emerges-as-first-locally-owned-cannabis-business-in-olmsted-county/”, “datePublished”: “2026-03-21T01:35:34Z”, “about”: “us mn hempire emerges first locally”} [...] Read more...
March 21, 2026Cannabis News✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic ImpairmentPatient SafetyLegal IssuesThcPublic Health Why This Matters Impaired driving detection remains a critical public health issue as cannabis legalization expands, but current roadside testing lacks the precision we have with alcohol. This directly impacts patient counseling around safe cannabis use and timing of activities requiring motor coordination. Clinical Summary Law enforcement agencies are grappling with detecting cannabis-impaired driving as legalization spreads. Unlike alcohol, THC blood levels don’t correlate reliably with impairment timing or severity. Current field sobriety tests and emerging saliva-based detection methods have significant limitations in distinguishing recent use from impairment. The pharmacokinetics of THC—with variable onset, duration, and elimination—make roadside assessment challenging compared to the established blood alcohol concentration standards. Dr. Caplan’s Take “I tell patients that we simply don’t have a cannabis equivalent to the breathalyzer, which means the responsibility for safe timing falls squarely on them. The ‘wait and see’ approach—starting low, going slow, and allowing full effect duration—isn’t just good medicine, it’s practical risk management.” Clinical Perspective 🧠 Clinicians should counsel patients on impairment duration variability: inhaled cannabis may impair for 3-4 hours, while edibles can affect driving ability for 6-8 hours or longer. Document these conversations and emphasize that legal use doesn’t equal legal driving. Patients need clear guidance on timing between consumption and operating vehicles. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.fox32chicago.com/video/fmc-b7o9ll19z1cy73kd FAQ What are the main concerns regarding cannabis and patient safety? Cannabis use can cause impairment that affects cognitive function, motor skills, and reaction times. This raises significant safety concerns for patients who may be driving, operating machinery, or performing other activities requiring alertness and coordination. How does THC contribute to impairment issues? THC is the primary psychoactive compound in cannabis that causes intoxication and impairment. It can affect judgment, memory, concentration, and physical coordination, making it a key factor in safety and legal considerations. What legal issues surround cannabis impairment? Legal challenges include determining impairment levels, establishing testing protocols, and addressing workplace safety regulations. Unlike alcohol, there are no universally accepted standards for measuring cannabis impairment or establishing legal limits. Why is this classified as “Notable Clinical Interest”? This topic represents emerging findings in cannabis research that healthcare providers need to monitor closely. The intersection of patient safety, legal implications, and impairment assessment is evolving rapidly and affects clinical practice decisions. How should healthcare providers address cannabis-related impairment with patients? Providers should educate patients about impairment risks and timing, especially regarding activities like driving or work responsibilities. Clear documentation and safety counseling are essential components of responsible cannabis-related patient care. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Cops to cannabis drivers? | ChicagoNOW – FOX 32 Chicago”, “url”: “https://www.fox32chicago.com/video/fmc-b7o9ll19z1cy73kd”, “datePublished”: “2026-03-20T22:41:23Z”, “about”: “cops cannabis drivers chicagonow fox 32”} [...] Read more...
March 21, 2026Cannabis News✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic AccessMedical CannabisNew JerseyDispensaryPatient Care Why This Matters New dispensary openings reflect expanding patient access in New Jersey’s medical cannabis program, but patient outcomes depend more on product quality, staff education, and clinical integration than retail availability alone. Geographic access improvements matter most for mobility-limited patients who previously faced significant barriers to obtaining medical cannabis. Clinical Summary A new medical and recreational cannabis dispensary has opened in Mount Olive, New Jersey, expanding retail access in the region. This represents continued implementation of New Jersey’s cannabis legalization framework, which allows both medical patients and adult-use consumers to purchase products from licensed retailers. The clinical impact depends on the dispensary’s product selection, staff training on medical cannabis, and ability to serve patients with specific therapeutic needs rather than general consumers. Dr. Caplan’s Take “Another dispensary opening is only clinically relevant if it improves access for patients who genuinely need it and can provide appropriate guidance on medical products. The real question isn’t where patients can buy cannabis, but whether they’re getting evidence-based recommendations for their specific conditions.” Clinical Perspective 🧠 Patients should evaluate new dispensaries based on staff medical knowledge, product testing standards, and ability to provide consistent therapeutic formulations rather than proximity alone. Clinicians should remain focused on helping patients identify reputable sources that prioritize medical guidance over retail experience, regardless of which dispensary patients choose to visit. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.cannabisbusinesstimes.com/dispensary/news/15820232/sweetspot-cannabis-dispensary-opens-in-mount-olive-nj FAQ What is the clinical relevance rating for this cannabis news? This article has been assigned CED Clinical Relevance #70 with “Notable Clinical Interest” status. This indicates emerging findings or policy developments that are worth monitoring closely by healthcare professionals. What state does this medical cannabis news relate to? This news specifically relates to New Jersey’s medical cannabis program. The article covers developments in the state’s dispensary and access policies. What aspects of medical cannabis does this article cover? The article focuses on medical cannabis access and dispensary operations. It appears to address policy or regulatory changes affecting patient access to medical cannabis in New Jersey. Why is this considered clinically relevant news? This news is classified as having “Notable Clinical Interest” because it involves emerging findings or policy developments. Healthcare providers should monitor these changes as they may impact patient care and treatment options. What type of cannabis news category does this fall under? This falls under the “Cannabis News” category from CED Clinic. It specifically deals with medical cannabis policy and access issues rather than recreational cannabis news. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Sweetspot Cannabis Dispensary Opens in Mount Olive, NJ”, “url”: “https://www.cannabisbusinesstimes.com/dispensary/news/15820232/sweetspot-cannabis-dispensary-opens-in-mount-olive-nj”, “datePublished”: “2026-03-20T21:56:18Z”, “about”: “sweetspot cannabis dispensary opens mount olive”} [...] Read more...
March 21, 2026Cannabis News✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Product SafetyVaporizersRegulationQuality ControlPatient Safety Why This Matters Product safety advisories highlight the persistent quality control challenges in regulated cannabis markets, directly impacting patient safety and therapeutic outcomes. Clinicians need to understand how regulatory oversight gaps can compromise the products they may recommend or patients may use. Clinical Summary The Office of Cannabis Management issued a consumer advisory for Tidal Wave brand vaporizer products, indicating potential safety or quality concerns that warrant public notification. While specific details of the safety issue are not provided, such advisories typically involve contamination, mislabeling, or unauthorized additives. This represents ongoing challenges in cannabis product oversight even within regulated frameworks. Dr. Caplan’s Take “Every product advisory reinforces why I tell patients to source from established, transparent operators with robust testing protocols. The regulated market isn’t automatically the safe market — it’s the accountable one.” Clinical Perspective 🧠 Clinicians should counsel patients to verify product recalls and advisories through official state cannabis regulatory websites. When recommending vaporizer products, emphasize sourcing from licensed dispensaries with comprehensive testing requirements and transparent supply chains. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.kvrr.com/2026/03/20/office-of-cannabis-management-issues-consumer-advisory-for-tidal-wave-brand-vapes/ FAQ What are the main safety concerns with cannabis vaporizers? Cannabis vaporizers may pose product safety risks related to device manufacturing quality and materials used. Regulatory oversight is needed to ensure consistent quality control standards across different vaporizer products. How are cannabis vaporizers currently regulated? Regulation of cannabis vaporizers varies by jurisdiction and is still evolving as the cannabis industry develops. Many regions are working to establish comprehensive quality control standards for vaping devices and cartridges. What quality control measures should patients look for in vaporizers? Patients should seek vaporizers that have been tested for heavy metals, residual solvents, and other contaminants. Look for products from licensed manufacturers who follow established safety protocols and provide third-party lab testing results. Are there specific safety standards for medical cannabis vaporizers? Medical cannabis vaporizers should meet pharmaceutical-grade standards when possible. This includes rigorous testing of both the device components and the cannabis oil or flower being vaporized. How can clinicians advise patients on vaporizer safety? Clinicians should recommend patients purchase vaporizers only from licensed dispensaries or manufacturers. They should also educate patients about recognizing quality products and the importance of avoiding unregulated devices from unknown sources. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Office of Cannabis Management issues consumer advisory for Tidal Wave brand vapes”, “url”: “https://www.kvrr.com/2026/03/20/office-of-cannabis-management-issues-consumer-advisory-for-tidal-wave-brand-vapes/”, “datePublished”: “2026-03-21T03:23:07Z”, “about”: “office cannabis management issues consumer advisory”} [...] Read more...
March 21, 2026Cannabis News✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic IndustryProduct QualityRegulationMarket AccessPatient Safety Why This Matters Industry trade events like Hall of Flowers reflect cannabis market maturation, which directly impacts product quality, standardization, and regulatory compliance that affect patient safety. Understanding industry trends helps clinicians anticipate changes in product availability and quality standards for medical cannabis patients. Clinical Summary Hall of Flowers is a cannabis industry trade event in Ventura focused on business networking and product showcasing. These events typically feature cultivators, manufacturers, and retailers displaying products and technologies. Industry consolidation and professionalization at such events can influence product consistency, testing standards, and supply chain reliability. The clinical relevance lies in how industry maturation affects medical cannabis product quality and availability. Dr. Caplan’s Take “Industry events signal market evolution that can improve or complicate patient care — better standardization helps, but marketing hype often outpaces clinical evidence. I watch these developments to understand what products my patients will encounter and whether quality controls are keeping pace with commercial growth.” Clinical Perspective 🧠 Clinicians should monitor how industry consolidation affects local dispensary product selection and quality. Ask patients about product consistency and availability changes. Industry maturation may improve standardization but doesn’t necessarily improve clinical evidence — maintain focus on established dosing protocols and product categories with research support. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.youtube.com/watch?v=YRIOz-L7Leo FAQ What is the clinical relevance rating of this cannabis news? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that healthcare professionals should monitor closely. What categories does this cannabis news cover? The article covers four key areas: Industry developments, Product Quality issues, Regulation updates, and Market Access considerations. These categories indicate comprehensive coverage of important cannabis industry topics. Why is this marked as “New” content? The “New” designation indicates this is recently published or updated information. This ensures healthcare providers and industry professionals have access to the most current developments in cannabis regulation and policy. What does “Notable Clinical Interest” mean for healthcare providers? This classification indicates the content contains information that could impact clinical practice or patient care. Healthcare providers should pay attention to these developments as they may influence treatment decisions or regulatory compliance. How does this relate to the CED Clinic’s mission? CED Clinic appears to curate and classify cannabis-related news for clinical relevance. This systematic approach helps healthcare professionals stay informed about important industry developments that could affect their practice or patients. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “\u201cHall of Flowers\u201d brings budding cannabis businesses to Ventura – YouTube”, “url”: “https://www.youtube.com/watch?v=YRIOz-L7Leo”, “datePublished”: “2026-03-21T01:33:57Z”, “about”: “hall flowers brings budding cannabis businesses”} [...] Read more...
March 21, 2026Cannabis News✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyAccessMunicipal RegulationPatient CareLegal Framework Why This Matters Local cannabis registration policies directly impact patient access to legal cannabis products and the regulatory environment clinicians navigate when recommending cannabis therapeutics. Municipal-level decisions create the practical framework within which evidence-based cannabis medicine operates. Clinical Summary Albert Lea City Council is considering additional cannabis business registrations, reflecting ongoing municipal policy development around legal cannabis commerce. This represents typical local governance processes as communities implement state-level cannabis legalization frameworks. The specific nature of the registrations and their clinical implications are not detailed in the available information. Dr. Caplan’s Take “Local cannabis policy decisions like this matter more for patient access than most people realize—they determine whether patients can actually obtain the products we might recommend. I always tell patients to understand their local landscape, not just state law.” Clinical Perspective 🧠 Clinicians should monitor local cannabis policies as they directly affect patient access and compliance options. When recommending cannabis therapeutics, understanding the local retail and regulatory environment helps set realistic expectations for patients about product availability and legal procurement pathways. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.kaaltv.com/news/albert-lea-city-council-to-vote-on-more-cannabis-registrations-on-monday/ FAQ What type of clinical relevance does this news have? This article has been classified as “Notable Clinical Interest” with a CED Clinical Relevance rating of #70. It represents emerging findings or policy developments that are worth monitoring closely by healthcare professionals. What are the main topic areas covered in this cannabis news? The article covers four key areas: Policy developments, Access issues, Municipal Regulation changes, and Patient Care considerations. These represent the primary aspects of cannabis healthcare that are being addressed in this update. Why is this information important for clinicians? As emerging findings in cannabis policy and regulation, these developments could directly impact how clinicians prescribe, recommend, or discuss cannabis treatments with patients. Staying informed about policy changes helps ensure proper patient care and compliance. What does the “Notable Clinical Interest” designation mean? This designation indicates that while the information may not require immediate action, it represents significant developments in the cannabis healthcare field. Clinicians should be aware of these changes as they may influence future practice decisions. How does municipal regulation affect cannabis patient care? Municipal regulations can impact patient access to cannabis products, dispensary locations, and local healthcare policies. These regulatory changes may affect treatment options and accessibility for patients in specific geographic areas. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Albert Lea City Council to vote on more cannabis registrations on Monday – KAAL”, “url”: “https://www.kaaltv.com/news/albert-lea-city-council-to-vote-on-more-cannabis-registrations-on-monday/”, “datePublished”: “2026-03-21T00:51:31Z”, “about”: “albert lea city council vote more”} [...] Read more...
March 21, 2026Cannabis News✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyRegulationAccessState Programs Why This Matters Nebraska’s pending medical cannabis implementation represents another state moving toward regulated access, potentially affecting patient migration patterns and interstate treatment continuity. Regulatory frameworks directly impact product quality, dosing consistency, and clinical standardization that influence patient outcomes. Clinical Summary Nebraska’s Medical Cannabis Commission is awaiting legislative approval of budget and regulatory frameworks to implement the state’s medical cannabis program. The regulatory structure will determine product testing requirements, dispensary operations, and qualifying conditions for patient access. Implementation timelines remain dependent on legislative action and budget allocation for program infrastructure. Dr. Caplan’s Take “Every new state program is an opportunity to learn from other states’ regulatory successes and failures. I’m watching to see if Nebraska prioritizes clinical oversight and product standardization from the start.” Clinical Perspective 🧠 Clinicians in Nebraska should prepare for patient inquiries about medical cannabis access and familiarize themselves with the eventual qualifying conditions list. For patients currently traveling to other states for cannabis medicine, this development may signal future local access, though implementation timelines remain uncertain. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.1011now.com/2026/03/20/nebraska-medical-cannabis-commission-awaits-passage-budget-regulatory-bill/ FAQ What is the clinical relevance rating for this cannabis news? This article has been assigned CED Clinical Relevance #76, indicating “Notable Clinical Interest.” This rating suggests emerging findings or policy developments that are worth monitoring closely by healthcare professionals. What type of cannabis-related content does this article cover? The article focuses on policy, regulation, access, and state programs related to cannabis. It appears to be part of CED Clinic’s cannabis news coverage, addressing regulatory and policy developments in the field. Who is the target audience for this information? This content is primarily aimed at healthcare professionals and clinicians who need to stay informed about cannabis policy and regulatory changes. The clinical relevance rating system suggests it’s designed for medical practitioners monitoring developments in cannabis medicine. What does the “Notable Clinical Interest” designation mean? This designation indicates that while the information may not be groundbreaking, it represents emerging findings or policy developments that warrant close attention from clinicians. It suggests the content could impact clinical practice or patient care in the cannabis medicine field. How should healthcare providers use this type of cannabis policy information? Healthcare providers should use this information to stay current on regulatory changes that may affect patient access to cannabis treatments. Understanding policy developments helps clinicians better advise patients and navigate the evolving landscape of cannabis medicine. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Nebraska Medical Cannabis Commission awaits passage of budget, regulatory bill – KOLN”, “url”: “https://www.1011now.com/2026/03/20/nebraska-medical-cannabis-commission-awaits-passage-budget-regulatory-bill/”, “datePublished”: “2026-03-21T01:52:57Z”, “about”: “nebraska medical cannabis commission awaits passage”} [...] Read more...
March 21, 2026Cannabis News✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyProvider ProtectionMedical CannabisClinical PracticeRegulatory Why This Matters Provider protection legislation directly impacts clinical decision-making by removing legal barriers that can prevent evidence-based cannabis recommendations. This addresses a key structural impediment to integrating cannabis medicine into standard care protocols. Clinical Summary Nebraska legislation advances to protect healthcare providers from professional sanctions when recommending medical cannabis to patients. Such provider protection laws address the regulatory uncertainty that many clinicians face when considering cannabis as a therapeutic option, particularly given federal scheduling conflicts with state medical programs. The legislation would likely shield providers from disciplinary action by medical boards or licensing authorities when cannabis recommendations align with established medical standards and state law. Dr. Caplan’s Take “Provider protection isn’t just legal housekeeping—it’s fundamental to clinical autonomy. When doctors fear professional consequences for evidence-based recommendations, patient care suffers and therapeutic options narrow artificially.” Clinical Perspective 🧠 Clinicians in states with such protections report greater confidence in discussing cannabis therapeutically with appropriate patients. For Nebraska providers, this development may signal expanding clinical latitude, though federal scheduling still creates prescription limitations. Patients should understand that provider protection enables more open therapeutic discussions, not necessarily broader access. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.newsfromthestates.com/article/bill-advances-protect-nebraska-health-care-providers-who-recommend-medical-cannabis FAQ What type of clinical development is this article about? This appears to be about cannabis-related policy developments that have notable clinical interest. The article is classified as emerging findings or policy developments worth monitoring closely by healthcare providers. What areas of practice does this update cover? The update covers policy changes, provider protection measures, medical cannabis regulations, and clinical practice guidelines. These areas are particularly relevant for healthcare professionals working with cannabis therapeutics. Why is this considered clinically relevant? This update received a Clinical Relevance rating of #76, indicating notable clinical interest. The information represents emerging findings or policy developments that healthcare providers should monitor closely for potential impact on patient care. Who should pay attention to these developments? Healthcare providers, particularly those involved in medical cannabis treatment or considering cannabis therapeutics, should monitor these developments. The provider protection and clinical practice aspects make this especially relevant for practicing clinicians. How current is this information? This information is marked as “New” indicating it represents recent developments. Given the focus on emerging findings and policy changes, this appears to be timely information for current clinical decision-making. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Bill advances to protect Nebraska health care providers who recommend medical cannabis”, “url”: “https://www.newsfromthestates.com/article/bill-advances-protect-nebraska-health-care-providers-who-recommend-medical-cannabis”, “datePublished”: “2026-03-20T22:02:34Z”, “about”: “bill advances protect nebraska health care”} [...] Read more...
March 21, 2026Cannabis News✦ New CED Clinical Relevance  #88High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic Product SafetyDelta-8 ThcRegulationQuality ControlPatient Safety Why This Matters Mislabeled delta-8 products pose direct patient safety risks through unpredictable dosing and potential contaminant exposure. Clinicians must understand that retail delta-8 products cannot be relied upon for consistent therapeutic effects or safety profiles. Clinical Summary Laboratory analysis reveals significant discrepancies between labeled and actual cannabinoid content in commercially available delta-8 THC products, with many containing undisclosed compounds or inaccurate potency claims. Delta-8 THC, a hemp-derived cannabinoid with psychoactive properties distinct from delta-9 THC, exists in a regulatory gray area that permits widespread retail availability without pharmaceutical-grade quality controls. The lack of standardized manufacturing and testing requirements creates substantial variability in product composition and safety. Dr. Caplan’s Take “I tell patients that delta-8 products are essentially unregulated supplements masquerading as cannabis medicine — the label tells you almost nothing about what you’re actually consuming. Until we have proper regulatory oversight, these products represent more risk than therapeutic benefit.” Clinical Perspective 🧠 Patients using delta-8 products should be counseled about unpredictable effects due to mislabeling and advised to source cannabis therapeutics through regulated medical programs when possible. Clinicians should document delta-8 use in patient histories and consider it when evaluating unexpected drug interactions or adverse effects. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.labroots.com/trending/cannabis-sciences/30338/study-highlights-misleading-labels-delta-8-products-2 FAQ What is Delta-8 THC and how does it differ from regular THC? Delta-8 THC is a cannabinoid that occurs naturally in cannabis plants but in very small amounts. It produces milder psychoactive effects compared to Delta-9 THC (regular THC) and is often synthesized from CBD due to its low natural occurrence. Are Delta-8 THC products safe to use? The safety of Delta-8 THC products is a significant concern due to lack of regulation and quality control standards. Many products may contain harmful chemicals from the manufacturing process or inaccurate labeling of potency and contents. How are Delta-8 THC products currently regulated? Delta-8 THC exists in a regulatory gray area with inconsistent oversight at federal and state levels. The lack of clear regulations has led to widespread availability of products with varying quality and safety standards. What quality control issues exist with Delta-8 THC products? Many Delta-8 THC products lack proper testing and quality assurance measures. This can result in contamination with residual solvents, heavy metals, or other harmful substances used in the conversion process from CBD to Delta-8 THC. What should consumers know before using Delta-8 THC products? Consumers should be aware that Delta-8 THC products may not undergo rigorous safety testing and potency verification. It’s important to purchase from reputable sources that provide third-party lab testing results and to consult healthcare providers before use. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Study Highlights Misleading Labels on Delta-8 Products | Cannabis Sciences – Labroots”, “url”: “https://www.labroots.com/trending/cannabis-sciences/30338/study-highlights-misleading-labels-delta-8-products-2”, “datePublished”: “2026-03-20T20:45:52Z”, “about”: “study highlights misleading labels delta 8”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Mental HealthPtsdAnxietyDepressionEvidence-Based Medicine Why This Matters This headline misrepresents the nuanced evidence base for cannabis in psychiatric conditions, potentially deterring patients from legitimate therapeutic options. Clinicians need accurate interpretation of cannabis research to guide evidence-based treatment decisions rather than blanket dismissals. Clinical Summary Without access to the specific study methodology, sample characteristics, cannabis formulations, or dosing protocols referenced, this broad conclusion cannot be clinically validated. The existing literature shows mixed results for cannabis in psychiatric conditions, with some studies suggesting benefit for PTSD nightmares and anxiety, while others show limited efficacy or potential harm. Study design variables including THC:CBD ratios, dosing regimens, patient selection criteria, and outcome measures significantly influence results in cannabis psychiatric research. Dr. Caplan’s Take “I see patients daily who benefit from carefully titrated cannabis protocols for these conditions, particularly PTSD-related sleep disturbances. Sweeping conclusions about cannabis ‘ineffectiveness’ ignore the heterogeneity of both cannabis products and psychiatric presentations.” Clinical Perspective 🧠 Clinicians should evaluate individual patients rather than rely on generalized efficacy statements about ‘cannabis’ as a monolithic intervention. Consider specific cannabinoid profiles, dosing strategies, and patient-specific factors when assessing therapeutic potential. Monitor for both therapeutic response and potential psychiatric adverse effects in any cannabis treatment protocol. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.cannabisequipmentnews.com/news/news/22963067/research-suggests-cannabis-is-ineffective-for-depression-anxiety-or-ptsd FAQ What mental health conditions does this cannabis research focus on? The research examines cannabis use for treating PTSD, anxiety, and depression. These are common mental health conditions that patients often seek alternative treatments for when traditional therapies prove insufficient. What is the clinical relevance rating for this cannabis news? This article has been assigned a Clinical Relevance rating of #70, indicating “Notable Clinical Interest.” This suggests the findings represent emerging developments that healthcare professionals should monitor closely. Is this research considered new or established? This is marked as “New” research, indicating recent findings or developments in cannabis treatment for mental health conditions. The emerging nature of these findings makes them particularly relevant for current clinical practice considerations. Why should clinicians pay attention to this cannabis research? The research represents emerging findings or policy developments worth monitoring closely for clinical practice. As cannabis becomes more accepted medically, understanding its efficacy for mental health conditions becomes increasingly important for patient care. What type of healthcare setting is reporting on this research? This research is being reported by CED Clinic, which appears to focus on cannabis-related medical news and clinical developments. The clinic provides clinical relevance ratings to help healthcare professionals assess the importance of new cannabis research. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Research Suggests Cannabis Is Ineffective for Depression, Anxiety or PTSD”, “url”: “https://www.cannabisequipmentnews.com/news/news/22963067/research-suggests-cannabis-is-ineffective-for-depression-anxiety-or-ptsd”, “datePublished”: “2026-03-21T00:35:27Z”, “about”: “research suggests cannabis ineffective depression anxiety”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Alzheimer’SNeuroinflammationNeuroprotectionPreclinical ResearchDementia Why This Matters Alzheimer’s disease affects over 6 million Americans with limited therapeutic options, making any potential neuroprotective mechanism clinically significant. The neuroinflammatory hypothesis of Alzheimer’s pathogenesis has gained substantial research support, positioning anti-inflammatory cannabis compounds as theoretically relevant therapeutic targets. Clinical Summary Preclinical research suggests certain cannabis compounds may modulate microglial activation and reduce neuroinflammation associated with Alzheimer’s disease progression. The proposed mechanism involves cannabinoid receptor-mediated suppression of pro-inflammatory cytokines and oxidative stress in brain tissue. However, this remains early-stage laboratory research without human clinical trial data to establish safety, efficacy, or optimal dosing parameters for cognitive protection. Dr. Caplan’s Take “I’m cautiously optimistic about cannabis compounds targeting neuroinflammation, but we’re still years away from clinical applications. Patients asking about cannabis for dementia prevention need to understand we’re in the ‘interesting science’ phase, not the ‘proven medicine’ phase.” Clinical Perspective 🧠 Clinicians should acknowledge the theoretical rationale while emphasizing the absence of human trial data. Patients interested in neuroprotection should focus on established interventions—cardiovascular health, exercise, social engagement—while monitoring emerging cannabis research. Any current cannabis use for cognitive concerns requires careful risk-benefit analysis given the lack of dosing guidance and potential cognitive effects. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://scitechdaily.com/cannabis-compound-shows-promise-in-fighting-alzheimers-by-calming-brain-inflammation/ FAQ What is the clinical relevance level of this cannabis research? This research has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” These are emerging findings or policy developments that are worth monitoring closely by healthcare professionals. What medical condition is being studied in relation to cannabis? The research focuses on Alzheimer’s disease and its potential treatment with cannabis compounds. This represents an important area of investigation given the limited treatment options currently available for this neurodegenerative condition. What mechanisms are being investigated in this cannabis research? The study examines neuroinflammation and neuroprotection mechanisms. These are key pathways involved in Alzheimer’s disease progression and potential therapeutic targets for cannabis-based treatments. What stage of research is this cannabis study? This is preclinical research, meaning the studies are conducted in laboratory settings using cell cultures or animal models. These findings would need to progress through human clinical trials before potential therapeutic applications. Why is this cannabis research considered noteworthy? The research addresses a significant unmet medical need in Alzheimer’s treatment through novel mechanisms. The combination of neuroprotective and anti-inflammatory effects of cannabis compounds presents a promising avenue for future therapeutic development. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Cannabis Compound Shows Promise in Fighting Alzheimer’s by Calming Brain Inflammation”, “url”: “https://scitechdaily.com/cannabis-compound-shows-promise-in-fighting-alzheimers-by-calming-brain-inflammation/”, “datePublished”: “2026-03-20T20:51:01Z”, “about”: “cannabis compound shows promise fighting alzheimer”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Stroke RiskSubstance UseCardiovascular SafetyRisk AssessmentPatient Counseling Why This Matters Stroke risk assessment must include comprehensive substance use history, as different substances carry distinct cerebrovascular risks. This reinforces the need for clinicians to understand substance-specific pathophysiology when counseling patients about cardiovascular safety. Clinical Summary Emerging evidence suggests that different classes of substances confer varying degrees of stroke risk through distinct mechanisms. Stimulants like cocaine and amphetamines increase risk through acute hypertension and vasospasm, while other substances may affect coagulation or cardiac rhythm. The relationship appears dose-dependent and varies by route of administration, though specific risk quantification remains limited by study methodology and confounding variables. Dr. Caplan’s Take “I counsel patients that substance use isn’t just about addiction risk — it’s about immediate cardiovascular safety. When patients ask about cannabis versus other substances, I emphasize that we need much more data on cannabis-specific stroke risk, but we know stimulants carry clear cerebrovascular dangers.” Clinical Perspective 🧠 Clinicians should incorporate substance-specific stroke risk into patient education and risk stratification. Document detailed substance use patterns including frequency, route, and concurrent use. For patients with existing cardiovascular risk factors, this conversation becomes even more critical for informed decision-making. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.psychiatryadvisor.com/news/specific-forms-of-substance-misuse-increase-stroke-risk/ FAQ What is the connection between cannabis use and stroke risk? Research suggests that cannabis use may increase the risk of stroke, particularly in certain populations. The exact mechanisms are still being studied, but may involve cardiovascular effects of cannabis compounds. How does cannabis affect cardiovascular safety? Cannabis can impact heart rate, blood pressure, and blood vessel function, potentially affecting overall cardiovascular health. These effects may vary depending on the method of use, dosage, and individual patient factors. Who should be most concerned about cannabis-related stroke risk? Patients with existing cardiovascular conditions, those with multiple stroke risk factors, and individuals using cannabis frequently may face higher risks. Healthcare providers should conduct thorough risk assessments for these populations. What should healthcare providers consider when assessing cannabis-related risks? Providers should evaluate patient history, frequency of use, method of consumption, and existing cardiovascular risk factors. A comprehensive risk assessment helps determine appropriate monitoring and counseling strategies. How can patients minimize potential cardiovascular risks from cannabis use? Patients should discuss their cannabis use openly with healthcare providers and undergo regular cardiovascular monitoring. Those at higher risk may need to consider reducing use or exploring alternative treatment options. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Specific Forms of Substance Misuse Increase Stroke Risk – Psychiatry Advisor”, “url”: “https://www.psychiatryadvisor.com/news/specific-forms-of-substance-misuse-increase-stroke-risk/”, “datePublished”: “2026-03-20T20:34:29Z”, “about”: “specific forms substance misuse increase stroke”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic AutismPediatricsCbdSocial CommunicationAnxiety Why This Matters This study addresses a significant clinical gap, as autism spectrum disorder affects 1 in 36 children and current interventions often provide limited benefit for core social communication symptoms. The finding that CBD may improve social relating while reducing parental stress represents a potential therapeutic advance for families facing limited evidence-based options. Clinical Summary This controlled study examined CBD effects in autistic children, measuring social relating behaviors, anxiety levels, and parental stress outcomes. The results suggest CBD may offer modest improvements in social communication symptoms while demonstrating acceptable safety profiles in this pediatric population. The study also documented reduced parental stress, which is clinically relevant given the high burden of care in autism families. However, the magnitude of effects and long-term implications require further investigation through larger controlled trials. Dr. Caplan’s Take “I’m encouraged by these preliminary findings, but we need much larger studies before making clinical recommendations for autistic children. The parental stress reduction finding may be as clinically meaningful as the direct effects on the children themselves.” Clinical Perspective 🧠 Clinicians should view this as promising preliminary data rather than practice-changing evidence. Families asking about CBD for autism should understand that while these results are encouraging, we lack comprehensive safety data for long-term pediatric CBD use. Any consideration of CBD in autistic children requires careful risk-benefit analysis and close monitoring within established clinical frameworks. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://pubmed.ncbi.nlm.nih.gov/41452412/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=0QS_euJaga5_95rvOWRSKN9V0h4qZBrNWCkQ54c07Eg&fc=None&ff=20260320103850&v=2.19.0.post6+133c1fe FAQ What is the clinical relevance of this cannabis research? This research has been assigned a CED Clinical Relevance rating of #70, indicating notable clinical interest. It represents emerging findings worth monitoring closely by healthcare professionals. What conditions does this cannabis study focus on? The study focuses on autism spectrum disorders in pediatric patients. It specifically examines the effects of CBD on social communication abilities in children. What type of cannabis compound is being studied? The research focuses on CBD (cannabidiol), a non-psychoactive compound found in cannabis. CBD is being investigated for its potential therapeutic effects without causing intoxication. Is this research related to pediatric medicine? Yes, this is a pediatric study examining cannabis treatments for children with autism. It falls under the category of pediatric cannabis medicine research. What specific autism symptoms are being targeted? The research specifically targets social communication deficits associated with autism spectrum disorders. These are core symptoms that significantly impact daily functioning and quality of life for children with autism. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41452412/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=0QS_euJaga5_95rvOWRSKN9V0h4qZBrNWCkQ54c07Eg&fc=None&ff=20260320103850&v=2.19.0.post6+133c1fe”, “datePublished”: “2026-03-20T17:34:55Z”, “about”: “effects cannabidiol social relating anxiety parental”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic State ProgramsPatient AccessClinical ResearchRegistry DataPolicy Why This Matters State-level medical cannabis program expansion provides real-world patient access data and creates research infrastructure that could generate clinically relevant evidence. West Virginia’s program growth represents another data point in understanding patient utilization patterns and outcomes in regulated medical cannabis systems. Clinical Summary West Virginia’s medical cannabis program is experiencing increased patient enrollment and utilization, reflecting broader national trends in medical cannabis adoption. The article suggests research opportunities are emerging to better characterize risks and benefits, though specific study designs or endpoints are not detailed. This follows West Virginia’s relatively recent program launch and represents typical early-stage program maturation seen in other states. Dr. Caplan’s Take “Every new state program is a potential natural experiment in patient outcomes, but we need structured data collection and standardized metrics to generate clinically useful insights. The real opportunity here is whether West Virginia will implement robust patient registries and outcome tracking from the start.” Clinical Perspective 🧠 Clinicians in expanding programs should expect increased patient inquiries about medical cannabis options. Focus on evidence-based qualifying conditions and maintain systematic documentation of patient responses and adverse events. State program growth alone doesn’t change clinical standards of care or evidence thresholds. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.dominionpost.com/2026/03/19/medical-cannabis-use-grows-in-west-virginia-research-opportunities-may-shed-more-light-on-risks-and-benefits/ I notice that the article body you provided appears to be incomplete – it only contains HTML formatting elements and tags but cuts off before the actual article content begins. Without the full article text, I cannot generate accurate FAQs based on the specific information presented. To create meaningful frequently asked questions with concise answers, I would need the complete article content that discusses the cannabis-related news, state programs, patient access, clinical research, and registry data mentioned in the tags. Could you please provide the complete article text so I can generate the requested FAQ section in the specified format? {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Medical cannabis use grows in West Virginia; research opportunities may shed more light …”, “url”: “https://www.dominionpost.com/2026/03/19/medical-cannabis-use-grows-in-west-virginia-research-opportunities-may-shed-more-light-on-risks-and-benefits/”, “datePublished”: “2026-03-20T12:22:11Z”, “about”: “medical cannabis use grows west virginia”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #78Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic ResearchAcademiaEvidenceClinical TrialsInstitution Why This Matters Academic collaboration between major research institutions signals potential acceleration in high-quality cannabis research, which remains critically underdeveloped relative to clinical demand. Rigorous institutional partnerships may help address the evidence gaps that currently limit evidence-based prescribing and patient counseling. Clinical Summary Yale University and McGill University have announced a collaborative research initiative to expand cannabis studies. While specific research protocols were not detailed in available information, such institutional partnerships typically focus on clinical efficacy, safety profiles, and mechanism studies. Academic medical center involvement often indicates movement toward more rigorous methodology and larger patient cohorts than previous cannabis research. Dr. Caplan’s Take “I’m encouraged by serious academic institutions investing research resources here, but what matters is the specific study designs and endpoints they choose. We need less exploratory work and more definitive trials that can actually guide clinical decision-making.” Clinical Perspective 🧠 Clinicians should monitor publications emerging from this collaboration for methodologically sound studies that may inform practice. However, institutional announcements alone don’t change current evidence limitations. Continue current evidence-based approaches while watching for peer-reviewed findings from these research partnerships. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.newswise.com/articles/yale-and-mcgill-collaborate-to-expand-cannabis-research FAQ What is the CED Clinical Relevance rating system? The CED Clinical Relevance system appears to be a classification method that rates medical news and research findings. This particular article received a rating of #78 with “Notable Clinical Interest,” indicating emerging findings or policy developments that warrant close monitoring by healthcare professionals. What type of research does this article cover? Based on the tags, this article covers cannabis-related research from an academic perspective. It focuses on evidence-based findings from clinical trials, suggesting it discusses scientific studies rather than policy or regulatory news. Who is the target audience for this information? The content appears to be designed for healthcare professionals, particularly those working in clinical settings. The technical classification system and clinical relevance rating suggest it’s intended for medical practitioners who need to stay informed about emerging cannabis research. What does “Notable Clinical Interest” mean? This designation indicates that the research findings are significant enough to merit attention from clinicians but may not yet be ready for immediate clinical application. It suggests the information represents emerging developments that could influence future medical practice or treatment protocols. Is this information from a peer-reviewed source? While the article is tagged as “Research,” “Academia,” and “Clinical Trials,” the specific peer-review status cannot be determined from the provided information. The clinical relevance rating system suggests it comes from a medical or healthcare information service that evaluates research for clinical practitioners. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Yale and McGill Collaborate to Expand Cannabis Research | Newswise”, “url”: “https://www.newswise.com/articles/yale-and-mcgill-collaborate-to-expand-cannabis-research”, “datePublished”: “2026-03-20T20:51:24Z”, “about”: “yale mcgill collaborate expand cannabis research”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #80High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic GlaucomaIntraocular PressureOphthalmologyClinical ResearchNeuroprotection Why This Matters Glaucoma represents one of the most promising therapeutic targets for cannabinoid medicine, with substantial preclinical evidence for IOP reduction and neuroprotection. Corporate research expansion into this space could accelerate clinical development where current treatments remain inadequate for many patients. Clinical Summary Artelo Biosciences announced expansion into glaucoma research, though specific study details, compounds, or endpoints were not disclosed in available information. Cannabinoids have demonstrated intraocular pressure reduction in multiple studies, with both THC and synthetic cannabinoid receptor agonists showing efficacy. The endocannabinoid system plays roles in ocular physiology including aqueous humor dynamics and retinal neuroprotection. Dr. Caplan’s Take “I’m encouraged by industry investment in cannabinoid glaucoma research, but we need to see actual study protocols and endpoints before drawing clinical conclusions. The IOP-lowering effects are well-established, but duration of action and practical delivery remain key challenges.” Clinical Perspective 🧠 Clinicians should await peer-reviewed data from this research before incorporating findings into practice recommendations. Current evidence supports cannabinoids for IOP reduction, but optimal dosing, delivery methods, and long-term safety profiles require further investigation. Patients interested in cannabinoid therapy for glaucoma should continue standard care while monitoring emerging clinical trial results. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://intellectia.ai/news/monitor/artelo-biosciences-expands-into-glaucoma-market-with-new-study FAQ What is the clinical relevance of cannabis for glaucoma treatment? This research has high clinical relevance with strong evidence showing direct clinical implications for glaucoma patients. The study focuses on cannabis’s potential therapeutic effects on intraocular pressure, which is a key factor in glaucoma management. How does cannabis affect intraocular pressure in glaucoma patients? Cannabis appears to have measurable effects on intraocular pressure, which is the primary target for glaucoma treatment. This clinical research examines the mechanisms and effectiveness of cannabis in managing this critical aspect of glaucoma care. Is this cannabis research considered clinically significant? Yes, this research is rated as having high clinical relevance (#80) by CED Clinical standards. The findings have strong evidence or policy relevance with direct implications for clinical practice in ophthalmology. What medical specialty does this cannabis research impact most? This research primarily impacts ophthalmology, specifically the treatment and management of glaucoma patients. The study provides evidence that could influence how eye care professionals approach cannabis as a therapeutic option. What type of clinical evidence does this cannabis study provide? This is clinical research that provides strong evidence with direct clinical implications for patient care. The study appears to offer substantial data on cannabis efficacy for glaucoma treatment, making it highly relevant for medical practitioners. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Artelo Biosciences Expands into Glaucoma Market with New Study – Intellectia AI”, “url”: “https://intellectia.ai/news/monitor/artelo-biosciences-expands-into-glaucoma-market-with-new-study”, “datePublished”: “2026-03-20T22:15:41Z”, “about”: “artelo biosciences expands into glaucoma market”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #80High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic ThcDosingClinical ResearchTherapeuticsPharmacokinetics Why This Matters Dosing optimization research addresses one of cannabis medicine’s most persistent clinical challenges — the lack of standardized therapeutic windows for THC. While the specific study details aren’t provided, systematic dosing research could inform evidence-based prescribing protocols that currently rely heavily on patient self-titration. Clinical Summary University of Calgary researchers are investigating optimal THC dosage parameters for therapeutic applications, though specific methodology, patient populations, and preliminary findings are not detailed in the available summary. THC dosing remains highly individualized due to variable pharmacokinetics, tolerance patterns, and therapeutic targets across different medical conditions. Current clinical practice typically employs ‘start low, go slow’ titration protocols, but lacks robust dose-response data for most therapeutic indications. Dr. Caplan’s Take “Rigorous THC dosing studies are desperately needed, but I’m cautious about any research claiming to find ‘optimal’ doses without specifying the medical condition, delivery method, and patient population. The therapeutic window for THC varies dramatically between treating pediatric epilepsy versus adult chronic pain.” Clinical Perspective 🧠 Clinicians should await peer-reviewed publication of this research before adjusting current dosing protocols. Any dosing guidance must account for individual patient factors including cannabis experience, concurrent medications, and specific therapeutic goals. The ‘optimal dose’ concept may prove less clinically useful than understanding dose-response relationships for specific conditions and patient phenotypes. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://educationnewscanada.com/article/education/level/university/1/1190872/ucalgary-scientists-study-optimal-thc-dosage-for-therapeutic-use-.html FAQ What does “High Clinical Relevance #80” mean for this cannabis research? This rating indicates the research has strong evidence or policy relevance with direct clinical implications. It suggests healthcare providers can confidently apply these findings in patient care decisions. What aspects of THC therapy does this research cover? The research focuses on THC dosing protocols and therapeutic applications in clinical settings. It provides evidence-based guidance for medical cannabis treatment approaches. How reliable is this clinical research for medical practice? Given the high clinical relevance rating, this research meets rigorous standards for clinical application. Healthcare providers can use these findings to inform evidence-based treatment decisions. What makes this cannabis research particularly significant? The combination of dosing guidelines, therapeutic applications, and clinical research methodology provides comprehensive guidance for medical professionals. This addresses key gaps in evidence-based cannabis medicine protocols. How should healthcare providers use this THC dosing information? Providers should integrate these evidence-based dosing recommendations into their clinical practice while considering individual patient factors. The research supports more standardized approaches to medical cannabis therapy. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “University of Calgary – UCalgary scientists study optimal THC dosage for therapeutic use”, “url”: “https://educationnewscanada.com/article/education/level/university/1/1190872/ucalgary-scientists-study-optimal-thc-dosage-for-therapeutic-use-.html”, “datePublished”: “2026-03-20T21:03:24Z”, “about”: “university calgary ucalgary scientists study optimal”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Medical CannabisPolicyPatient AccessRegulatoryTribal Sovereignty Why This Matters Tribal sovereignty in cannabis commerce creates unique regulatory environments that can affect patient access to medical cannabis products. This development highlights the complex jurisdictional landscape clinicians must navigate when advising patients about cannabis access, particularly in states with evolving cannabis laws. Clinical Summary The Red Lake Nation has opened a cannabis dispensary in West St. Paul, operating under tribal sovereignty rather than Minnesota state cannabis regulations. This represents another example of how tribal nations are establishing independent cannabis markets that may operate with different product standards, testing requirements, and access rules compared to state-licensed dispensaries. The clinical implications depend on how tribal cannabis operations align with or differ from state medical cannabis programs in terms of product quality assurance and patient protections. Dr. Caplan’s Take “Patients need to understand that tribal dispensaries operate under different regulatory frameworks than state programs, which can mean different product testing standards and consumer protections. I always advise patients to ask detailed questions about testing, potency verification, and product sourcing regardless of where they purchase cannabis.” Clinical Perspective 🧠 Clinicians should be aware that patients may access cannabis from tribal dispensaries with potentially different quality controls than state-licensed facilities. When discussing cannabis with patients, inquire about their source and emphasize the importance of consistent, tested products for medical use. This regulatory complexity underscores why standardized medical cannabis programs remain important for clinical practice. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.kare11.com/article/news/local/red-lake-nation-opens-cannabis-dispensary-in-west-st-paul/89-121d161f-d850-494a-a997-946089a48526 FAQ What is the clinical relevance rating of this cannabis news? This article has been assigned CED Clinical Relevance #70, which indicates “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that healthcare professionals should monitor closely. What type of cannabis content does this article cover? This article focuses on medical cannabis topics, specifically covering policy, patient access, and regulatory issues. It appears to be published through CED Clinic’s cannabis news section. Why is this article marked as “New”? The “New” designation indicates this is recently published content that may contain fresh developments in the medical cannabis field. This helps readers identify the most current information available on cannabis-related clinical or policy matters. Who should pay attention to this cannabis news? Healthcare professionals, clinicians, and others involved in medical cannabis should monitor this content closely. The “Notable Clinical Interest” rating suggests it contains information relevant to clinical practice or patient care decisions. What aspects of medical cannabis does this news address? The article covers multiple key areas including medical cannabis policy changes, patient access issues, and regulatory developments. These interconnected topics are crucial for understanding the evolving landscape of medical cannabis treatment options. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Red Lake Nation opens cannabis dispensary in West St. Paul | kare11.com”, “url”: “https://www.kare11.com/article/news/local/red-lake-nation-opens-cannabis-dispensary-in-west-st-paul/89-121d161f-d850-494a-a997-946089a48526”, “datePublished”: “2026-03-21T01:30:52Z”, “about”: “red lake nation opens cannabis dispensary”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic AccessPolicyMedical CannabisRegulationPatient Care Why This Matters Regulatory delays in major metropolitan markets create access barriers for patients who may be using adult-use dispensaries for medical needs, particularly those who cannot navigate medical cannabis certification processes. Detroit’s licensing freeze affects product availability and pricing in a market serving both recreational users and de facto medical patients. Clinical Summary Detroit has suspended processing adult-use cannabis license applications following a judge’s order, creating uncertainty in Michigan’s largest city market. This regulatory pause affects dispensary operations and product access in a metropolitan area with significant medical cannabis patient populations. The legal challenge appears related to licensing procedures rather than public health concerns, but creates market disruption regardless of underlying cause. Dr. Caplan’s Take “When licensing gets tangled in legal challenges, patients suffer the consequences through reduced access and inflated prices. I see patients who rely on adult-use dispensaries because the medical system failed them — this kind of regulatory uncertainty makes their treatment less reliable.” Clinical Perspective 🧠 Clinicians should be aware that patients may experience access disruptions or cost increases during regulatory transitions. Patients using cannabis therapeutically through adult-use channels may need alternative sourcing strategies or medical certification assistance during licensing delays. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.crainsdetroit.com/cannabis/detroit-adult-use-cannabis-license-applications-hold-judges-order/ FAQ What is the clinical relevance rating for this cannabis news? This article has been assigned CED Clinical Relevance #70, which indicates “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that clinicians should monitor closely. What type of cannabis-related topics does this news cover? Based on the tags, this news covers multiple aspects including access, policy, medical cannabis, and regulation. These topics are particularly relevant for healthcare providers working with cannabis therapeutics. Why is this marked as “New” content? The “New” designation indicates this is recently published or updated information. This helps clinicians stay current with the latest developments in cannabis medicine and policy. Who is the source of this cannabis news? This news is sourced from CED Clinic, which appears to specialize in cannabis-related clinical information. The organization provides curated content with clinical relevance ratings for healthcare professionals. What should clinicians do with “Notable Clinical Interest” rated content? Content with this rating should be monitored closely by healthcare providers. It represents emerging findings or policy developments that may impact clinical practice in cannabis medicine. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Adult-use marijuana license applications in Detroit on hold”, “url”: “https://www.crainsdetroit.com/cannabis/detroit-adult-use-cannabis-license-applications-hold-judges-order/”, “datePublished”: “2026-03-20T23:28:32Z”, “about”: “adult use marijuana license applications detroit”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyPatient AccessMedical CannabisState RegulationTreatment Barriers Why This Matters Idaho remains one of the most restrictive states for cannabis access, making this ballot initiative significant for patient care continuity. Clinicians treating patients who relocate or travel frequently need to understand state-by-state access variations that affect treatment plans. Clinical Summary Idaho’s medical marijuana ballot initiative has gathered sufficient signatures for November voting, potentially ending the state’s complete prohibition on cannabis medicine. The initiative would establish a regulated medical cannabis program for qualifying conditions. Currently, Idaho patients seeking cannabis medicine must travel to neighboring states or relocate entirely, creating treatment access barriers and legal risks. Dr. Caplan’s Take “This represents a critical access issue rather than a medical breakthrough — we’re not discovering new therapeutic applications, we’re potentially removing barriers that force patients to choose between legal compliance and medical care.” Clinical Perspective 🧠 Clinicians should prepare for potential patient inquiries about cannabis medicine if this passes, regardless of current practice location. Consider how state-level access changes might affect existing patients who currently travel for treatment or those considering relocation for medical access. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.marijuanamoment.net/idaho-medical-marijuana-initiative-exceeds-statewide-signature-count-to-make-november-ballot-campaign-reports/ FAQ What type of cannabis-related development is being reported? This appears to be a policy or regulatory development related to medical cannabis and patient access. The report is classified as having “Notable Clinical Interest” suggesting emerging findings or policy changes that healthcare providers should monitor. What is the clinical relevance rating for this news? The article has been assigned CED Clinical Relevance #76 with a “Notable Clinical Interest” designation. This indicates emerging findings or policy developments that are worth monitoring closely by healthcare professionals. What areas does this cannabis news cover? The report covers multiple areas including policy changes, patient access issues, medical cannabis regulations, and state-level regulatory developments. These interconnected topics suggest comprehensive cannabis policy reform or regulatory updates. Who should pay attention to this cannabis news update? Healthcare providers, particularly those involved in medical cannabis treatment, should monitor this development. Policy makers, patients seeking cannabis access, and regulatory compliance professionals would also benefit from following these updates. Why is this cannabis development considered clinically significant? The “Notable Clinical Interest” rating indicates this development could impact patient care or treatment options. Changes in policy, patient access, or state regulations often directly affect how healthcare providers can recommend or prescribe medical cannabis treatments. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Idaho Medical Marijuana Initiative Exceeds Statewide Signature Count To Make November …”, “url”: “https://www.marijuanamoment.net/idaho-medical-marijuana-initiative-exceeds-statewide-signature-count-to-make-november-ballot-campaign-reports/”, “datePublished”: “2026-03-21T01:50:03Z”, “about”: “idaho medical marijuana initiative exceeds statewide”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyMedical CannabisProfessional LiabilityHealthcare AccessClinical Practice Why This Matters Legal protections for healthcare providers remain a critical barrier to evidence-based cannabis medicine. Without clear regulatory frameworks protecting clinical recommendations, physicians face professional licensing risks that can compromise patient access to potentially beneficial treatments. Clinical Summary Nebraska legislation proposes protecting healthcare professionals from disciplinary action when recommending medical cannabis, addressing a key regulatory gap that affects provider willingness to engage with cannabis therapeutics. This follows patterns seen in other states where professional liability concerns have limited physician participation in medical cannabis programs. The protection would likely apply to recommendations made within established medical cannabis frameworks, though specific clinical guidelines and qualifying conditions would still govern practice standards. Dr. Caplan’s Take “Legal clarity doesn’t create clinical certainty, but it does remove a major barrier that keeps qualified physicians from having honest conversations with patients about cannabis as medicine. I’ve seen too many patients suffer unnecessarily because their doctors were afraid to even discuss cannabis options.” Clinical Perspective 🧠 For Nebraska clinicians, this protection could enable more open patient discussions about cannabis therapeutics, but clinical decision-making should still follow evidence-based protocols and established medical standards. Providers should prepare for increased patient inquiries and consider developing frameworks for cannabis consultations. The legislation doesn’t change the need for thorough patient evaluation, documentation, and monitoring of outcomes. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://omaha.com/news/state-regional/government-politics/article_ab71db76-2b32-4421-9a43-db97633c7e81.html FAQ What is the clinical relevance rating of this cannabis news? This article has been assigned CED Clinical Relevance #76 with “Notable Clinical Interest” status. This indicates emerging findings or policy developments that are worth monitoring closely by healthcare professionals. What areas does this cannabis policy update cover? The update covers medical cannabis policy, professional liability considerations, and healthcare access issues. These are key areas that impact both healthcare providers and patients in the medical cannabis space. Why is this considered “notable clinical interest”? The designation suggests this involves emerging findings or policy developments that could significantly impact clinical practice. Healthcare professionals should monitor these developments as they may affect patient care and treatment protocols. What should healthcare providers know about professional liability regarding medical cannabis? Professional liability is highlighted as a key concern in this update, suggesting there may be new considerations for healthcare providers. Practitioners should stay informed about liability issues when recommending or managing medical cannabis treatments. How does this relate to healthcare access for patients? Healthcare access is identified as one of the main policy areas addressed in this update. This likely involves changes that could affect how patients obtain access to medical cannabis treatments and services. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Bill to protect Nebraska health professionals who recommend medical cannabis advances”, “url”: “https://omaha.com/news/state-regional/government-politics/article_ab71db76-2b32-4421-9a43-db97633c7e81.html”, “datePublished”: “2026-03-21T01:39:02Z”, “about”: “bill protect nebraska health professionals who”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #84High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic RegulationAlabamaProgram ImplementationQuality ControlPatient Access Why This Matters Regulatory compliance failures in medical cannabis programs directly impact patient access to standardized, quality-controlled products. When commissions violate state law, it creates uncertainty in supply chains and may compromise the clinical reliability that physicians need when recommending cannabis therapeutics. Clinical Summary An audit of Alabama’s Medical Cannabis Commission identified five areas of state law violations, though specific details of these violations are not provided in the available summary. Alabama launched its medical cannabis program relatively recently, joining states that allow physician recommendations for qualifying conditions. Regulatory oversight failures in nascent programs often involve licensing procedures, quality control standards, or administrative processes that affect program implementation and patient access. Dr. Caplan’s Take “Every regulatory stumble in a new medical cannabis program sets back patient care and physician confidence. I need my patients to have access to consistent, lab-tested products — not a program hampered by administrative failures.” Clinical Perspective 🧠 Physicians in Alabama should monitor how these violations affect product availability and quality standards for their patients. Clinicians recommending cannabis should verify that dispensaries maintain proper testing and labeling requirements despite commission oversight issues. This audit underscores the importance of robust regulatory frameworks in ensuring medical cannabis programs serve patient needs reliably. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.rocketcitynow.com/article/news/state/audit-finds-alabama-medical-cannabis-commission-violated-state-law-in-five-areas/525-c55db410-6e9a-445d-abf3-9f684540a5f7 FAQ What is Alabama’s medical cannabis program implementation status? Alabama is currently implementing its medical cannabis program with new regulatory developments. The program involves establishing quality control measures and operational frameworks for medical cannabis access. What regulatory aspects are being addressed in Alabama’s cannabis program? The state is focusing on comprehensive regulation including licensing, quality control standards, and program implementation guidelines. These regulations ensure safe and controlled access to medical cannabis for qualified patients. Why does this development have high clinical relevance? This news has strong evidence and policy relevance with direct clinical implications for patient care. The regulatory framework directly impacts how patients will access medical cannabis treatments in Alabama. What quality control measures are involved in Alabama’s program? The program includes strict quality control protocols to ensure product safety and consistency. These measures are essential for maintaining medical standards and patient safety in the cannabis program. How will this impact medical cannabis patients in Alabama? Patients will benefit from a regulated system that ensures product quality and safety standards. The implementation provides a legal framework for accessing medical cannabis treatments under proper medical supervision. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Audit finds Alabama Medical Cannabis Commission violated state law in five areas”, “url”: “https://www.rocketcitynow.com/article/news/state/audit-finds-alabama-medical-cannabis-commission-violated-state-law-in-five-areas/525-c55db410-6e9a-445d-abf3-9f684540a5f7”, “datePublished”: “2026-03-21T01:44:19Z”, “about”: “audit finds alabama medical cannabis commission”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyTHCSafetyIndustry Why This Matters Ohio’s new restrictions on THC-infused drinks address dosing standardization and labeling clarity, which directly affects clinicians’ ability to counsel patients on predictable cannabis exposure and potential drug interactions. Beverage products present particular clinical concerns because liquid formulations may have inconsistent THC distribution, variable absorption rates, and higher overdose risk compared to other delivery methods, making regulatory oversight essential for patient safety. Clinicians should inform patients about these regulatory changes and counsel them that unregulated or older products may have unreliable potency information, which complicates accurate dose assessment and risk stratification. Clinical Summary Ohio has implemented new regulatory restrictions on THC-infused beverages, which reflects broader regulatory trends across states establishing stricter controls on cannabis edible products. These restrictions likely address concerns about dosing consistency, packaging standards, and prevention of accidental consumption by minors, issues that have been documented in emergency department visits and poison control center calls. For clinicians, understanding local regulatory changes is important for counseling patients about legal product availability and for recognizing patterns in cannabis-related adverse events that may result from unregulated or improperly labeled products. Patients in Ohio seeking cannabis beverages for therapeutic purposes will need to navigate these new limitations, potentially affecting access for those using these products for symptom management or preference over other consumption methods. Clinicians should stay informed about state-specific cannabis regulations to provide accurate guidance on legal options and to support patients in making informed decisions about cannabis use. Understanding these regulatory landscapes helps clinicians anticipate patient needs and counsel on compliant, quality-assured alternatives when restricted products are no longer available. Dr. Caplan’s Take “These restrictions on THC beverages are clinically sound because drinks create unpredictable absorption patterns and dosing challenges that I see repeatedly in patients who underestimate onset time and consume too much, whereas we can counsel patients more effectively on other delivery methods with clearer pharmacokinetics.” Clinical Perspective 🍃 As Ohio implements restrictions on THC-infused beverages, clinicians should recognize that regulatory changes often lag behind product availability and consumer use patterns, meaning patients may still encounter these products despite local limitations. The shift toward liquid formulations raises particular clinical concerns because beverages can be consumed more casually than traditional cannabis products, potentially leading to unintended overconsumption, delayed onset effects (which patients may not recognize), and increased risks in vulnerable populations such as adolescents and pregnant individuals. While regulatory frameworks attempt to standardize dosing and labeling, enforcement gaps and interstate commerce complicate the actual products patients access in practice. Given these dynamics, primary care and mental health providers should maintain awareness of THC beverage availability, ask specific questions about cannabis consumption patterns during substance use screening, and educate patients about delayed absorption kinetics and the risks of redosing before effects manifest. Understanding the local regulatory landscape helps clinicians better counsel patients about both legal 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS Related Articles CED Digest: 20 Items — March 20, 2026State audit on Medical Cannabis Commission – WBRCTHC-infused drinks face new restrictions – Columbus – NBC4 📰 Source: https://www.nbc4i.com/video/thc-infused-drinks-face-new-restrictions-in-ohio/11627429/ Further Reading Evidence WatchCannabidiol & Glucose Tolerance: Clinical Research Findings Cannabis Policy WirePolicy Watch: 10 Regulatory Updates — March 20, 2026 CED Clinic BlogCCB Deputy Director Miles Appointed Acting Executive Director [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchMental HealthNeurologySafety Why This Matters Understanding the shared genetic vulnerability across alcohol, tobacco, opioid, and cannabis use disorders enables clinicians to identify high-risk patients who may be predisposed to multiple substance addictions and implement more targeted prevention and treatment strategies. Patients with one substance use disorder should be screened more thoroughly for others, as the common genetic basis suggests interventions addressing underlying neurobiological mechanisms could benefit multiple addiction conditions simultaneously. This knowledge supports personalized medicine approaches where treatment plans account for cross-addiction risk rather than treating each substance use disorder in isolation. Clinical Summary # Clinical Summary A large-scale genetic study from Rutgers University identified significant shared genetic vulnerability between alcohol, tobacco, and opioid use disorders, with emerging evidence suggesting cannabis use disorder may share similar genetic pathways. The research employed genome-wide association studies to analyze genetic factors contributing to addiction across these substance classes, revealing common biological mechanisms that predispose individuals to multiple forms of substance use disorder. These findings have direct implications for clinical risk stratification, as patients with a personal or family history of one substance use disorder may warrant heightened vigilance for addiction risk across other substances. Clinicians should consider this shared genetic architecture when counseling patients about substance use, particularly those with known addiction vulnerabilities or complex substance use histories. Understanding these interconnected genetic pathways may also inform future pharmacological interventions that target common neural mechanisms rather than treating each addiction in isolation. For practitioners managing patients with opioid use disorder or other addictions, recognizing the genetic predisposition to polysubstance addiction—including cannabis—supports more comprehensive screening and preventive counseling strategies. Dr. Caplan’s Take “What this genetic research tells us clinically is that patients with a personal or family history of alcohol, tobacco, or opioid addiction are at genuinely higher risk for cannabis use disorder, and we need to screen for and address these vulnerabilities explicitly rather than assuming cannabis is a safer alternative for people with addictive predispositions.” Clinical Perspective 💊 The emerging evidence that alcohol, tobacco, opioid, and cannabis use disorders share overlapping genetic vulnerabilities has important implications for clinical assessment and treatment planning. While this research helps explain why certain patients show patterns of polysubstance use or sequential addiction, clinicians should recognize that genetic predisposition is neither deterministic nor sufficient to cause addiction on its own; environmental, social, and psychological factors remain critical contributors that interact with biological susceptibility. When evaluating patients with substance use disorders, this knowledge suggests value in screening for multiple addictive substances rather than focusing narrowly on the presenting problem, particularly in those with positive family histories of addiction. Practically, this supports a more integrated addiction medicine approach where treatment protocols addressing one substance may benefit from consideration of shared neurobiological mechanisms, and where patients with polysubstance involvement might benefit from unified rather than siloed intervention strategies. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://neurosciencenews.com/genetics-addiction-impulse-control-30350/ Further Reading Evidence WatchThe Brain Science Behind the Munchies – Nautilus Magazine Evidence WatchIGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial Cannabis Policy WirePolicy Watch: 10 Regulatory Updates — March 20, 2026 [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyMedical CannabisHealthcare Why This Matters This legislation directly addresses a critical barrier to evidence-based care by allowing physicians to recommend cannabis without fear of professional consequences, enabling clinicians to offer patients an additional treatment option for conditions where cannabis may have therapeutic benefit. Removing this legal constraint could improve access to medical cannabis for patients with qualifying conditions while giving clinicians the autonomy to make individualized treatment recommendations based on clinical judgment rather than regulatory fear. For patients, this means potential expanded treatment options; for clinicians, it clarifies that recommending cannabis operates within professional standards of care. Clinical Summary Nebraska’s legislature has progressed a proposal that would shield physicians from professional discipline when recommending medical cannabis to eligible patients, addressing a significant barrier to cannabis medicine practice in the state. Currently, doctors face potential licensing consequences for cannabis recommendations despite the federal and state legal frameworks evolving to permit medical use, creating hesitation among clinicians who might otherwise consider cannabis as a therapeutic option for appropriate patients. This legislative action recognizes that the threat of disciplinary action by medical boards has deterred evidence-based discussions about cannabis and limited patient access to a potentially beneficial treatment modality. If enacted, the proposal would align Nebraska’s regulatory environment with other states that have decriminalized physician cannabis recommendations and would reduce the professional risk that currently prevents candid conversations about cannabis within clinical practice. Removing this regulatory barrier may empower Nebraska physicians to engage in informed shared decision-making with patients who might benefit from medical cannabis without fear of licensure consequences. For clinicians in Nebraska and similar jurisdictions, passage of this measure would enable more transparent cannabis counseling and help patients access a legitimate therapeutic option when appropriate. Dr. Caplan’s Take “What this legislation does is remove the artificial barrier that’s kept many of us from having an honest clinical conversation with patients who might benefit from cannabis, and that matters because the evidence supports its use for specific conditions like chronic pain and chemotherapy-induced nausea, yet physicians have been practicing in fear rather than practicing medicine.” Clinical Perspective 🏥 This Nebraska legislative initiative addresses a significant barrier to evidence-based prescribing by shielding physicians from professional discipline when recommending cannabis for medical conditions. Currently, many states’ medical boards maintain prohibitions or restrictions on cannabis recommendations despite its legal medical status, creating a chilling effect on provider counseling and limiting patient access to a treatment option some evidence suggests may benefit certain conditions like chronic pain or chemotherapy-induced nausea. However, clinicians should note that removing legal barriers does not resolve underlying uncertainties about cannabis efficacy, optimal dosing, long-term safety profiles, and drug interactions, particularly in vulnerable populations such as pregnant patients or those with psychiatric history. The complexity is further compounded by variable cannabis potency across products and the limited number of rigorous clinical trials compared to conventional pharmaceuticals. As such protections may expand in other states, providers should simultaneously strengthen their cannabis literacy through continuing education and implement careful patient screening and monitoring protocols to ensure 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS Related Articles CED Digest: 239 Items — March 17, 2026 📰 Source: https://nebraskapublicmedia.org/es/news/news-articles/legislature-advances-proposal-that-would-remove-medical-cannabis-roadblock/ Further Reading CED Clinic BlogCCB Deputy Director Miles Appointed Acting Executive Director Research DigestResearch Digest: 20 Recent Studies – March 19, 2026 Cannabis Policy WirePolicy Watch: 10 Regulatory Updates — March 20, 2026 [...] Read more...
March 20, 2026Cannabis NewsCED DigestMarch 20, 2026. 20 items curated for clinical relevance. Above Threshold Alabama Medical Cannabis Sales Gear for Spring 2026 LaunchAlabama’s medical cannabis program is preparing to begin retail sales in spring 2026, affecting clinicians’ ability to recommend cannabis products to qualifying patients in the state.Read more →Cannabis compounds CBD and CBG may help reverse fatty liver disease, study findsA study investigates CBD and CBG’s potential therapeutic effects on fatty liver disease, relevant for clinicians considering cannabinoid applications in hepatic conditions.Read more →From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …This article examines regulatory enforcement actions against cannabis beverage companies, highlighting FDA oversight challenges and compliance risks relevant to clinical practice and patient safety considerations.Read more →Cannabis Compounds CBD and CBG Show Promise in Reducing Liver Fat and Improving …Recent research indicates CBD and CBG may reduce hepatic steatosis and improve metabolic markers, providing clinicians with potential therapeutic targets for managing cannabis-related liver health concerns in patients.Read more →New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …Read more →New Top Cannabis Regulator Sets Priorities In First Board MeetingA new cannabis regulator outlined their policy priorities at an initial board meeting, establishing foundational direction for industry oversight and clinical practice standards.Read more →Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road AheadBrazil implements new cannabis regulations affecting medical access and clinical practice, requiring clinicians to understand updated legal frameworks and their impact on patient care delivery.Read more →2 Greater Cincinnati breweries file lawsuit over Ohio ban on THC beverages – WLWTTwo Greater Cincinnati breweries are challenging Ohio’s ban on THC-infused beverages, raising legal and regulatory questions relevant to cannabis product classification and state-level THC market restrictions.Read more →New Ohio law means THC-infused drinks won’t be available on many store shelves – WTVGOhio’s new law restricts THC-infused beverage distribution in retail locations, affecting product availability and clinical considerations for patient access and dosing recommendations.Read more →Lawmakers strike down bill capping THC levels in Oregon’s cannabis edibles – YahooRead more →Attempt to limit potency of THC in marijuana edibles fails at Oregon LegislatureOregon legislators failed to pass a bill restricting THC potency in cannabis edibles, leaving higher-dose products available and relevant to clinician counseling on dosing risks and patient safety.Read more →Cannabis Compounds CBD and CBG Slash Liver Fat and Restore Metabolic HealthCBD and CBG demonstrate potential to reduce hepatic steatosis and improve metabolic parameters, offering possible therapeutic applications for cannabis clinicians treating patients with fatty liver disease.Read more →Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMedThis article examines formulation and fabrication methods for delivering cannabinoids through oral mucosal tissues, relevant to clinicians seeking alternative administration routes beyond smoking or standard ingestion.Read more →Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORMLCBD-dominant cannabis products demonstrate clinical efficacy for anxiety treatment, providing evidence-based therapeutic applications relevant to clinician prescribing decisions and patient care protocols.Read more →Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORMLCannabis extracts demonstrated significant pain reduction in myofascial pain clinical trials, providing clinicians evidence-based data for treating this common musculoskeletal condition.Read more →As a Medical Cannabis Patient, I’m Watching This Supreme Court Case CloselyRead more →The Week in Weed: March 2026 | Seyfarth Shaw LLP – JDSupraThis article covers weekly cannabis legal and regulatory updates from March 2026, relevant for clinicians needing current information on changing laws and compliance requirements affecting clinical practice.Read more →Marijuana gummies sold in Ohio recalled. Why, where they were sold – The Columbus DispatchMarijuana gummies sold in Ohio were recalled, requiring clinicians to monitor patients for potential adverse effects and advise them on product safety concerns.Read more →New Group Launches Ahead of Medicare CBD Pilots – Cannabis WireA new organization is forming to prepare for upcoming Medicare cannabidiol pilot programs, which could expand clinical access to CBD for Medicare beneficiaries.Read more →Marijuana Status Based Prohibition Tag Archives – Powers Law Firm PAThis archive covers legal prohibition statuses of marijuana across jurisdictions, providing clinicians essential reference material for understanding regulatory frameworks affecting patient care and prescription guidelines.Read more → Digest-Level Clinical Commentary Dr. Caplan’s Take These items reflect a field at an inflection point where rigorous hepatoprotective and anxiolytic evidence is finally matching clinical intuition, yet the regulatory landscape remains fractured by potency debates and interstate commerce conflicts that undermine the standardization necessary for evidence-based prescribing. The convergence of emerging liver disease data with established anxiety and pain efficacy suggests I should be counseling patients on cannabinoid-specific outcomes rather than whole-plant generalities, while simultaneously acknowledging that legislative battles over THC caps and beverage access signal continued policy resistance to nuanced dosing science. What’s clinically actionable here is that formulation standardization and oral delivery innovation are advancing faster than our regulatory frameworks, creating a gap where informed dosing conversations with patients become even more essential. Clinical Perspective These items reflect a maturing cannabis market increasingly focused on clinical applications and regulatory standardization, with particular emphasis on metabolic and pain management indications supported by emerging evidence. The concurrent regulatory discussions around potency caps and product formulation suggest policymakers are grappling with how to balance consumer access against public health considerations as the industry expands from illicit markets into mainstream retail channels. The prevalence of research on specific cannabinoid profiles like CBD and CBG indicates a shift toward component-based therapeutic approaches rather than whole-plant formulations in clinical practice. Medical CannabisRegulatory PolicyResearch & Health BenefitsCannabis BeveragesCannabinoid Science 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS Related Articles CED Digest: 230 Items — March 18, 2026CED Digest: 239 Items — March 17, 2026Alabama Medical Cannabis Sales Gear for Spring 2026 Launch Further Reading Cannabis Policy WirePolicy Watch: 10 Regulatory Updates — March 20, 2026 CED Clinic BlogCCB Deputy Director Miles Appointed Acting Executive Director Research DigestResearch Digest: 20 Recent Studies – March 19, 2026 [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic ImpairmentPolysubstanceSafetyNitrous OxideMotor Vehicle Why This Matters This case highlights the critical clinical reality of polysubstance impairment involving cannabis and nitrous oxide, substances that can have synergistic effects on psychomotor function. For clinicians, it underscores the importance of comprehensive substance use assessment and patient education about impairment risks when cannabis is combined with other psychoactive substances. Clinical Summary The case involves fatal motor vehicle collision allegedly involving cannabis and nitrous oxide (‘fast gas’) intoxication. Cannabis impairs reaction time, attention, and coordination through CB1 receptor activation in motor control regions. Nitrous oxide causes brief but profound CNS depression and oxygen displacement. When combined, these substances can create compounded psychomotor impairment beyond either substance alone, though specific interaction mechanisms remain poorly characterized in the literature. Dr. Caplan’s Take “I consistently counsel patients that cannabis impairment is unpredictable and prolonged, and combining it with any other psychoactive substance — including nitrous oxide — creates unknown and potentially dangerous interaction effects. The ‘it’s just cannabis’ mentality ignores real impairment risks that can have devastating consequences.” Clinical Perspective 🧠 Clinicians should explicitly discuss driving safety and polysubstance risks during cannabis consultations, particularly with younger patients who may encounter nitrous oxide recreationally. Assessment should include questions about concurrent substance use patterns. This case reinforces why evidence-based impairment education, not prohibition messaging, serves patient safety best. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://www.irishtimes.com/crime-law/courts/2026/03/20/accused-man-high-on-cannabis-and-fast-gas-at-time-of-fatal-co-limerick-crash-garda-says/ FAQ What is the clinical relevance of this cannabis-related finding? This research has been classified as having “Notable Clinical Interest” with a CED Clinical Relevance rating of #70. It represents emerging findings or policy developments that healthcare providers should monitor closely for potential impact on patient care. What does polysubstance use mean in relation to cannabis impairment? Polysubstance use refers to the concurrent or combined use of multiple substances, including cannabis with other drugs or alcohol. This combination can significantly increase impairment levels and safety risks compared to using cannabis alone. Why is nitrous oxide mentioned alongside cannabis in this study? Nitrous oxide appears to be one of the substances being studied in combination with cannabis use. The research likely examines how these substances interact and their combined effects on impairment and safety outcomes. What safety concerns are associated with cannabis and polysubstance use? Combined substance use can lead to unpredictable and heightened impairment effects that may not be apparent to users. This increased impairment poses significant safety risks, particularly for activities requiring coordination, judgment, or quick reflexes like driving. How should healthcare providers use this information in clinical practice? Providers should be aware of the increased risks associated with polysubstance use involving cannabis. This knowledge can inform patient counseling, risk assessment, and treatment planning, especially for patients who may be combining cannabis with other substances. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Accused man high on cannabis and ‘fast gas’ at time of fatal Co Limerick crash, garda says”, “url”: “https://www.irishtimes.com/crime-law/courts/2026/03/20/accused-man-high-on-cannabis-and-fast-gas-at-time-of-fatal-co-limerick-crash-garda-says/”, “datePublished”: “2026-03-20T22:48:56Z”, “about”: “accused man high cannabis fast gas”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyAccessRegulatoryMedical CannabisPatient Care Why This Matters Legislative barriers to medical cannabis access create treatment discontinuities that can compromise patient outcomes, particularly for conditions where cannabis provides symptom relief when conventional therapies fail. Removing regulatory roadblocks allows for more consistent therapeutic relationships and treatment protocols. Clinical Summary Nebraska’s legislature is advancing proposals to eliminate administrative barriers that currently impede medical cannabis access for qualified patients. These regulatory hurdles have created gaps between patient medical needs and legal access pathways. The legislative changes would streamline the process for both patients and healthcare providers within the existing medical cannabis framework. Dr. Caplan’s Take “Regulatory complexity shouldn’t determine medical outcomes—when patients have legitimate medical needs and legal pathways exist, administrative barriers become therapeutic obstacles. This is about creating sustainable, predictable access for established medical indications.” Clinical Perspective 🧠 Clinicians should monitor how these changes affect referral pathways and patient access timelines. Patients currently navigating Nebraska’s medical cannabis system may experience more streamlined processes, but the underlying medical criteria and clinical considerations remain unchanged. Focus stays on appropriate patient selection and ongoing clinical monitoring. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://nebraskapublicmedia.org/es/news/news-articles/legislature-advances-proposal-that-would-remove-medical-cannabis-roadblock/ FAQ What is the CED Clinical Relevance rating system? The CED Clinical Relevance system appears to be a rating scale that categorizes medical cannabis news and developments. This article received a rating of #76 with “Notable Clinical Interest,” indicating emerging findings or policy developments worth monitoring closely. What type of cannabis-related content does this cover? This content focuses on medical cannabis policy, access, and regulatory developments. It appears to be clinical news specifically related to cannabis medicine rather than recreational use. What does “Notable Clinical Interest” mean? Notable Clinical Interest indicates that the content contains emerging findings or policy developments in medical cannabis that healthcare professionals should monitor closely. It suggests the information has potential clinical implications for patient care. Who is the target audience for this information? The content appears to be designed for healthcare professionals, particularly those working with medical cannabis patients. The clinical focus and technical categorization suggest it’s intended for medical practitioners and researchers. What categories does this article cover? Based on the tags shown, this article covers Policy, Access, Regulatory, and Medical Cannabis topics. These categories indicate comprehensive coverage of the legal, administrative, and clinical aspects of medical cannabis. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Legislature advances proposal that would remove medical cannabis roadblock”, “url”: “https://nebraskapublicmedia.org/es/news/news-articles/legislature-advances-proposal-that-would-remove-medical-cannabis-roadblock/”, “datePublished”: “2026-03-20T22:31:56Z”, “about”: “legislature advances proposal would remove medical”} [...] Read more...
March 20, 2026Cannabis News✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Medical CannabisHealthcare PolicyProvider ProtectionClinical PracticeState Regulation Why This Matters Legal protection for healthcare providers removes a significant barrier to clinical cannabis recommendations, potentially improving patient access to legitimate medical cannabis therapy. This addresses the regulatory uncertainty that has historically prevented many clinicians from engaging with cannabis medicine despite patient need. Clinical Summary Nebraska legislation advances to provide legal protections for healthcare providers who recommend medical cannabis to qualified patients. This type of provider protection law typically shields clinicians from professional licensing discipline or legal liability when making cannabis recommendations within established medical cannabis programs. The legislation reflects growing recognition that healthcare providers need clear legal frameworks to participate in state-regulated medical cannabis systems without professional risk. Dr. Caplan’s Take “Provider protection laws are essential infrastructure for functional medical cannabis programs — clinicians can’t serve patients effectively while fearing professional consequences. This is about creating the basic legal framework that allows evidence-based cannabis medicine to actually happen in clinical practice.” Clinical Perspective 🧠 For clinicians in states with similar protections, this represents standard regulatory evolution that enables proper patient care. Providers should still follow established clinical guidelines and documentation standards when recommending cannabis therapy. Patients benefit when their physicians can discuss cannabis options without regulatory fear, leading to more comprehensive treatment conversations. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on Xin Share on LinkedIn🦥 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS 📰 Source: https://nebraskaexaminer.com/2026/03/20/bill-advances-to-protect-nebraska-health-care-providers-who-recommend-medical-cannabis/ FAQ What is the clinical significance of this cannabis-related development? This development has been classified with notable clinical interest, indicating emerging findings or policy changes that healthcare providers should monitor closely. It represents important developments in the medical cannabis field that could impact clinical practice. How does this relate to healthcare policy? The article focuses on healthcare policy developments related to medical cannabis. These policy changes may affect how healthcare providers can prescribe, recommend, or discuss cannabis treatments with patients. What protections are being discussed for healthcare providers? The article addresses provider protection measures in the context of medical cannabis practice. These protections likely relate to legal safeguards for healthcare professionals who recommend or oversee medical cannabis treatments. How might this impact current clinical practice? The developments discussed could change how healthcare providers approach medical cannabis in their clinical practice. Providers may need to update their protocols, documentation, or patient counseling approaches based on these emerging guidelines. Why should healthcare professionals pay attention to this news? This information is categorized as having notable clinical interest, suggesting it contains emerging findings or policy developments worth monitoring. Healthcare providers should stay informed about these changes to ensure compliant and effective patient care. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Bill advances to protect Nebraska health care providers who recommend medical cannabis”, “url”: “https://nebraskaexaminer.com/2026/03/20/bill-advances-to-protect-nebraska-health-care-providers-who-recommend-medical-cannabis/”, “datePublished”: “2026-03-20T22:02:42Z”, “about”: “bill advances protect nebraska health care”} [...] Read more...
Cannabis Recipes
January 27, 2026CED Clinic Recipes Cannabis-Infused Spinach Artichoke Dip Cozy, Savory, Crowd-Loving Comfort A bubbling classic, thoughtfully infused. Creamy without being heavy, savory without shouting, and built for portion-by-the-spoon dosing control. ⏱️ Ready: ~25 minutes 🍽️ Servings: 4 🧈 Infusion: Cannabutter 🌾 Gluten-free: Dip itself Ingredients Steps Dosing FAQ Download Recipe Card (PDF) Quick Safety Reminders Friendly reminders that prevent the most common edible mishaps. ✅ Portion first, then enjoy. The spoon is your measuring tool. ✅ Wait at least 90 minutes before reassessing effects. ✅ Label leftovers clearly if others share your fridge. Introduction There is something almost universally reassuring about a bubbling dish of spinach and artichoke dip fresh from the oven. It is creamy without being heavy, savory without shouting, and familiar in the best possible way. This cannabis-infused version keeps everything people love about the classic, while offering a smoke-free, food-forward way to enjoy cannabinoids with more control and predictability. This recipe works especially well for people who want gentle relaxation alongside real food, those who prefer edibles over inhalation, and experienced users who appreciate dosing flexibility by the spoonful instead of the square. TL;DR This is a creamy, oven-baked cannabis-infused spinach artichoke dip that comes together quickly and fits easily into a shared meal or quiet night in. Using infused butter folded into dairy-rich ingredients creates a smooth texture and relatively steady onset. ✅ Ready in about 25 minutes ✅ Approx. 10 to 22 mg THC per serving, depending on portion ✅ Naturally gluten-free and easy to microdose Why You’ll Love This Recipe Most edibles lean sweet, highly processed, or both. This dip goes in the opposite direction. It is savory, protein-rich, and built around familiar ingredients that already belong on a dinner table. The technique is simple, the equipment minimal, and the results feel indulgent without tipping into excess. Because it is portionable by the scoop, this recipe makes it easier to adjust dose without committing to a full edible at once. That makes it particularly appealing for social settings, or for people still learning how their body responds to infused foods. Functional Perks of This Feel-Good Treat Small choices that add up to a smoother experience. ✨ Uses dairy fats to support cannabinoid absorption and consistency. ✨ Easy to scale portions up or down without changing the recipe. ✨ Smoke-free and discreet, suitable for shared meals. ✨ Comfort food that still includes fiber and micronutrients. Pro Tip: Warm, fat-containing dishes like this often feel smoother and longer lasting than sugar-heavy edibles, even at similar milligram levels. Health Benefits: Food That Talks To Your Body Spinach contributes vitamins A, C, and K, along with minerals that support normal immune and vascular function. Artichokes add fiber and compounds that support digestive health, which matters more than many people realize when it comes to edible cannabis absorption. Cannabinoids interact with the endocannabinoid system, a regulatory network involved in mood, pain modulation, appetite, and sleep. When paired with a balanced meal or snack, infused foods like this dip may feel more integrated into the body’s natural rhythms than standalone edibles. As with any infused recipe, this works best as a supportive tool rather than a cure-all. Some people may find it useful for evening relaxation or stress reduction, especially when used thoughtfully and at modest doses. Simple ingredients, big comfort. A flat lay of spinach, artichokes, cheeses, and infused butter ready for mixing. Ingredients & Equipment You’ll Need 🥬 Ingredients ➕ 1 cup fresh spinach, finely chopped 🥬 ➕ ½ cup canned or jarred artichoke hearts, drained and chopped 🌿 ➕ ½ cup cream cheese, softened 🧀 ➕ ¼ cup sour cream or plain Greek yogurt 🥛 ➕ ¼ cup shredded mozzarella cheese 🧀 ➕ 2 tablespoons cannabis-infused butter, melted 🧈 ➕ 1 garlic clove, minced 🧄 ➕ ½ teaspoon salt ➕ ¼ teaspoon black pepper 🛠️ Equipment ➕ Medium mixing bowl ➕ Baking dish or small casserole ➕ Silicone spatula or spoon ➕ Oven Even mixing helps keep dosing consistent. A bowl of creamy dip mid-mix with visible texture. How To Make Cannabis-Infused Spinach Artichoke Dip (Step-by-Step) Step 1 Preheat and Combine Preheat your oven to 375°F, or about 190°C. In a medium bowl, combine the spinach, artichokes, cream cheese, sour cream, mozzarella, infused butter, garlic, salt, and pepper. Mix until everything looks evenly distributed and creamy, with no large streaks of butter remaining. Pro Tip: Even mixing matters for dosing. Take an extra minute here to avoid concentrated pockets of infused fat. Step 2 Bake Gently Transfer the mixture into your baking dish and spread it into an even layer. Bake uncovered for 15 to 20 minutes, until the surface looks lightly golden and the edges are bubbling. Avoid overbaking, as excessive heat can dry the dip and may degrade cannabinoids. Step 3 Rest and Serve Remove from the oven and let the dip rest for about 5 minutes. This brief cooling period helps the texture set and makes serving safer and more pleasant. Golden, warm, and ready to portion. Freshly baked dip with lightly browned edges. Dosing Guide: Potent, But Predictable Potency Calculation Using the default assumption of 3.5 g cannabis at 20 percent THC: 3.5 g × 0.20 × 1,000 mg per g ≈ 700 mg THC in the full batch of infused butter. If that butter is evenly distributed so that 2 tablespoons contain approximately 87.5 mg THC, then this recipe carries about that amount total. Breakdown Per Serving This dip reasonably makes 4 servings. Portion Estimated THC How it looks in real life Full serving ≈ 21.9 mg THC A generous scoop, better for experienced users Half serving ≈ 10.9 mg THC A moderate scoop, still meaningful for many Quarter serving ≈ 5.5 mg THC A small scoop, a reasonable beginner target Suggested Starting Doses Beginner-friendly use often falls in the 2.5 to 5 mg range, which may be closer to a quarter serving or less. Intermediate users may feel comfortable around 5 to 10 mg. Higher doses should be approached cautiously, especially in social settings. If you are newer to edibles, start with the smallest portion, wait at least 90 minutes, and only consider increasing on another day once you understand how that amount feels. Quick Math: DIY Dosing Calculator THC percentage × grams of flower × 1,000 = estimated total mg THC. Account for roughly 20 to 30 percent loss during decarboxylation and infusion. Divide by the number of servings to estimate mg per serving. ⚠️ Dosing Caveat: All dosing numbers are estimates. Actual potency can vary based on flower THC accuracy, decarboxylation temperature and duration, infusion efficiency, storage conditions, and individual metabolism, tolerance, and gut health. Start low, wait at least 90 minutes before reassessing effects, and adjust slowly across different days rather than in a single session. 💡 Microdose Tip For barely-there effects, start with a teaspoon instead of a scoop. Pair with non-infused food so you can keep eating without escalating dose. How To Make This Non-Euphoric Or Gently Altering For a lower-altering version, substitute CBD-dominant infused butter or use a high-CBD to low-THC ratio such as 10:1. This can emphasize body comfort with minimal intoxication. Some people also experiment with non-decarboxylated preparations rich in acidic cannabinoids, though effects and evidence differ and are typically subtler. True non-euphoric effects depend on individual physiology, not just the label on the infusion. Flavor & Pairing Suggestions For calm evenings, earthy and herb-forward profiles often feel grounding alongside creamy dishes. For light uplift and conversation, subtle citrus-leaning profiles can brighten the richness. For pain-dominated nights, deeper, savory profiles may feel more settling. For creative focus with food, balanced profiles without heavy sedation are often preferred. Pro Tip: Pay attention to how you respond personally rather than relying on strain names alone. Easy to share, easy to scale. Dip served with crisp vegetables. Creative Ways To Use This Dip ➕ Spoon over roasted vegetables. ➕ Spread on toast or flatbread. ➕ Use as a filling for stuffed mushrooms or chicken. ➕ Stir a small amount into warm pasta. ➕ Serve with carrots, bell peppers, or seeded crackers. ➕ Add a dollop to scrambled eggs or an omelet. Pro Tip: For microdosing, try using a single teaspoon at a time rather than a full scoop. Serving Ideas & Mood Pairings This dip fits beautifully into moments that call for comfort without chaos. 🌧️ Ideal for quiet evenings with a favorite show. 🎧 Best enjoyed after a long workday when decision fatigue is real. 🧺 Pairs well with soft lighting, warm food, and no urgent plans. Storage Tips & Shelf Life Store leftovers in an airtight container in the refrigerator for up to four days. Reheat gently and stir well to redistribute infused fats before serving. Avoid repeated high-heat reheating, which can affect both texture and potency. Changes in smell, visible mold, or separation that will not remix are signs to discard. Cannabinoid potency may slowly decline over time, so older batches can feel milder. Troubleshooting Common Mistakes Dip feels oily or separated. The mixture may not have been fully blended. Stir thoroughly before baking next time. Texture is too thick. Add a tablespoon of sour cream or yogurt and mix gently. Effects feel stronger than expected. Reduce portion size or dilute with a non-infused batch. Cannabis & Culinary Culture Infused cooking has been quietly moving from novelty toward normalcy. Recipes like this reflect a broader shift away from excess and toward intentional use that fits into real meals and real lives. When food and cannabinoids are combined thoughtfully, they can support a sense of agency rather than mystery. That shift helps reduce stigma and makes cannabis feel less like an event and more like a tool. Final Thoughts This spinach artichoke dip shows how infused cooking can feel normal, nourishing, and grounded. It is not about pushing limits, but about bringing intention into the kitchen. If you make this recipe, consider sharing your variations or how you chose to portion it. Thoughtful food has a way of starting good conversations, both at the table and beyond. FAQ: Cannabis-Infused Spinach Artichoke Dip How do I make cannabis infused spinach artichoke dip at home? You combine a classic spinach artichoke dip base with a measured amount of cannabis-infused butter, then bake gently. The key steps are even mixing and mindful portioning. Can I make this with CBD instead of THC? Yes. Using CBD-dominant infused butter can create a gentler, less intoxicating version that some people prefer. How long does this dip last in the fridge? Generally up to four days when stored airtight and kept cold. What is a good beginner dose for this recipe? Many beginners start around 2.5 to 5 mg THC, which may be a small fraction of a serving. Can I make this without cannabutter? You can make the base dip without infusion, then add infused butter to individual portions for more control. Is this recipe gluten-free? Yes, the dip itself is gluten-free. Pairings may vary. Can this help with stress or sleep? Some people find infused savory foods supportive for evening relaxation, though effects vary. How strong is homemade dip compared to dispensary edibles? Homemade recipes can be less precise unless carefully measured, which is why conservative dosing matters. Can I freeze this dip? Freezing is possible but may alter texture. Potency may also drift over time. Can I use this as a base for other dishes? Yes. It works well as a spread, filling, or sauce with careful portioning. Recipe Card (PDF) Prefer a one-page printable? Download the clinic-formatted recipe card. Download Recipe Card (PDF) Back to top [...] Read more...
August 3, 2023Ingredients -1.5 cups all-purpose flour -1 Tbsp sugar (canna-sugar may be substituted to increase potency) -1 Tbsp baking powder -1 Tsp salt -1 large egg -1.25 cups whole milk (canna-milk may be substituted to increase potency) -3 Tbsp of melted canna-butter or oil -​1 teaspoon vanilla extract (optional) Instructions 1. In a bowl, combine dry ingredients 2. In another bowl, combine wet ingredients 3. Stir the wet ingredients into the dry ingredients until just combined ​Do not over-mix, batter will be thick and slightly lumpy 4. Heat a large frying pan with with a small amount of butter or oil 5. Pour 1 cup of batter in the center of the pan. Fry 2–3 minutes before flipping 6. Fry an additional 3–5 minutes or until pancake reaches your preferred doneness and remove from pan 7. Garnish with your favorite toppings; powdered sugar, syrup, butter, chocolate chips or whatever you might enjoy! Original recipe from cannabis wiki [...] Read more...
August 3, 2023Ingredients 1 can whole peeled tomatoes 28 oz. 1 jar roasted red peppers 12 oz. 4 large eggs ½ cup plain Greek yogurt ¼ cup CannaOil plus more for drizzling 1 teaspoon coriander seeds 1 teaspoon cumin seeds 6 garlic cloves divided 2 medium shallots divided Kosher salt Freshly ground black pepper Mint leaves and crusty bread for serving Crush coriander and cumin seeds, pressing down firmly with even pressure. Transfer seeds to a small heatproof bowl. Slice 2 garlic cloves as thinly and evenly as you can; add to bowl with seeds. Finely chop the remaining 4 garlic cloves. Cut half of 1 shallot into thin rounds and then add to the same bowl with seeds and garlic. Chop remaining shallots. Open a jar of red peppers and pour off any liquid. Remove peppers and coarsely chop. Combine ¼ cup oil and seed/garlic/shallot mix in the skillet you used for crushing seeds. Heat over medium and cook, stirring constantly with a wooden spoon, until seeds are sizzling and fragrant and garlic and shallots are crisp and golden, about 3 minutes. Place a strainer over the same heatproof bowl and pour in the contents of the skillet, making sure to scrape in seeds and other solids. Do this quickly before garlic or shallots start to burn. Reserve oil. Spread out seed mixture across paper towels to cool. Season with salt and pepper. Return strained CannaOil to skillet and heat over medium. Add remaining chopped garlic and shallot and cook, stirring often, until shallot is translucent and starting to turn brown around the edges, about 5 minutes. Season with salt and lots of pepper. Add chopped peppers to the skillet and stir to incorporate. Using your hands, lift whole peeled tomatoes out of the can, leaving behind tomato liquid, and crush up with your hands as you add to the skillet. Discard leftover liquid. Season with more salt and pepper. Cook shakshuka, stirring often, until thickened and no longer runs together when a spoon is dragged through, 10–12 minutes. Reduce heat to low. Using the back of a wooden spoon, create four 2″-wide nests in tomato sauce. Working one at a time, carefully crack an egg into each nest. Cover skillet and cook, simmering very gently and reducing heat if necessary, until whites of eggs are set while yolks are still jammy, 7–10 minutes. Uncover skillet and remove from heat. Season tops of eggs with salt and pepper. Top shakshuka with dollops of yogurt, sprinkle with seed mixture, then drizzle with more olive oil. Finish by scattering mint leaves over top. ​ Serve pita or crusty bread alongside. This recipe is available for download HERE Original recipe from eat your cannabis.com [...] Read more...
August 3, 2023Ingredients 2 lbs of potatoes 4 tablespoons cannabutter 4 tablespoons sour cream or plain cream cheese Salt and pepper ¼ to ½ cup of milk or cannamilk for increased potency 2 cloves of garlic minced or 1 tsp of garlic powder Instructions Cut the potatoes in half or quarters to make medium-sized pieces. Place the potatoes in a saucepan filled with water and bring to a boil. Cook until fork-tender, between 20–30 minutes. Drain the potatoes and remove their skins. Add the cannabutter, garlic and sour cream to the bowl along with a splash of milk (don’t add it all at once.) Mash the contents, adding just a splash of milk each time until you’ve reached the desired consistency. ​ Stir in salt and pepper to taste. This recipe is available for download HERE original recipe from satorimj.com [...] Read more...
August 3, 2023Ingredients 2/3 cup Cannabis oil (coconut or olive oil will work) 4 large potatoes peeled 3 tbsp salt Instructions Preheat your oven to 400 degrees Fahrenheit and line a large baking sheet with parchment paper. Cut your peeled potatoes into strips (cut them into fries!) and spread them evenly on the baking sheet. Drizzle the cannabis-infused oil over them and season with salt. Try to coat each fry relatively evenly with the oil so that there is a consistent potency. Cook the fries until they are golden brown. Around 15–20 minutes. Allow the fires to cool down, around 5 minutes. Divide the fries into equal proportions and serve. This recipe is available for download HERE Original recipe from thecannaschool.com [...] Read more...
August 3, 2023This soup can be enhanced with any of your favorite vegetables. Materials Soup Pot Frying Pan Hand-Blender or Regular blender (optional) Ingredients ​3 cups vegetable stock 1 cup chopped broccoli 1/2 red onion, chopped 2 stalks of celery, chopped 1 and 1/2 cup heavy cream (canna-cream may be substituted or blended with regular cream for increased potency) 2 TBSP olive oil Fresh cilantro (optional) Salt and Pepper to taste ​Canna-Oil (dose-dependent) Directions 1. Heat vegetable stock and broccoli in a large pot Boil for around 6 minutes 2. On another burner, saute garlic, onion and celery in olive oil until soft — about 4 minutes ​​ 3. Take the pan off the heat and add desired dose of canna-oil to vegetables Stir thoroughly and then pour mixture in to the big soup pot Be sure to scrape all material to get the maximum amount of canna-oil 4. Heat for another 6–8 minutes then reduce heat to low and add heavy cream, add salt and pepper to taste ​ 5. Let simmer for 5 minutes, serve hot  ​Garnish with cilantro if desired This recipe is available for download HERE The original recipe is from Royal Queen Seeds [...] Read more...
August 3, 2023Materials -Medium Sauce-Pan -​Thermometer -Mesh-sieve or cheesecloth Ingredients -​6 grams cannabis flower -2 cups oil (olive, coconut, canola or vegetable oil) Directions ​ ​1. Decarboxylate the cannabis Heat the oven to 225°F. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. ​Take care not to let the temperature go over 225°F and burn (if this happens, you can lose potency). Bake for about 35–40 minutes, then remove from the oven and cool before grinding into a coarse powder. ​ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Heat the oil in a saucepan over medium-low heat. Add the decarboxylated cannabis and cook, taking care not to let the temperature go over 200°F for about 45 minutes. 3. Remove from heat and let sit, undisturbed, for 10 minutes 4. Strain through a fine mesh-sieve set over a bowl. Press carefully with a spoon to extract as much oil as possible ​The oil will keep for up to 6 weeks if covered and refrigerated. This recipe is available for download HERE Original recipe from Vice.com [...] Read more...
August 3, 2023Ingredients 6 cups fresh or frozen blueberries (you may substitute some pitted cherries too!) 1 Tbsp lemon juice 1/4 cup all-purpose flour 1/2 cup white sugar (you may add canna-sugar for increased potency) 1/4 tsp cinnamon 2 Tbsp canna-butter, cut into small pieces (you may substitute canna-coconut oil) 2x pie crust recipe or store bought Directions Preheat oven to 350°F/175°C. Line a cookie sheet with parchment paper. Cream the regular butter, cannabutter, brown sugar & white sugar together until fluffy. Beat in eggs one at a time. Beat in the vanilla. In a small bowl, mix together the flour, cinnamon, baking soda & salt. Add to the creamed mixture. Mix well. Add the mini chocolate chips & mini marshmallows. Mix until evenly distributed. Evenly space the graham crackers on the prepared liner. Use a 2 oz scoop to portion the cookies & place in the center of the graham cracker. Bake for 12–15 minutes. Allow the cookies to cool. Push all of the baked cookies together & drizzle with coating chocolate. Allow the chocolate to set & enjoy! This recipe is available for download HERE Original recipe from myedibleschef.com [...] Read more...
March 24, 2025Cannabis-Infused Citrus-Caramel Blondies   🍊 A Sweet, Zesty Escape—No Passport Required   Why This Recipe Deserves a Spot in Your Stash     Imagine golden, chewy blondies infused with citrusy brightness, melty caramel swirls, and a carefully measured dose of cannabis. They’re elegant, indulgent, and just subversive enough to be fun.   Unlike their brownie cousins, these aren’t drowned in chocolate. Instead, the orange zest and caramel shine—and so does the cannabis, bringing its own set of therapeutic perks. The result? Dessert with benefits.     Functional Perks of This Feel-Good Treat     ✔️ Zesty orange brings a vitamin C boost and bright flavor   ✔️ Cannabutter delivers relaxation, anti-inflammatory effects, and mood lift   ✔️ Caramel makes it dessert—no further defense needed     What You’ll Need:   🛠️ Materials     Mixing bowls   9×9-inch baking pan   Parchment paper   🥣 Ingredients     1 cup all-purpose flour   ½ teaspoon baking powder   ¼ teaspoon salt   ½ cup cannabutter, melted 🧈   ¾ cup brown sugar, packed 🍯   1 large egg 🥚   1 teaspoon vanilla extract   Zest of one orange 🍊   ½ cup caramel chips or chopped soft caramels 🍬     Step-by-Step Instructions     🔥 Step 1: Prep     Preheat oven to 350°F (175°C)   Line your 9×9-inch baking pan with parchment paper       🥄 Step 2: Mix Dry Ingredients     In a bowl, whisk together flour, baking powder, and salt     🍯 Step 3: Mix Wet Ingredients     In a separate bowl, combine melted cannabutter and brown sugar   Stir until smooth, then beat in the egg and vanilla extract   Fold in the orange zest     🍪 Step 4: Combine & Add Caramel     Gradually fold the dry ingredients into the wet mixture   Stir in caramel chips or chopped soft caramels     🔥 Step 5: Bake & Cool     Spread batter evenly in the pan   Bake for 20–25 minutes until the edges are golden and the center is soft but set   Cool completely before slicing for clean edges and even effects     Dosing Guide: Know Before You Munch     💡 Assumes 20% THC flower used to make cannabutter.   ½ cup cannabutter ≈ 350mg THC   1 pan = 16 blondies     🍪 Per-Blondie Estimates:     1 blondie ≈ 21.9mg THC   ½ blondie ≈ 10.9mg THC   ¼ blondie ≈ 5.4mg THC   ⏳ Edibles take 60–90 minutes to take effect and may last 4–8 hours.   ⚠️ Start with ¼ blondie. Wait. Don’t redose just because you “don’t feel it yet.”   💡 Why Cannabutter Potency Varies—And What That Means for You     Homemade cannabutter isn’t one-size-fits-all. Even with precise flower measurements, your final potency can shift based on multiple factors:     🧪 Key Influences:       THC/CBD content of the flower used (lab test or product label required)   Decarboxylation accuracy (temperature and time affect THC activation)   Infusion method (time, temperature, and fat type all matter)   Straining technique (squeezing plant matter vs. not can extract more THC or chlorophyll)   Butter quality and fat content (higher fat = better cannabinoid binding)     ✅ Best Practices:     Lab test your cannabutter if possible   If not, calculate conservatively using flower THC percentage   Label every batch with strain, date, and estimated potency   Use the same method every time to improve consistency     Storage Tips     Store in an airtight container at room temp for 3–4 days   Refrigerate to extend freshness up to 10 days   Freeze individually wrapped pieces to make them last longer         Serving Ideas     Post-dinner treat with tea or warm milk   Midweek wind-down reward   Holiday gift for your most enlightened friends   A flavorful, functional twist on bake sale classics (for private audiences only, obviously)     🍊 Flavor & Strain Pairings: Choose Your Vibe       The flavor of these blondies is already a win—but pairing them with the right cannabis strain can subtly shape your experience. Think of it as aromatherapy, but edible.   Zesty & uplifting? Try strains like Tangie, Lemon Skunk, or Jack Herer. These citrus-forward profiles complement the orange zest and may support creativity, lightness, or social energy.   Mellow & dreamy? Infuse your butter with something like Granddaddy Purple, Northern Lights, or Wedding Cake. You’ll lean into the rich caramel while inviting deeper relaxation.   Balanced with focus? Strains like Harlequin or ACDC offer CBD-rich calm without sedation, great for daytime nibbling or stress support.   No matter your pick, aim for decarbed, lab-tested flower so you can dose with precision and enjoy the ride.   😬 Troubleshooting: Blondie Blunders & Easy Fixes       Don’t worry—baking with cannabis isn’t complicated, but it is chemistry. If something feels off, here’s how to course-correct:   Blondies came out dry? Your cannabutter may have been overheated or you baked a minute too long. Next time, reduce your infusion heat and check for doneness earlier.   They’re too oily or greasy? Either your batter wasn’t fully emulsified or the cannabutter separated during mixing. Try stirring longer before adding dry ingredients.   No noticeable effects? Review your decarboxylation process—it’s likely underdone. You want dry, golden cannabis—not dark brown, not green and grassy.   Too strong? Yep, it happens. Slice into smaller portions next time, and consider reducing the cannabutter to half butter, half regular.   💡 Pro tip: Take notes on each batch—timing, strain, effects. Your future self will thank you.     📊 Quick Dosing Math: Make It Personal       Not every batch of cannabutter is the same—and not every blondie needs to hit the same. Here’s a quick, DIY math formula to keep things accurate:   (THC % × 1,000) × Grams of Cannabis = Total mg THC   Total mg THC ÷ Tablespoons of Butter = mg per Tbsp   Let’s say:   3.5g of 20% THC flower = 700mg THC   If that goes into ½ cup of butter (8 tbsp), you’ve got ~87.5mg THC per tbsp   If your recipe uses 4 tbsp of that, total recipe = 350mg   Divide by number of blondies (16), you get ~21.9mg per piece   🔍 Want it lower dose? Use less cannabutter and supplement with regular butter.     🧠 Cannabis in the Kitchen: Edibles as Modern Ritual       Cannabis in food isn’t just a trend—it’s a reawakening. Across the country, more people are skipping the smoke and choosing edibles as a more mindful, intentional way to engage with cannabis.   Edibles allow for full-body effects, long-lasting relief, and the joy of flavor. They’re part chemistry, part culinary art, and all about enhancing the experience—not just the outcome.   This recipe is part of that shift: it’s about pleasure, wellness, and creating food you actually want to eat (not just tolerate to get the benefits). That’s what functional food should be.     🌙 When to Eat These: A Mood-Based Serving Guide       This recipe isn’t just for when you’re hungry—it’s for when you need a little something extra.   🍂 After a long day of peopling: Pair with a blanket and a “Do Not Disturb” mindset   🎁 As a lowkey edible gift: For the friend who bakes, meditates, and microdoses   📚 For a creative session: A half piece + journal = unexpected brilliance   🌧 On a rainy afternoon: Served warm with tea, a record playing in the background   🎉 After dinner on holidays: Quietly magical with zero social drama required   As always: start low, go slow, and make space for the experience.     📥 Want the printable version of this recipe?   Cannabis_Infused_Citrus_Caramel_Blondies_Recipe_Card         [...] Read more...
April 1, 2025Cannabis-Infused Honey Recipe — Sweet, Sticky, and Blissfully Effective Why You’ll Love This Cannabis-Infused Honey Honey has been a trusted natural remedy for centuries, but when combined with cannabis, it transforms into one of the most versatile, easy-to-make edibles. This cannabis-infused honey recipe is perfect for sweetening tea, drizzling on toast, enriching salad dressings, or even enjoying straight off the spoon. Unlike baked edibles, infused honey is easy to dose, gentle on digestion, and offers all the soothing benefits of cannabis without turning on your oven every time you want a treat.   Health Benefits of Cannabis-Infused Honey This isn’t just about getting buzzed — it’s about enhancing your wellness with the natural powers of both honey and cannabis: 🍯 Antibacterial properties — soothes sore throats and supports immune health. 🧘 Digestive support — gentle on your gut and helpful for calming upset stomachs. 💖 Rich in antioxidants — promotes skin, heart, and brain health. 🍃 Natural sweetener — say goodbye to refined sugar guilt. 🌿 Cannabis effects — promotes stress relief, relaxation, and calm.   Ingredients & Equipment for Homemade Cannabis Honey   🧂 Ingredients: 3.5 grams decarboxylated cannabis (roughly 20% THC recommended) 1 cup raw or local honey   🛠️ Tools: Small saucepan or double boiler Cheesecloth or fine mesh strainer Mason jar or glass storage jar (bonus points for style)   How to Make Cannabis-Infused Honey (Step-by-Step)   Step 1: Decarboxylate the Cannabis Before you can infuse cannabis into honey, you need to activate the THC through a process called decarboxylation. 1.Preheat oven to 225°F (105°C). 2.Break up cannabis into small pieces and spread on a parchment-lined baking sheet. 3.Bake for 30–40 minutes, stirring every 10 minutes, until light golden and aromatic.   Step 2: Infuse the Honey 1.Combine decarboxylated cannabis and honey in a small saucepan or double boiler over low heat. 2.Simmer gently for 40–60 minutes, stirring occasionally. Keep the heat low to preserve cannabinoids.   Step 3: Strain & Store 1.Allow the mixture to cool slightly. 2.Strain through cheesecloth into a clean mason jar. 3.Store at room temperature for up to 6 months or in the fridge for even longer freshness.   Dosing Guide: How Potent is Your Cannabis Honey?   💡 Potency Calculation (assuming 20% THC cannabis) 3.5 grams cannabis = ~700 mg THC total 1 cup honey = 16 tablespoons = 48 teaspoons Approximate THC per serving: 1 tablespoon ≈ 43.75 mg THC 1 teaspoon ≈ 14.6 mg THC ½ teaspoon ≈ 7.3 mg THC ¼ teaspoon ≈ 3.6 mg THC (great beginner dose) ⚠️ Dosing Caveat: Please note that this dosing guide is an estimate and should be used cautiously. Factors like the exact potency of your cannabis, decarboxylation efficiency, infusion temperature, and individual tolerance can all significantly affect the final strength of your honey. Variables such as the actual THC percentage of your cannabis, how well you decarboxylate it, infusion time and temperature, and even how thoroughly you strain your honey can all influence the final potency. When in doubt, start with a very small dose and gradually adjust only after observing the full effects.     Pro Tip: Honey-based edibles may take 30–90 minutes to fully kick in, so be patient before reaching for another spoonful.   Creative Ways to Use Cannabis-Infused Honey   Stir into tea, coffee, or warm milk ☕ Drizzle on pancakes, yogurt, or fresh fruit 🥞🍓 Whisk into homemade salad dressings or marinades 🥗 Spread on warm biscuits, toast, or cornbread Or — no shame — enjoy it straight from the spoon 🍯   💬 Cannabis-Infused Honey FAQs   How do you make cannabis-infused honey at home?  To make cannabis-infused honey at home, simply decarboxylate your cannabis, gently heat it with honey for about an hour, strain it, and store. This easy cannabis honey recipe only requires cannabis, honey, and basic kitchen tools. How do you decarboxylate cannabis for honey infusion? Decarboxylation is the process of activating THC. Bake broken-up cannabis buds on parchment paper at 225°F (105°C) for 30–40 minutes, stirring every 10 minutes until lightly golden and aromatic. Can you make edibles with honey instead of butter? Yes, cannabis-infused honey is a popular alternative to cannabutter, allowing you to make edibles without butter or oil. It’s perfect for sweet recipes, beverages, and microdosing. How long does cannabis-infused honey last? When stored in a sealed jar away from light and heat, cannabis-infused honey can last up to 6 months at room temperature and even longer if refrigerated. How strong is homemade cannabis honey? The strength depends on how much cannabis you use and its THC percentage. A typical batch with 3.5 grams of 20% THC cannabis yields about 700 mg THC total. Refer to the dosing guide above for per-teaspoon breakdowns. What is the best beginner dose for cannabis honey? For beginners, start with ¼ teaspoon of cannabis honey, which typically contains around 3.6 mg of THC. This allows you to experience mild effects without overwhelming potency. What are the benefits of cannabis-infused honey? Cannabis-infused honey combines the natural antibacterial, antioxidant, and digestive benefits of honey with the relaxing, stress-reducing, and soothing effects of cannabis. Can I microdose with cannabis honey? Yes, cannabis honey is excellent for microdosing. Small amounts, such as ¼ to ½ teaspoon, can offer subtle relaxation and wellness benefits without strong psychoactive effects. What are the best ways to use cannabis honey? The best ways to use cannabis honey include stirring it into tea, drizzling on toast, adding to yogurt or oatmeal, using it in salad dressings, or enjoying it straight from the spoon. Does cannabis honey help with stress and relaxation? Yes, many people use cannabis honey to naturally reduce stress and promote relaxation. It is especially popular in bedtime teas and calming rituals.   Final Thoughts: The Liquid Gold of Cannabis Edibles ✅ Easy to make, even easier to enjoy. ✅ Versatile for recipes, drinks, or direct consumption. ✅ Potent, but microdose-friendly. ✅ Stores beautifully — no freezer required. ✅ An herbal remedy that has stood the test of time, now with a modern twist.   Join the Conversation Made this recipe? Share your favorite way to use cannabis-infused honey in the comments. Tag your creations with #CannabisHoney and share the sticky, sweet love.   Contact Us!       [...] Read more...
August 3, 2023Ingredients 1 cup breadcrumbs 1/2 cup canna-milk 1 lb ground beef 1/2 lb ground pork 1/2 lb Italian sausage, casing removed 1 small onion, finely diced 3 cloves garlic, minced 1 cup grated parmesean cheese 1/4 cup chopped parsley 2 large eggs, beaten 2 Tbsp canna-oil 1 (32oz) jar marinara sauce Instructions 1. In a small bowl, stir bread crumbs with canna-milk until evenly combined. Let sit 15 minutes, or while you prep other ingredients. 2. In a large bowl, use your hands to combine beef, pork, sausage, onion, and garlic. Season with salt and pepper, then gently stir in breadcrumb mixture, eggs, Parmesan, and parsley until just combined. Form mixture into 1” balls. 3. In a large high-sided skillet over medium heat, heat oil. Working in batches, sear meatballs on all sides to develop a crust. Set meatballs aside, reduce heat to medium-low, and add sauce to skillet. Bring sauce to a simmer then immediately add meatballs back to skillet. Cover and simmer until cooked through, about 8 minutes more original recipe from eatyourcannabis.com [...] Read more...
August 3, 2023This recipe may be used with heavy cream or whole milk. Materials -Medium Sauce-Pan -​Thermometer -Mesh-sieve or cheesecloth Ingredients ​6 grams cannabis flower 2 cups whole milk or heavy cream ​ Directions ​ ​1. Decarboxylate the cannabis Heat the oven to 225°F. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. ​Take care not to let the temperature go over 225°F and burn (if this happens, you can lose potency). Bake for about 35–40 minutes, then remove from the oven and cool before grinding into a coarse powder. ​ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Heat the milk or heavy cream, in a saucepan over medium-low heat. Add the decarboxylated cannabis and cook, taking care not to let the temperature go over 200°F for about 45 minutes. 3. Remove from heat and let sit, undisturbed, for 10 minutes 4. Strain through a fine mesh-sieve set over a bowl. Press carefully with a spoon to extract as much oil as possible ​The milk will keep for up to 6 weeks if covered and refrigerated. This recipe is available for download HERE Original recipe from Vice.com [...] Read more...
April 30, 2025Cannabis-Infused Spicy Hot Chocolate — Sip, Soothe, and Feel the Glow There’s hot chocolate… and then there’s this: a creamy, cocoa-rich, cannabis-kissed mug of firelight and calm. This spicy hot chocolate recipe doesn’t just warm your hands—it grounds your mood, softens your edges, and coaxes a little smile from deep within. Whether you’re wrapping up a snow day or settling into a self-care night, this edible drink delivers comfort with a kick. What makes it unique? It’s got the usual luxuries—dark chocolate, warm milk, a swirl of vanilla—but also a whisper of cayenne, a hint of cinnamon, and a measured dose of cannabis-infused coconut oil. That’s what elevates this drink into a relaxing ritual for the senses, not just a sweet treat. Imagine this: steam curling from a deep mug, the first sip surprising you with just the right amount of heat, followed by silky, slow-building calm. Yeah, we’re going there. Why Cannabis-Infused Hot Chocolate Is a Game-Changer Let’s talk about why this particular edible drink hits differently—literally and emotionally. It’s cozy, medicinal, customizable, and shockingly easy to make. Here’s what this cup brings to the table: 🍫 Cocoa is a natural mood booster—rich in flavonoids that support heart health and calm your nervous system. 🔥 Cinnamon and cayenne add warmth, circulation support, and metabolic benefits, all while deepening the flavor. 🌿 Cannabis-infused coconut oil delivers THC or CBD in a fat-soluble form, promoting relaxation and relief. 💤 The drink is great before bed—especially when you want something soothing without the sugar crash. 🥛 It’s adaptable—you can make it vegan, low-sugar, or even non-euphoric with CBD or CBG. Ingredients & Equipment You won’t need anything fancy, but intention and quality ingredients go a long way. Choose a chocolate you love, a milk that foams well, and cannabis oil that’s been decarboxylated and infused properly. Ingredients 🥛 2 cups whole milk (or oat/almond for dairy-free) 🍫 ¼ cup dark chocolate chips (or chopped chocolate bar, 60–75% cacao) 🥥 1 tablespoon cannabis-infused coconut oil 🌿 ½ teaspoon ground cinnamon 🌶️ ⅛ teaspoon cayenne pepper (adjust to taste) 🍨 1 teaspoon vanilla extract 💧 Optional: maple syrup or agave for sweetness Equipment 🛠️ Small saucepan 🛠️ Whisk 🛠️ Mug (bonus points if it’s oversized or cozy-looking) How to Make Cannabis-Infused Spicy Hot Chocolate Step 1: Warm the Milk In a small saucepan over medium heat, pour in your milk of choice. Heat it until it’s steamy but not boiling—boiling can scald the milk and affect flavor. Give it a gentle stir now and then to keep things smooth. Step 2: Add the Chocolate & Spice Lower the heat and whisk in the dark chocolate chips. Stir constantly until melted and fully blended. Then add cinnamon, cayenne, and vanilla extract. The aroma should start to bloom at this point—this is where it starts to smell like winter magic. Step 3: Stir in the Cannabis-Infused Coconut Oil Turn the heat to low and stir in the cannabis oil until fully incorporated. You should see a glossy finish and slightly thicker texture. This is your sip of serenity. Step 4: Pour & Garnish Remove from heat and pour into your favorite mug. Top with whipped cream, marshmallows, a cinnamon stick—or nothing at all. Sometimes the best moments are unadorned. Dosing Guide: How Much Is in My Mug? Here’s a quick calculation based on 1 tablespoon of infused coconut oil made with 3.5g of 20% THC cannabis (700mg total): 💡 1 tbsp infused oil = ~43.75mg THC 🍫 2 servings per recipe = ~21.9mg THC per mug 🫖 ½ mug = ~10.9mg THC 🥄 ¼ mug = ~5.5mg THC Beginner-Friendly Tip: If you’re new to edibles, start with just ¼ mug (~5mg THC), wait at least 90 minutes, and see how your body responds. Onset is typically 30–90 minutes, and effects may last 4–6 hours.   ⚠️ Dosing Caveat: This dosing guide is an estimate. Actual potency can vary based on your cannabis’s THC percentage, how well it was decarboxylated, the infusion method used, and your body’s individual sensitivity to edibles. Start low, sip slow, and allow plenty of time before increasing your dose. Want a Non-Euphoric Version? Absolutely possible. Simply swap in one of the following instead of THC-infused oil: 🌿 CBD oil for anti-anxiety and anti-inflammatory benefits 🌿 CBG or CBC oil for mood lift without intoxication 🌿 Use a 10:1 CBD:THC blend to dramatically lower the euphoric effect You can even make CBDA or THCA infusions if you want the raw, non-psychoactive cannabinoids while keeping the warm beverage vibe intact. Creative Ways to Use Spicy Hot Chocolate 🍪 Pair it with a CBD cookie for a double-chill snack 📚 Sip it while reading, journaling, or watching snowfall 🧘 Drink it before a bath, meditation, or nighttime stretch 🧊 Let it cool slightly and pour over vanilla ice cream for a spicy affogato 🌌 Make it part of your bedtime ritual instead of a glass of wine 🎨 Use it to start your creative time—writing, drawing, ideation Cannabis and chocolate are both dopamine influencers, which may be why this drink boosts mood as much as it does comfort. Final Thoughts: Sip Slow, Soothe Deep Cannabis-infused spicy hot chocolate is more than a winter drink—it’s a moment. A small act of nourishment that warms your hands, calms your nerves, and adds a little spark to an otherwise ordinary evening. With simple ingredients, beginner-friendly dosing, and endless opportunities to customize, this recipe is a cozy favorite waiting to happen. Let it be your gentle nightcap, your creative warm-up, or your winter-weather hug in a mug. Have you tried this recipe—or customized it your way? Share your creations, post your photos, and tag #InfusedHotChocolate so we can raise a cup to calm, together. ☕✨ FAQ: Cannabis-Infused Hot Chocolate, Answered   How do I make cannabis-infused hot chocolate at home? Use a base of milk and dark chocolate, infuse it with cannabis coconut oil, and spice it with cinnamon and cayenne for warmth and effect. What’s the best way to dose THC in hot drinks? Use measured amounts of infused oil. Stir well and divide evenly between servings. Avoid guessing—precision matters with edibles. Can I use cannabutter instead of coconut oil? You can, but it won’t emulsify as cleanly. Coconut oil blends better into hot liquids. Will the THC degrade when heated? As long as you don’t boil the mixture, THC remains stable. Low, steady heat is your friend. Can I make this with CBD instead? Yes! Just use CBD-infused oil in place of THC oil. It won’t be intoxicating, but still soothing. How long do effects last from cannabis hot chocolate? Typically 4–6 hours depending on dose, metabolism, and tolerance. What’s the best milk to use? Whole milk gives the richest mouthfeel. Oat milk and almond milk are great for dairy-free versions. If you’re daring, we have posted a recipe here on CEDclinic.com for making medicated milk! How strong is homemade cannabis hot chocolate? That depends on your infusion strength. This recipe yields ~22mg THC per mug using standard oil. Can I refrigerate and reheat it later? Yes—store in the fridge for up to 3 days. Reheat gently without boiling. Is this a good edible for beginners? Yes, if dosed carefully. Start with ¼ mug or less, especially your first time. [...] Read more...
August 3, 2023Servings: 12 Ingredients 1 cup soybean oil ½ ounce ganja shake 2 large egg yolks 1 teaspoon fresh lemon juice Pinch of salt 1 teaspoon white vinegar ½ teaspoon Dijon mustard ​Directions In a double boiler, combine the oil and ganja. Heat over low until the ganja smell is pronounced but not nutty or burnt. (The oil should have an earthy green tint to it.) Let cool. Remove and strain the herb, squeezing the weed in a metal strainer against the mesh with the back of a spoon to wring out every drop of oil. Make sure that all your ingredients have been brought to room temperature — this is crucial! ​In a small metal bowl, use an immersion blender or whisk to thoroughly blend the egg yolks, lemon juice, salt, vinegar, and mustard. This can also be done in a food processor or blender. ​Using a ½ teaspoon measure, very slowly add the infused oil to the small metal bowl, a few drops at a time, while constantly blending on low or whisking until the mayo is thick and starting to form ribbons. (If it’s too thick, you can add room-temperature water in tiny increments.) If your mixture “breaks,” it can be repaired by whisking some more room-temperature egg yolks in a separate bowl, then slowly whisking those yolks into the “broken” mayo mixture. If that doesn’t do it, add a few drops of hot water. ​Cover and chill; it’ll keep in the refrigerator for 4 to 5 days. Original recipe from: Boudreaux, Ashley. The Official High Times Cannabis Cookbook. Red Eyed Deviled Eggs. https://saltonverde.com/wp-content/uploads/2017/09/10-High_Times_Cannabis_Cookbook.pdf [...] Read more...
August 3, 2023Ingredients 1 package of Instant Ramen Vegetable or Beef broth (use the amount listed on the package for water) Frozen vegetable medley One egg or tofu Dried seaweed (to garnish) Sesame Seeds (to garnish) Cannabis Tincture Directions 1. Follow the instructions on the ramen package, but swap the water out for broth 2. Add the frozen veggies when broth gets hot 3. Crack an egg in the hot broth and stir for a few minutes You can also use a hard-boiled egg or chopped tofu ​ 4. Add as much cannabis tincture that you want. If you are unsure, start with 1–2 drops 5. Top soup with dried seaweed and sesame seeds Original recipe from Satori MJ [...] Read more...
February 3, 2026CED Clinic Recipes Cannabis-Infused Barbecue Sauce Smoky, Sweet, Slow-Burn Comfort A backyard classic, thoughtfully infused. Tomato-forward, gently smoky, and designed for portion-by-the-tablespoon dosing control. ⏱️ Ready: ~25 minutes 🍽️ Servings: ~8 (2 tbsp each) 🫒 Infusion: Olive oil 🌶️ Heat: Adjustable Ingredients Steps Dosing FAQ Download Recipe Card (PDF) Quick Safety Reminders Friendly reminders that prevent the most common infused-food mishaps. ✅ Portion first, then enjoy. A tablespoon is your measuring tool. ✅ Wait at least 90 minutes before reassessing effects. Many people choose 2 hours after a full meal. ✅ Label leftovers clearly if others share your fridge. Introduction There is something almost universally reassuring about a good barbecue sauce. It is sweet without being candy-like, smoky without shouting, and it makes even simple food feel intentional. This cannabis-infused version keeps everything people love about a classic sauce while offering a smoke-free, food-forward way to enjoy cannabinoids with more control and predictability. This recipe works especially well for people who prefer edibles over inhalation, those who want dosing flexibility by the spoonful instead of the square, and experienced users who appreciate an infused staple that fits easily into real dinners. TL;DR This is a stovetop cannabis-infused barbecue sauce that comes together quickly and is built for portion-by-the-tablespoon dosing control. Using infused olive oil folded into a tomato base helps the sauce feel consistent, easy to store, and easy to dilute. ✅ Ready in about 25 minutes ✅ Approx. 5 to 11 mg THC per serving, depending on portion ✅ Typical onset: 60 to 90 minutes, sometimes longer with a full meal Why You’ll Love This Recipe Most edibles lean sweet, highly processed, or both. This sauce goes the other direction. It is savory, meal-friendly, and built around familiar ingredients that already belong on a dinner table. The technique is simple, the equipment minimal, and the result tastes like barbecue sauce first. Because it is portionable by the spoon, this recipe makes it easier to adjust dose without committing to a full edible at once. That makes it particularly appealing for shared meals, cookouts, and anyone still learning how their body responds to infused foods. Functional Perks of This Feel-Good Treat Small choices that add up to a smoother experience. ✨ Uses olive oil fats, which may support cannabinoid absorption and steadier onset for many people. ✨ Easy to scale portions up or down without changing the recipe. ✨ Smoke-free and discreet, suitable for shared meals. ✨ Works as a condiment, so dosing can stay measured and intentional. Pro Tip: For more consistent dosing, stir the sauce well before each use. Infused fats can settle slightly during storage. Health Benefits: Food That Talks To Your Body Tomatoes contribute lycopene and other plant compounds, and they pair naturally with olive oil in a way many people find both satisfying and filling. Garlic and onion provide classic aromatic depth, plus a range of plant compounds commonly associated with antioxidant support in the broader diet context. Cannabinoids interact with the endocannabinoid system, a regulatory network involved in mood, appetite, pain modulation, and sleep. In culinary use, the goal is not a promise of medical outcomes, but a measured way to explore effects that vary widely between individuals. As with any infused recipe, this works best as a supportive tool rather than a cure-all. For many people, modest dosing paired with real food feels more manageable than a stand-alone edible. Simple ingredients, big payoff. Tomatoes, spices, vinegar, and infused olive oil ready to simmer. Ingredients & Equipment You’ll Need 🍅 Ingredients ➕ 1 cup fresh tomatoes, chopped 🍅 ➕ ¼ cup onion, finely diced 🧅 ➕ 2 tablespoons cannabis-infused olive oil 🫒 ➕ ½ cup apple cider vinegar ➕ ¼ cup molasses or honey 🍯 ➕ 2 tablespoons tomato paste ➕ 1 tablespoon smoked paprika ➕ 1 teaspoon Worcestershire sauce ➕ 1 teaspoon garlic powder 🧄 ➕ 1 teaspoon salt ➕ ½ teaspoon black pepper ➕ ½ teaspoon cayenne, optional 🌶️ 🛠️ Equipment ➕ Medium saucepan ➕ Whisk or spoon ➕ Immersion blender or countertop blender ➕ Measuring spoons ➕ Jar with lid (or airtight container) Gentle simmer equals better sauce. Low heat helps flavor stay rounded and dosing stay steadier. How To Make Cannabis-Infused Barbecue Sauce (Step-by-Step) Step 1 Soften the Onions and Tomatoes Warm the cannabis-infused olive oil in a saucepan over medium heat. Add onions and tomatoes and cook for about 5 minutes, stirring occasionally, until the mixture softens and smells sweet rather than sharp. If anything begins to brown aggressively, lower the heat. Pro Tip: Keep the heat gentle. Hard boiling can flatten sweetness and make the vinegar feel louder than you want. Step 2 Build the Flavor Stir in tomato paste, molasses or honey, vinegar, Worcestershire sauce, smoked paprika, garlic powder, salt, pepper, and cayenne if using. Simmer gently for 15 to 20 minutes, stirring occasionally, until thickened and glossy. Step 3 Blend, Cool, and Store Blend until smooth using an immersion blender, or carefully transfer to a countertop blender. Cool slightly, then transfer to a jar and label clearly. Refrigerate. Glossy, smooth, and portion-ready. A jar that makes dosing feel measured rather than mysterious. Dosing Guide: Potent, But Predictable Potency Calculation Using the default assumption of 3.5 g cannabis at 20 percent THC: 3.5 g × 0.20 × 1,000 mg per g ≈ 700 mg THC in the starting flower. If decarboxylation and infusion together yield about 25 percent capture, the oil may contain approximately: 700 mg × 0.25 ≈ 175 mg THC in the full oil batch. If that oil batch is 4 tablespoons total, then: 175 mg ÷ 4 tbsp ≈ 43.75 mg THC per tbsp This recipe uses 2 tablespoons infused oil, so the sauce contains about: 2 tbsp × 43.75 mg ≈ 87.5 mg THC total. Breakdown Per Serving This sauce yields about 1 cup or 16 tablespoons. A common serving is 2 tablespoons, which makes roughly 8 servings. Portion Estimated THC How it looks in real life Full serving (2 tbsp) ≈ 10.9 mg THC A sauced plate, often better for intermediate users Half serving (1 tbsp) ≈ 5.4 mg THC A light brush or measured spoonful, a cautious start for many Quarter serving (½ tbsp) ≈ 2.7 mg THC A small drizzle, useful for beginners and microdosers Suggested Starting Doses Beginner-friendly use often falls in the 1 to 2.5 mg range, which may be closer to a quarter serving or less depending on your batch strength. Intermediate users may feel comfortable around 5 to 10 mg. Higher doses should be approached cautiously, especially in social settings. If you are newer to edibles, start with the smallest portion, wait at least 90 minutes, and consider making any increase on another day once you understand how that amount feels. Quick Math: DIY Dosing Calculator THC percentage × grams of flower × 1,000 = estimated total mg THC. Account for a realistic capture rate. Many home methods land around 20 to 30 percent after decarb and infusion. Divide by tablespoons or servings in the finished recipe to estimate mg per portion. ⚠️ Dosing Caveat: All dosing numbers are estimates. Actual potency can vary based on flower THC labeling accuracy, decarboxylation temperature and duration, infusion efficiency, storage conditions (heat, light, time), and individual factors like metabolism, tolerance, recent meals, and gut motility. Start low, wait patiently, and avoid stacking doses while you are still waiting for the first one. 💡 Microdose Tip For barely-there effects, start with a teaspoon of sauce (or less). Pair with non-infused food so you can keep eating without escalating dose. How To Make This Non-Euphoric Or Gently Altering For a lower-altering version, use CBD-dominant infused olive oil or a high-CBD to low-THC ratio such as 10:1. You can also use 1 tablespoon infused oil plus 1 tablespoon regular olive oil to reduce potency while keeping the flavor and texture consistent. True non-euphoric results depend on individual physiology and dose, not just what is written on a label. Flavor & Pairing Suggestions For calm evenings, earthy and herb-forward profiles often feel grounding alongside smoky, tomato-rich dishes. For light uplift and conversation, subtle citrus-leaning profiles can brighten vinegar and paprika notes. For sleep-forward nights, many people prefer calmer, body-heavy profiles and smaller portions. For social cookouts, choose lower doses and allow more time before deciding on seconds. Pro Tip: Strain names are not guarantees. Treat them as hints, then let your personal response guide future choices. Easy to share, easy to scale. A measured spoonful adds flavor and keeps dosing intentional. Creative Ways To Use This Sauce ➕ Brush lightly onto grilled chicken, ribs, tempeh, tofu, or vegetables near the end of cooking. ➕ Stir into baked beans or lentils for smoky depth. ➕ Use as a burger sauce or sandwich spread, measured by the tablespoon. ➕ Mix with plain yogurt for a barbecue crema. ➕ Add a small spoonful to roasted sweet potatoes or roasted cauliflower. ➕ Combine with a non-infused sauce for an easy dilution strategy. Pro Tip: For microdosing, start with a teaspoon and let time do its work before you decide on more. Serving Ideas & Mood Pairings This sauce fits best into moments that call for comfort without chaos. 🌤️ Great for weekend grilling where you can take your time. 🎧 Ideal for post-work dinners when you want your evening to downshift. 🕯️ Pairs well with soft lighting, a simple meal, and no urgent plans. Storage Tips & Shelf Life Store in an airtight container in the refrigerator for up to 2 weeks. Stir well before each use to redistribute infused fats. Reheat gently. Avoid repeated high-heat reheating, which can change both texture and potency. Potency may drift gradually over time, so older sauce can feel milder. Troubleshooting Common Mistakes Too acidic. Add a small amount of honey or molasses, warm gently, and retaste. Too thin. Simmer uncovered for a few extra minutes, stirring to prevent sticking. Too thick. Stir in a tablespoon of water at a time while warm. Effects feel stronger than expected. Reduce portion size next time, or dilute with non-infused sauce. Cannabis & Culinary Culture Infused cooking has been quietly moving from novelty toward normalcy. Condiments like barbecue sauce are part of that shift because they keep cannabis in the background and dinner in the foreground. When a recipe is portionable and familiar, it becomes easier to use thoughtfully. That shift helps reduce stigma and makes cannabis feel less like an event and more like a tool. Final Thoughts This barbecue sauce shows how infused cooking can feel normal, nourishing, and grounded. It is not about pushing limits, but about bringing intention into the kitchen and control to the plate. If you make this recipe, consider noting your infusion strength and the portion that felt right. That single habit turns cooking into something repeatable. FAQ: Cannabis-Infused Barbecue Sauce How do I make cannabis-infused barbecue sauce at home? Simmer a simple tomato base with seasonings, then blend smooth. The key is measured infused oil, gentle heat, and consistent portions. How long does cannabis-infused barbecue sauce take to kick in? Many people notice effects in 60 to 90 minutes. With a full meal, onset can be later. Waiting longer is often the safer choice before adding more. Can I cook with this sauce at high heat? Gentle reheating is preferred. If grilling, brush near the end rather than early to preserve flavor and reduce unnecessary heat exposure. What is a good beginner dose for this sauce? Many beginners start around 1 to 2.5 mg THC, which may be a quarter serving or less depending on your batch. A teaspoon can be a useful starting point. Can I make this with CBD instead of THC? Yes. CBD-dominant infused olive oil can create a gentler experience that many people prefer for calm evenings. How do I make it less strong? Use less infused oil, replace part with regular olive oil, or mix the finished sauce with a non-infused barbecue sauce to dilute mg per tablespoon. How long does infused barbecue sauce last in the fridge? Up to 2 weeks when stored airtight and kept cold. Stir before use. Discard if it smells off or shows visible spoilage. Can I freeze cannabis-infused barbecue sauce? Freezing is possible. Texture may change slightly after thawing, so stir well. Label clearly and portion for convenience. Why does my sauce feel separated after chilling? Infused fats can settle. Warm gently and stir thoroughly to recombine, then measure your portion. How do I label infused condiments safely? Include the date made, “infused,” and your estimated mg per tablespoon. Clear labeling prevents accidental dosing. Can I use store-bought infused oil? Yes, if potency is clearly labeled. Recalculate mg per tablespoon based on the label and your total yield. Recipe Card (PDF) Prefer a one-page printable? Download the clinic-formatted recipe card. Download Recipe Card (PDF) Back to top   [...] Read more...
August 3, 2023Ingredients 4 Pork chops Salt and pepper 1 Tbsp minced rosemary 2 Cloves minced garlic 1/2 Cup canna-butter 1 Tbps canna-oil Instructions 1. Preheat oven to 375°F. Season pork chops with salt and pepper 2. In a small bowl, combine canna-butter with rosemary and garlic. Set aside 3. In an oven-safe skillet over medium heat, heat canna-oil and add pork chops. Sear until golden, about 4 minutes, flip and cook for another 4 minutes. 4. Brush pork-chops generously with the garlic canna-butter mixture and place skillet in the oven to bake for 10–12 minutes. Serve with more garlic butter. ​If you do not have an oven-safe skillet, you may use a regular one and transfer to a baking dish. Be sure to collect all the oil from the pan when transferring. This recipe is available for download HERE Original recipe from Eat Your Cannabis.com [...] Read more...
October 3, 2025Ingredients Cupcakes: 2 cups flour 1 cup sugar 1 Tbsp baking powder 1/4 Tsp salt 1 cup milk 2 eggs 1/4 cup canna-oil (vegetable is best) 1/4 vegetable oil 2 Tsp vanilla extract 1/3 cup rainbow sprinkles Frosting: 1 cup sugar 1 cup egg whites 1lb butter, salted, room temperature 1 Tsp vanilla extract ​ Directions ​Cupcakes: Preheat oven to 350°F. Line a cupcake pan with cupcake liners. Mix all of the dry ingredients together in a medium bowl. Whisk all of the liquid ingredients together until blended. Add the liquid ingredients to the dry ingredients & mix until there are no large lumps. Do not overmix. Gently stir in the rainbow sprinkles until just blended. ​ Use a 2-ounce portion scoop & fill each cupcake liner with one scoop. Bake for 15–18 minutes or until a toothpick inserted in the middle comes out clean. Remove from the oven & allow to cool a bit before removing them from the pan. Frosting: Put 2 inches of water into a medium-size pot, & bring to a boil. Place the sugar & egg whites into a small stainless bowl that will sit on top of the pot of boiling water, or use a double boiler system. DO NOT allow the bowl with the egg white mixture to directly touch the boiling water or the egg whites will cook very quickly. Whisk constantly until temperature reaches 140°F/60°C or until the sugar has completely dissolved & the egg whites are hot to the touch. DO NOT leave unattended or you will have a sweet egg white scramble! Use a hand mixer or pour the egg white mixture into a bowl that is fitted for a stand mixer. Using the whisk attachment, begin to whip until the meringue is thick & glossy, about 10 minutes on medium-high. Place the mixer on low speed, add the cubes of butter, a couple at a time, until incorporated. Continue beating until it has reached a silky smooth texture. If the buttercream curdles simply keep mixing & it will become smooth. If the buttercream is too runny, refrigerate for about 15 minutes before continuing mixing. Add the vanilla & continue to beat on low speed until well combined. Once the cupcakes have completely cooled, place a large star tip into a piping bag & fill with the buttercream. Pipe a rosette onto each cupcake & add the sprinkles on top. Serve immediately, the same day or keep in an airtight container in the fridge for up to 4 days. They can also be frozen for up to 3 months. This recipe is available for download HERE Original recipe from myedibleschef.com 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → [...] Read more...
April 5, 2025Cannabis-Infused Peanut Butter — Spreadable Happiness in Every Spoonful Why You’ll Love This Cannabis-Infused Peanut Butter Peanut butter is already a pantry hero: protein-packed, creamy, satisfying. But infuse it with cannabis and it becomes something legendary. Smooth, spreadable, and infused with relaxing cannabinoids, this recipe transforms an everyday snack into a versatile edible that can be eaten by the spoonful or tucked into your favorite snack combos. Whether you’re a seasoned edible enthusiast or a curious first-timer, this cannabis-infused peanut butter recipe is a delicious way to enjoy the therapeutic benefits of THC in one of the most comforting forms around. If you’ve been wondering how to make cannabis-infused peanut butter at home, you’re in the right place. This is an easy cannabis peanut butter recipe for beginners that doesn’t require baking or complicated tools. Health Benefits of Cannabis-Infused Peanut Butter Cannabis and peanut butter are both nutritional powerhouses in their own right. Together, they make a functional food that offers both nourishment and relief. 🌿 Plant-based protein: Supports muscle repair and sustained energy 💪 Healthy fats: Helps with nutrient absorption and brain function 🌿 Keeps you fuller, longer: Ideal for appetite control 🌿 Cannabis compounds: May support stress relief, pain management, and restful sleep 🌿 Fat-soluble cannabinoids: Enhanced THC absorption thanks to peanut butter’s natural oils If you’re curious about the benefits of cannabis-infused peanut butter, it combines nutritious whole foods with cannabinoid therapy in a convenient, low-effort format. Ingredients & Equipment You’ll Need 🥜 Ingredients:   1️⃣ 3.5 grams decarboxylated cannabis (preferably 20% THC)2️⃣ 1 cup natural peanut butter (unsweetened, smooth or crunchy) 🛠️ Equipment:   👉 Small saucepan or double boiler👉 Cheesecloth or fine mesh strainer👉 Mason jar or recycled peanut butter jar How to Make Cannabis-Infused Peanut Butter (Step-by-Step) Step 1: Decarboxylate Your Cannabis   Before infusion, cannabis needs to be heated gently to activate its cannabinoids.1. Preheat oven to 225°F (105°C).2. Break up cannabis and spread it on a parchment-lined baking sheet.3. Bake for 30–40 minutes, stirring every 10 minutes until lightly toasted and fragrant. This step is essential if you’re learning how to decarboxylate cannabis for peanut butter and ensures the THC is activated for full potency. Step 2: Infuse the Peanut Butter   1. In a saucepan or double boiler over low heat, combine decarboxylated cannabis with the peanut butter.2. Simmer gently for 30–60 minutes, stirring occasionally. Be careful not to overheat—keep it low and slow. Not only is this a safe method for how to infuse peanut butter with cannabis, it’s also mess-free and ideal for homemade cannabis edibles without baking. Step 3: Strain & Store   1. Let the mixture cool slightly.2. Strain through cheesecloth into a mason jar.3. Store at room temperature for up to 2 months, or refrigerate for up to 6 months.   Dosing Guide: Nutty But Necessary 💡 Potency Calculation: (Assuming 20% THC cannabis) 🔷 3.5 grams cannabis = ~700 mg THC🔷 1 cup = 16 tablespoons = 48 teaspoons 🧐 Breakdown per Serving:   🥄 1 tablespoon ≈ 43.75 mg THC🥄 1 teaspoon ≈ 14.6 mg THC🥄 ½ teaspoon ≈ 7.3 mg THC🥄 ¼ teaspoon ≈ 3.6 mg THC 🥄 Beginner dose: Start with ¼ teaspoon (about 3.6 mg THC) Pro Tip: Peanut butter is rich in fat, which helps your body absorb THC more effectively than low-fat edibles. Expect a stronger effect and longer duration. If you’re looking for a cannabis peanut butter dosage guide for homemade edibles, this section provides clear math and a responsible approach to consumption. ⚠️ Dosing Caveat: This dosing guide offers a helpful estimate, but the actual potency of your cannabis-infused peanut butter may vary. Factors such as THC percentage, how well you decarboxylate, infusion time and temperature, how thoroughly you strain, and your individual sensitivity can all affect the strength. Start low, wait at least 90 minutes to feel the effects, and adjust gradually as needed.   Creative Ways to Use Cannabis Peanut Butter Wondering about the best ways to use cannabis peanut butter in food and drinks? Here are some ideas: ▻  Spread it on toast or crackers 🍞▻  Dip apple slices or banana chunks 🍎🍌▻  Swirl it into oatmeal or yogurt bowls 🧅▻  Blend into protein shakes or smoothies 🧏‍♂️▻  Add a spoonful to brownies or cookie dough▻  Drizzle over pancakes or waffles 🧀▻  Just eat it straight from the spoon (we’re not judging) 🥄   Frequently Asked Questions About Cannabis-Infused Peanut Butter [...] Read more...
August 3, 2023Cannabis infused sugar offers a simple way to enhance your baked goods or beverages. Materials Mason Jar ​Cheesecloth Baking Sheet 9in x 13in Baking Pan Ingredients -3 grams of cannabis flower -1/2 cup of high-proof alcohol, such as Everclear -1/2 cup granulated sugar Directions 1. Decarboxylate the cannabis Heat the oven to 225°F. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. ​Take care not to let the temperature go over 225°F and burn (if this happens, you can lose potency). Bake for about 35–40 minutes, then remove from the oven and cool before grinding into a coarse powder. ​ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Transfer the cannabis to a jar and cover with the alcohol. Screw the lid on tight and shake every 5 minutes for 20 minutes. 3. Strain through a cheesecloth set over a bowl, discarding solids. Mix the strained alcohol with the sugar and spread into an even layer in a glass 9-by-13-inch baking dish. ​ 4. Bake at 200°F, stirring occasionally, until the alcohol has evaporated and the sugar is lightly golden. This recipe is available for download HERE The original recipe is from Vice.com [...] Read more...
April 8, 2025  Cannabis-Infused Chocolate Sauce — Decadence That Loves You Back 🍫 Why You’ll Love This Cannabis Chocolate Sauce Warm, rich, and silky-smooth, this cannabis-infused chocolate sauce takes indulgence to the next level. Whether you’re spooning it over a scoop of ice cream, dipping fresh strawberries, or swirling it into your coffee, this easy cannabis chocolate recipe for beginners delivers full flavor with gentle effects. For cannabis users, the beauty of this recipe lies in its simplicity and flexibility. It’s a no-bake, fast-to-make edible that can be dosed by the spoonful and stored for weeks. And thanks to the fat content in cream and chocolate, it also provides a reliable absorption pathway for THC. Benefits of Cannabis-Infused Chocolate Sauce Here’s what makes this recipe more than just dessert: 🍫 Dark Chocolate – Packed with antioxidants and supports heart health. 🌿 Cannabis – Offers natural stress relief, relaxation, and anti-inflammatory benefits. 🧠 Mood-Boosting – Chocolate and THC both increase feel-good neurotransmitters like anandamide and serotonin. 🥄 Fat-Rich Carrier – Cream and cannabutter help improve THC absorption. ❄️ Refrigerator Friendly – Easy to store and dose over time. Pro Tip: This recipe is especially helpful for those managing anxiety, chronic pain, or poor appetite with cannabis. https://cedclinic.com/category/cannabis-recipes/ Ingredients & Equipment You’ll Need 🍫 Ingredients: ½ cup heavy cream 🥛 4 oz dark chocolate (70% cacao or higher), chopped 🍫 2 tablespoons cannabutter 🧈 1 tablespoon honey or maple syrup (optional) 🍯 ½ teaspoon vanilla extract 🛠️ Equipment: Small saucepan Whisk or silicone spatula Mason jar or glass container with lid How to Make Cannabis Chocolate Sauce (Step-by-Step) Step 1: Warm the Cream In a small saucepan over low heat, warm the cream until just steaming. Avoid boiling—too much heat can degrade THC and ruin the chocolate’s texture. Step 2: Melt and Infuse Add chopped dark chocolate and cannabutter to the warm cream. Stir continuously with a whisk or silicone spatula until the mixture is fully melted and glossy. Step 3: Sweeten & Store Stir in your sweetener and vanilla extract. Once smooth, pour into a glass jar. Let it cool before sealing and refrigerating. Pro Tip: This cannabis chocolate sauce thickens as it cools—reheat gently before serving for best consistency. Dosing Guide: Sweet, But Strong 💡 Potency Calculation Assuming cannabutter made from 3.5g cannabis at 20% THC = ~700mg total THC 1 tbsp cannabutter ≈ 87.5mg THC 2 tbsp used in recipe = ~175mg THC total 🍫 Per Serving (Approx. 6 Servings) 1 tbsp sauce ≈ 29mg THC ½ tbsp sauce ≈ 14.5mg THC ¼ tbsp (¾ tsp) ≈ 7.25mg THC Beginner Dose: Start with ¼–½ tablespoon for ~7–14mg THC Pro Tip: Chocolate’s natural fats help THC absorb more efficiently, meaning it might feel stronger than baked edibles.   Creative Ways to Use Cannabis Chocolate Sauce 🍓 Drizzle over fresh fruit like strawberries, bananas, or apples 🍦 Pour on top of ice cream, pancakes, or waffles ☕ Stir into coffee or hot milk for a DIY cannabis mocha 🍩 Use as a glaze for donuts or cupcakes 🍪 Dip cookies or pretzels for an instant edible treat 🥣 Swirl into oatmeal or yogurt for a rich breakfast upgrade Pro Tip: For microdosing, try mixing ½ teaspoon of the sauce into your morning coffee or spreading lightly over toast. FAQ: Cannabis Chocolate Sauce — Answers to Common Questions   [...] Read more...
May 11, 2025Cannabis-Infused Mac and Cheese — Comfort Food with a Kick of Calm TL;DR 🧀✨ ➕ This mac And cheese blends creamy nostalgia with THC-infused comfort ➕ Ideal for stress relief, pain support, or a sleepy evening wind-down ➕ Easy for beginners, with a precise dosing guide for 4 levels of strength ➕ Offers strain pairing advice and chef tips for cannabis cooking success ➕ Includes use ideas, answers to top cannabis recipe questions, and smart serving swaps Why Cannabis-Infused Mac and Cheese is the Ultimate Feel-Good Meal There’s comfort food, and then there’s comfort food with benefits. Mac and cheese already owns the crown for cozy indulgence — it’s warm, melty, and hits the dopamine button with every forkful. But when you layer in cannabis-infused butter? Now we’re talking serotonin and endocannabinoids. This is more than a stoner snack. It’s a smartly dosed edible that doubles as a satisfying, therapeutic dish for everything from anxiety and sleep trouble to post-work pain management. The rich fats in cheese enhance THC absorption, the warm carbs boost serotonin, and the creamy texture adds emotional comfort. Whether you’re microdosing for a mellow night or dialing up for deeper effects, this recipe is both beginner-friendly and gourmet-adaptable. 👃 The scent of bubbling cheddar… 🧈 The silkiness of infused butter folding into pasta… 🍽️ The ease of a one-dish dose that actually tastes like dinner… Yes, this is your new favorite edible. 🧠 Why Mac And Cheese + Cannabis Is a Genius Combo Cannabis-infused mac and cheese isn’t just delicious — it’s strategically smart for both absorption and wellness. ✅ Fat + THC = Enhanced Bioavailability The rich fats in cheese and butter help the body absorb cannabinoids more effectively, meaning your dose goes further with fewer surprises. ✅ Warmth, Comfort, and Slow Digestion Hot meals like mac and cheese are digested more gradually than sugary edibles, allowing for a slower onset and longer-lasting effects. ✅ Functional and Flexible This recipe works as a solo meal, side dish, or part of a larger comfort-food night — no dessert required. ✅ Therapeutic Potential Depending on the strain, you can craft a version that supports sleep, eases pain, settles anxiety, or gently stimulates appetite — all with one bowl. ✅ Customizable Dosing Control the potency with simple butter swaps. Whether you want 5mg or 25mg, this dish makes it easy to adapt. 👨‍⚕️ Pro Tip: Cannabis is fat-soluble, meaning edibles made with oils or butters tend to hit harder and last longer than smoking or vaping. Eating THC with fats slows the onset but boosts the duration — expect 1 to 2 hours before full effect, and a 6+ hour ride depending on dose. 🍽️ Ingredients & Equipment — What You’ll Need to Make Infused Mac and Cheese This is a stovetop-friendly recipe with optional baking for a crispy finish. You don’t need fancy tools — just a pot, a whisk, and the willingness to stir with purpose. Ingredients: ☑️ 2 cups elbow macaroni (or any pasta with nooks and crannies) ☑️ 2 tablespoons cannabis-infused butter 🧈 visit here for the recipe ☑️ 2 tablespoons all-purpose flour ☑️ 1 cup whole milk or unsweetened oat/almond milk 🥛 ☑️ 1½ cups shredded cheddar cheese (sharp is best!) 🧀 ☑️ ½ teaspoon salt ☑️ ¼ teaspoon ground black pepper ☑️ ¼ teaspoon smoked paprika (optional, but adds lovely warmth) Equipment: 📌 Large pot for boiling pasta 📌 Medium saucepan for cheese sauce 📌 Whisk (for that smooth béchamel texture) 📌 Strainer 📌 Spoon or spatula for folding pasta into cheese 📌 Optional: Baking dish (if you like a crisped, golden crust)   👩‍🍳 How to Make Cannabis Mac and Cheese, Step-by-Step 🔥 Step 1: Cook the Pasta Bring a large pot of salted water to a boil. Cook the pasta until al dente — tender but still firm to the bite. Drain and set aside. 💡 Don’t overcook it. Mushy pasta dulls the whole experience, both in taste and in texture. 🧈 Step 2: Start the Cheese Sauce In a saucepan over low heat, melt your cannabis-infused butter. Add flour and whisk constantly for about 1 minute to create a smooth roux — this step is key for preventing grainy sauce. 💡 Low heat is your friend here. High temps can degrade THC and CBD, especially during prolonged exposure. 🥛 Step 3: Build the Base Slowly pour in your milk while whisking constantly. Let it simmer over low-medium heat until the mixture thickens to a silky texture. This usually takes about 5–7 minutes. 🧀 Step 4: Add the Cheese Turn off the heat and stir in the shredded cheddar, salt, pepper, and paprika. Whisk until completely smooth. 💡 Want extra velvet? Add a touch of cream cheese or a splash of heavy cream. 🍲 Step 5: Combine and Serve Add the drained pasta to your cheese sauce and fold gently until fully coated. Serve hot in bowls, or transfer to a buttered baking dish and bake at 375°F for 10 minutes for a bubbly, crispy top. 🚫 Common Mistakes to Avoid (And How to Fix Them) 🤯 Overheating the cannabis butter High heat breaks down cannabinoids. Stick to low–medium heat when melting infused butter — never let it sizzle or brown. ⏳ Adding cheese too early If the milk/flour mixture isn’t thickened before the cheese goes in, you’ll get a grainy or separated sauce. Always thicken first, then melt cheese off heat. 🍝 Using the wrong pasta Avoid thin noodles or large shells that don’t hold sauce well. Elbows, cavatappi, or small shells are best for trapping creamy goodness (and even dosing). 🥄 Forgetting to taste Cannabis butter may have herbal notes that impact the final flavor. Taste before serving and adjust seasoning — a pinch more salt or an extra dash of paprika can help balance. 🌿 Dosing Guide — Make It Mellow or Make It Potent The beauty of this recipe lies in its built-in flexibility. You can microdose, medicate, or munch without needing a calculator. 💡 Base Calculation (Assuming 20% THC Flower) Let’s say your cannabis-infused butter is made with: 3.5 grams of cannabis at 20% THC Fully decarboxylated and infused into ½ cup (8 tbsp) butter That yields approximately 700mg THC total in the butter Divide that into 8 tablespoons → ~87.5mg THC per tablespoon This recipe uses 2 tablespoons of infused butter → ~175mg THC total Makes 4 servings → ~43.75mg THC per serving ⚖️ Dose Adjustments 🧀 1 full serving = ~43.75mg THC 🧀 ½ serving = ~21.8mg THC 🧀 ¼ serving = ~10.9mg THC (ideal for newer users) 🧀 ⅛ serving = ~5.5mg THC (great for microdosing) 🔁 Want to Adjust the Dose? Here’s How: 🌱 For a stronger dose (double strength): Use 4 tbsp infused butter instead of 2, and reduce flour by 1 tbsp to maintain sauce texture. Final dose: ~87.5mg THC per serving (use with extreme caution). 🌱 For a milder dose (half strength): Use 1 tbsp infused butter and 1 tbsp regular butter. Adjust flour to 2 tbsp total. Final dose: ~21.8mg THC per serving. 🌱 For a microdose (¼ strength): Use just ½ tbsp infused butter and 1½ tbsp regular butter. Adjust flour accordingly. Final dose: ~10.9mg per full bowl, or ~5.5mg per smaller portion. 🌱 Want a Non-Euphoric Version? You can absolutely make this dish with non-intoxicating cannabinoids: 🔸 CBD-rich butter: Use hemp flower or CBD isolate 🔸 CBG or CBDA: Add these for anti-inflammatory and anxiety-calming properties 🔸 5:1 or 10:1 CBD:THC ratio: Keeps euphoric effects low, great for daytime or sensitive users 👩‍⚕️ Pro Tip: Many patients find 2–5mg THC combined with 20mg CBD to be calming without being sedating. Great for chronic pain, muscle tension, or stress without couchlock. ⚠️ Dosing Caveat: Please remember that this dosing guide is only an approximation. The final potency of your cannabis-infused mac and cheese may vary based on factors like the THC content of your cannabis, how thoroughly it was decarboxylated, how evenly it was infused, how well the butter was stirred in, and your individual sensitivity to THC. We recommend starting with a small amount (¼–½ serving), waiting at least 90 minutes, and adjusting slowly from there. 🍴 Creative Ways to Use Cannabis Mac and Cheese This isn’t just a fork-and-done kind of recipe. Infused mac and cheese can be dressed up, stretched out, and turned into something unforgettable — or just ultra-comforting. 🧂 As a decadent side dish Pairs beautifully with grilled vegetables, roast chicken, or barbecued anything. 🍳 Baked into muffin tins Scoop into a greased muffin tray, top with a sprinkle of parmesan, and bake at 375°F for 10–12 minutes. Portion-controlled and party-ready. 🌯 Rolled into a quesadilla or breakfast burrito Yes, seriously. Mac and cheese + scrambled egg + tortilla = high-protein, high-happy brunch. 🍔 Stuffed into burgers Make a deep well in your patty, fill with a spoonful of infused mac, then grill and seal. Over-the-top in the best way. 🌿 Topped with greens Add wilted spinach, kale, or roasted broccoli to turn your edible into a full meal. Fiber + fat = balance. 🍄 Savory truffle remix Drizzle with truffle oil or toss in sautéed mushrooms for a luxury edible night in. 🥣 Mixed with hot sauce and crumbled chips Instant comfort with crunch, spice, and chew — especially good when you’re already feeling the effects. 🍷 Pairing Suggestions: What to Sip with This Dish Cannabis edibles and alcohol aren’t the best mix — but that doesn’t mean you can’t have something elegant in hand. 🌿 Herbal tea Chamomile, rooibos, or peppermint helps soothe digestion and pairs well with creamy foods. 🍋 Lemon water with cucumber Brightens the palate and gently detoxes — perfect if you’re having a heavier meal. 🍺 Hop-forward non-alcoholic beer Pairs beautifully with cheddar and paprika notes, while enhancing the cozy effect. 🥛 Oat milk + turmeric latte Golden milk meets cannabis comfort — creamy, anti-inflammatory, and ideal for bedtime. 🍀 Cannabis Strain Pairings: Flavor Meets Function 🎨 For Creativity & Social Energy: Try Jack Herer or Pineapple Express — uplifting strains with citrusy notes that play well with cheddar. 🛋️ For Relaxation & Sleep: Go with Granddaddy Purple or Bubba Kush — both deepen the sense of comfort and round out the heaviness of the dish. 🌿 For Functional Calm: Harlequin (high-CBD) or Cannatonic offers gentle calm with minimal intoxication — great for daytime mac consumption. 👨‍🍳 Pro Tip: Cheese-heavy foods mellow out the bitterness of earthy strains, while paprika and black pepper enhance terpene profiles like beta-caryophyllene and limonene. These can offer mild anti-inflammatory and mood-lifting benefits — all while making your food taste amazing. ❤️ Final Thoughts: The High-Comfort Dinner You Didn’t Know You Needed Cannabis-infused mac and cheese is more than an edible — it’s a full-body experience. Whether you’re easing into the evening after a hard day, finding gentle relief from chronic pain, or just craving a cozy bowl of something warm and therapeutic, this dish delivers. With flexible dosing, endless remix possibilities, and a base recipe that’s hard to mess up, it’s an edible everyone should have in their back pocket. 👨‍⚕️ Whether you’re microdosing with mindfulness or treating yourself to a higher dose of relaxation, remember: the magic is in the mix of fat, function, and flavor. If you make this — and we hope you do — tag your dish at #InfusedMacAndCheese or drop a comment with your favorite add-ins! Frequently Asked Questions about Cannabis-Infused Mac and Cheese: How do you make cannabis-infused mac and cheese at home? Start with decarboxylated cannabis, infuse it into butter, and substitute that butter into a classic roux-based mac and cheese recipe. This blog walks you through each step, making it beginner-friendly. Is mac and cheese a good food for edibles? Yes! The fats in cheese and butter help with THC absorption, making mac and cheese one of the most effective and delicious edible formats — especially for long-lasting effects. What’s the best strain for making savory cannabis edibles? Strains like Jack Herer, Harlequin, or Granddaddy Purple work well, depending on whether you want an energetic or relaxing result. Look for terpene profiles that match your mood goals. And, keep in mind – the top of any given plant may be different from the middle and bottom of the plant. Strain names are a suggestion of the right ball park – not a brand prescription type experience! Can I make cannabis mac and cheese without cannabutter? You can use infused oil, or infused milk, or add a cannabis tincture directly to the sauce (post-cooking). Just be aware that alcohol-based tinctures may affect texture and taste. All of these recipes are free on CEDclinic.com What is the ideal beginner dose for cannabis-infused mac and cheese? Start with ~5–10mg THC. That’s about ¼ to ½ serving of this recipe using standard infused butter. Always wait 90 minutes before deciding if you want more. Does heating mac and cheese destroy THC? THC begins to degrade at temps above 300°F. Cooking the butter into a sauce on low heat is safe. Baking for a short time at 375°F is fine too — the interior doesn’t reach THC-damaging temps. How long does the high from cannabis mac and cheese last? Expect effects to start 45–90 minutes after eating and last 4–8 hours. The fat content may lengthen onset slightly but deepen intensity. Can I freeze cannabis mac and cheese? Yes, it freezes beautifully. Just note that freezing doesn’t affect potency. Clearly label portions and dose to avoid surprises later! What’s the shelf life of cannabis-infused mac and cheese? In the fridge: 3–4 days. In the freezer: up to 2 months. Reheat gently to preserve cannabinoids. Can I make cannabis mac and cheese gluten-free? Absolutely. Just add lots of cardboard and stir. Just kidding! Use gluten-free pasta and swap flour for a GF thickener like cornstarch or arrowroot. Texture may vary slightly, but the flavor and dosing remain. [...] Read more...
August 3, 2023Ingredients 3 Tbsp mayonnaise 2 Tsp Dijon mustard 1/2 Tsp salt 1/2 Tsp pepper 2 Eggs, lightly beaten 1lb Lump crab meat 2 Tbps finely chopped parsley 3 Tbsp canna-butter Instructions 1. Whisk together mayonnaise, mustard, salt, pepper and eggs. Then gently stir in crab meat, panko and parsley. 2. Shape mixture in to 12 (3-inch) patties, pressing gently to flatten. Cover with plastic wrap and refrigerate for 1hr. 3. Melt half the canna-butter in large, nonstick skillet over medium heat. Add 6 patties to the pan and cook for 2 minutes on each side, or until golden brown. Repeat with the remaining half of canna-butter and remaining 6 patties. The recipe is available for download HERE original recipe from eat your cannabis.com [...] Read more...
August 3, 2023Materials -Medium Sauce-Pan -​Thermometer -Mesh-sieve or cheesecloth Ingredients -​6 grams cannabis flower -1 pound unsalted butter Directions ​ ​1. Decarboxylate the cannabis Heat the oven to 225°F. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. ​Take care not to let the temperature go over 225°F and burn (if this happens, you can lose potency). Bake for about 35–40 minutes, then remove from the oven and cool before grinding into a coarse powder. ​ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Heat the butter in a saucepan over medium-low heat. Add the decarboxylated cannabis and cook, taking care not to let the temperature go over 200°F for about 45 minutes. 3. Remove from heat and let sit, undisturbed, for 10 minutes 4. Strain through a fine mesh-sieve set over a bowl. Press carefully with a spoon to extract as much oil as possible ​The milk will keep for up to 6 weeks if covered and refrigerated. This recipe is available for download HERE Original recipe from Vice.com [...] Read more...
August 3, 2023Ingredients 4 eggs 1 cup white sugar ½ cup brown sugar, packed 1 ¼ cups grapeseed oil ¼ cup canna-oil 2 tsp vanilla extract 1 ¾ cups pure pumpkin puree 3 cups all-purpose flour 1 tbsp ground cinnamon 1 tbsp pumpkin spice 2 tsp baking powder 2 tsp baking soda 1 tbsp orange zest, optional Directions Preheat the oven to 350°F/175°C. Line a jumbo muffin tin with liners. Place the eggs, white sugar, brown sugar, grapeseed oil & canna-oil into a bowl fitted for a stand mixer or use a whisk to thoroughly beat ingredients together. Blend in the pumpkin & vanilla extract. In a small bowl mix the dry ingredients together. Add to the wet ingredients & mix until just blended. Stir in the orange zest (optional). Divide the batter evenly between 12 muffin cups using a muffin scoop, about 3 ounces each. Sprinkle with pumpkin seeds. Bake for 22–25 minutes or until a toothpick inserted into the middle comes out clean. ​ Allow to cool, remove from the tins & sprinkle with cinnamon. This recipe is available for download HERE Original recipe from myedibleschef.com [...] Read more...
March 4, 2026Cannabis-Infused Roasted Red Pepper & Walnut Dip (Muhammara)         This recipe brings together roasted red peppers, toasted walnuts, warm spices, and olive oil into a deeply flavorful Middle Eastern dip called muhammara. It is earthy, slightly sweet, lightly smoky, and remarkably versatile. Here we add a simple twist: cannabis-infused olive oil. Because cannabinoids dissolve into fat, this type of recipe allows both flavor and infusion to blend naturally into the dish. The result is a dip that works equally well as a snack, sandwich spread, or part of a full mezze plate. TL;DR: Muhammara in Plain English 🌶 Roast or use jarred red peppers. 🌰 Blend peppers with walnuts, garlic, lemon, and spices. 🫒 Add cannabis-infused olive oil for flavor and infusion. 🥣 Serve as a dip, spread, or sauce. Health Benefits: A Dip That Loves You Back 🌶 Red peppers contain vitamin C, carotenoids, and antioxidant compounds. 🌰 Walnuts provide omega-3 fatty acids and plant polyphenols. 🫒 Olive oil contributes monounsaturated fats associated with cardiovascular benefits. 🌿 Cannabinoids interact with the endocannabinoid system, which participates in regulation of mood, appetite, inflammation, and sleep. This combination makes muhammara both nutritionally rich and satisfying. What You’ll Need 🛠 Equipment Food processor or blender Spatula Serving bowl 🌶 Ingredients 1 cup roasted red peppers (jarred or homemade) ½ cup walnuts 2 tbsp cannabis-infused olive oil 1 tbsp lemon juice 1 garlic clove ½ tsp cumin ½ tsp smoked paprika ½ tsp salt Optional garnish: Chopped walnuts Extra olive oil Fresh parsley Step-by-Step Instructions Step 1: Combine ingredients Add roasted peppers, walnuts, garlic, lemon juice, cumin, paprika, and salt to a food processor. Step 2: Blend to desired texture Pulse until the mixture becomes spreadable but still slightly textured. Muhammara traditionally keeps some walnut grit. Step 3: Add infused oil While blending, slowly drizzle in the cannabis-infused olive oil. This distributes cannabinoids evenly throughout the dip. Step 4: Adjust consistency If the mixture is too thick, add 1 tablespoon of water and blend again. Step 5: Serve Transfer to a serving bowl and drizzle with additional olive oil. Top with chopped walnuts if desired. Dosing Guide Because cannabinoids dissolve into fat, the infused olive oil in this recipe distributes dose throughout the dip. The most reliable approach is to calculate potency from your oil. Interactive Dose Calculator (Infused Oil Recipes) Calculate your approximate dose per serving. THC potency of infused oil (mg per tablespoon) Tablespoons of infused oil used Total servings in recipe Calculate Dose ⚠️ Dosing note: These numbers are estimates. Potency depends on infusion accuracy, oil potency, mixing, and personal sensitivity. Always test a small portion first and wait long enough before increasing dose. Creative Ways to Use This Dip Serve with: Cucumber slices Carrots Pita bread Spread onto: Sandwiches Wraps Flatbread pizzas Use as: Pasta sauce alternative Roasted vegetable topping Grilled meat condiment Storage Tips & Shelf Life Store muhammara in an airtight container in the refrigerator. It typically remains fresh for 4–5 days. If infused, label the container clearly so that others understand the contents. A thin layer of olive oil on top can help preserve texture and flavor. Final Thoughts Muhammara is one of those rare recipes that feels impressive but is remarkably easy to make. The ingredients are simple, the method is forgiving, and the flavor is bold enough to anchor an entire meal. With infused olive oil, it becomes both culinary and functional. Just remember that dosing matters, labeling matters, and sharing food responsibly matters. Good cooking is generous. Smart dosing is thoughtful. This recipe lets you do both. Frequently Asked Questions About Cannabis-Infused Muhammara How strong is this recipe? The potency depends entirely on the infused olive oil you use. If the oil contains 40 mg THC per tablespoon and you use two tablespoons across four servings, each serving would contain approximately 20 mg THC. The interactive calculator above can help you estimate dose more precisely. Can I make this recipe without THC? Yes. You can use regular olive oil or a CBD-dominant infused oil if you want the flavor and nutritional benefits without psychoactive effects. How long does infused muhammara last? Stored in an airtight container in the refrigerator, muhammara typically remains fresh for four to five days. Because this version contains infused oil, it should be labeled clearly and kept out of reach of children. Can I freeze muhammara? Yes, though the texture may soften slightly after thawing. Stirring the dip well and adding a small drizzle of fresh olive oil usually restores consistency. What foods pair best with this dip? Muhammara pairs well with pita bread, cucumbers, roasted vegetables, grilled meats, sandwiches, and grain bowls. Its smoky sweetness complements both Mediterranean and Middle Eastern dishes. Why use infused olive oil instead of butter? Olive oil blends naturally with the flavor profile of muhammara and distributes cannabinoids evenly throughout the dip because cannabinoids dissolve readily in fat. [...] Read more...
September 15, 2025🥦 Cannabis-Infused Veggie Stir Fry Quick, Colorful, and Infused with Chill — Dinner Just Got Elevated TL;DR Light, fast, and full of fiber, this stir fry is your new go-to for feel-good food with functional benefits. Using cannabis-infused coconut oil, it delivers a calming, anti-inflammatory lift that complements the natural nutrition of fresh veggies. Each serving is ~43.75mg THC, or scale it down to 10mg for a microdosed dinner. ✅ Anti-inflammatory ✅ Easy to digest ✅ Infused for mental calm ✅ Ready in 15 minutes ⸻ Why You’ll Love This Recipe It’s fast. It’s fresh. It’s forgiving. This cannabis-infused veggie stir fry is perfect for weeknights when you want real nourishment—without turning your brain into vegetable soup. Coconut oil enhances THC absorption, and the rainbow of vegetables provides everything from antioxidants to gut-healing fiber. This is dinner you can feel good about—physically and mentally. ⸻ Health Benefits: This Is the Real “High” Fiber Diet ✨ This stir fry isn’t just infused—it’s functional. Here’s what it brings to the table: •🧠 Cannabis: Calms the nervous system, eases digestion, supports endocannabinoid tone •🥥 Coconut Oil: Rich in healthy fats to improve THC absorption and brain function •🌈 Broccoli & Bell Pepper: Packed with vitamin C, antioxidants, and phytonutrients •🥕 Carrots & Snap Peas: Fiber-rich, great for gut health and blood sugar balance •🌶️ Ginger & Garlic: Anti-inflammatory, immune-boosting, and flavorful ⸻ What You’ll Need 🛠️ Materials: •Wok or large sauté pan •Wooden spoon or spatula 🥕 Ingredients: •2 tbsp cannabis-infused coconut oil 🥥 •1 cup broccoli florets 🥦 •1 red bell pepper, sliced 🌶️ •1 carrot, julienned 🥕 •½ cup snap peas •2 cloves garlic, minced •1 tbsp ginger, grated •2 tbsp low-sodium soy sauce or tamari •Optional toppings: sesame seeds, sliced green onions, chili flakes ⸻ Step-by-Step Instructions 🔥 1. Heat the Oil In your wok or skillet, heat the infused coconut oil over medium. Add garlic and ginger and sauté for 30 seconds until aromatic but not browned. 🌈 2. Cook the Veggies Toss in broccoli, carrots, and bell pepper. Stir-fry for 3–4 minutes. Add snap peas and cook for 2 more minutes, just until veggies are crisp-tender. 🥢 3. Season and Serve Pour in soy sauce or tamari. Stir to coat everything evenly. Optional: Top with sesame seeds, scallions, or chili flakes for a little extra heat. Serve hot over brown rice, quinoa, or cauliflower rice for a full meal. ⸻ 🍃 Dosing Guide: Healthy, But Still Potent Even when it’s packed with veggies, this stir fry can still pack a punch. 💡 Potency Calculation: •2 tbsp infused coconut oil = ~87.5mg THC •This recipe makes 2 hearty servings 🧐 Breakdown per Serving: •Full serving = ~43.75mg THC •Half serving = ~21.9mg THC •¼ serving = ~10.9mg THC (ideal for beginners) 🔬 Pro Tip: Coconut oil enhances THC bioavailability, so even small portions may feel stronger than you expect. Start with a quarter plate and see how you feel. 🧠 Creative Ways to Use Cannabis Stir Fry This isn’t just a plate of stir-fried veggies—it’s an infused flavor canvas. 🥬 Wrap It Up Spoon the stir fry into lettuce leaves or tortillas for a grab-and-go option with crunch. 🍜 Noodle Bowl Base Layer it over rice noodles or soba with a drizzle of infused sesame sauce. 🍳 Brunch Remix Top with a fried egg, tofu, or sliced avocado for an infused brunch bowl. 🌯 Infused Burrito Add some black beans and roll it into a wrap with guacamole and greens. ⸻ 💡 Pro Tips for Perfect Results • Pre-cut your veggies so cooking is fast and even. • Don’t overcook—you want them bright and slightly crisp, not mushy. • Add protein like tofu, shrimp, or grilled chicken if you want something heartier. • Start small: ¼ plate may be plenty for new users due to the oil’s high bioavailability. • Pair with a CBD beverage or herbal tea for a calming, full-body effect. ⸻ ❌ Common Mistakes to Avoid 🔻 Overheating the Oil If the pan’s too hot, you risk degrading cannabinoids. Medium heat is best. 🔻 Ignoring Portion Size Don’t forget: this is a medicated meal. That “one more bite” could tip the scale. 🔻 Poor Mixing Stir thoroughly after seasoning to evenly distribute the infused oil and flavor. ⸻ 🌿 Strain Suggestions: For a Lighter, Brighter High Choose cannabis strains that enhance energy, creativity, or relaxation without sedation. ✅ For Mood & Energy: •Super Lemon Haze – bright, zesty, great daytime uplift •Tangie – citrus-forward and creativity-boosting ✅ For Calm Focus: •Harlequin – high CBD for body ease with mental clarity •Jack Herer – balanced, euphoric, light-hearted ✅ For Anti-Inflammation: •ACDC – low THC, high CBD, non-intoxicating relief •Pennywise – mellow and soothing with a gentle mental buzz ⚠️ A Note About Strains: Strain names can be misleading. What’s labeled “Super Lemon Haze” in one dispensary might feel completely different from another shop’s version. That’s because: 1) There’s no consistent strain genome across the cannabis industry. 2) Effects vary due to terpene profiles, cannabinoid ratios, and cultivation conditions. 3) Your individual tolerance, body chemistry, and gut health all shape how you feel. 👉 Take all strain suggestions with a diamond-sized grain of salt. Focus more on the effect you’re seeking—calm, uplifted, focused—and choose based on your response over time. 📌 Save & Share 💬 Have a favorite veggie combo you swear by? Drop it in the comments! 📸 Snap your stir fry creation and tag #InfusedVeggieStirFry on Instagram to get featured! . . . Downloadable Recipe Card: Stir Fry Recipe 🌿 Cannabis-Infused Veggie Stir Fry Why You’ll Love This Recipe It’s fast. It’s flavorful. It’s full of fiber and phytonutrients. And with cannabis-infused coconut oil in the mix, this veggie stir fry doesn’t just fuel your body—it eases your mind. Health Benefits ✔ Loaded with antioxidants from colorful veggies ✔ Supports gut health with fiber-rich ingredients ✔ Cannabis = anti-inflammatory, calming, and digestive-friendly ✔ Coconut oil = improves THC absorption and heart health Ingredients 2 tbsp cannabis-infused coconut oil 1 cup broccoli florets 1 red bell pepper, sliced 1 carrot, julienned ½ cup snap peas 2 cloves garlic, minced 1 tbsp ginger, grated 2 tbsp low-sodium soy sauce or tamari Optional: sesame seeds, green onions, chili flakes Instructions Heat the Oil: In a wok or skillet, warm cannabis-infused coconut oil over medium heat. Add garlic and ginger—sauté for 30 seconds. Cook the Veggies: Add broccoli, carrots, and bell pepper. Stir-fry for 3–4 minutes. Toss in snap peas and cook for another 2 minutes. Season & Serve: Stir in soy sauce. Add chili flakes or sesame seeds if using. Serve over brown rice, quinoa, or cauliflower rice. Dosing Guide 2 tbsp infused coconut oil = 87.5mg THC Makes ~2 servings Dose per Serving: 🥦 Full = ~43.75mg THC 🥄 Half = ~21.9mg THC 👶 ¼ serving = ~10.9mg THC Pro Tip: Coconut oil boosts bioavailability—dose mindfully! Strain Reminder: Strains aren’t always what they claim. Names can change, effects can vary, and testing isn’t always rigorous. Take these suggestions with a diamond-sized grain of salt 💎—and trust your body, not just the label. For more recipes and expert cannabis guidance: CEDclinic.com   [...] Read more...
August 3, 2023Ingredients 2 cups shredded green cabbage 1 Tbsp lime juice 1/2 Tsp salt 3 Tbsp cilantro 1/4 cup canna-oil 1 tomato, diced 1/2 cup salsa 1/2 onion, diced 1 jalapeno, diced 1 avocado, sliced Meat of choice (fish or a ground meat like beef or turkey) 4 corn tortillas Directions 1. Cook choice of meat with fajita seasoning in frying pan, set aside 2. In a large bowl, mix shredded cabbage, line juice, salt and cilantro 3. In a separate bowl, mix canna-oil with tomato, onion, jalapeno and salsa 4. Wrap the tortillas in paper towels and heat in the microwave for 30 seconds, or until warm 5. Fill each tortilla with meat, cabbage mixture, cannabis salsa mixture and diced avocado ​Serve with lime wedge The recipe is available for download HERE Original recipe from Eat Your Cannabis [...] Read more...
August 3, 2023Ingredients 4 quarts popped popcorn 1 cup brown sugar 1/2 cup corn syrup light 1/2 cup cannabis butter 1/2 tsp salt 1/2 tsp pepper 1 tsp vanilla extract 1/2 tsp baking soda Instructions Preheat your oven to 250 degrees Fahrenheit. Spray a large shallow roasting pan with cooking spray and add popcorn. In a separate bowl mix brown sugar, corn syrup, cannabis butter, and salt in a heavy saucepan. Stirring constantly, bring to a boil over medium heat. Boil 5 minutes without stirring. Remove from heat. Stir in baking soda and vanilla; mix well. Pour syrup over warm popcorn, stirring to coat evenly. Bake for 45 minutes, stirring occasionally. ​ Enjoy! Keep refrigerated for extended shelf life. This recipe is available for download HERE Original recipe from thecannaschool.com [...] Read more...
May 8, 2025Cannabis Chocolate Chip Morsels Recipe | Easy 1mg Edibles for Microdosing 🍫 Cannabis-Infused Semi-Sweet Chocolate Chip Morsels — Tiny Treats, Micro Moments of Calm These little morsels may be small, but they pack a perfectly portioned punch of calm. Each chocolate chip holds just 1mg of THC, making them ideal for microdosing, mellow snacking, or adding to recipes for an infused twist. Whether you’re sprinkling them into cookies, oatmeal, or straight into your mouth (no judgment), these melt-in-your-mouth bites are a discreet and delicious way to medicate. Think of them as edible Legos — build your dose exactly how you like it, 1mg at a time. 🍫 Why You’ll Love These These infused chocolate chips are: 🍬 Sweet-but-not-too-sweet 🌿 Easy to dose (1mg per chip = flexible freedom) 🧠 Great for beginners and microdosers 🧁 Versatile — snack on them, bake with them, melt them down 🥣 Made from pantry staples + your favorite cannabis infusion 🧂 Ingredients & Tools You’ll Need 🛠️ Equipment: ✨ Double boiler (or glass bowl over a pot of water) ✨ Silicone chocolate chip or dropper mold ✨ Small rubber spatula or spoon ✨ Kitchen scale (for precision) 🍫 Ingredients: ✨ 1 cup high-quality semi-sweet chocolate chips or chopped bar ✨ 1 tablespoon cannabis-infused MCT oil or coconut oil (at 20% THC = 43.75mg THC):  See here for cannabis infused oil recipe 👉 Note: this recipe above is for 1mg THC per morsel. See the section below with the police officer for an easy tweak to make each morsel 5mg or 10mg!  ✨ Optional: ½ tsp vanilla extract or a pinch of sea salt for flavor 👨‍🍳 Step-by-Step Instructions Step 1: Melt the Chocolate Using a double boiler over low heat, slowly melt your chocolate chips or chopped chocolate bar. Stir gently with a spatula until smooth and glossy. Avoid overheating—low and slow preserves both flavor and cannabinoid potency. Step 2: Stir in the Infusion Once fully melted, remove from heat and stir in your cannabis-infused oil. Mix thoroughly to ensure the THC is evenly distributed. Add vanilla or salt if using. Stir again. 🧠 Pro Tip: If the oil begins to separate, keep stirring and allow it to cool just slightly before pouring. 🌀 Baker’s Note: To make sure each morsel holds a consistent dose, take your time when mixing. Stir slowly and thoroughly so the cannabis oil is fully incorporated before molding. A well-mixed batch means each bite delivers the calm you intended—no surprises, just sweet reliability. Step 3: Mold and Chill Using a dropper or spoon, portion the chocolate into your silicone mold. For 1mg-per-chip accuracy, use a mold with roughly 44 cavities (ahem ahem)  — this ensures that each morsel contains ~1mg of THC based on 43.75mg infused oil. Place the mold in the fridge for 20–30 minutes until set. Step 4: Pop & Store Once firm, remove from the mold and store in an airtight container in the refrigerator or a cool pantry. Keep away from heat, children, and curious roommates. 🧮 Dosing Guide: Microdose with Confidence With 1 tablespoon of 20% THC oil (~43.75mg THC total) spread across 44 morsels: 🍫 1 morsel = ~1mg THC 🍫 2 morsels = ~2mg THC 🍫 5 morsels = ~5mg THC 🍫 10 morsels = ~10mg THC Perfect for microdosing, layering effects, or creating precision edibles. ⚠️ Dosing Caveat: Your final THC per morsel may vary depending on how thoroughly the oil is mixed, how precise your mold sizing is, and the exact potency of your cannabis infusion. Always test a single morsel first, wait 60–90 minutes, and adjust as needed. When in doubt, label your batch and start small. 🧁 Creative Ways to Use These Morsels 🍪 Fold them into cookie dough or brownie batter before baking 🥣 Sprinkle them over yogurt, granola, or oatmeal 🍓 Melt and drizzle over strawberries or toast 🧊 Drop them into warm milk for quick infused hot chocolate 🧁 Stir into cannabis peanut butter for layered microdosing 🍫 Mix with CBD chips to balance your buzz 💡 Pro Tip: Assuming you’ve kept a good and consistently even mixture going while cooking, each morsel ought to be fairly close to 1mg THC, they make it easy to dose baked goods with confidence. Whether you’re making a batch of cookies or brownies, you can scale the potency to match your needs—without complicated math or messy measurements. 🍃 Non-Euphoric Alternatives To avoid the high but still get therapeutic benefits, use a CBD-, CBG-, or CBC-infused oil in place of THC. You’ll still get relaxation and mood support, but without intoxication. A 20:1 CBD to THC blend makes these perfect for daytime use or sensitive consumers. Common Mistakes & How to Avoid Them 🚫🤔 Mistake #1: Overheating the chocolate. It’s tempting to rush the melting process, but high heat can cause chocolate to seize or burn—and worse, it can degrade your cannabinoids. Stick to a double boiler on low heat and remove from heat as soon as it’s smooth and glossy. Mistake #2: Not mixing thoroughly. If your cannabis-infused oil isn’t fully incorporated, you risk uneven dosing. Stir slowly but thoroughly for at least a full minute to ensure the oil is emulsified throughout the chocolate. Mistake #3: Using the wrong mold size. This recipe relies on accurate portioning. If your mold is too big or too small, each morsel could pack an unpredictable punch. Use molds with about 44–50 cavities to stay in that sweet 1mg range. Mistake #4: Skipping the test dose. Every batch varies slightly. Try one chip, wait 90 minutes, and gauge the effect before munching down a handful. Cannabis Strain Recommendations for Chocolate Lovers 🍀🍫 When it comes to cannabis and chocolate, flavor and effect both matter. For earthy richness and a relaxing body high, Granddaddy Purple and Northern Lights melt beautifully into cocoa-based recipes. These strains deepen the chocolate’s richness and support winding down. Looking for an energizing, focus-friendly option? Chocolope and Jack Herer add a subtle brightness that pairs beautifully with semi-sweet chocolate and provide creative, social effects without heaviness. Prefer no high at all? ACDC or Charlotte’s Web offer a high-CBD profile that supports calm without couch-lock, perfect for daytime nibbling or when clarity matters most. Expert Cannabis Cooking Tips from Chefs 👨‍🍳🌿 Professional edible chefs know: texture is everything when it comes to chocolate. Chef-level tip? Add your infused oil after the chocolate has cooled just slightly off heat. This protects potency and helps your oil blend more evenly without separation. Another pro move: Use emulsifiers like a tiny pinch of lecithin (sunflower or soy) to stabilize your chocolate mixture. This keeps cannabinoids from pooling and enhances bioavailability—meaning the effects kick in smoother and more consistently. And don’t forget: chefs use infrared thermometers to keep chocolate at ideal working temp (between 88°F and 91°F for semi-sweet). A little precision goes a long way in making edibles that are as beautiful as they are effective. Perfect Pairings for Morsel Moments 🍷🫖 These morsels may be tiny, but they shine with the right match. For a cozy evening: pair 2–3 morsels with a warm mug of cinnamon chai or peppermint tea. The herbal heat enhances the chocolate while keeping the vibe soft and gentle. For an indulgent twist: a glass of ruby port, dark rum, or a coffee liqueur pairs beautifully with semi-sweet chocolate and rounds out the experience with deeper body relaxation. Feeling social? Try a dark stout or nitro cold brew. The roasted notes pair perfectly with the chocolate, while the caffeine adds balance to low-dose THC. Want a snack? Try pairing the morsels with roasted almonds, orange slices, or a sprinkle of sea salt popcorn for a sweet-salty contrast that enhances absorption and makes microdosing feel gourmet. 🤩  Want Stronger Morsels? Here’s How to Make 5mg or 10mg Chips If you’ve tried the 1mg version and feel comfortable adjusting your dose, here’s how to scale your batch for 5mg or 10mg per morsel — while keeping the same great texture and flavor.   💡 Reminder: Always decarboxylate your cannabis first, mix thoroughly, and use precise molds for best results. 🧮 To Make 5mg THC per Morsel: ▲ Use the same mold (44 cavities) ▲ Instead of 1 tbsp infused oil (≈ 43.75mg THC), use 5 tbsp of cannabis-infused oil ▲ That gives you ~219mg THC total ÷ 44 pieces = ~5mg per chip 🥄 Note: 5 tbsp = ¼ cup + 1 tbsp, so adjust your chocolate ratio slightly if needed to maintain smooth consistency 🧮 To Make 10mg THC per Morsel: 🔺 Same mold (44 cavities) 🔺 Use 10 tbsp cannabis-infused oil (≈ 437mg THC total) 🔺 This yields ~10mg THC per morsel ⚠️ You may need to add ~¼ cup more chocolate to maintain firmness and snap. Taste and texture can change slightly with high oil ratios, so test a small batch first if unsure. ⚖️ How to Make 0.5mg THC Per Morsel: Use the same 44-cavity silicone mold Instead of 1 tbsp of infused oil (~43.75mg THC), use ½ tablespoon That gives you ~21.9mg THC ÷ 44 pieces = ~0.5mg per morsel 🔄 For easy measuring: ½ tbsp = 1½ teaspoons 💡 Pro Tip: Because such a small amount of oil is used, your mixture may feel slightly thicker than the higher-dose batches. Stir gently and thoroughly to ensure the oil is fully integrated, and consider adding a touch of coconut oil or a drop of lecithin to preserve that smooth chocolate texture. 🧘 Why Make a 0.5mg Edible? These ultra-low-dose morsels are great for: ⊙ Cannabis newcomers who want to avoid overwhelm ⊙ Daytime users who want the benefits without mental cloudiness ⊙ Combining with CBD for a therapeutic entourage effect ⊙ Layering effects over time with full control A 0.5mg morsel lets you add or subtract from your day’s cannabis experience, one clean, precise step at a time. 🍬 Why Would Someone Want 5mg or 10mg? While microdosing is ideal for many, some medical users need more pronounced relief from: ⚡︎ chronic pain ⚡︎ severe anxiety or panic ⚡︎ muscle spasticity ⚡︎ nausea or chemotherapy support Offering precise 5mg or 10mg morsels gives you layered flexibility. One for daytime. Two for bedtime. Three? Make sure you’ve cleared your calendar.   How do I make cannabis chocolate chips at home? Melt chocolate, mix in infused oil, pour into molds, chill, and portion. That’s it! Can I use cannabutter instead of oil? Technically yes, but it may not blend as smoothly and could affect consistency. Infused oils (especially MCT or coconut) work best for clean texture and even THC distribution. Do I need a mold? Silicone molds make it easiest, but you can spoon droplets onto parchment paper. Just keep portions consistent. Will heating the chocolate destroy THC? Not if you’re careful. Melt over low heat and stir off the burner. THC begins to degrade at temps over ~300°F (149°C). How long do these morsels last? Stored properly, they’ll keep for 3 months in a cool, dark place or longer in the fridge. Can I bake with them? Yes! The THC will survive typical baking temps if you don’t overbake. Great for cookies, cakes, or pancakes. Is 1mg strong enough? For beginners or microdosers, yes. You can always layer multiple morsels over time. And dose a chocolate chip cookie with the number of morsels you want, based on the dosage you prefer! What strain should I use for mellow effects? Try Northern Lights or Granddaddy Purple for a chill vibe. For creativity, go with Jack Herer or Lemon Skunk. Keep in mind, though. Anyone can call any plant, by any name. A name may be what you think it is, but perhaps not too. [...] Read more...